{"PMC3323317": [["The outbreak of severe acute respiratory syndrome (SARS) that emerged in China in November 2002 was caused by a novel coronavirus (SARS-CoV) that was detected in lungs, nasopharyngeal aspirates, and feces of infected patients (1\u20134).", [["lungs", "ANATOMY", 162, 167], ["nasopharyngeal aspirates", "ANATOMY", 169, 193], ["feces", "ANATOMY", 199, 204], ["acute respiratory syndrome", "DISEASE", 23, 49], ["SARS", "DISEASE", 51, 55], ["SARS", "DISEASE", 131, 135], ["coronavirus", "ORGANISM", 118, 129], ["SARS-CoV", "ORGANISM", 131, 139], ["lungs", "ORGAN", 162, 167], ["nasopharyngeal aspirates", "MULTI-TISSUE_STRUCTURE", 169, 193], ["feces", "ORGANISM_SUBDIVISION", 199, 204], ["patients", "ORGANISM", 217, 225], ["patients", "SPECIES", 217, 225], ["SARS-CoV", "SPECIES", 131, 139], ["severe acute respiratory syndrome", "PROBLEM", 16, 49], ["SARS", "PROBLEM", 51, 55], ["a novel coronavirus (SARS-CoV)", "PROBLEM", 110, 140], ["nasopharyngeal aspirates", "TEST", 169, 193], ["severe", "OBSERVATION_MODIFIER", 16, 22], ["acute", "OBSERVATION_MODIFIER", 23, 28], ["respiratory syndrome", "OBSERVATION", 29, 49], ["lungs", "ANATOMY", 162, 167], ["nasopharyngeal", "ANATOMY", 169, 183], ["aspirates", "OBSERVATION", 184, 193], ["infected", "OBSERVATION_MODIFIER", 208, 216]]], ["This outbreak in humans is striking because of the high rate of illness and death associated with it.", [["illness", "DISEASE", 64, 71], ["death", "DISEASE", 76, 81], ["humans", "ORGANISM", 17, 23], ["humans", "SPECIES", 17, 23], ["humans", "SPECIES", 17, 23], ["illness", "PROBLEM", 64, 71], ["death", "PROBLEM", 76, 81]]], ["The SARS-CoV outbreak likely resulted from zoonotic transmission, and natural animal reservoirs of viruses nearly identical to SARS-CoV increase the likelihood of its reemergence in humans (5).", [["SARS", "DISEASE", 4, 8], ["SARS", "DISEASE", 127, 131], ["SARS-CoV", "ORGANISM", 4, 12], ["SARS-CoV", "ORGANISM", 127, 135], ["humans", "ORGANISM", 182, 188], ["humans", "SPECIES", 182, 188], ["SARS-CoV", "SPECIES", 4, 12], ["SARS-CoV", "SPECIES", 127, 135], ["humans", "SPECIES", 182, 188], ["The SARS-CoV outbreak", "PROBLEM", 0, 21], ["zoonotic transmission", "PROBLEM", 43, 64], ["natural animal reservoirs of viruses", "PROBLEM", 70, 106], ["SARS", "PROBLEM", 127, 131], ["CoV", "PROBLEM", 132, 135], ["zoonotic", "OBSERVATION_MODIFIER", 43, 51], ["reservoirs", "OBSERVATION_MODIFIER", 85, 95], ["viruses", "OBSERVATION", 99, 106]]]], "5f67a1728f161c8c28fe9c0aac724c8ba87ffc2c": [["The COVID-19 Pandemic and Mayo Clinic Proceedings Q1 T he United States of America and the world remain gripped in the COVID-19 crisis, with the number of cases and deaths steadily increasing.", [["deaths", "DISEASE", 165, 171]]], ["This crisis has profoundly stressed health care systems and the nation's capability in caring for patients afflicted by the disease; has imposed pervasive economic hardships with incalculable consequences; has altered our behavior by the need for social distancing and the wearing of face masks, by proscribing meetings and gatherings, and by eliciting shelter-in-place directives; has limited the freedom of travel and the ready supply of things we all took for granted; and has left us still dazed by its unanticipated appearance, its rapid dissemination, and the fearsomeness of its present and future impact.", [["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 98, 106], ["the disease", "PROBLEM", 120, 131], ["face masks", "TREATMENT", 284, 294], ["left", "ANATOMY_MODIFIER", 480, 484], ["rapid", "OBSERVATION_MODIFIER", 537, 542], ["dissemination", "OBSERVATION", 543, 556]]], ["If ever there was a Black Swan phenomenon e an entirely unforeseen, rare phenomenon with profound and lasting consequences 1 e COVID-19 is it.", [["a Black Swan phenomenon", "PROBLEM", 18, 41], ["rare phenomenon", "PROBLEM", 68, 83], ["profound and lasting consequences", "PROBLEM", 89, 122], ["profound", "OBSERVATION_MODIFIER", 89, 97]]]], "db4b207c6719b22001686d3aa96195957ed501b2": [["infected patients.", [["infected", "DISEASE", 0, 8], ["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17]]], ["However, the conclusions drawn from different studies are inconsistent.", [["the conclusions", "TEST", 9, 24], ["different studies", "TEST", 36, 53]]], ["[2] [3] [4] In order to obtain a definitive conclusion on the association between the levels of CK-MB and the risk of mortality in COVID-19 patients, a quantitative meta-analysis was conducted on the basis of published data.", [["CK-MB", "GENE_OR_GENE_PRODUCT", 96, 101], ["patients", "ORGANISM", 140, 148], ["CK", "PROTEIN", 96, 98], ["patients", "SPECIES", 140, 148], ["CK-MB", "TEST", 96, 101], ["COVID", "TEST", 131, 136], ["a quantitative meta-analysis", "TEST", 150, 178]]]], "f856d3e86b9bf774e7b81cb2dc54afab7e48d4b8": [["The link was sent to 200 NMO patients and finally 157 filled forms were gathered.", [["NMO", "DISEASE", 25, 28], ["patients", "ORGANISM", 29, 37], ["patients", "SPECIES", 29, 37]]], ["Mean age and mean disease duration were 38\u00b110.8 and 6\u00b14 years, respectively.", [["Mean age", "TEST", 0, 8], ["mean disease duration", "TEST", 13, 34], ["mean disease", "OBSERVATION", 13, 25]]]], "PMC7128440": [["Health-care workers face an elevated risk of exposure to infectious diseases, including the novel coronavirus (COVID-19) in China.", [["infectious diseases", "DISEASE", 57, 76], ["coronavirus", "ORGANISM", 98, 109], ["infectious diseases", "PROBLEM", 57, 76], ["the novel coronavirus", "PROBLEM", 88, 109], ["COVID", "TEST", 111, 116], ["infectious", "OBSERVATION", 57, 67]]], ["It is imperative to ensure the safety of health-care workers not only to safeguard continuous patient care but also to ensure they do not transmit the virus.", [["patient", "ORGANISM", 94, 101], ["patient", "SPECIES", 94, 101], ["the virus", "PROBLEM", 147, 156]]], ["COVID-19 can spread via cough or respiratory droplets, contact with bodily fluids, or from contaminated surfaces.1 According to recent guidelines from the China National Health Commission, pneumonia caused by COVID-19 was included as a Group B infectious disease, which is in the same category as other infectious viruses such as severe acute respiratory syndrome (SARS) and highly pathogenic avian influenza (HPAI).", [["respiratory droplets", "ANATOMY", 33, 53], ["COVID-19", "CHEMICAL", 0, 8], ["cough", "DISEASE", 24, 29], ["pneumonia", "DISEASE", 189, 198], ["COVID-19", "CHEMICAL", 209, 217], ["infectious disease", "DISEASE", 244, 262], ["acute respiratory syndrome", "DISEASE", 337, 363], ["SARS", "DISEASE", 365, 369], ["avian influenza", "DISEASE", 393, 408], ["HPAI", "DISEASE", 410, 414], ["avian influenza", "ORGANISM", 393, 408], ["avian influenza", "SPECIES", 393, 408], ["COVID-19", "SPECIES", 209, 217], ["HPAI", "SPECIES", 410, 414], ["COVID", "TEST", 0, 5], ["cough", "PROBLEM", 24, 29], ["respiratory droplets", "PROBLEM", 33, 53], ["bodily fluids", "TREATMENT", 68, 81], ["pneumonia", "PROBLEM", 189, 198], ["a Group B infectious disease", "PROBLEM", 234, 262], ["other infectious viruses", "PROBLEM", 297, 321], ["severe acute respiratory syndrome", "PROBLEM", 330, 363], ["SARS", "PROBLEM", 365, 369], ["highly pathogenic avian influenza (HPAI)", "PROBLEM", 375, 415], ["respiratory droplets", "OBSERVATION", 33, 53], ["pneumonia", "OBSERVATION", 189, 198], ["infectious", "OBSERVATION", 244, 254], ["infectious", "OBSERVATION", 303, 313], ["severe", "OBSERVATION_MODIFIER", 330, 336], ["acute", "OBSERVATION_MODIFIER", 337, 342], ["respiratory syndrome", "OBSERVATION", 343, 363]]], ["However, current guidelines suggest ensuring protective measures for all health-care workers similar to those indicated for Group A infections\u2014a category reserved for highly infectious pathogens, such as cholera and plague.2 WHO confirmed 8098 cases and 774 (9\u00b76%) deaths during the SARS outbreak in 2002, of which health-care workers accounted for 1707 (21%) cases.", [["infectious pathogens", "DISEASE", 174, 194], ["cholera", "DISEASE", 204, 211], ["plague", "DISEASE", 216, 222], ["deaths", "DISEASE", 265, 271], ["SARS", "DISEASE", 283, 287], ["protective measures", "TREATMENT", 45, 64], ["Group A infections\u2014a category", "PROBLEM", 124, 153], ["highly infectious pathogens", "PROBLEM", 167, 194], ["infectious", "OBSERVATION", 174, 184]]]], "451d679d22735e853442bcdd98e2091c7fb68680": [["IntroductionYellow head virus (YHV) has been emerging for the past two decades in Thailand.", [["Yellow head virus", "ORGANISM", 12, 29], ["Yellow head virus", "SPECIES", 12, 29], ["YHV", "SPECIES", 31, 34], ["Yellow head virus", "PROBLEM", 12, 29]]], ["Virulence of the virus is known to cause devastation in shrimp farming 2-3 days after the onset of disease.", [["the virus", "PROBLEM", 13, 22], ["disease", "PROBLEM", 99, 106], ["virus", "OBSERVATION", 17, 22], ["known to cause", "UNCERTAINTY", 26, 40], ["devastation", "OBSERVATION_MODIFIER", 41, 52], ["disease", "OBSERVATION", 99, 106]]], ["The infected shrimp exhibits yellow coloration on cephalothorax area and pale color throughout the body.", [["cephalothorax area", "ANATOMY", 50, 68], ["body", "ANATOMY", 99, 103], ["shrimp", "ORGANISM", 13, 19], ["body", "ORGANISM_SUBDIVISION", 99, 103], ["shrimp", "SPECIES", 13, 19], ["The infected shrimp", "PROBLEM", 0, 19], ["yellow coloration on cephalothorax area", "PROBLEM", 29, 68], ["pale color throughout the body", "PROBLEM", 73, 103], ["infected", "OBSERVATION_MODIFIER", 4, 12], ["shrimp", "OBSERVATION", 13, 19], ["yellow coloration", "OBSERVATION", 29, 46], ["cephalothorax", "OBSERVATION_MODIFIER", 50, 63], ["area", "OBSERVATION_MODIFIER", 64, 68], ["pale color", "OBSERVATION", 73, 83], ["body", "ANATOMY", 99, 103]]], ["The enormous economical loss of shrimp production in Thailand by YHV infection started from 1991-1995.", [["infection", "DISEASE", 69, 78], ["shrimp", "ORGANISM", 32, 38], ["YHV", "SPECIES", 65, 68], ["The enormous economical loss of shrimp production", "PROBLEM", 0, 49], ["YHV infection", "PROBLEM", 65, 78], ["enormous", "OBSERVATION_MODIFIER", 4, 12], ["economical", "OBSERVATION_MODIFIER", 13, 23], ["loss", "OBSERVATION_MODIFIER", 24, 28], ["shrimp production", "OBSERVATION", 32, 49], ["infection", "OBSERVATION", 69, 78]]], ["In the latter years of yellow head disease outbreak, the diagnostic of YHV contamination in post-larvae must be determined prior to culturing.", [["head", "ANATOMY", 30, 34], ["yellow head disease", "DISEASE", 23, 42], ["head", "ORGANISM_SUBDIVISION", 30, 34], ["YHV", "ORGANISM", 71, 74], ["YHV", "SPECIES", 71, 74], ["yellow head disease outbreak", "PROBLEM", 23, 51], ["YHV contamination", "PROBLEM", 71, 88], ["culturing", "TEST", 132, 141], ["head", "ANATOMY", 30, 34], ["disease", "OBSERVATION", 35, 42]]], ["Therefore, the promising preventive methods of the disease have to be considered.", [["the disease", "PROBLEM", 47, 58], ["disease", "OBSERVATION", 51, 58]]], ["The attenuation or inhibition of YHV propagation is one of the preventive methods for developing antiviral agents nowadays.", [["YHV", "SPECIES", 33, 36], ["inhibition of YHV propagation", "TREATMENT", 19, 48], ["the preventive methods", "TREATMENT", 59, 81], ["antiviral agents", "TREATMENT", 97, 113], ["attenuation", "OBSERVATION_MODIFIER", 4, 15]]], ["YHV is classified in the order of Nidovirales, genus Okavirus, and family Roniviridae.", [["YHV", "SPECIES", 0, 3], ["Nidovirales", "TREATMENT", 34, 45], ["Roniviridae", "TREATMENT", 74, 85]]], ["The rod-shaped virus contains positive single-stranded RNA as a genomic material with approximately 26 kbp.", [["positive single-stranded RNA", "RNA", 30, 58], ["The rod-shaped virus", "PROBLEM", 0, 20], ["positive single-stranded RNA", "PROBLEM", 30, 58], ["rod-shaped", "OBSERVATION_MODIFIER", 4, 14], ["virus", "OBSERVATION", 15, 20], ["positive", "OBSERVATION_MODIFIER", 30, 38], ["single-stranded RNA", "OBSERVATION_MODIFIER", 39, 58], ["26 kbp", "OBSERVATION_MODIFIER", 100, 106]]], ["Structural protein components of the virus are composed of three major types including gp116, gp64 spike glycoprotein, and p20 nucleocapsid protein [1, 2] .", [["gp116", "GENE_OR_GENE_PRODUCT", 87, 92], ["gp64 spike glycoprotein", "GENE_OR_GENE_PRODUCT", 94, 117], ["p20", "GENE_OR_GENE_PRODUCT", 123, 126], ["gp116", "PROTEIN", 87, 92], ["gp64 spike glycoprotein", "PROTEIN", 94, 117], ["p20 nucleocapsid protein", "PROTEIN", 123, 147], ["the virus", "PROBLEM", 33, 42], ["gp64 spike glycoprotein", "TEST", 94, 117], ["p20 nucleocapsid protein", "TEST", 123, 147], ["protein components", "OBSERVATION", 11, 29], ["virus", "OBSERVATION", 37, 42]]], ["Among viral genetic variation, the genotypes of YHV are closely related to the Gill-associated virus (GAV) that is less virulent (or provides less virulence).", [["YHV", "GENE_OR_GENE_PRODUCT", 48, 51], ["Gill-associated virus", "ORGANISM", 79, 100], ["GAV", "ORGANISM", 102, 105], ["YHV", "DNA", 48, 51], ["YHV", "SPECIES", 48, 51], ["GAV", "SPECIES", 102, 105], ["the genotypes of YHV", "PROBLEM", 31, 51], ["the Gill-associated virus", "PROBLEM", 75, 100], ["virus", "OBSERVATION", 95, 100], ["less", "OBSERVATION_MODIFIER", 115, 119], ["virulent", "OBSERVATION_MODIFIER", 120, 128]]], ["A recent study revealed that YHV are composed of five open reading frames (ORFs) [3] .", [["YHV", "GENE_OR_GENE_PRODUCT", 29, 32], ["YHV", "DNA", 29, 32], ["open reading frames", "DNA", 54, 73], ["ORFs", "DNA", 75, 79], ["YHV", "SPECIES", 29, 32], ["A recent study", "TEST", 0, 14]]], ["Among those, the ORF1ab encodes for chymotrypsin-like proteinase (3CLP), nidovirus accessory protease, and RNA-dependent RNA polymerase (RdRp), which have been known to be involved in the replication complexes, and also contained the metal-ion binding domain (MIB) [4] .", [["ORF1ab", "GENE_OR_GENE_PRODUCT", 17, 23], ["chymotrypsin-like proteinase", "GENE_OR_GENE_PRODUCT", 36, 64], ["3CLP", "GENE_OR_GENE_PRODUCT", 66, 70], ["nidovirus accessory protease", "GENE_OR_GENE_PRODUCT", 73, 101], ["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 107, 135], ["RdRp", "GENE_OR_GENE_PRODUCT", 137, 141], ["ORF1ab", "DNA", 17, 23], ["chymotrypsin-like proteinase", "PROTEIN", 36, 64], ["3CLP", "PROTEIN", 66, 70], ["nidovirus accessory protease", "PROTEIN", 73, 101], ["RNA-dependent RNA polymerase", "PROTEIN", 107, 135], ["RdRp", "PROTEIN", 137, 141], ["replication complexes", "PROTEIN", 188, 209], ["metal-ion binding domain", "PROTEIN", 234, 258], ["MIB", "PROTEIN", 260, 263], ["chymotrypsin", "TEST", 36, 48], ["proteinase (3CLP)", "TREATMENT", 54, 71], ["nidovirus accessory protease", "TREATMENT", 73, 101], ["RNA-dependent RNA polymerase (RdRp", "PROBLEM", 107, 141]]], ["Chymotrypsin-like proteinase (3CLP) was first and well characterized in GAV.", [["Chymotrypsin-like proteinase", "GENE_OR_GENE_PRODUCT", 0, 28], ["3CLP", "GENE_OR_GENE_PRODUCT", 30, 34], ["GAV", "CANCER", 72, 75], ["Chymotrypsin-like proteinase", "PROTEIN", 0, 28], ["3CLP", "PROTEIN", 30, 34], ["Chymotrypsin", "TEST", 0, 12]]], ["The enzyme employs a \"Cys-His catalytic dyad\" and possesses trans-cleavage activity [4, 5] .", [["Cys", "CHEMICAL", 22, 25], ["His", "CHEMICAL", 26, 29], ["The enzyme", "TEST", 0, 10], ["His catalytic dyad\"", "TREATMENT", 26, 45]]], ["The sequence alignment showed that 3CLP of GAV successfully located between I 2866 and G 3006 in YHVand interestingly, the putative 3CLP of YHV shared remarkably high identities (up to 87.9 %) in their amino acid sequences.", [["amino acid", "CHEMICAL", 202, 212], ["amino acid", "CHEMICAL", 202, 212], ["GAV", "CANCER", 43, 46], ["G 3006", "GENE_OR_GENE_PRODUCT", 87, 93], ["YHVand", "GENE_OR_GENE_PRODUCT", 97, 103], ["YHV", "GENE_OR_GENE_PRODUCT", 140, 143], ["amino acid", "AMINO_ACID", 202, 212], ["3CLP", "DNA", 35, 39], ["GAV", "DNA", 43, 46], ["I 2866", "DNA", 76, 82], ["putative 3CLP", "DNA", 123, 136], ["YHV", "DNA", 140, 143], ["The sequence alignment", "TEST", 0, 22], ["their amino acid sequences", "TEST", 196, 222], ["high identities", "OBSERVATION", 162, 177]]], ["Moreover, the two proteolytic cleavage sites for 3CLP; 2838 LVTHE\u2193VNTGN 2847 and 6455 KVNHE\u2193LYHVA 6464 (the cleavage site is indicated by \u2193) are conserved between the GAV and YHV sequences.", [["GAV", "GENE_OR_GENE_PRODUCT", 167, 170], ["proteolytic cleavage sites", "PROTEIN", 18, 44], ["LYHVA 6464", "DNA", 92, 102], ["cleavage site", "DNA", 108, 121], ["\u2193", "DNA", 138, 139], ["GAV and YHV sequences", "DNA", 167, 188], ["the two proteolytic cleavage sites", "PROBLEM", 10, 44], ["VNTGN", "TEST", 66, 71], ["KVNHE", "TEST", 86, 91], ["LYHVA", "TEST", 92, 97], ["the cleavage site", "PROBLEM", 104, 121], ["the GAV and YHV sequences", "TEST", 163, 188]]], ["However, the specific role of 3CLP in YHV is yet unclear.", [["YHV", "DISEASE", 38, 41], ["3CLP", "GENE_OR_GENE_PRODUCT", 30, 34], ["YHV", "CANCER", 38, 41], ["3CLP", "PROTEIN", 30, 34], ["YHV", "SPECIES", 38, 41]]], ["It has been postulated that the 3CLP in YHV is involved in the regulation of viral replication complex activity [4] , like 3CLP in other Coronaviruses that process the downstream replicase domains including RdRp and helicase enzyme [6] .", [["3CLP", "GENE_OR_GENE_PRODUCT", 32, 36], ["YHV", "GENE_OR_GENE_PRODUCT", 40, 43], ["3CLP", "GENE_OR_GENE_PRODUCT", 123, 127], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 137, 150], ["RdRp", "GENE_OR_GENE_PRODUCT", 207, 211], ["3CLP", "DNA", 32, 36], ["YHV", "DNA", 40, 43], ["viral replication complex", "PROTEIN", 77, 102], ["3CLP", "PROTEIN", 123, 127], ["downstream replicase domains", "DNA", 168, 196], ["RdRp", "PROTEIN", 207, 211], ["helicase enzyme", "PROTEIN", 216, 231], ["YHV", "SPECIES", 40, 43], ["RdRp and helicase enzyme", "TEST", 207, 231], ["viral replication", "OBSERVATION", 77, 94]]], ["The other encoding protease that is found in both YHV and CLP is Nidovirus accessory protease that is widely known as papain-like protease (PLP).", [["YHV", "GENE_OR_GENE_PRODUCT", 50, 53], ["papain-like protease", "GENE_OR_GENE_PRODUCT", 118, 138], ["PLP", "GENE_OR_GENE_PRODUCT", 140, 143], ["protease", "PROTEIN", 19, 27], ["YHV", "PROTEIN", 50, 53], ["Nidovirus accessory protease", "PROTEIN", 65, 93], ["papain-like protease", "PROTEIN", 118, 138], ["PLP", "PROTEIN", 140, 143], ["YHV", "SPECIES", 50, 53], ["The other encoding protease", "PROBLEM", 0, 27], ["CLP", "PROBLEM", 58, 61], ["Nidovirus accessory protease", "TREATMENT", 65, 93], ["CLP", "OBSERVATION", 58, 61]]], ["This enzyme contains the canonical \"Cys-His catalytic dyad\" and a distinctive \u03b1+\u03b2 fold that is typically found in proteins that function as transcription factor involved in subgenomic messenger RNA (sgmRNA) synthesis [3] .", [["Cys", "CHEMICAL", 36, 39], ["His", "CHEMICAL", 40, 43], ["\u03b1+\u03b2", "GENE_OR_GENE_PRODUCT", 78, 81], ["subgenomic messenger RNA", "GENE_OR_GENE_PRODUCT", 173, 197], ["sgmRNA", "GENE_OR_GENE_PRODUCT", 199, 205], ["Cys-His catalytic dyad", "PROTEIN", 36, 58], ["\u03b1", "PROTEIN", 78, 79], ["transcription factor", "PROTEIN", 140, 160], ["subgenomic messenger RNA", "RNA", 173, 197], ["sgmRNA", "PROTEIN", 199, 205], ["This enzyme", "TEST", 0, 11], ["His catalytic dyad\"", "PROBLEM", 40, 59], ["a distinctive \u03b1+\u03b2 fold", "PROBLEM", 64, 86], ["transcription factor", "PROBLEM", 140, 160], ["subgenomic messenger RNA", "PROBLEM", 173, 197], ["subgenomic messenger RNA", "OBSERVATION", 173, 197]]], ["However, the sequence alignment showed that, unlike the 3CLP, the PLP of YHVand GAV share only 73.7 % identities in their amino acid sequences [3] .IntroductionThe prevention of viral propagation has focused on this key enzymatic reaction as well [7, 8] .", [["amino acid", "CHEMICAL", 122, 132], ["PLP", "CHEMICAL", 66, 69], ["amino acid", "CHEMICAL", 122, 132], ["PLP", "GENE_OR_GENE_PRODUCT", 66, 69], ["YHVand", "GENE_OR_GENE_PRODUCT", 73, 79], ["amino acid", "AMINO_ACID", 122, 132], ["3CLP", "PROTEIN", 56, 60], ["PLP", "PROTEIN", 66, 69], ["YHVand GAV", "PROTEIN", 73, 83], ["the sequence alignment", "TEST", 9, 31], ["their amino acid sequences", "TEST", 116, 142], ["viral propagation", "PROBLEM", 178, 195], ["viral propagation", "OBSERVATION", 178, 195]]], ["The inhibition of YHV propagation was only accomplished by YHV-protease dsRNA [9, 10] .", [["YHV", "GENE_OR_GENE_PRODUCT", 18, 21], ["YHV-protease", "GENE_OR_GENE_PRODUCT", 59, 71], ["YHV", "DNA", 18, 21], ["YHV", "PROTEIN", 59, 62], ["YHV", "SPECIES", 18, 21], ["YHV", "SPECIES", 59, 62], ["YHV propagation", "TREATMENT", 18, 33]]], ["Therefore, this viral protease could possibly be a potential target in therapeutic approach, likewise the development of viral protease inhibitors (PI) for HIV-1, HCV, and SARS, illustrate a high achievement in drug pharmaceutical.", [["SARS", "DISEASE", 172, 176], ["PI", "SIMPLE_CHEMICAL", 148, 150], ["HIV-1", "ORGANISM", 156, 161], ["HCV", "ORGANISM", 163, 166], ["viral protease", "PROTEIN", 16, 30], ["HIV-1", "SPECIES", 156, 161], ["HIV-1", "SPECIES", 156, 161], ["HCV", "SPECIES", 163, 166], ["this viral protease", "PROBLEM", 11, 30], ["viral protease inhibitors", "TREATMENT", 121, 146], ["HIV", "PROBLEM", 156, 159], ["HCV", "PROBLEM", 163, 166], ["SARS", "PROBLEM", 172, 176]]], ["The 3CLP-specific inhibitors were rationally designed based on the three-dimensional structure of the viral proteases with computer-assisted molecular modeling.", [["3CLP", "SIMPLE_CHEMICAL", 4, 8], ["viral proteases", "PROTEIN", 102, 117], ["The 3CLP-specific inhibitors", "TREATMENT", 0, 28], ["the viral proteases", "PROBLEM", 98, 117], ["viral proteases", "OBSERVATION", 102, 117]]], ["The Xray crystallographic determining the three-dimensional structure thus provide a better in-depth understanding of the association of proteins and their other target peptides.", [["The Xray crystallographic", "TEST", 0, 25]]], ["Unfortunately, crystal structure of YHV protease is not yet available; a computer-assisted homology modeling of 3CLP of YHV is currently in progress in order to obtain the molecular basis of protease cleavage site.IntroductionTherefore, regarding the successful therapeutic approach targeting viral components for HIV-1, HCV and SARS, the YHV-3CLP protease should be the best target inhibiting viral propagation in YHV.", [["SARS", "DISEASE", 329, 333], ["YHV protease", "GENE_OR_GENE_PRODUCT", 36, 48], ["HIV-1", "ORGANISM", 314, 319], ["HCV", "ORGANISM", 321, 324], ["YHV-3CLP", "ORGANISM", 339, 347], ["YHV", "CANCER", 415, 418], ["YHV protease", "PROTEIN", 36, 48], ["3CLP", "PROTEIN", 112, 116], ["YHV", "PROTEIN", 120, 123], ["protease cleavage site", "PROTEIN", 191, 213], ["YHV-3CLP protease", "PROTEIN", 339, 356], ["HIV-1", "SPECIES", 314, 319], ["YHV", "SPECIES", 120, 123], ["HIV-1", "SPECIES", 314, 319], ["HCV", "SPECIES", 321, 324], ["YHV", "SPECIES", 339, 342], ["YHV", "SPECIES", 415, 418], ["YHV protease", "TREATMENT", 36, 48], ["3CLP of YHV", "TREATMENT", 112, 123], ["protease cleavage site", "PROBLEM", 191, 213], ["the successful therapeutic approach", "TREATMENT", 247, 282], ["viral components", "TREATMENT", 293, 309], ["HIV", "PROBLEM", 314, 317], ["HCV", "PROBLEM", 321, 324], ["SARS", "PROBLEM", 329, 333], ["the YHV-3CLP protease", "TREATMENT", 335, 356], ["viral propagation in YHV", "PROBLEM", 394, 418]]], ["In this study, the homology modeling approach was used to construct the 3D structure of the YHV protease.", [["YHV protease", "GENE_OR_GENE_PRODUCT", 92, 104], ["YHV protease", "PROTEIN", 92, 104], ["this study", "TEST", 3, 13], ["the homology modeling approach", "TREATMENT", 15, 45], ["the YHV protease", "TREATMENT", 88, 104]]], ["Molecular docking based virtual screening of synthetic small molecules from the National Cancer Institute (NCI) diversity set against the YHV protease model was performed.", [["Cancer", "DISEASE", 89, 95], ["YHV protease", "PROTEIN", 138, 150], ["YHV", "SPECIES", 138, 141], ["the YHV protease model", "TREATMENT", 134, 156]]], ["The program Autodock4 is used as the docking tool in this study for several reasons.", [["Autodock4", "CHEMICAL", 12, 21], ["Autodock4", "PROTEIN", 12, 21], ["this study", "TEST", 53, 63]]], ["Last, AutoDock has also been shown to be useful in blind docking in which the location of the binding site is not known.", [["blind docking", "PROBLEM", 51, 64], ["the binding site", "PROBLEM", 90, 106], ["binding site", "OBSERVATION", 94, 106]]], ["The complexes of the proteasehit ligand were subsequently investigated for intermolecular interactions by molecular dynamics simulations.Materials and methodsMultiple sequence alignment and homology modeling Sequence analyses, homology modeling and molecular mechanics calculation were performed on the Discovery Studio 2.5 package (Accelrys Inc., CA, USA).", [["proteasehit", "CHEMICAL", 21, 32], ["proteasehit ligand", "GENE_OR_GENE_PRODUCT", 21, 39], ["proteasehit ligand", "PROTEIN", 21, 39], ["intermolecular interactions", "PROBLEM", 75, 102], ["Multiple sequence alignment", "TEST", 158, 185], ["homology modeling Sequence analyses", "TEST", 190, 225], ["homology modeling", "TEST", 227, 244], ["molecular mechanics calculation", "TEST", 249, 280]]], ["The amino acid sequence of the yellow head virus (YHV) protease was retrieved from the NCBI database (www.ncbi.nlm.nih.gov), covering 196 amino acid residues (Ser 2828 to Asp 3023 ) of the YHV replicase polyprotein 1a (Accession number: ACA21300).", [["amino acid", "CHEMICAL", 4, 14], ["amino acid", "CHEMICAL", 138, 148], ["amino acid", "CHEMICAL", 4, 14], ["amino acid", "CHEMICAL", 138, 148], ["Ser", "CHEMICAL", 159, 162], ["Asp", "CHEMICAL", 171, 174], ["amino acid", "AMINO_ACID", 4, 14], ["yellow head virus", "ORGANISM", 31, 48], ["YHV", "GENE_OR_GENE_PRODUCT", 50, 53], ["amino acid", "AMINO_ACID", 138, 148], ["Ser 2828", "AMINO_ACID", 159, 167], ["Asp 3023", "AMINO_ACID", 171, 179], ["amino acid sequence", "PROTEIN", 4, 23], ["yellow head virus (YHV) protease", "PROTEIN", 31, 63], ["YHV replicase polyprotein 1", "DNA", 189, 216], ["yellow head virus", "SPECIES", 31, 48], ["yellow head virus", "SPECIES", 31, 48], ["YHV", "SPECIES", 50, 53], ["The amino acid sequence", "TEST", 0, 23], ["the yellow head virus", "PROBLEM", 27, 48], ["protease", "TREATMENT", 55, 63], ["amino acid residues", "TEST", 138, 157], ["Asp", "TEST", 171, 174], ["the YHV replicase polyprotein", "TREATMENT", 185, 214]]], ["All of the template coordinates used for homology modeling were retrieved from the protein data bank (www.pdb.org), which include the eight protease enzymes from both microorganisms (tobacco etch virus, entry 1LVM; rhinovirus, entry 1CQQ; hepatitis A virus, entry 1HAV; Staphylococcus aureus, entry 1AGJ; Achromobacter lyticus, entry 1ARB) and higher organisms (bovine \u03b2-trypsin, entry 5PTP; human factor B, entry 1DLE; human heparin binding protein, entry 1A7S).", [["hepatitis A", "DISEASE", 239, 250], ["heparin", "CHEMICAL", 426, 433], ["tobacco etch virus", "ORGANISM", 183, 201], ["rhinovirus", "ORGANISM", 215, 225], ["hepatitis A virus", "ORGANISM", 239, 256], ["Staphylococcus aureus", "ORGANISM", 270, 291], ["Achromobacter lyticus", "ORGANISM", 305, 326], ["bovine", "ORGANISM", 362, 368], ["\u03b2-trypsin", "GENE_OR_GENE_PRODUCT", 369, 378], ["PTP", "GENE_OR_GENE_PRODUCT", 387, 390], ["human", "ORGANISM", 392, 397], ["factor B", "GENE_OR_GENE_PRODUCT", 398, 406], ["human", "ORGANISM", 420, 425], ["heparin binding protein, entry 1A7S", "GENE_OR_GENE_PRODUCT", 426, 461], ["protease enzymes", "PROTEIN", 140, 156], ["Achromobacter lyticus, entry 1ARB", "PROTEIN", 305, 338], ["bovine \u03b2-trypsin", "PROTEIN", 362, 378], ["entry 5PTP", "PROTEIN", 380, 390], ["human factor B", "PROTEIN", 392, 406], ["entry 1DLE", "PROTEIN", 408, 418], ["human heparin binding protein", "PROTEIN", 420, 449], ["entry 1A7S", "PROTEIN", 451, 461], ["hepatitis A virus", "SPECIES", 239, 256], ["Staphylococcus aureus", "SPECIES", 270, 291], ["Achromobacter lyticus", "SPECIES", 305, 326], ["bovine", "SPECIES", 362, 368], ["human", "SPECIES", 392, 397], ["human", "SPECIES", 420, 425], ["tobacco etch virus", "SPECIES", 183, 201], ["hepatitis A virus", "SPECIES", 239, 256], ["1HAV", "SPECIES", 264, 268], ["Staphylococcus aureus", "SPECIES", 270, 291], ["Achromobacter lyticus", "SPECIES", 305, 326], ["human", "SPECIES", 392, 397], ["human", "SPECIES", 420, 425], ["homology modeling", "TEST", 41, 58], ["the eight protease enzymes", "TEST", 130, 156], ["rhinovirus", "PROBLEM", 215, 225], ["hepatitis A virus", "PROBLEM", 239, 256], ["Staphylococcus aureus", "PROBLEM", 270, 291], ["higher organisms", "PROBLEM", 344, 360], ["bovine \u03b2-trypsin", "TEST", 362, 378], ["human factor B", "TEST", 392, 406], ["human heparin binding protein", "TREATMENT", 420, 449]]], ["All eight template sequences were multiple-aligned according to their structural superimposition of the C\u03b1 atoms on the \"align and superimpose proteins\" protocol.", [["C\u03b1", "CHEMICAL", 104, 106], ["C\u03b1 atoms", "SIMPLE_CHEMICAL", 104, 112], ["template sequences", "DNA", 10, 28], ["C\u03b1 atoms", "PROTEIN", 104, 112], ["All eight template sequences", "TEST", 0, 28], ["superimpose proteins\" protocol", "TREATMENT", 131, 161]]], ["The YHV protease sequence was then automatically aligned to a set of aligned template sequences on the \"align multiple sequences\" protocol of which the pairwise alignment algorithm is modified from the ClustalW 1.8 [11] .", [["YHV protease sequence", "DNA", 4, 25], ["aligned template sequences", "DNA", 69, 95], ["YHV", "SPECIES", 4, 7], ["The YHV protease sequence", "TEST", 0, 25], ["the pairwise alignment algorithm", "TEST", 148, 180]]], ["This alignment protocol allows keeping the existing aligned sequences of the templates as a rigid element and thus the pre-aligned target sequence could be mobile.", [["rigid element", "DNA", 92, 105], ["pre-aligned target sequence", "DNA", 119, 146], ["This alignment protocol", "TEST", 0, 23], ["the pre-aligned target sequence", "TEST", 115, 146]]], ["Sequence identities and similarities between the target and template sequences were calculated on the GeneDoc v2.7 [12] .", [["target and template sequences", "DNA", 49, 78], ["Sequence identities", "TEST", 0, 19], ["template sequences", "TEST", 60, 78]]], ["The structural model of the YHV protease was constructed based on the unconventional sequence alignment between the target and template profile using the Modeller 9v4 [13] implemented in the \"build homology models\" protocol.", [["YHV protease", "GENE_OR_GENE_PRODUCT", 28, 40], ["YHV protease", "PROTEIN", 28, 40], ["YHV", "SPECIES", 28, 31], ["the YHV protease", "TREATMENT", 24, 40], ["the unconventional sequence alignment", "TEST", 66, 103]]], ["Insertion and deletions in the target sequence with respect to the templates were defined as loops and further refined within this protocol.", [["target sequence", "DNA", 31, 46], ["Insertion and deletions in the target sequence", "TREATMENT", 0, 46], ["this protocol", "TREATMENT", 126, 139], ["loops", "OBSERVATION", 93, 98]]], ["The best quality model with highest discrete optimized protein energy (DOPE) score was subsequently subjected to the \"minimization\" protocol based on the charmm22 force field [14] to remove unreasonable atomic contacts (steepest descent and conjugate gradient methods until the model reaching 0.", [["the \"minimization\" protocol", "TREATMENT", 113, 140], ["unreasonable atomic contacts", "PROBLEM", 190, 218], ["conjugate gradient methods", "TREATMENT", 241, 267]]], ["The stereochemical qualities of the energy-minimized model were assessed by PROCHECK v3.5 [15] via submitting the coordinates to the JCSG structure validation server (www.jcsg.org).Ligand preparationThe 1364 files (in sdf MDL MOL format) of the NCI diversity dataset were obtained from the Office of the Associated Director of the Developmental Therapeutics Program (DTP), Division of Cancer Treatment and Diagnosis, National Cancer Institute, more information is available at NCI/DTP Open Chemical Repository [16] .", [["Cancer", "DISEASE", 385, 391], ["Cancer", "DISEASE", 426, 432], ["Cancer Treatment", "TREATMENT", 385, 401], ["Cancer", "OBSERVATION", 385, 391]]], ["As a description from the official NCI/DTP page, these small molecules from NCI dataset have been collected from almost 140,000 compounds on plates.", [["NCI dataset", "TEST", 76, 87], ["small", "OBSERVATION_MODIFIER", 55, 60]]], ["They were screened following the criteria of DTP, which are hydrogen bond acceptor, hydrogen bond donor, positive charge, aromatic, hydrophobic, acid, base, and pharmacophores.", [["DTP", "CHEMICAL", 45, 48], ["DTP", "CHEMICAL", 45, 48], ["hydrogen", "CHEMICAL", 60, 68], ["hydrogen", "CHEMICAL", 84, 92], ["DTP", "SIMPLE_CHEMICAL", 45, 48], ["DTP", "PROBLEM", 45, 48], ["hydrogen bond acceptor", "TREATMENT", 60, 82], ["hydrogen bond donor", "TREATMENT", 84, 103]]], ["Therefore, the selections of 1364 compounds have passed the formal mentioned criteria.", [["the selections", "TEST", 11, 25]]], ["Thereby, this set of ligand is suitable to use as a model for finding the antagonists of protease from YHV.Ligand preparationThe 3D structure of ligands were prepared by adding hydrogen atoms and rectifying an appropriate bond order and the chiral center check (stereo-chemistry) using LigPrep 2.2 with the default setting [17] .", [["hydrogen atoms", "CHEMICAL", 177, 191], ["hydrogen", "CHEMICAL", 177, 185], ["YHV", "GENE_OR_GENE_PRODUCT", 103, 106], ["hydrogen atoms", "SIMPLE_CHEMICAL", 177, 191], ["protease", "PROTEIN", 89, 97], ["YHV", "PROTEIN", 103, 106], ["protease", "TREATMENT", 89, 97], ["hydrogen atoms", "TREATMENT", 177, 191], ["LigPrep", "TREATMENT", 286, 293]]], ["The output 1523 ligand conformations were stored in SYBYL mol2 format.", [["The output", "TEST", 0, 10], ["output", "OBSERVATION_MODIFIER", 4, 10]]], ["The rotational bonds of ligands were treated as flexible using python script, prepare_ligand4.py.", [["prepare_ligand4", "SIMPLE_CHEMICAL", 78, 93], ["The rotational bonds of ligands", "TREATMENT", 0, 31], ["prepare_ligand4", "TREATMENT", 78, 93]]], ["This script was implemented in the AutoDock program [18] [19] [20] .Docking procedureThe minimized structure of YHV-protease model was obtained from the previous section (homology modeling and minimization processes).", [["YHV-protease", "GENE_OR_GENE_PRODUCT", 112, 124], ["YHV", "PROTEIN", 112, 115], ["protease", "PROTEIN", 116, 124], ["Docking procedure", "TREATMENT", 68, 85], ["YHV-protease model", "TREATMENT", 112, 130], ["the previous section", "TREATMENT", 149, 169]]], ["AutoDockTools version 1.5.2 was used to assign the Kollman united atom charges and the solvent parameter to this protein, as well as to perform the grid set-up process.", [["AutoDockTools version", "TREATMENT", 0, 21], ["the Kollman united atom charges", "TREATMENT", 47, 78], ["the solvent parameter", "TREATMENT", 83, 104]]], ["The grid boxes were generated around the catalytic residues (C152, H30, D70; as presented in Fig. 2c ).", [["grid boxes", "DNA", 4, 14], ["The grid boxes", "TEST", 0, 14], ["the catalytic residues", "TREATMENT", 37, 59], ["H30", "TREATMENT", 67, 70], ["D70", "TREATMENT", 72, 75]]], ["The H30 protonated state was set to be HIP (add H atoms both \u03b4 and \u03b5 positions) by the N position point to D40.", [["H30", "CHEMICAL", 4, 7], ["H", "CHEMICAL", 48, 49], ["N", "CHEMICAL", 87, 88], ["HIP", "SIMPLE_CHEMICAL", 39, 42], ["HIP", "PROTEIN", 39, 42], ["H atoms", "PROTEIN", 48, 55], ["\u03b4", "PROTEIN", 61, 62], ["D40", "PROTEIN", 107, 110], ["HIP (add H atoms", "TREATMENT", 39, 55], ["HIP", "ANATOMY", 39, 42]]], ["The grid points spacing was 0.375 \u00c5 in the box-sizes 60, 60, and 60 \u00c5 in each dimension.", [["The grid points spacing", "TEST", 0, 23], ["spacing", "OBSERVATION_MODIFIER", 16, 23], ["sizes", "OBSERVATION_MODIFIER", 47, 52]]], ["AutoGrid 4.0 was used to calculate the grid affinity maps for following atom types: A (aromatic carbon), C, HD, N, NA (hydrogen-bond-accepting N), OA (hydrogenbond-accepting O), S, SA (hydrogen-bond-accepting S), Cl, F, Br, I, P, and e (electrostatic).Docking procedureThe protein-ligand docking performed 50 trial runs using Lamarckian genetic algorithm search.", [["NA", "CHEMICAL", 115, 117], ["OA", "CHEMICAL", 147, 149], ["Cl", "CHEMICAL", 213, 215], ["carbon", "CHEMICAL", 96, 102], ["C", "CHEMICAL", 105, 106], ["HD", "CHEMICAL", 108, 110], ["N", "CHEMICAL", 112, 113], ["hydrogen", "CHEMICAL", 119, 127], ["N", "CHEMICAL", 143, 144], ["O", "CHEMICAL", 174, 175], ["S", "CHEMICAL", 178, 179], ["hydrogen", "CHEMICAL", 185, 193], ["S", "CHEMICAL", 209, 210], ["Cl", "CHEMICAL", 213, 215], ["F", "CHEMICAL", 217, 218], ["Br", "CHEMICAL", 220, 222], ["I", "CHEMICAL", 224, 225], ["P", "CHEMICAL", 227, 228], ["A (aromatic carbon", "SIMPLE_CHEMICAL", 84, 102], ["C", "SIMPLE_CHEMICAL", 105, 106], ["NA", "SIMPLE_CHEMICAL", 115, 117], ["hydrogen-bond-accepting N)", "SIMPLE_CHEMICAL", 119, 145], ["OA", "SIMPLE_CHEMICAL", 147, 149], ["hydrogenbond-accepting O)", "SIMPLE_CHEMICAL", 151, 176], ["SA", "SIMPLE_CHEMICAL", 181, 183], ["hydrogen-bond-accepting S)", "SIMPLE_CHEMICAL", 185, 211], ["Cl, F, Br", "SIMPLE_CHEMICAL", 213, 222], ["AutoGrid", "TEST", 0, 8], ["the grid affinity maps", "TEST", 35, 57], ["A (aromatic carbon)", "TREATMENT", 84, 103], ["HD", "TREATMENT", 108, 110], ["NA", "TEST", 115, 117], ["OA", "PROBLEM", 147, 149], ["hydrogenbond", "TEST", 151, 163], ["Cl", "TEST", 213, 215], ["Docking procedure", "TREATMENT", 252, 269], ["OA", "ANATOMY", 147, 149], ["Br", "ANATOMY", 220, 222]]], ["The population size was set to 150.", [["The population size", "TEST", 0, 19], ["population", "OBSERVATION_MODIFIER", 4, 14], ["size", "OBSERVATION_MODIFIER", 15, 19]]], ["This score is calculated from the following equation:Estimated Free Energy of Binding \u00bc Final Intermolecular Energy \u00fe Final Total Internal Energy\u00feTorsional Free Energy\u2212Unbound System 0 s Energy At the same time, all of these results were rescored using FRED program [21] .", [["This score", "TEST", 0, 10]]], ["The anchor binding mode of ligands and protein were analyzed using SiMMap server (http://simmap. life.nctu.edu.tw/) [22] .Molecular dynamics simulationsThe ligand-YHV protease complexes obtained from molecular docking were subsequently applied to molecular dynamics (MD) simulations.", [["ligand-YHV protease complexes", "PROTEIN", 156, 185], ["The anchor binding mode of ligands and protein", "TREATMENT", 0, 46], ["SiMMap server", "TREATMENT", 67, 80], ["The ligand-YHV protease complexes", "TREATMENT", 152, 185], ["molecular docking", "TREATMENT", 200, 217]]], ["The AMBER99SB-ILDN force field [23] was used to simulate the protein structures and the ionization state of amino acid residues was set according to the standard protocol.", [["amino acid", "CHEMICAL", 108, 118], ["amino acid", "CHEMICAL", 108, 118], ["amino acid", "AMINO_ACID", 108, 118], ["AMBER99SB", "PROTEIN", 4, 13], ["amino acid residues", "TREATMENT", 108, 127]]], ["To mimic catalytic conditions of cysteine proteases, the side chain of His30 was protonated at both \u03b4and \u03b5-nitrogen atoms (HIP form), while the side chain of Cys152 was deprotonated (minus cysteine; CYM form).", [["cysteine", "CHEMICAL", 33, 41], ["His30", "CHEMICAL", 71, 76], ["Cys152", "CHEMICAL", 158, 164], ["cysteine", "CHEMICAL", 33, 41], ["His30", "CHEMICAL", 71, 76], ["\u03b5-nitrogen", "CHEMICAL", 105, 115], ["Cys152", "CHEMICAL", 158, 164], ["cysteine", "CHEMICAL", 189, 197], ["CYM", "CHEMICAL", 199, 202], ["cysteine", "AMINO_ACID", 33, 41], ["His30", "SIMPLE_CHEMICAL", 71, 76], ["\u03b4and \u03b5-nitrogen atoms", "SIMPLE_CHEMICAL", 100, 121], ["HIP", "SIMPLE_CHEMICAL", 123, 126], ["Cys152", "SIMPLE_CHEMICAL", 158, 164], ["cysteine", "AMINO_ACID", 189, 197], ["cysteine proteases", "PROTEIN", 33, 51], ["cysteine proteases", "TREATMENT", 33, 51], ["Cys152", "TEST", 158, 164], ["cysteine proteases", "OBSERVATION", 33, 51], ["HIP", "ANATOMY", 123, 126]]], ["The N-and C-terminal ends of amino acid chains were capped with acetyl (ACE) and methyl amino (NME) groups, respectively.", [["amino acid", "CHEMICAL", 29, 39], ["acetyl (ACE) and methyl amino", "CHEMICAL", 64, 93], ["NME", "CHEMICAL", 95, 98], ["N", "CHEMICAL", 4, 5], ["C", "CHEMICAL", 10, 11], ["amino acid", "CHEMICAL", 29, 39], ["acetyl", "CHEMICAL", 64, 70], ["ACE", "CHEMICAL", 72, 75], ["methyl amino", "CHEMICAL", 81, 93], ["NME", "CHEMICAL", 95, 98], ["amino acid chains", "AMINO_ACID", 29, 46], ["acetyl", "SIMPLE_CHEMICAL", 64, 70], ["ACE", "SIMPLE_CHEMICAL", 72, 75], ["methyl amino (NME)", "SIMPLE_CHEMICAL", 81, 99], ["N-and C-terminal ends", "PROTEIN", 4, 25], ["The N", "TEST", 0, 5], ["C-terminal ends of amino acid chains", "TREATMENT", 10, 46], ["acetyl (ACE) and methyl amino (NME) groups", "TREATMENT", 64, 106], ["amino acid", "OBSERVATION", 29, 39]]], ["The GROMACS topology files for each ligand were generated using the ACPYPE script Sousa 2012 [24] , in which the general AMBER force field (GAFF) parameters [25] were applied and atomic partial charges were calculated using the AM1-BCC method [26] , implemented in the Antechamber module.", [["atomic partial charges", "TREATMENT", 179, 201]]], ["Each complex was solvated in a rectangular box of TIP3P water [27] keeping a distance of 1.0 nm between the solutes and the sides of the solvent box.", [["TIP3P", "CHEMICAL", 50, 55], ["a rectangular box of TIP3P water", "TREATMENT", 29, 61], ["the solvent box", "TREATMENT", 133, 148], ["solvent box", "OBSERVATION", 137, 148]]], ["Sodium ions were added to neutralize the charge of the system.Molecular dynamics simulationsThe MD simulations were carried out on the explicitsolvent periodic boundary conditions using the GROMACS v4.5.5 [28] [29] [30] .", [["Sodium ions", "CHEMICAL", 0, 11], ["Sodium", "CHEMICAL", 0, 6], ["Sodium ions", "SIMPLE_CHEMICAL", 0, 11], ["Sodium ions", "TREATMENT", 0, 11]]], ["Each solvated system was energy-minimized by two steps using the steepest descent method either until the maximum force is smaller than 1000 kJ mol \u22121 nm -1 on any atom or until additional steps result in a potential energy change of less than 1 kJ mol \u22121 to reduce undesirable atomic contacts.", [["the steepest descent method", "TREATMENT", 61, 88]]], ["At first, positioned restraints with a force constant of 1000 kJ mol \u22121 nm -1 were applied to all heavy atoms of the proteins and ligands (if presented), allowing water molecules and counterions to relax their position.", [["restraints", "TREATMENT", 21, 31], ["a force constant of 1000 kJ mol \u22121 nm", "TREATMENT", 37, 74]]], ["Afterward, the energyminimized systems were equilibrated in three phases with the positioned restraints described earlier.", [["the positioned restraints", "TREATMENT", 78, 103]]], ["The first step is heating up each system from 50 to 300 K over 50 ps under the NVT condition using the Berendsen thermostat [31, 32] .", [["the Berendsen thermostat", "TREATMENT", 99, 123]]], ["The following step is conducted under the NPT condition at 1 bar pressure over 100 ps using the Parrinello-Rahman barostat [33, 34] .", [["the Parrinello-Rahman barostat", "TREATMENT", 92, 122]]], ["Once each system was sufficiently equilibrated around the target temperature and pressure, the positioned restraints were then gradually reduced to zero kJ mol \u22121 nm -1 with four rounds of 50 ps-NPT simulations.", [["pressure", "TREATMENT", 81, 89], ["the positioned restraints", "TREATMENT", 91, 116], ["50 ps", "TREATMENT", 189, 194], ["NPT simulations", "TREATMENT", 195, 210], ["pressure", "OBSERVATION_MODIFIER", 81, 89]]], ["After the equilibrations, an unrestrained dynamics production was subsequently performed under the NPT condition with snapshots collected every 1 ps.", [["an unrestrained dynamics production", "PROBLEM", 26, 61]]], ["For all dynamics runs, the LINCS algorithm [35] was applied to fix all hydrogen related bond lengths, facilitating the use of a 2 f. time step.", [["hydrogen", "CHEMICAL", 71, 79], ["hydrogen", "CHEMICAL", 71, 79], ["the LINCS algorithm", "TREATMENT", 23, 42], ["bond lengths", "OBSERVATION", 88, 100]]], ["A short-range nonbonded interaction cut-off distance of 1.0 nm was used.", [["A short-range nonbonded interaction cut", "TREATMENT", 0, 39], ["short", "OBSERVATION_MODIFIER", 2, 7]]], ["The particle mesh Ewald method was used to account for long-range electrostatics [36, 37] .Molecular dynamics simulationsAll dynamics analyses were performed using tools available within the GROMACS suite [38] .", [["The particle mesh Ewald method", "TREATMENT", 0, 30], ["All dynamics analyses", "TEST", 121, 142], ["particle mesh", "OBSERVATION", 4, 17]]], ["Hydrogen bonds observed in the ligand-YHV protease complexes and their percentage occupancy were also analyzed from MD trajectories using the tool available in the GROMACS suite.", [["Hydrogen", "CHEMICAL", 0, 8], ["Hydrogen", "CHEMICAL", 0, 8], ["Hydrogen", "SIMPLE_CHEMICAL", 0, 8], ["ligand-YHV protease complexes", "PROTEIN", 31, 60], ["Hydrogen bonds", "PROBLEM", 0, 14], ["YHV protease complexes", "TREATMENT", 38, 60], ["bonds", "OBSERVATION_MODIFIER", 9, 14], ["ligand", "ANATOMY", 31, 37]]], ["A hydrogen bond is defined by the default geometrical criteria: donor-acceptor distance \u2264 0.35 nm and protondonor-acceptor angle \u2264 30\u00b0.", [["hydrogen", "CHEMICAL", 2, 10], ["hydrogen bond", "OBSERVATION", 2, 15]]], ["The Grace v5.1.2 [39] was used to plot the 2D data and the 3D images were created and rendered with the PyMOL v1.3.1 [40] .YHV inhibition assayFluorogenic peptide YHV substrate was dissolved in dimethyl sulfoxide (DMSO) at 25 mM and diluted with YHV reaction buffer (20 mM Tris-HCl pH 7.5, 200 mM NaCl, 1 mM EDTA and 1 mM DTT) to obtain 100 \u03bcM YHV substrate.", [["dimethyl sulfoxide", "CHEMICAL", 194, 212], ["DMSO", "CHEMICAL", 214, 218], ["Tris-HCl", "CHEMICAL", 273, 281], ["NaCl", "CHEMICAL", 297, 301], ["dimethyl sulfoxide", "CHEMICAL", 194, 212], ["DMSO", "CHEMICAL", 214, 218], ["Tris-HCl", "CHEMICAL", 273, 281], ["NaCl", "CHEMICAL", 297, 301], ["EDTA", "CHEMICAL", 308, 312], ["DTT", "CHEMICAL", 322, 325], ["YHV", "SIMPLE_CHEMICAL", 123, 126], ["dimethyl sulfoxide", "SIMPLE_CHEMICAL", 194, 212], ["DMSO", "SIMPLE_CHEMICAL", 214, 218], ["EDTA", "SIMPLE_CHEMICAL", 308, 312], ["YHV", "SPECIES", 123, 126], ["The Grace v", "TEST", 0, 11], ["the 3D images", "TEST", 55, 68], ["the PyMOL v", "TEST", 100, 111], ["YHV inhibition", "TREATMENT", 123, 137], ["assayFluorogenic peptide YHV substrate", "PROBLEM", 138, 176], ["dimethyl sulfoxide (DMSO", "TREATMENT", 194, 218], ["YHV reaction buffer", "TREATMENT", 246, 265], ["Tris", "TEST", 273, 277], ["HCl pH", "TEST", 278, 284], ["NaCl", "TEST", 297, 301], ["EDTA", "TEST", 308, 312], ["1 mM DTT", "TEST", 317, 325]]], ["YHV protease inhibitors (gifted from NCI) were resuspended in dimethyl sulfoxide (DMSO) to obtain 6.7 \u03bcM and diluted with YHV reaction buffer to obtain 75 nM YHV protease inhibitors.", [["dimethyl sulfoxide", "CHEMICAL", 62, 80], ["DMSO", "CHEMICAL", 82, 86], ["dimethyl sulfoxide", "CHEMICAL", 62, 80], ["DMSO", "CHEMICAL", 82, 86], ["YHV protease", "GENE_OR_GENE_PRODUCT", 0, 12], ["dimethyl sulfoxide", "SIMPLE_CHEMICAL", 62, 80], ["DMSO", "SIMPLE_CHEMICAL", 82, 86], ["YHV", "SIMPLE_CHEMICAL", 122, 125], ["YHV", "SPECIES", 0, 3], ["YHV protease inhibitors", "TREATMENT", 0, 23], ["dimethyl sulfoxide (DMSO", "TREATMENT", 62, 86], ["YHV reaction buffer", "TREATMENT", 122, 141], ["75 nM YHV protease inhibitors", "TREATMENT", 152, 181]]], ["Purified YHV protease enzyme (gifted from Dr. Pongsak Khunrae) was dissolved in YHV reaction buffer (20 mM Tris-HCl pH 7.5, 200 mM NaCl, 1 mM EDTA and 1 mM DTT).", [["Tris-HCl", "CHEMICAL", 107, 115], ["NaCl", "CHEMICAL", 131, 135], ["Tris-HCl", "CHEMICAL", 107, 115], ["NaCl", "CHEMICAL", 131, 135], ["EDTA", "CHEMICAL", 142, 146], ["DTT", "CHEMICAL", 156, 159], ["YHV protease", "GENE_OR_GENE_PRODUCT", 9, 21], ["YHV", "SIMPLE_CHEMICAL", 80, 83], ["YHV protease enzyme", "PROTEIN", 9, 28], ["YHV", "SPECIES", 9, 12], ["Purified YHV protease enzyme", "TEST", 0, 28], ["Tris", "TEST", 107, 111], ["HCl pH", "TEST", 112, 118], ["NaCl", "TEST", 131, 135], ["EDTA", "TEST", 142, 146], ["DTT", "TEST", 156, 159]]], ["The determination of YHV inhibition assay was performed by incubating 30 \u03bcl YHV protease with equal volume of 75 nM inhibitor at room temperature for 3 min.", [["YHV", "GENE_OR_GENE_PRODUCT", 21, 24], ["YHV protease", "PROTEIN", 76, 88], ["YHV", "SPECIES", 21, 24], ["YHV", "SPECIES", 76, 79], ["YHV inhibition assay", "TEST", 21, 41]]], ["Then, fluorogenic peptide YHV substrate diluted in YHV reaction buffer was added.", [["YHV", "CHEMICAL", 26, 29], ["YHV", "SIMPLE_CHEMICAL", 51, 54], ["YHV", "SPECIES", 51, 54], ["fluorogenic peptide YHV substrate", "TREATMENT", 6, 39], ["YHV reaction buffer", "TREATMENT", 51, 70]]], ["The YHV protease in reaction mixture without inhibitor was used as negative control while the reaction mixture excluded YHV protease was used as positive control.", [["YHV protease", "GENE_OR_GENE_PRODUCT", 4, 16], ["YHV protease", "GENE_OR_GENE_PRODUCT", 120, 132], ["YHV protease", "PROTEIN", 4, 16], ["YHV protease", "PROTEIN", 120, 132], ["YHV", "SPECIES", 4, 7], ["YHV", "SPECIES", 120, 123], ["The YHV protease in reaction mixture", "TREATMENT", 0, 36], ["inhibitor", "TREATMENT", 45, 54], ["the reaction mixture", "PROBLEM", 90, 110], ["YHV protease", "TREATMENT", 120, 132]]], ["The reactions were measured by using fluorescence microplate reader with excitation/emission at 340/ 485 nm for 5 min.", [["excitation/emission", "TREATMENT", 73, 92]]], ["Rate of reaction was calculated as % activity.Structural model of YHV proteaseWe performed a comparative modeling approach using multiple templates followed by an energy minimization to construct a theoretical model for the YHV protease.", [["YHV protease", "GENE_OR_GENE_PRODUCT", 224, 236], ["YHV proteaseWe", "PROTEIN", 66, 80], ["YHV protease", "PROTEIN", 224, 236], ["YHV", "SPECIES", 66, 69], ["multiple templates", "TREATMENT", 129, 147], ["an energy minimization", "TREATMENT", 160, 182], ["the YHV protease", "TREATMENT", 220, 236]]], ["Because a multiple alignment is the key step in homology modeling, our model was cautiously done since there is only limited sequence identity to such templates.", [["multiple", "OBSERVATION_MODIFIER", 10, 18], ["alignment", "OBSERVATION_MODIFIER", 19, 28]]], ["Ab initio modeling and protein threading are now very effective and invaluable methods to use for structural prediction of non-or lowtemplate identity proteins, and their online version are currently accessible [41] [42] [43] [44] [45] [46] [47] .", [["[41] [42] [43] [44] [45] [46] [47]", "CHEMICAL", 211, 245], ["[41] [42] [43] [44] [45] [46] [47]", "SIMPLE_CHEMICAL", 211, 245], ["non-or lowtemplate identity proteins", "PROTEIN", 123, 159], ["Ab initio modeling", "TEST", 0, 18], ["protein threading", "TREATMENT", 23, 40]]], ["In our case, the search for template coordinates available from the protein data bank performed on several BLAST and threading web-servers did not provide us with the consensus template structures or a satisfied model (data not shown), and none of them exhibits acceptable percentage of identities/similarities to the YHV protease.", [["YHV protease", "GENE_OR_GENE_PRODUCT", 318, 330], ["YHV protease", "PROTEIN", 318, 330], ["the protein data bank", "TEST", 64, 85]]], ["A tertiary structure of the YHV protease should have significant conserved fold like other proteases, and thus Fig. 1 Structural comparison of YHV protease to eight template proteases.", [["YHV protease", "GENE_OR_GENE_PRODUCT", 28, 40], ["YHV protease", "GENE_OR_GENE_PRODUCT", 143, 155], ["YHV protease", "PROTEIN", 28, 40], ["proteases", "PROTEIN", 91, 100], ["YHV protease", "PROTEIN", 143, 155], ["template proteases", "PROTEIN", 165, 183], ["YHV", "SPECIES", 143, 146], ["the YHV protease", "TREATMENT", 24, 40], ["significant conserved fold like other proteases", "PROBLEM", 53, 100], ["YHV protease", "TREATMENT", 143, 155], ["eight template proteases", "TREATMENT", 159, 183], ["tertiary structure", "OBSERVATION", 2, 20], ["fold", "OBSERVATION", 75, 79]]], ["Secondary structure assignment is based on the sequence alignment as described in Methods.", [["the sequence alignment", "TEST", 43, 65]]], ["The amino acid residues responsible for \u03b2-strand and \u03b1-helical structures are shown in green and red colors, respectively.", [["amino acid", "CHEMICAL", 4, 14], ["amino acid", "CHEMICAL", 4, 14], ["amino acid", "AMINO_ACID", 4, 14], ["\u03b2-strand", "SIMPLE_CHEMICAL", 40, 48], ["The amino acid residues", "TEST", 0, 23], ["\u03b2-strand and \u03b1-helical structures", "PROBLEM", 40, 73], ["amino", "OBSERVATION", 4, 9], ["acid residues", "OBSERVATION", 10, 23]]], ["The catalytic triad residues are indicated in yellow rectangles allow the development of our own method used for the target-template sequence alignment as described in the Materials and methods section.", [["The catalytic triad residues", "PROBLEM", 0, 28], ["yellow rectangles", "PROBLEM", 46, 63], ["the target-template sequence alignment", "TREATMENT", 113, 151], ["yellow rectangles", "OBSERVATION", 46, 63]]], ["The model templates used in this study were selected according to an extremely high structural similarity in the two-domain antiparallel \u03b2-barrel fold, which is the hallmark of trypsin-like proteases even though these structures exhibit a limited sequence identity to the YHV protease, ranging from 14 to 20 % of the aligned regions ( Fig. 1 and Table 1 ).", [["trypsin", "GENE_OR_GENE_PRODUCT", 177, 184], ["YHV protease", "GENE_OR_GENE_PRODUCT", 272, 284], ["trypsin", "PROTEIN", 177, 184], ["proteases", "PROTEIN", 190, 199], ["YHV protease", "PROTEIN", 272, 284], ["The model templates", "TREATMENT", 0, 19], ["this study", "TEST", 28, 38], ["an extremely high structural similarity", "PROBLEM", 66, 105], ["trypsin-like proteases", "PROBLEM", 177, 199], ["the YHV protease", "TEST", 268, 284], ["antiparallel", "ANATOMY_MODIFIER", 124, 136], ["\u03b2-barrel fold", "ANATOMY", 137, 150]]], ["The selected templates were three cysteine proteases from tobacco etch virus (PDB entry 1LVM) [48] , rhinovirus (PDB entry 1CQQ) [49] , hepatitis A virus (PDB entry 1HAV) [50] , and the other five proteases of non-viral proteins, bovine \u03b2-trypsin (PDB entry 5PTP) [51] , protease domain of human factor B (PDB entry 1DLE) [52] , epidermolytic toxin B from Staphylococcus aureus (PDB entry 1AGJ), lysine-specific protease I from Achromobacter lyticus (PDB entry 1ARB) [53] , and trypsin-like folded human heparin binding protein (PDB entry 1A7S) [54] .Structural model of YHV proteaseAfter energy minimization of the homology model, results of Ramachandran plots from PROCHECK showed that more than 95 % of the residues were in the most favored and additional allowed regions, indicating a good quality model could be obtained (Supplementary data Fig. S1 ).", [["hepatitis A", "DISEASE", 136, 147], ["lysine", "CHEMICAL", 396, 402], ["heparin", "CHEMICAL", 504, 511], ["cysteine", "CHEMICAL", 34, 42], ["lysine", "CHEMICAL", 396, 402], ["tobacco etch virus", "ORGANISM", 58, 76], ["PDB entry 1LVM", "GENE_OR_GENE_PRODUCT", 78, 92], ["rhinovirus", "ORGANISM", 101, 111], ["PDB entry 1CQQ", "GENE_OR_GENE_PRODUCT", 113, 127], ["hepatitis A virus", "ORGANISM", 136, 153], ["PDB entry 1HAV", "GENE_OR_GENE_PRODUCT", 155, 169], ["bovine", "ORGANISM", 230, 236], ["\u03b2-trypsin", "GENE_OR_GENE_PRODUCT", 237, 246], ["PDB entry 5PTP", "GENE_OR_GENE_PRODUCT", 248, 262], ["human", "ORGANISM", 290, 295], ["factor B", "GENE_OR_GENE_PRODUCT", 296, 304], ["PDB entry 1DLE", "GENE_OR_GENE_PRODUCT", 306, 320], ["epidermolytic toxin B", "GENE_OR_GENE_PRODUCT", 329, 350], ["Staphylococcus aureus", "ORGANISM", 356, 377], ["PDB entry 1AGJ", "GENE_OR_GENE_PRODUCT", 379, 393], ["lysine-specific protease I", "GENE_OR_GENE_PRODUCT", 396, 422], ["Achromobacter lyticus", "ORGANISM", 428, 449], ["PDB entry 1ARB", "GENE_OR_GENE_PRODUCT", 451, 465], ["trypsin", "GENE_OR_GENE_PRODUCT", 478, 485], ["human", "ORGANISM", 498, 503], ["heparin binding protein", "GENE_OR_GENE_PRODUCT", 504, 527], ["S1", "GENE_OR_GENE_PRODUCT", 851, 853], ["cysteine proteases", "PROTEIN", 34, 52], ["proteases", "PROTEIN", 197, 206], ["non-viral proteins", "PROTEIN", 210, 228], ["bovine \u03b2-trypsin", "PROTEIN", 230, 246], ["PDB entry 5PTP", "PROTEIN", 248, 262], ["51", "PROTEIN", 265, 267], ["protease domain", "PROTEIN", 271, 286], ["human factor B", "PROTEIN", 290, 304], ["PDB entry 1DLE) [52", "PROTEIN", 306, 325], ["epidermolytic toxin B", "PROTEIN", 329, 350], ["PDB entry 1AGJ", "PROTEIN", 379, 393], ["lysine-specific protease I", "PROTEIN", 396, 422], ["Achromobacter lyticus (PDB entry 1ARB", "PROTEIN", 428, 465], ["trypsin", "PROTEIN", 478, 485], ["human heparin binding protein", "PROTEIN", 498, 527], ["PDB entry 1A7S", "PROTEIN", 529, 543], ["S1", "PROTEIN", 851, 853], ["tobacco", "SPECIES", 58, 65], ["hepatitis A virus", "SPECIES", 136, 153], ["bovine", "SPECIES", 230, 236], ["human", "SPECIES", 290, 295], ["Staphylococcus aureus", "SPECIES", 356, 377], ["Achromobacter lyticus", "SPECIES", 428, 449], ["human", "SPECIES", 498, 503], ["tobacco etch virus", "SPECIES", 58, 76], ["hepatitis A virus", "SPECIES", 136, 153], ["human", "SPECIES", 290, 295], ["Staphylococcus aureus", "SPECIES", 356, 377], ["Achromobacter lyticus", "SPECIES", 428, 449], ["human", "SPECIES", 498, 503], ["YHV", "SPECIES", 571, 574], ["The selected templates", "TREATMENT", 0, 22], ["three cysteine proteases", "TREATMENT", 28, 52], ["rhinovirus (PDB entry", "TEST", 101, 122], ["hepatitis A virus", "PROBLEM", 136, 153], ["non-viral proteins", "TREATMENT", 210, 228], ["bovine \u03b2-trypsin (PDB entry", "TREATMENT", 230, 257], ["human factor B", "TEST", 290, 304], ["epidermolytic toxin B", "PROBLEM", 329, 350], ["Staphylococcus aureus", "PROBLEM", 356, 377], ["lysine", "TREATMENT", 396, 402], ["trypsin", "TEST", 478, 485], ["folded human heparin binding protein", "TREATMENT", 491, 527], ["Ramachandran plots from PROCHECK", "TEST", 643, 675], ["the residues", "PROBLEM", 706, 718]]], ["This final model adopted the two-domain antiparallel \u03b2barrel fold-like structure resembling the templates (Fig. 2a and b) with less than 3 \u00c5 of the C \u03b1 -atom root mean square deviation (RMSD) between the model and such templates ( Table 1) .", [["C", "CHEMICAL", 148, 149], ["C \u03b1", "PROTEIN", 148, 151], ["the two-domain antiparallel \u03b2barrel fold", "TREATMENT", 25, 65], ["\u03b2barrel fold", "OBSERVATION", 53, 65]]], ["Although the overall fold of the YHV protease seemed closer to those of the non-viral serine proteases than the three viral cysteine proteases, the atomic coordinates of the catalytic triad residues, His30, Asp(Glu)70, and Cys152 (numbering of YHV protease) were highly conserved among the four viral C-type cysteine proteases; yellow head, tobacco etch, rhino-and hepatitis A viruses (Fig. 2c) .", [["head", "ANATOMY", 335, 339], ["Glu", "CHEMICAL", 211, 214], ["rhino-and hepatitis A viruses", "DISEASE", 355, 384], ["serine", "CHEMICAL", 86, 92], ["cysteine", "CHEMICAL", 124, 132], ["His30", "CHEMICAL", 200, 205], ["Asp", "CHEMICAL", 207, 210], ["Glu", "CHEMICAL", 211, 214], ["Cys152", "CHEMICAL", 223, 229], ["cysteine", "CHEMICAL", 308, 316], ["YHV protease", "GENE_OR_GENE_PRODUCT", 33, 45], ["His30", "GENE_OR_GENE_PRODUCT", 200, 205], ["Asp(Glu)70", "GENE_OR_GENE_PRODUCT", 207, 217], ["Cys152", "AMINO_ACID", 223, 229], ["YHV protease", "GENE_OR_GENE_PRODUCT", 244, 256], ["head", "ORGANISM_SUBDIVISION", 335, 339], ["tobacco", "ORGANISM", 341, 348], ["rhino", "ORGANISM", 355, 360], ["hepatitis A viruses", "ORGANISM", 365, 384], ["YHV protease", "PROTEIN", 33, 45], ["non-viral serine proteases", "PROTEIN", 76, 102], ["viral cysteine proteases", "PROTEIN", 118, 142], ["catalytic triad residues", "PROTEIN", 174, 198], ["Cys152", "PROTEIN", 223, 229], ["YHV protease", "PROTEIN", 244, 256], ["viral C-type cysteine proteases", "PROTEIN", 295, 326], ["tobacco", "SPECIES", 341, 348], ["YHV", "SPECIES", 33, 36], ["tobacco", "SPECIES", 341, 348], ["hepatitis A viruses", "SPECIES", 365, 384], ["the YHV protease", "TREATMENT", 29, 45], ["the non-viral serine proteases", "TREATMENT", 72, 102], ["the three viral cysteine proteases", "TREATMENT", 108, 142], ["the catalytic triad residues", "PROBLEM", 170, 198], ["His30", "TEST", 200, 205], ["Asp(Glu)", "TEST", 207, 215], ["Cys152", "TEST", 223, 229], ["YHV protease", "TREATMENT", 244, 256], ["the four viral C-type cysteine proteases", "PROBLEM", 286, 326], ["yellow head, tobacco etch", "PROBLEM", 328, 353], ["rhino", "PROBLEM", 355, 360], ["hepatitis A viruses", "PROBLEM", 365, 384], ["head", "ANATOMY", 335, 339], ["tobacco etch", "OBSERVATION", 341, 353]]], ["These also indicated a high accuracy of the modeled YHV protease and it was reasonable to use this model for subsequent docking experiments.Structural model of YHV proteaseStructural analysis of 3c-proteases in several species revealed that there were three conserved residues, His, Asp or Glu, and Cys, known as the catalytic triad.", [["Glu", "CHEMICAL", 290, 293], ["His", "CHEMICAL", 278, 281], ["Asp", "CHEMICAL", 283, 286], ["Glu", "CHEMICAL", 290, 293], ["Cys", "CHEMICAL", 299, 302], ["YHV protease", "GENE_OR_GENE_PRODUCT", 52, 64], ["Asp", "AMINO_ACID", 283, 286], ["Glu", "AMINO_ACID", 290, 293], ["Cys", "AMINO_ACID", 299, 302], ["YHV protease", "PROTEIN", 52, 64], ["3c-proteases", "PROTEIN", 195, 207], ["catalytic triad", "PROTEIN", 317, 332], ["YHV", "SPECIES", 52, 55], ["YHV", "SPECIES", 160, 163], ["the modeled YHV protease", "TREATMENT", 40, 64], ["this model", "TREATMENT", 94, 104], ["YHV proteaseStructural analysis", "TEST", 160, 191], ["proteases", "PROBLEM", 198, 207], ["Asp", "TEST", 283, 286], ["Glu", "TEST", 290, 293], ["Cys", "TEST", 299, 302], ["the catalytic triad", "PROBLEM", 313, 332], ["high", "OBSERVATION_MODIFIER", 23, 27]]], ["They located on the center between two lobes of anti-parallel b-strands.", [["anti-parallel b-strands", "DNA", 48, 71], ["lobes", "ANATOMY_MODIFIER", 39, 44], ["anti-parallel b-strands", "OBSERVATION", 48, 71]]], ["According to the nomenclature of Schechter and Berger [55] , these catalytic residues positioned around the S 2 to S' 2 sub-sites of protease enzyme to serve P 2 to P' 2 positions of peptide substrate.", [["S 2 to S' 2 sub-sites", "DNA", 108, 129], ["protease enzyme", "PROTEIN", 133, 148], ["P 2", "DNA", 158, 161], ["P' 2 positions", "DNA", 165, 179], ["these catalytic residues", "PROBLEM", 61, 85], ["protease enzyme", "TREATMENT", 133, 148]]], ["Furthermore, most of the 3c-proteases preferred glutamine as the P1 site for substrate, and in some cases the minor preference seems to be glutamic acid [4] .", [["glutamine", "CHEMICAL", 48, 57], ["glutamic acid", "CHEMICAL", 139, 152], ["glutamine", "CHEMICAL", 48, 57], ["glutamic acid", "CHEMICAL", 139, 152], ["glutamine", "AMINO_ACID", 48, 57], ["glutamic acid", "SIMPLE_CHEMICAL", 139, 152], ["3c-proteases", "PROTEIN", 25, 37], ["P1 site", "DNA", 65, 72], ["the 3c-proteases", "TREATMENT", 21, 37], ["glutamine", "TREATMENT", 48, 57], ["glutamic acid", "TEST", 139, 152]]], ["Generally, residues of S 1 pocket are Thr147 and His167 (YHV protease numbering).", [["Thr", "CHEMICAL", 38, 41], ["His", "CHEMICAL", 49, 52], ["S 1", "GENE_OR_GENE_PRODUCT", 23, 26], ["Thr147", "AMINO_ACID", 38, 44], ["His167", "AMINO_ACID", 49, 55], ["YHV protease", "GENE_OR_GENE_PRODUCT", 57, 69], ["Thr", "TEST", 38, 41]]], ["In addition, the surrounding residues around the S 1 subsite were also conserved among 3c-protease.", [["3c-protease", "GENE_OR_GENE_PRODUCT", 87, 98], ["S 1 subsite", "PROTEIN", 49, 60], ["protease", "PROTEIN", 90, 98], ["the surrounding residues", "PROBLEM", 13, 37], ["the S 1 subsite", "TREATMENT", 45, 60], ["3c-protease", "TREATMENT", 87, 98]]], ["This neighbor pocket is named \"pocket A\" which is composed of Lys148, Asp149, Gly170, Ala172, and Ser173.Molecular docking with NCI databaseIn order to identify the small molecules that specifically bind to YHV protease, a docking study analysis was performed against small molecules from NCI diversity dataset.", [["Lys148", "CHEMICAL", 62, 68], ["Asp", "CHEMICAL", 70, 73], ["Gly", "CHEMICAL", 78, 81], ["Ala", "CHEMICAL", 86, 89], ["Ser173", "CHEMICAL", 98, 104], ["Lys148", "GENE_OR_GENE_PRODUCT", 62, 68], ["Asp149", "AMINO_ACID", 70, 76], ["Gly170", "AMINO_ACID", 78, 84], ["Ala172", "AMINO_ACID", 86, 92], ["Ser173", "AMINO_ACID", 98, 104], ["YHV protease", "GENE_OR_GENE_PRODUCT", 207, 219], ["YHV protease", "PROTEIN", 207, 219], ["Asp", "TEST", 70, 73], ["Gly", "TEST", 78, 81], ["Ala", "TEST", 86, 89], ["the small molecules", "PROBLEM", 161, 180], ["a docking study analysis", "TEST", 221, 245], ["small molecules", "PROBLEM", 268, 283]]], ["All 1364 compounds from NCI diversity II were docked into the modeled structure of YHV-protease, 43 compounds were selected from this screening step based on docking scores.", [["YHV-protease", "GENE_OR_GENE_PRODUCT", 83, 95], ["YHV", "PROTEIN", 83, 86], ["protease", "PROTEIN", 87, 95], ["protease", "TREATMENT", 87, 95], ["this screening step", "TEST", 129, 148], ["docking scores", "TEST", 158, 172]]], ["Therefore, the FRED program combinations with SiMMap server (http://simmap.life.nctu.edu.tw/) were used to justify the reliable possibility of the binding mode.", [["SiMMap server", "DNA", 46, 59], ["SiMMap server (http://simmap.life.nctu.edu.tw/)", "TREATMENT", 46, 93]]], ["The SiMMap server was used to identify the site-moiety map between the functional group(s) of these ligands to the residues around the binding site (Fig. 3) .", [["SiMMap server", "DNA", 4, 17], ["binding site", "PROTEIN", 135, 147], ["these ligands", "TREATMENT", 94, 107], ["binding site", "OBSERVATION", 135, 147]]], ["As shown in the SiMMap moieties, there were four spheres which represent two types of interactions.", [["SiMMap moieties", "PROTEIN", 16, 31], ["two types", "OBSERVATION_MODIFIER", 73, 82]]], ["H moiety refered to the hydrogen bonding, while V moiety refered to van der Waals force.", [["H", "CHEMICAL", 0, 1], ["H", "CHEMICAL", 0, 1], ["hydrogen", "CHEMICAL", 24, 32], ["H moiety", "SIMPLE_CHEMICAL", 0, 8], ["V moiety", "SIMPLE_CHEMICAL", 48, 56]]], ["Anchor H1 illustrated the binding residues; Asp149 and Cys152 prefer to form hydrogen bonding interactions with the following functional groups; hydroxyl, 1\u00b0amine, azo (also named diimide or diazene compound), hydrazine and carboxamide moieties.", [["Asp", "CHEMICAL", 44, 47], ["Cys152", "CHEMICAL", 55, 61], ["hydroxyl", "CHEMICAL", 145, 153], ["1\u00b0amine", "CHEMICAL", 155, 162], ["azo", "CHEMICAL", 164, 167], ["diazene", "CHEMICAL", 191, 198], ["hydrazine", "CHEMICAL", 210, 219], ["carboxamide", "CHEMICAL", 224, 235], ["Asp", "CHEMICAL", 44, 47], ["Cys152", "CHEMICAL", 55, 61], ["hydrogen", "CHEMICAL", 77, 85], ["hydroxyl", "CHEMICAL", 145, 153], ["1\u00b0amine", "CHEMICAL", 155, 162], ["azo", "CHEMICAL", 164, 167], ["diimide", "CHEMICAL", 180, 187], ["diazene", "CHEMICAL", 191, 198], ["hydrazine", "CHEMICAL", 210, 219], ["carboxamide", "CHEMICAL", 224, 235], ["Anchor H1", "GENE_OR_GENE_PRODUCT", 0, 9], ["Asp149", "AMINO_ACID", 44, 50], ["Cys152", "AMINO_ACID", 55, 61], ["hydroxyl", "SIMPLE_CHEMICAL", 145, 153], ["1\u00b0amine", "SIMPLE_CHEMICAL", 155, 162], ["azo (also named diimide or diazene compound", "SIMPLE_CHEMICAL", 164, 207], ["hydrazine", "SIMPLE_CHEMICAL", 210, 219], ["carboxamide moieties", "SIMPLE_CHEMICAL", 224, 244], ["H1", "PROTEIN", 7, 9], ["Anchor H1", "TREATMENT", 0, 9], ["the binding residues", "PROBLEM", 22, 42], ["Asp", "TEST", 44, 47], ["hydrogen bonding interactions", "TREATMENT", 77, 106], ["hydroxyl", "TREATMENT", 145, 153], ["1\u00b0amine", "TREATMENT", 155, 162], ["azo", "TREATMENT", 164, 167], ["diimide", "TREATMENT", 180, 187], ["diazene compound", "TREATMENT", 191, 207], ["hydrazine and carboxamide moieties", "TREATMENT", 210, 244], ["binding residues", "OBSERVATION", 26, 42]]], ["Similar to anchor H1, H2 specified the consistent functional groups with the position Gly170 which are ether, carbonyl, amide, alcohol, and sulfonyl groups, respectively.", [["H2", "CHEMICAL", 22, 24], ["Gly170", "CHEMICAL", 86, 92], ["ether, carbonyl, amide, alcohol", "CHEMICAL", 103, 134], ["sulfonyl", "CHEMICAL", 140, 148], ["H2", "CHEMICAL", 22, 24], ["Gly", "CHEMICAL", 86, 89], ["ether", "CHEMICAL", 103, 108], ["carbonyl", "CHEMICAL", 110, 118], ["amide", "CHEMICAL", 120, 125], ["alcohol", "CHEMICAL", 127, 134], ["sulfonyl", "CHEMICAL", 140, 148], ["Gly170", "AMINO_ACID", 86, 92], ["ether", "SIMPLE_CHEMICAL", 103, 108], ["carbonyl", "SIMPLE_CHEMICAL", 110, 118], ["amide", "SIMPLE_CHEMICAL", 120, 125], ["alcohol", "SIMPLE_CHEMICAL", 127, 134], ["sulfonyl groups", "SIMPLE_CHEMICAL", 140, 155], ["anchor H1", "PROBLEM", 11, 20], ["H2", "TREATMENT", 22, 24], ["carbonyl, amide", "TREATMENT", 110, 125], ["functional groups", "OBSERVATION", 50, 67]]], ["For anchor H3, Ser173 plays the role that interacts with ether, nitro, sulphonyl, carboxy, and carboxamide groups.", [["Ser173", "CHEMICAL", 15, 21], ["ether, nitro, sulphonyl, carboxy, and carboxamide", "CHEMICAL", 57, 106], ["ether", "CHEMICAL", 57, 62], ["nitro", "CHEMICAL", 64, 69], ["sulphonyl", "CHEMICAL", 71, 80], ["carboxy", "CHEMICAL", 82, 89], ["carboxamide", "CHEMICAL", 95, 106], ["anchor H3", "GENE_OR_GENE_PRODUCT", 4, 13], ["Ser173", "GENE_OR_GENE_PRODUCT", 15, 21], ["ether", "SIMPLE_CHEMICAL", 57, 62], ["nitro", "SIMPLE_CHEMICAL", 64, 69], ["sulphonyl, carboxy,", "SIMPLE_CHEMICAL", 71, 90], ["carboxamide", "SIMPLE_CHEMICAL", 95, 106], ["H3", "PROTEIN", 11, 13], ["nitro", "TREATMENT", 64, 69], ["sulphonyl", "TREATMENT", 71, 80], ["carboxy", "TREATMENT", 82, 89], ["carboxamide groups", "TREATMENT", 95, 113]]], ["In additional, the van der Waals interactions between three residues around binding pocket; Lys148, Gly170, and Ala172, and the hydrophobic moieties; phenol, benzene, alkene etc. were represented by V1 anchor.", [["phenol", "CHEMICAL", 150, 156], ["benzene", "CHEMICAL", 158, 165], ["Lys148", "CHEMICAL", 92, 98], ["Gly", "CHEMICAL", 100, 103], ["Ala172", "CHEMICAL", 112, 118], ["phenol", "CHEMICAL", 150, 156], ["benzene", "CHEMICAL", 158, 165], ["alkene", "CHEMICAL", 167, 173], ["Lys148", "AMINO_ACID", 92, 98], ["Gly170", "AMINO_ACID", 100, 106], ["Ala172", "AMINO_ACID", 112, 118], ["phenol", "SIMPLE_CHEMICAL", 150, 156], ["benzene", "SIMPLE_CHEMICAL", 158, 165], ["alkene", "SIMPLE_CHEMICAL", 167, 173], ["the van der Waals interactions", "TREATMENT", 15, 45], ["binding pocket", "TEST", 76, 90], ["Gly", "TEST", 100, 103], ["Ala172", "TEST", 112, 118]]], ["These analyses assisted us to understand the mode of binding of ligands and to classify ligand-group which followed the interaction modes.Molecular docking with NCI databaseThe 43 screened small molecules can be categorized into three groups.", [["The 43 screened small molecules", "TREATMENT", 173, 204]]], ["Considering at group one, there are 32 compounds which are able to form hydrogen bonds with residues in the catalytic cleft and/or pocket A (Fig. 4) .", [["hydrogen", "CHEMICAL", 72, 80], ["residues in the catalytic cleft", "PROBLEM", 92, 123], ["32 compounds", "OBSERVATION_MODIFIER", 36, 48], ["catalytic cleft", "OBSERVATION", 108, 123]]], ["Moreover, these compounds are also representing cation-\u03c0 and \u03c0-\u03c0 interactions with those mentioned residues.Molecular docking with NCI databaseCompounds in this group share common aromatic nucleus and also carboxamide group, the peptide-bond-like structure ( ) where its structure mimics peptide bond.", [["carboxamide", "CHEMICAL", 206, 217], ["carboxamide", "CHEMICAL", 206, 217], ["cation-\u03c0", "SIMPLE_CHEMICAL", 48, 56], ["\u03c0-\u03c0", "SIMPLE_CHEMICAL", 61, 64], ["carboxamide", "SIMPLE_CHEMICAL", 206, 217], ["carboxamide group", "TREATMENT", 206, 223], ["the peptide", "TEST", 225, 236], ["aromatic nucleus", "ANATOMY", 180, 196]]], ["Group two is composed of only two compounds which present only cation-\u03c0 interactions.", [["cation-\u03c0", "SIMPLE_CHEMICAL", 63, 71]]], ["Compounds in group three consist of various types of core structures.", [["core", "ANATOMY_MODIFIER", 53, 57]]], ["These seven compounds interact with residues around the catalytic cleft with weak van der Waals interactions.Molecular docking with NCI databaseAfter all viral protease inhibitors with crystal structures were deeply analyzed, the general features of the protease inhibitors always consist of the carboximide group and aromatic moieties and at present are: Leupeptins, Saquinavir, Nelfinavir, Ritonavir, Indianavir, Amprenavir, Lopinavir, Fig. 5 The comparison between a the known protease inhibitor, Nelfinavir and b NSC319990 oriented on the binding site of YHV protease, both 2D and 3D views, as well as c the superimpose structures and the three common interactions Chymostatins, Antipain, Elastinal, and \u03b2-MAPI.", [["carboximide", "CHEMICAL", 296, 307], ["Leupeptins", "CHEMICAL", 356, 366], ["Saquinavir", "CHEMICAL", 368, 378], ["Nelfinavir", "CHEMICAL", 380, 390], ["Ritonavir", "CHEMICAL", 392, 401], ["Indianavir", "CHEMICAL", 403, 413], ["Amprenavir", "CHEMICAL", 415, 425], ["Lopinavir", "CHEMICAL", 427, 436], ["Nelfinavir", "CHEMICAL", 500, 510], ["NSC319990", "CHEMICAL", 517, 526], ["carboximide", "CHEMICAL", 296, 307], ["Leupeptins", "CHEMICAL", 356, 366], ["Saquinavir", "CHEMICAL", 368, 378], ["Nelfinavir", "CHEMICAL", 380, 390], ["Ritonavir", "CHEMICAL", 392, 401], ["Indianavir", "CHEMICAL", 403, 413], ["Amprenavir", "CHEMICAL", 415, 425], ["Lopinavir", "CHEMICAL", 427, 436], ["Nelfinavir", "CHEMICAL", 500, 510], ["NSC319990", "CHEMICAL", 517, 526], ["Chymostatins", "CHEMICAL", 669, 681], ["carboximide", "SIMPLE_CHEMICAL", 296, 307], ["aromatic moieties", "SIMPLE_CHEMICAL", 318, 335], ["Leupeptins", "SIMPLE_CHEMICAL", 356, 366], ["Saquinavir", "SIMPLE_CHEMICAL", 368, 378], ["Nelfinavir", "SIMPLE_CHEMICAL", 380, 390], ["Ritonavir", "SIMPLE_CHEMICAL", 392, 401], ["Indianavir", "SIMPLE_CHEMICAL", 403, 413], ["Amprenavir", "SIMPLE_CHEMICAL", 415, 425], ["Lopinavir", "SIMPLE_CHEMICAL", 427, 436], ["Nelfinavir", "SIMPLE_CHEMICAL", 500, 510], ["b NSC319990", "SIMPLE_CHEMICAL", 515, 526], ["YHV protease", "GENE_OR_GENE_PRODUCT", 559, 571], ["Chymostatins", "SIMPLE_CHEMICAL", 669, 681], ["Antipain", "SIMPLE_CHEMICAL", 683, 691], ["Elastinal", "SIMPLE_CHEMICAL", 693, 702], ["\u03b2-MAPI", "SIMPLE_CHEMICAL", 708, 714], ["YHV protease", "PROTEIN", 559, 571], ["Antipain", "PROTEIN", 683, 691], ["Elastinal", "PROTEIN", 693, 702], ["MAPI", "PROTEIN", 710, 714], ["the catalytic cleft", "PROBLEM", 52, 71], ["all viral protease inhibitors", "TREATMENT", 150, 179], ["crystal structures", "TREATMENT", 185, 203], ["the protease inhibitors", "TREATMENT", 250, 273], ["the carboximide group and aromatic moieties", "TREATMENT", 292, 335], ["Leupeptins", "TREATMENT", 356, 366], ["Saquinavir", "TREATMENT", 368, 378], ["Nelfinavir", "TREATMENT", 380, 390], ["Ritonavir", "TREATMENT", 392, 401], ["Indianavir", "TREATMENT", 403, 413], ["Amprenavir", "TREATMENT", 415, 425], ["Lopinavir", "TREATMENT", 427, 436], ["a the known protease inhibitor", "TREATMENT", 468, 498], ["Nelfinavir", "TREATMENT", 500, 510], ["YHV protease", "TREATMENT", 559, 571], ["both 2D and 3D views", "TEST", 573, 593], ["Chymostatins", "TREATMENT", 669, 681], ["Antipain", "TREATMENT", 683, 691], ["Elastinal", "TREATMENT", 693, 702], ["\u03b2-MAPI", "TREATMENT", 708, 714], ["aromatic moieties", "OBSERVATION", 318, 335]]], ["These features were also found in our 11 candidate compounds from 32 compounds in group one which contains aromatic moiety, carboximide, hydroxy, carbonyl, ether, and ester groups.", [["carboximide", "CHEMICAL", 124, 135], ["hydroxy, carbonyl, ether, and ester", "CHEMICAL", 137, 172], ["carboximide", "CHEMICAL", 124, 135], ["hydroxy", "CHEMICAL", 137, 144], ["carbonyl", "CHEMICAL", 146, 154], ["ether", "CHEMICAL", 156, 161], ["ester", "CHEMICAL", 167, 172], ["aromatic moiety", "SIMPLE_CHEMICAL", 107, 122], ["carboximide", "SIMPLE_CHEMICAL", 124, 135], ["hydroxy, carbonyl, ether", "SIMPLE_CHEMICAL", 137, 161], ["ester", "SIMPLE_CHEMICAL", 167, 172], ["carboximide", "TREATMENT", 124, 135], ["hydroxy", "TREATMENT", 137, 144], ["carbonyl", "TREATMENT", 146, 154], ["ester groups", "TREATMENT", 167, 179], ["aromatic moiety", "OBSERVATION", 107, 122]]], ["All 11 two-dimensional structures as well as properties were presented in Table 2 .", [["11 two", "OBSERVATION_MODIFIER", 4, 10]]], ["In order to better understand the mode of actions of these small molecules via strong hydrogen bonds, the orientations of Nelfinavir, a representative of known protease inhibitors, and compound NSC319990 (the best docking score with carboximide functional group, Rank3) have been compared.", [["Nelfinavir", "CHEMICAL", 122, 132], ["NSC319990", "CHEMICAL", 194, 203], ["hydrogen", "CHEMICAL", 86, 94], ["Nelfinavir", "CHEMICAL", 122, 132], ["NSC319990", "CHEMICAL", 194, 203], ["carboximide", "CHEMICAL", 233, 244], ["Nelfinavir", "SIMPLE_CHEMICAL", 122, 132], ["NSC319990", "SIMPLE_CHEMICAL", 194, 203], ["carboximide", "SIMPLE_CHEMICAL", 233, 244], ["Rank3", "SIMPLE_CHEMICAL", 263, 268], ["Rank3", "PROTEIN", 263, 268], ["strong hydrogen bonds", "TREATMENT", 79, 100], ["Nelfinavir", "TREATMENT", 122, 132], ["known protease inhibitors", "TREATMENT", 154, 179]]], ["The post-docking analyses revealed that one-half of NSC319990 is oriented at the same area as Nelfinavir.", [["NSC319990", "CHEMICAL", 52, 61], ["Nelfinavir", "CHEMICAL", 94, 104], ["NSC319990", "CHEMICAL", 52, 61], ["Nelfinavir", "CHEMICAL", 94, 104], ["NSC319990", "SIMPLE_CHEMICAL", 52, 61], ["Nelfinavir", "SIMPLE_CHEMICAL", 94, 104], ["The post-docking analyses", "TEST", 0, 25], ["Nelfinavir", "TREATMENT", 94, 104]]], ["These two molecules lay along the sub-sites S 2 (H30, S67-D70, I168 and V169) to S 1 (T147, K148, D149 and H167) of YHV protease.", [["H167", "CHEMICAL", 107, 111], ["S 1", "GENE_OR_GENE_PRODUCT", 81, 84], ["YHV protease", "GENE_OR_GENE_PRODUCT", 116, 128], ["S 1", "DNA", 81, 84], ["YHV protease", "PROTEIN", 116, 128], ["H30", "TEST", 49, 52], ["S67", "TEST", 54, 57], ["S", "TEST", 81, 82], ["K148", "TEST", 92, 96], ["D149", "TEST", 98, 102], ["YHV protease", "TREATMENT", 116, 128], ["two", "OBSERVATION_MODIFIER", 6, 9], ["molecules", "OBSERVATION_MODIFIER", 10, 19], ["lay", "OBSERVATION_MODIFIER", 20, 23], ["sub", "OBSERVATION_MODIFIER", 34, 37]]], ["There are three common types of binding between these two compounds as presented in Fig. 5 .", [["three", "OBSERVATION_MODIFIER", 10, 15], ["common types", "OBSERVATION_MODIFIER", 16, 28]]], ["First, \u03c0-\u03c0 interaction between 6-membered aromatic ring and residue His30 (one of the catalytic triad) have been observed from both compounds.", [["His30", "CHEMICAL", 68, 73], ["His30", "CHEMICAL", 68, 73], ["6-membered aromatic ring", "SIMPLE_CHEMICAL", 31, 55], ["His30", "AMINO_ACID", 68, 73], ["catalytic triad", "PROTEIN", 86, 101], ["6-membered aromatic ring and residue His30", "TREATMENT", 31, 73], ["the catalytic triad", "TREATMENT", 82, 101], ["aromatic ring", "OBSERVATION", 42, 55]]], ["Second, the dipole-dipole electrostatic interaction between ligands and binding residues in pocket A, Asp149, and Cys152 were formed.", [["Asp", "CHEMICAL", 102, 105], ["Cys", "CHEMICAL", 114, 117], ["pocket A", "SIMPLE_CHEMICAL", 92, 100], ["Asp149", "AMINO_ACID", 102, 108], ["Cys152", "AMINO_ACID", 114, 120], ["the dipole-dipole electrostatic interaction between ligands and binding residues in pocket", "PROBLEM", 8, 98], ["Asp", "TEST", 102, 105], ["Cys", "TEST", 114, 117], ["pocket", "OBSERVATION_MODIFIER", 92, 98]]], ["N-atom of decahydroisoquinoline of Nelfinavir, and S-atom of benzo(d)thiazole of NSC319990 held the negative dipole and acted as nucleophile to form interaction with either thiol group of Cys152 or carboxylic group of Asp149.", [["N-atom", "CHEMICAL", 0, 6], ["decahydroisoquinoline", "CHEMICAL", 10, 31], ["Nelfinavir", "CHEMICAL", 35, 45], ["S-atom", "CHEMICAL", 51, 57], ["benzo(d)thiazole", "CHEMICAL", 61, 77], ["NSC319990", "CHEMICAL", 81, 90], ["thiol", "CHEMICAL", 173, 178], ["Cys152", "CHEMICAL", 188, 194], ["Asp149", "CHEMICAL", 218, 224], ["N", "CHEMICAL", 0, 1], ["decahydroisoquinoline", "CHEMICAL", 10, 31], ["Nelfinavir", "CHEMICAL", 35, 45], ["S", "CHEMICAL", 51, 52], ["benzo(d)thiazole", "CHEMICAL", 61, 77], ["NSC319990", "CHEMICAL", 81, 90], ["thiol", "CHEMICAL", 173, 178], ["Cys152", "CHEMICAL", 188, 194], ["carboxylic", "CHEMICAL", 198, 208], ["Asp", "CHEMICAL", 218, 221], ["decahydroisoquinoline", "SIMPLE_CHEMICAL", 10, 31], ["Nelfinavir", "SIMPLE_CHEMICAL", 35, 45], ["S-atom", "SIMPLE_CHEMICAL", 51, 57], ["benzo(d)thiazole", "SIMPLE_CHEMICAL", 61, 77], ["NSC319990", "SIMPLE_CHEMICAL", 81, 90], ["Cys152", "SIMPLE_CHEMICAL", 188, 194], ["Asp149", "AMINO_ACID", 218, 224], ["decahydroisoquinoline", "TREATMENT", 10, 31], ["Nelfinavir", "TREATMENT", 35, 45], ["benzo(d)thiazole", "TREATMENT", 61, 77], ["Asp", "TEST", 218, 221]]], ["Third, the van der Waals interactions between the residues Gly170 and Ala172, which were defined as V1 anchor, and the fused rings of both compounds have been monitored.", [["Gly170", "CHEMICAL", 59, 65], ["Ala172", "CHEMICAL", 70, 76], ["Gly170", "GENE_OR_GENE_PRODUCT", 59, 65], ["Ala172", "AMINO_ACID", 70, 76], ["V1 anchor", "PROTEIN", 100, 109], ["the fused rings of both compounds", "TREATMENT", 115, 148], ["fused rings", "OBSERVATION", 119, 130]]], ["Considering at the compound NSC319990, as mentioned above, one-half of this compound is perfectly occupied on the binding pocket along the sub-site S 2 to S 1 of YHV protease.", [["NSC319990", "CHEMICAL", 28, 37], ["NSC319990", "CHEMICAL", 28, 37], ["NSC319990", "SIMPLE_CHEMICAL", 28, 37], ["S 1", "GENE_OR_GENE_PRODUCT", 155, 158], ["YHV protease", "GENE_OR_GENE_PRODUCT", 162, 174], ["sub-site S 2 to S 1", "DNA", 139, 158], ["YHV protease", "PROTEIN", 162, 174], ["this compound", "PROBLEM", 71, 84], ["the binding pocket", "PROBLEM", 110, 128], ["YHV protease", "TREATMENT", 162, 174], ["pocket", "OBSERVATION_MODIFIER", 122, 128], ["sub", "OBSERVATION_MODIFIER", 139, 142]]], ["Moreover, another-half of NSC319990 lies on the S3 sub-pocket (M137, I168-I171, and A180-T182).", [["NSC319990", "CHEMICAL", 26, 35], ["NSC319990", "CHEMICAL", 26, 35], ["NSC319990", "CANCER", 26, 35], ["NSC319990", "DNA", 26, 35], ["A180", "PROTEIN", 84, 88], ["A180", "TEST", 84, 88]]], ["These observations suggested that the screened compounds might possess the protease inhibitor properties as the known one, Nelfinavir.", [["Nelfinavir", "CHEMICAL", 123, 133], ["Nelfinavir", "CHEMICAL", 123, 133], ["Nelfinavir", "SIMPLE_CHEMICAL", 123, 133], ["the screened compounds", "PROBLEM", 34, 56], ["the protease inhibitor properties", "TREATMENT", 71, 104], ["Nelfinavir", "TREATMENT", 123, 133]]], ["These sets of ligands not only possessed strong hydrogen bonds with the surrounded residues in the binding pocket but also are reported as the potent inhibitory agents targeting several proteins including the malarial parasite plastid (Table 2) .MD simulations of protease-ligand complexesStability of the complexes between the first five hit compounds ((NSC122819, NSC345647, NSC319990, NSC50650, and NSC5069) and YHV protease was evaluated by performing MD simulations (Fig. 4) .", [["hydrogen", "CHEMICAL", 48, 56], ["NSC122819", "CHEMICAL", 355, 364], ["NSC345647", "CHEMICAL", 366, 375], ["NSC319990", "CHEMICAL", 377, 386], ["NSC50650", "CHEMICAL", 388, 396], ["YHV protease", "GENE_OR_GENE_PRODUCT", 415, 427], ["malarial parasite plastid", "PROTEIN", 209, 234], ["protease", "PROTEIN", 264, 272], ["YHV protease", "PROTEIN", 415, 427], ["the surrounded residues in the binding pocket", "PROBLEM", 68, 113], ["the potent inhibitory agents", "TREATMENT", 139, 167], ["the malarial parasite plastid", "TREATMENT", 205, 234], ["protease-ligand complexes", "TEST", 264, 289], ["YHV protease", "TREATMENT", 415, 427], ["hydrogen bonds", "OBSERVATION", 48, 62], ["surrounded", "OBSERVATION_MODIFIER", 72, 82], ["residues", "OBSERVATION", 83, 91], ["binding pocket", "OBSERVATION", 99, 113]]], ["The backbone RMSD values of each snapshot with respect to the initial structures obtained before energy minimizations were plotted over the course of 15 ns simulation time (Supplementary data Fig. S2 ).MD simulations of protease-ligand complexesAlthough the RMSD values for the apo simulation tended to be more deviated from the initial structure, those for the complex simulations had reached equilibrium well after t= 5 ns and remained fluctuated not more than \u22480.1 nm until the end of the simulations, indicating stability of the complex systems.", [["protease-ligand", "GENE_OR_GENE_PRODUCT", 220, 235], ["apo", "SIMPLE_CHEMICAL", 278, 281], ["S2", "PROTEIN", 197, 199], ["protease-ligand complexes", "PROTEIN", 220, 245], ["The backbone RMSD values", "TEST", 0, 24], ["energy minimizations", "TREATMENT", 97, 117], ["15 ns simulation time", "TREATMENT", 150, 171], ["protease-ligand complexes", "TREATMENT", 220, 245], ["the RMSD values", "TEST", 254, 269], ["the apo simulation", "TEST", 274, 292], ["the complex simulations", "PROBLEM", 358, 381], ["t= 5 ns", "TREATMENT", 417, 424], ["the simulations", "TEST", 488, 503], ["stability", "OBSERVATION_MODIFIER", 516, 525]]], ["Potential energies for interactions between the hit compounds and the enzyme were calculated as the sum of the electrostatic and van der Waals (vdW) energies over the last 5 ns of the simulations (Fig. 6) .", [["enzyme", "PROTEIN", 70, 76], ["Potential energies", "PROBLEM", 0, 18], ["the hit compounds", "PROBLEM", 44, 61], ["the enzyme", "TEST", 66, 76]]], ["It is noted that vdW interactions were found to be stronger than electrostatic interactions in all cases.", [["vdW interactions", "PROBLEM", 17, 33]]], ["The compounds NSC345647 and NSC319990 contribute more interaction energies than the other three complexes.", [["NSC345647", "CHEMICAL", 14, 23], ["NSC319990", "CHEMICAL", 28, 37], ["NSC345647", "CHEMICAL", 14, 23], ["NSC319990", "CHEMICAL", 28, 37], ["NSC345647", "SIMPLE_CHEMICAL", 14, 23], ["NSC319990", "SIMPLE_CHEMICAL", 28, 37]]], ["These results are consistent with the docking observations in that both compounds are the first two hits among the five.", [["consistent with", "UNCERTAINTY", 18, 33]]], ["Numbers of hydrogen bonds between the five hit compounds and the enzyme were then investigated throughout the 15 ns in all complex simulations (Supplementary data Fig. S3 ).", [["hydrogen", "CHEMICAL", 11, 19], ["enzyme", "PROTEIN", 65, 71], ["the five hit compounds", "PROBLEM", 34, 56], ["the enzyme", "TEST", 61, 71], ["hydrogen bonds", "OBSERVATION", 11, 25], ["five", "OBSERVATION_MODIFIER", 38, 42], ["hit compounds", "OBSERVATION", 43, 56]]], ["The analyses showed that the compounds NSC345647 and NSC319990 exhibit the largest hydrogen bond contributions among the five complexes as expected (Table 3 ).", [["NSC345647", "CHEMICAL", 39, 48], ["NSC319990", "CHEMICAL", 53, 62], ["NSC345647", "CHEMICAL", 39, 48], ["NSC319990", "CHEMICAL", 53, 62], ["hydrogen", "CHEMICAL", 83, 91], ["NSC345647", "SIMPLE_CHEMICAL", 39, 48], ["NSC319990", "SIMPLE_CHEMICAL", 53, 62], ["The analyses", "TEST", 0, 12], ["largest", "OBSERVATION_MODIFIER", 75, 82], ["hydrogen bond", "OBSERVATION", 83, 96]]], ["In particular, the compound NSC319990 makes strong hydrogen bonds with several residues including the catalytic triad of the protease (Fig. 7) .", [["NSC319990", "CHEMICAL", 28, 37], ["NSC319990", "CHEMICAL", 28, 37], ["hydrogen", "CHEMICAL", 51, 59], ["NSC319990", "SIMPLE_CHEMICAL", 28, 37], ["catalytic triad", "PROTEIN", 102, 117], ["protease", "PROTEIN", 125, 133], ["strong hydrogen bonds", "PROBLEM", 44, 65], ["several residues", "PROBLEM", 71, 87], ["the protease (Fig", "TREATMENT", 121, 138], ["hydrogen bonds", "OBSERVATION", 51, 65]]], ["Among these, the interaction between the N3 and N4 atoms of the compound and the side chain of Asp70 exhibits stability with the highest bond occupancy (95.8 % and 69.5 %, respectively).", [["Asp70", "CHEMICAL", 95, 100], ["N3", "CHEMICAL", 41, 43], ["N4", "CHEMICAL", 48, 50], ["Asp70", "CHEMICAL", 95, 100], ["Asp70", "SIMPLE_CHEMICAL", 95, 100], ["N3 and N4 atoms", "PROTEIN", 41, 56], ["Asp70", "PROTEIN", 95, 100], ["the N3 and N4 atoms", "TREATMENT", 37, 56], ["the highest bond occupancy", "TEST", 125, 151], ["compound", "OBSERVATION_MODIFIER", 64, 72], ["stability", "OBSERVATION_MODIFIER", 110, 119], ["highest", "OBSERVATION_MODIFIER", 129, 136], ["bond occupancy", "OBSERVATION", 137, 151]]], ["The Asp149 side chain (in pocket A) also makes strong hydrogen bonds with the N atoms of the compound (63.4 % and 61.6 %).", [["Asp149", "CHEMICAL", 4, 10], ["Asp", "CHEMICAL", 4, 7], ["hydrogen", "CHEMICAL", 54, 62], ["N", "CHEMICAL", 78, 79], ["Asp149 side chain", "PROTEIN", 4, 21], ["The Asp", "TEST", 0, 7], ["strong hydrogen bonds", "PROBLEM", 47, 68], ["149 side chain", "OBSERVATION_MODIFIER", 7, 21], ["strong", "OBSERVATION_MODIFIER", 47, 53], ["hydrogen bonds", "OBSERVATION", 54, 68]]], ["Furthermore, the \u03c0-\u03c0 interaction between the 6membered aromatic ring of the compound and His30 was observed (data not shown).", [["His30", "CHEMICAL", 89, 94], ["His30", "SIMPLE_CHEMICAL", 89, 94], ["aromatic ring", "OBSERVATION", 55, 68], ["compound", "OBSERVATION_MODIFIER", 76, 84]]], ["These strong hydrogen bonds observed in the NSC319990 complex are in agreement with the observations from molecular docking.YHV inhibitory assayThe same first five hit compounds were tested for YHV inhibitory assay using bacterial expressed YHV.", [["hydrogen", "CHEMICAL", 13, 21], ["NSC319990", "CHEMICAL", 44, 53], ["NSC319990 complex", "GENE_OR_GENE_PRODUCT", 44, 61], ["YHV", "SIMPLE_CHEMICAL", 124, 127], ["YHV", "SIMPLE_CHEMICAL", 194, 197], ["NSC319990 complex", "PROTEIN", 44, 61], ["bacterial expressed YHV", "PROTEIN", 221, 244], ["YHV", "SPECIES", 124, 127], ["YHV", "SPECIES", 194, 197], ["YHV", "SPECIES", 241, 244], ["These strong hydrogen bonds", "PROBLEM", 0, 27], ["YHV inhibitory assay", "TEST", 124, 144], ["YHV inhibitory assay", "TEST", 194, 214], ["bacterial expressed YHV", "PROBLEM", 221, 244], ["strong", "OBSERVATION_MODIFIER", 6, 12], ["hydrogen bonds", "OBSERVATION", 13, 27]]], ["Both NSC122819 and NSC345647 showed a strong inhibitory against YHV at our assay condition while NSC319990, NSC50650, and NSC5069 showed more than 50 % inhibitory.", [["NSC122819", "CHEMICAL", 5, 14], ["NSC345647", "CHEMICAL", 19, 28], ["NSC319990", "CHEMICAL", 97, 106], ["NSC50650", "CHEMICAL", 108, 116], ["NSC5069", "CHEMICAL", 122, 129], ["NSC122819", "CHEMICAL", 5, 14], ["NSC345647", "CHEMICAL", 19, 28], ["NSC319990", "CHEMICAL", 97, 106], ["NSC50650", "CHEMICAL", 108, 116], ["NSC5069", "CHEMICAL", 122, 129], ["NSC122819", "SIMPLE_CHEMICAL", 5, 14], ["NSC345647", "SIMPLE_CHEMICAL", 19, 28], ["YHV", "SIMPLE_CHEMICAL", 64, 67], ["NSC319990", "SIMPLE_CHEMICAL", 97, 106], ["NSC50650", "SIMPLE_CHEMICAL", 108, 116], ["NSC5069", "SIMPLE_CHEMICAL", 122, 129], ["YHV", "SPECIES", 64, 67]]], ["The best Fig. 7 Representation for the interactions between compound NSC319990 and YHV protease.", [["NSC319990", "SIMPLE_CHEMICAL", 69, 78], ["YHV protease", "GENE_OR_GENE_PRODUCT", 83, 95], ["YHV protease", "PROTEIN", 83, 95], ["YHV protease", "TREATMENT", 83, 95]]], ["The compound is shown in stick (C atoms in cyan) and three strong binding residues (Asp70, Asp149, and Gly170) are indicated.", [["C", "CHEMICAL", 32, 33], ["Asp70", "CHEMICAL", 84, 89], ["Asp", "CHEMICAL", 91, 94], ["Gly", "CHEMICAL", 103, 106], ["C atoms", "SIMPLE_CHEMICAL", 32, 39], ["Asp149", "AMINO_ACID", 91, 97], ["Gly170", "AMINO_ACID", 103, 109], ["stick (C atoms in cyan", "TREATMENT", 25, 47], ["Asp70", "TEST", 84, 89], ["Asp", "TEST", 91, 94]]], ["Hydrogen bonds are shown in magenta dotted lines.", [["Hydrogen", "CHEMICAL", 0, 8], ["Hydrogen", "CHEMICAL", 0, 8], ["magenta dotted lines", "CELL", 28, 48], ["magenta dotted lines", "CELL_LINE", 28, 48], ["Hydrogen bonds", "PROBLEM", 0, 14], ["dotted lines", "OBSERVATION", 36, 48]]], ["Distances of the important hydrogen bonds were plotted over the course of 15 ns simulation time Fig. 8 Percentage of YHV inhibition of the first five hit NCI compounds against bacterial expressed YHV protease using fluoroscopic assay.", [["hydrogen", "CHEMICAL", 27, 35], ["YHV protease", "GENE_OR_GENE_PRODUCT", 196, 208], ["YHV protease", "PROTEIN", 196, 208], ["YHV", "SPECIES", 196, 199], ["15 ns simulation time Fig", "TREATMENT", 74, 99], ["bacterial expressed YHV protease", "TREATMENT", 176, 208], ["fluoroscopic assay", "TEST", 215, 233], ["hydrogen bonds", "OBSERVATION", 27, 41]]], ["The final concentration of compounds were 75 nM docked-score compounds, NSC122819 also showed the strongest inhibition.", [["NSC122819", "CHEMICAL", 72, 81], ["NSC122819", "CHEMICAL", 72, 81], ["NSC122819", "SIMPLE_CHEMICAL", 72, 81]]], ["Further experiments will be necessary to understand the inhibiting mechanism of these compounds.ConclusionsIn this study, the homology model of YHV protease was created from multiple template technique.", [["YHV protease", "GENE_OR_GENE_PRODUCT", 144, 156], ["YHV protease", "PROTEIN", 144, 156], ["YHV", "SPECIES", 144, 147], ["this study", "TEST", 110, 120], ["YHV protease", "TREATMENT", 144, 156], ["multiple template technique", "TREATMENT", 174, 201]]], ["The modeled structure was used in virtual screening studies against a set of compounds in the NCI database.", [["virtual screening studies", "TEST", 34, 59]]], ["This investigation proposed a set of promising small molecules to inhibit or decrease the activity of protein YHV protease from the in silico studies model.", [["YHV protease", "GENE_OR_GENE_PRODUCT", 110, 122], ["protein YHV protease", "PROTEIN", 102, 122], ["This investigation", "TEST", 0, 18], ["promising small molecules", "PROBLEM", 37, 62], ["protein YHV protease", "TREATMENT", 102, 122], ["small", "OBSERVATION_MODIFIER", 47, 52], ["molecules", "OBSERVATION", 53, 62]]], ["The inhibiting activity of the best five docked-score compounds were tested against YHV protease in vitro.", [["YHV protease", "GENE_OR_GENE_PRODUCT", 84, 96], ["YHV protease", "PROTEIN", 84, 96], ["YHV", "SPECIES", 84, 87], ["YHV protease", "TREATMENT", 84, 96], ["activity", "OBSERVATION_MODIFIER", 15, 23]]], ["All of them showed a good degree of inhibition.", [["good degree", "OBSERVATION_MODIFIER", 21, 32]]], ["The best dockedscore, NSC122819, also showed the best inhibition.", [["NSC122819", "CHEMICAL", 22, 31], ["NSC122819", "CHEMICAL", 22, 31], ["NSC122819", "SIMPLE_CHEMICAL", 22, 31]]], ["This confirmed our successful homology and docking protocols to predict the potential inhibitors against YHV.", [["YHV", "SPECIES", 105, 108], ["docking protocols", "TREATMENT", 43, 60], ["the potential inhibitors", "TREATMENT", 72, 96], ["YHV", "PROBLEM", 105, 108]]], ["These compounds can be further tested against yellow head virus in cells and farm levels in the future.", [["cells", "ANATOMY", 67, 72], ["yellow head virus", "ORGANISM", 46, 63], ["cells", "CELL", 67, 72], ["yellow head virus", "SPECIES", 46, 63], ["yellow head virus in cells", "PROBLEM", 46, 72], ["farm levels", "TEST", 77, 88]]]], "PMC6069180": [["INTRODUCTIONVaccination has been spectacularly successful, but there remain important infections for which therapeutic or preventative vaccines either do not exist or are of insufficient efficacy.", [["infections", "DISEASE", 86, 96], ["INTRODUCTIONVaccination", "TREATMENT", 0, 23], ["important infections", "PROBLEM", 76, 96], ["preventative vaccines", "TREATMENT", 122, 143], ["infections", "OBSERVATION", 86, 96]]], ["One such example is infections caused by herpes simplex virus 1 (HSV-1) and HSV-2.", [["infections", "DISEASE", 20, 30], ["herpes simplex virus", "DISEASE", 41, 61], ["herpes simplex virus 1", "ORGANISM", 41, 63], ["HSV-1", "ORGANISM", 65, 70], ["HSV-2", "ORGANISM", 76, 81], ["herpes simplex virus 1", "SPECIES", 41, 63], ["HSV-1", "SPECIES", 65, 70], ["herpes simplex virus 1", "SPECIES", 41, 63], ["HSV-1", "SPECIES", 65, 70], ["HSV-2", "SPECIES", 76, 81], ["infections", "PROBLEM", 20, 30], ["herpes simplex virus", "PROBLEM", 41, 61], ["HSV", "TEST", 65, 68], ["HSV", "TEST", 76, 79], ["infections", "OBSERVATION", 20, 30]]], ["Recent estimates place the worldwide prevalence of HSV-1 at 67% and that of HSV-2 at 11% (1, 2).", [["HSV-1", "ORGANISM", 51, 56], ["HSV-2", "ORGANISM", 76, 81], ["HSV-1", "SPECIES", 51, 56], ["HSV-1", "SPECIES", 51, 56], ["HSV-2", "SPECIES", 76, 81], ["HSV", "TEST", 51, 54], ["HSV", "TEST", 76, 79]]], ["Currently, there is no vaccine for treating or preventing HSV-1 or HSV-2 infections.", [["HSV-2 infections", "DISEASE", 67, 83], ["HSV-1", "ORGANISM", 58, 63], ["HSV-2", "ORGANISM", 67, 72], ["HSV-1", "SPECIES", 58, 63], ["HSV-1", "SPECIES", 58, 63], ["HSV-2", "SPECIES", 67, 72], ["vaccine", "TREATMENT", 23, 30], ["HSV", "PROBLEM", 58, 61], ["HSV", "PROBLEM", 67, 70], ["2 infections", "PROBLEM", 71, 83], ["no", "UNCERTAINTY", 20, 22], ["HSV", "OBSERVATION", 67, 70], ["infections", "OBSERVATION", 73, 83]]], ["Several new candidate vaccines have been developed in recent years, some of which have entered clinical evaluation (3\u20137).", [["Several new candidate vaccines", "TREATMENT", 0, 30], ["clinical evaluation", "TEST", 95, 114], ["new", "OBSERVATION_MODIFIER", 8, 11]]], ["Another example is influenza virus infections.", [["influenza virus infections", "DISEASE", 19, 45], ["influenza virus", "ORGANISM", 19, 34], ["influenza virus", "SPECIES", 19, 34], ["influenza virus", "SPECIES", 19, 34], ["influenza virus infections", "PROBLEM", 19, 45], ["influenza virus infections", "OBSERVATION", 19, 45]]], ["Annual infection rates for influenza virus are between 5 and 20%, and the yearly death rate worldwide lies between 250,000 and 500,000 according to WHO estimates.", [["infection", "DISEASE", 7, 16], ["influenza virus", "DISEASE", 27, 42], ["death", "DISEASE", 81, 86], ["influenza virus", "ORGANISM", 27, 42], ["influenza virus", "SPECIES", 27, 42], ["influenza virus", "SPECIES", 27, 42], ["Annual infection rates", "PROBLEM", 0, 22], ["influenza virus", "PROBLEM", 27, 42], ["infection", "OBSERVATION", 7, 16]]], ["At this time, the vaccines remain seasonal, i.e., they need to be updated/reformulated for every influenza season.", [["the vaccines", "TREATMENT", 14, 26]]], ["Typical subunit vaccines are at least trivalent, comprising hemagglutinins (HAs) from H1N1 and H3N2 influenza A virus strains and an influenza B virus strain (referred to as TIV).", [["influenza A", "DISEASE", 100, 111], ["influenza B", "DISEASE", 133, 144], ["H1N1 and", "ORGANISM", 86, 94], ["H3N2 influenza A virus", "ORGANISM", 95, 117], ["influenza B virus", "ORGANISM", 133, 150], ["H3N2 influenza A virus", "SPECIES", 95, 117], ["influenza B virus", "SPECIES", 133, 150], ["H3N2 influenza A virus", "SPECIES", 95, 117], ["influenza B virus", "SPECIES", 133, 150], ["Typical subunit vaccines", "TREATMENT", 0, 24], ["hemagglutinins", "PROBLEM", 60, 74], ["H1N1", "PROBLEM", 86, 90], ["H3N2 influenza A virus strains", "PROBLEM", 95, 125], ["an influenza B virus strain", "PROBLEM", 130, 157]]], ["More recently, live attenuated influenza virus vaccines (LAIV) were introduced.", [["influenza virus", "DISEASE", 31, 46], ["live attenuated influenza virus", "ORGANISM", 15, 46], ["influenza virus vaccines", "SPECIES", 31, 55], ["LAIV", "SPECIES", 57, 61], ["live attenuated influenza virus vaccines", "TREATMENT", 15, 55], ["LAIV)", "TREATMENT", 57, 62]]], ["An updated systematic review and meta-analysis published in 2012 documented a mean efficacy for TIV of 62% against real-time (RT) PCR- or virus-confirmed influenza (all age groups) (8).", [["influenza", "DISEASE", 154, 163], ["meta-analysis", "TEST", 33, 46], ["TIV", "TEST", 96, 99], ["PCR", "TEST", 130, 133], ["virus", "PROBLEM", 138, 143], ["influenza", "PROBLEM", 154, 163], ["influenza", "OBSERVATION", 154, 163]]], ["The mean efficacy for LAIV in young children was higher, but little or no protection was found in adults (18 years and older).", [["LAIV", "CHEMICAL", 22, 26], ["children", "ORGANISM", 36, 44], ["children", "SPECIES", 36, 44], ["LAIV", "TREATMENT", 22, 26], ["mean", "OBSERVATION_MODIFIER", 4, 8]]], ["A recent study reported a mean overall vaccine efficacy of 48% for the 2015-2016 season and lower efficacies for persons 50 years of age and older (9).", [["persons", "SPECIES", 113, 120], ["A recent study", "TEST", 0, 14], ["lower efficacies", "OBSERVATION_MODIFIER", 92, 108]]], ["Thus, currently available influenza vaccines provide moderate protection against virologically confirmed disease, but the protection is not long-lasting (10) and is especially tenuous in the senior population.", [["influenza vaccines", "TREATMENT", 26, 44], ["moderate protection", "TREATMENT", 53, 72], ["virologically", "PROBLEM", 81, 94], ["disease", "PROBLEM", 105, 112], ["disease", "OBSERVATION", 105, 112], ["tenuous", "OBSERVATION_MODIFIER", 176, 183]]], ["Ongoing research is aimed at developing vaccines that elicit more potent antibody or T cell responses to conserved viral epitopes (11\u201313).", [["T cell", "ANATOMY", 85, 91], ["T cell", "CELL", 85, 91], ["conserved viral epitopes", "PROTEIN", 105, 129], ["developing vaccines", "TREATMENT", 29, 48], ["T cell responses", "PROBLEM", 85, 101], ["viral epitopes", "TEST", 115, 129]]], ["A third example concerns Mycobacterium tuberculosis infections, which affect about one-third of the world population, with yearly death rates of over 1 million.", [["Mycobacterium tuberculosis infections", "DISEASE", 25, 62], ["death", "DISEASE", 130, 135], ["Mycobacterium tuberculosis", "ORGANISM", 25, 51], ["Mycobacterium tuberculosis", "SPECIES", 25, 51], ["Mycobacterium tuberculosis", "SPECIES", 25, 51], ["Mycobacterium tuberculosis infections", "PROBLEM", 25, 62], ["Mycobacterium", "OBSERVATION_MODIFIER", 25, 38], ["tuberculosis", "OBSERVATION_MODIFIER", 39, 51], ["infections", "OBSERVATION", 52, 62]]], ["Of concern in the industrialized world is the rise of drug-resistant forms of the disease (14).", [["the disease", "PROBLEM", 78, 89], ["disease", "OBSERVATION", 82, 89]]], ["The only vaccine in use is the (live) bacillus Calmette-Gu\u00e9rin (BCG) vaccine, whose efficacy appears to be variable in adults.", [["Calmette-Gu\u00e9rin", "CHEMICAL", 47, 62], ["bacillus Calmette-Gu\u00e9rin", "ORGANISM", 38, 62], ["BCG", "ORGANISM", 64, 67], ["vaccine", "TREATMENT", 9, 16], ["the (live) bacillus Calmette", "TREATMENT", 27, 55], ["Gu\u00e9rin (BCG) vaccine", "TREATMENT", 56, 76]]], ["Candidate vaccines currently under development include virus-vectored vaccines presenting BCG antigens, adjuvanted subunit vaccines, and whole-cell vaccines (15\u201317).", [["whole-cell", "ANATOMY", 137, 147], ["cell", "CELL", 143, 147], ["BCG antigens", "PROTEIN", 90, 102], ["Candidate vaccines", "TREATMENT", 0, 18], ["virus-vectored vaccines", "TREATMENT", 55, 78], ["BCG antigens", "TREATMENT", 90, 102], ["adjuvanted subunit vaccines", "TREATMENT", 104, 131], ["whole-cell vaccines", "TREATMENT", 137, 156]]], ["Further examples include malaria and HIV/AIDS.", [["malaria and HIV/AIDS", "DISEASE", 25, 45], ["HIV", "SPECIES", 37, 40], ["HIV", "SPECIES", 37, 40], ["malaria", "PROBLEM", 25, 32], ["HIV/AIDS", "PROBLEM", 37, 45], ["malaria", "OBSERVATION", 25, 32]]], ["As these examples reveal, adequate protection against many important infections is not yet available.", [["infections", "DISEASE", 69, 79], ["many important infections", "PROBLEM", 54, 79], ["infections", "OBSERVATION", 69, 79]]], ["Research continues, and new immunization approaches appear to be urgently needed.INTRODUCTIONThe question of whether live attenuated vaccines that have retained some capacity for replication provide more robust protective immunity than inactivated nonreplicating vaccines was already debated more than 50 years ago (18\u201321).", [["new immunization approaches", "TREATMENT", 24, 51], ["live attenuated vaccines", "TREATMENT", 117, 141], ["some capacity", "PROBLEM", 161, 174], ["inactivated nonreplicating vaccines", "TREATMENT", 236, 271]]], ["Several more recent studies attempted to address the issue directly.", [["recent studies", "TEST", 13, 27]]], ["One such study compared immune responses to an HIV envelope antigen expressed from an attenuated replicating vector and a replication-defective adenovirus vector in a chimpanzee model (22).", [["HIV", "ORGANISM", 47, 50], ["adenovirus", "ORGANISM", 144, 154], ["chimpanzee", "ORGANISM", 167, 177], ["HIV envelope antigen", "PROTEIN", 47, 67], ["replication-defective adenovirus vector", "DNA", 122, 161], ["HIV", "SPECIES", 47, 50], ["HIV", "SPECIES", 47, 50], ["One such study", "TEST", 0, 14], ["an HIV envelope antigen", "PROBLEM", 44, 67], ["an attenuated replicating vector", "TREATMENT", 83, 115], ["a replication-defective adenovirus vector", "TREATMENT", 120, 161], ["defective", "OBSERVATION_MODIFIER", 134, 143], ["adenovirus vector", "OBSERVATION", 144, 161]]], ["Inoculation with the replicating recombinant resulted in a greater frequency of HIV envelope-specific interferon gamma-secreting peripheral blood lymphocytes, better priming of T cell proliferative responses, higher anti-envelope binding and neutralizing antibody titers, and better antibody-dependent cellular cytotoxicity.", [["peripheral blood lymphocytes", "ANATOMY", 129, 157], ["T cell", "ANATOMY", 177, 183], ["cellular", "ANATOMY", 302, 310], ["HIV", "ORGANISM", 80, 83], ["interferon gamma", "GENE_OR_GENE_PRODUCT", 102, 118], ["peripheral blood lymphocytes", "CELL", 129, 157], ["T cell", "CELL", 177, 183], ["cellular", "CELL", 302, 310], ["interferon gamma", "PROTEIN", 102, 118], ["secreting peripheral blood lymphocytes", "CELL_TYPE", 119, 157], ["HIV", "SPECIES", 80, 83], ["HIV envelope", "PROBLEM", 80, 92], ["specific interferon gamma", "TEST", 93, 118], ["secreting peripheral blood lymphocytes", "PROBLEM", 119, 157], ["T cell proliferative responses", "PROBLEM", 177, 207], ["higher anti-envelope binding", "PROBLEM", 209, 237], ["neutralizing antibody titers", "TEST", 242, 270], ["better antibody-dependent cellular cytotoxicity", "PROBLEM", 276, 323], ["blood lymphocytes", "ANATOMY", 140, 157], ["cell proliferative", "OBSERVATION", 179, 197], ["cellular cytotoxicity", "OBSERVATION", 302, 323]]], ["In another study, an attenuated vaccinia virus (MVTT) expressing the spike protein (S) of severe acute respiratory syndrome coronavirus (SARS-CoV) (MVTT-S) was compared with a replication-defective vaccinia virus (MVA) expressing the same protein (MVA-S).", [["acute respiratory syndrome coronavirus", "DISEASE", 97, 135], ["SARS", "DISEASE", 137, 141], ["vaccinia virus", "ORGANISM", 32, 46], ["MVTT", "CANCER", 48, 52], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 90, 135], ["SARS-CoV", "ORGANISM", 137, 145], ["vaccinia virus", "ORGANISM", 198, 212], ["MVA", "ORGANISM", 214, 217], ["spike protein", "PROTEIN", 69, 82], ["S", "PROTEIN", 84, 85], ["MVA-S", "PROTEIN", 248, 253], ["vaccinia virus", "SPECIES", 198, 212], ["vaccinia virus", "SPECIES", 32, 46], ["severe acute respiratory syndrome coronavirus", "SPECIES", 90, 135], ["SARS-CoV", "SPECIES", 137, 145], ["vaccinia virus", "SPECIES", 198, 212], ["MVA", "SPECIES", 214, 217], ["another study", "TEST", 3, 16], ["an attenuated vaccinia virus", "PROBLEM", 18, 46], ["the spike protein", "TEST", 65, 82], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 90, 135], ["SARS", "TEST", 137, 141], ["MVTT", "TEST", 148, 152], ["a replication", "TREATMENT", 174, 187], ["defective vaccinia virus", "PROBLEM", 188, 212], ["vaccinia virus", "OBSERVATION", 32, 46], ["severe", "OBSERVATION_MODIFIER", 90, 96], ["acute", "OBSERVATION_MODIFIER", 97, 102], ["respiratory syndrome coronavirus", "OBSERVATION", 103, 135], ["vaccinia virus", "OBSERVATION", 198, 212]]], ["Intranasal or intraoral vaccination of mice with MVTT-S produced 20- to 100-fold higher neutralizing antibody levels than MVA-S (23, 24).", [["intraoral", "ANATOMY", 14, 23], ["MVTT-S", "CHEMICAL", 49, 55], ["MVA-S", "CHEMICAL", 122, 127], ["mice", "ORGANISM", 39, 43], ["MVTT-S", "SIMPLE_CHEMICAL", 49, 55], ["mice", "SPECIES", 39, 43], ["mice", "SPECIES", 39, 43], ["Intranasal", "TREATMENT", 0, 10], ["MVTT", "TEST", 49, 53], ["neutralizing antibody levels", "TEST", 88, 116]]], ["Yet another study employed a mouse ocular challenge model to demonstrate that an attenuated replicating HSV-1 strain (ICP0\u2212), but not a replication-defective HSV-1 strain (ICP4\u2212), elicited a protective immune response (25).", [["ocular", "ANATOMY", 35, 41], ["mouse", "ORGANISM", 29, 34], ["HSV-1 strain", "ORGANISM", 104, 116], ["ICP0", "ORGANISM", 118, 122], ["HSV-1 strain", "ORGANISM", 158, 170], ["ICP4", "ORGANISM", 172, 176], ["ICP0", "PROTEIN", 118, 122], ["ICP4", "PROTEIN", 172, 176], ["mouse", "SPECIES", 29, 34], ["HSV-1", "SPECIES", 104, 109], ["HSV-1", "SPECIES", 158, 163], ["mouse", "SPECIES", 29, 34], ["HSV-1", "SPECIES", 104, 109], ["HSV-1", "SPECIES", 158, 163], ["another study", "TEST", 4, 17], ["a mouse ocular challenge model", "TREATMENT", 27, 57], ["an attenuated replicating HSV-1 strain", "PROBLEM", 78, 116], ["defective HSV", "PROBLEM", 148, 161], ["HSV", "OBSERVATION", 104, 107], ["defective", "OBSERVATION_MODIFIER", 148, 157], ["HSV", "OBSERVATION", 158, 161]]], ["These findings support the theory that attenuated replicating viruses induce more complete and more potent immune responses to autologous or heterologous antigens than the corresponding nonreplicating viruses.INTRODUCTIONWe hypothesized that a virus vector that could replicate in a controlled fashion with nearly the same efficiency as the respective wild-type virus (referred to here as a replication-competent controlled virus vector) would induce an even more potent and complete immune response to itself or an expressed heterologous antigen than a corresponding attenuated vector (26).", [["nonreplicating viruses", "ORGANISM", 186, 208], ["wild-type virus", "ORGANISM", 352, 367], ["heterologous antigens", "PROTEIN", 141, 162], ["heterologous antigen", "PROTEIN", 526, 546], ["attenuated replicating viruses", "PROBLEM", 39, 69], ["autologous or heterologous antigens", "PROBLEM", 127, 162], ["a virus vector", "TREATMENT", 242, 256], ["type virus", "PROBLEM", 357, 367], ["a replication-competent controlled virus vector", "TREATMENT", 389, 436], ["an expressed heterologous antigen", "PROBLEM", 513, 546], ["viruses", "OBSERVATION", 62, 69], ["nonreplicating", "OBSERVATION_MODIFIER", 186, 200], ["viruses", "OBSERVATION", 201, 208]]], ["Our hypothesis is in part based on the rational expectation that an efficiently replicating virus will produce a stronger inflammatory response than an attenuated virus and that the inflammatory response will result in potent activation of the innate immune system and, consequently, in strong and lasting B and T cell responses (27).", [["B", "ANATOMY", 306, 307], ["T cell", "ANATOMY", 312, 318], ["B", "CELL", 306, 307], ["T cell", "CELL", 312, 318], ["an efficiently replicating virus", "PROBLEM", 65, 97], ["a stronger inflammatory response", "PROBLEM", 111, 143], ["an attenuated virus", "PROBLEM", 149, 168], ["the inflammatory response", "PROBLEM", 178, 203], ["virus", "OBSERVATION", 163, 168], ["inflammatory", "OBSERVATION_MODIFIER", 182, 194]]], ["To realize such an immunization strategy, a regulation system must be employed that reliably and stringently controls viral replication and is capable of being turned on and off at will.", [["an immunization strategy", "TREATMENT", 16, 40], ["a regulation system", "TREATMENT", 42, 61], ["viral replication", "TREATMENT", 118, 135], ["viral replication", "OBSERVATION", 118, 135]]], ["However, virus disseminates after administration.", [["virus", "PROBLEM", 9, 14], ["virus", "OBSERVATION", 9, 14]]], ["Simply restricting the number of replication cycles will not be enough: depending on the number of cycles allowed, there will be a more or less pronounced manifestation of the toxicity typical for the viral vector used.", [["toxicity", "DISEASE", 176, 184], ["replication cycles", "TREATMENT", 33, 51], ["the toxicity", "PROBLEM", 172, 184], ["the viral vector", "TREATMENT", 197, 213], ["replication cycles", "OBSERVATION", 33, 51]]], ["Hence, the regulation system must be capable of exerting regional control over viral replication so that the immunizing virus replicates only in a locale in which it is certain not to cause a disease phenotype.INTRODUCTIONTo facilitate construction of a replication-competent controlled virus vector, advantage may be taken of gene switches developed previously for eukaryotic cells (28).", [["cells", "ANATOMY", 377, 382], ["cells", "CELL", 377, 382], ["eukaryotic cells", "CELL_TYPE", 366, 382], ["viral replication", "TREATMENT", 79, 96], ["the immunizing virus", "PROBLEM", 105, 125], ["a disease phenotype.INTRODUCTIONTo", "PROBLEM", 190, 224], ["a replication", "TREATMENT", 252, 265], ["competent controlled virus vector", "TREATMENT", 266, 299], ["gene switches", "TREATMENT", 327, 340], ["eukaryotic cells", "PROBLEM", 366, 382]]], ["This choice implies that the backbone virus must be selected from the group of viruses having a double-stranded DNA genome (e.g., herpesviruses) or producing a double-stranded DNA intermediate during replication and utilizing the host machinery for transcription.", [["DNA", "CELLULAR_COMPONENT", 112, 115], ["DNA", "CELLULAR_COMPONENT", 176, 179], ["double-stranded DNA genome", "DNA", 96, 122], ["double-stranded DNA intermediate", "DNA", 160, 192], ["the backbone virus", "PROBLEM", 25, 43], ["a double-stranded DNA genome", "TREATMENT", 94, 122], ["herpesviruses", "PROBLEM", 130, 143], ["a double-stranded DNA", "TREATMENT", 158, 179], ["the host machinery", "TREATMENT", 226, 244]]], ["It appears that the above-described requirements are best met by promoters of certain heat shock protein (HSP) genes that are stringently controlled by the reversibly heat-activated endogenous transcription factor HSF1 (28\u201330).", [["certain heat shock protein", "GENE_OR_GENE_PRODUCT", 78, 104], ["HSP", "GENE_OR_GENE_PRODUCT", 106, 109], ["HSF1", "GENE_OR_GENE_PRODUCT", 214, 218], ["promoters", "DNA", 65, 74], ["heat shock protein (HSP) genes", "DNA", 86, 116], ["reversibly heat-activated endogenous transcription factor", "PROTEIN", 156, 213], ["HSF1", "PROTEIN", 214, 218], ["28\u201330", "PROTEIN", 220, 225], ["certain heat shock protein (HSP) genes", "PROBLEM", 78, 116]]], ["A virus in which one or, preferably, two replication-essential genes are placed under the control of such a promoter could be activated to undergo one round of localized replication by administration of a mild heat dose to the inoculation region.", [["replication-essential genes", "DNA", 41, 68], ["promoter", "DNA", 108, 116], ["A virus", "PROBLEM", 0, 7], ["a mild heat dose", "TREATMENT", 203, 219], ["virus", "OBSERVATION", 2, 7], ["essential genes", "OBSERVATION", 53, 68], ["mild", "OBSERVATION_MODIFIER", 205, 209]]], ["Further rounds may be induced by repeated heat treatments.", [["repeated heat treatments", "TREATMENT", 33, 57]]], ["However, virus replication may be inefficient, because heat activation of HSP promoters is rapidly reversible, and may be unsafe, because unintended weak activation could be triggered by high fever, intoxication, etc., in an inoculated subject.", [["fever", "DISEASE", 192, 197], ["HSP", "GENE_OR_GENE_PRODUCT", 74, 77], ["HSP promoters", "DNA", 74, 87], ["virus replication", "TREATMENT", 9, 26], ["HSP promoters", "TREATMENT", 74, 87], ["unintended weak activation", "PROBLEM", 138, 164], ["high fever", "PROBLEM", 187, 197], ["intoxication", "PROBLEM", 199, 211]]], ["We previously described a two-component HSP promoter-based gene switch that lacks these unwanted properties (31) (Fig. 1A).", [["HSP", "GENE_OR_GENE_PRODUCT", 40, 43], ["HSP promoter", "DNA", 40, 52], ["a two-component HSP promoter", "TREATMENT", 24, 52]]], ["The first component comprises a gene for a small-molecule regulator (SMR)-activated transactivator (TA).", [["TA", "GENE_OR_GENE_PRODUCT", 100, 102], ["small-molecule regulator (SMR)-activated transactivator", "PROTEIN", 43, 98], ["TA", "PROTEIN", 100, 102], ["a small-molecule regulator", "PROBLEM", 41, 67], ["activated transactivator (TA)", "TREATMENT", 74, 103], ["small", "OBSERVATION_MODIFIER", 43, 48]]], ["The TA gene is controlled by a promoter cassette containing an HSP70B (HSPA7) promoter and a TA-responsive promoter (TRP).", [["TA", "GENE_OR_GENE_PRODUCT", 4, 6], ["HSP70B", "GENE_OR_GENE_PRODUCT", 63, 69], ["HSPA7", "GENE_OR_GENE_PRODUCT", 71, 76], ["TA", "GENE_OR_GENE_PRODUCT", 93, 95], ["TRP", "GENE_OR_GENE_PRODUCT", 117, 120], ["TA gene", "DNA", 4, 11], ["promoter cassette", "DNA", 31, 48], ["HSP70B (HSPA7) promoter", "DNA", 63, 86], ["TA-responsive promoter", "DNA", 93, 115], ["TRP", "DNA", 117, 120], ["a promoter cassette", "TREATMENT", 29, 48], ["an HSP70B (HSPA7) promoter", "TREATMENT", 60, 86], ["a TA-responsive promoter (TRP)", "TREATMENT", 91, 121]]], ["The second component is a TRP that drives a selected viral gene (VG).", [["TRP", "CHEMICAL", 26, 29], ["TRP", "GENE_OR_GENE_PRODUCT", 26, 29], ["viral gene", "DNA", 53, 63]]], ["Heat treatment prompts expression of the TA, which is inactive unless activated by its SMR.", [["TA", "GENE_OR_GENE_PRODUCT", 41, 43], ["TA", "PROTEIN", 41, 43], ["Heat treatment", "TREATMENT", 0, 14], ["inactive", "OBSERVATION", 54, 62]]], ["Activated TA mediates expression of the viral gene and autoactivates its own expression.", [["TA", "GENE_OR_GENE_PRODUCT", 10, 12], ["viral gene", "DNA", 40, 50]]], ["The gene switch is inactivated by withdrawal of the SMR or, in the present application, virus-mediated lysis of the host cell.", [["cell", "ANATOMY", 121, 125], ["host cell", "CELL", 116, 125], ["host cell", "CELL_TYPE", 116, 125], ["The gene switch", "TREATMENT", 0, 15], ["the SMR", "PROBLEM", 48, 55], ["virus-mediated lysis of the host cell", "TREATMENT", 88, 125], ["lysis", "OBSERVATION", 103, 108], ["host cell", "OBSERVATION", 116, 125]]], ["The present report presents the first study of immune responses induced by replication-competent controlled HSV-1 vectors in which one or two replication-essential genes are subjected to regulation by such a heat- and SMR-dependent gene switch.INTRODUCTION(This article was submitted to an online preprint archive [32].)Replication-competent controlled HSV-1 vectors. ::: RESULTSThe two-component HSP promoter-based gene switch employed in the vectors in the present study relied on the transactivator GLP65, which is activated by a narrow class of antiprogestins, including mifepristone and ulipristal (31, 33\u201335).", [["mifepristone", "CHEMICAL", 575, 587], ["ulipristal", "CHEMICAL", 592, 602], ["antiprogestins", "CHEMICAL", 549, 563], ["mifepristone", "CHEMICAL", 575, 587], ["ulipristal", "CHEMICAL", 592, 602], ["HSV-1", "ORGANISM", 108, 113], ["HSV-1", "ORGANISM", 353, 358], ["HSP", "GENE_OR_GENE_PRODUCT", 397, 400], ["GLP65", "GENE_OR_GENE_PRODUCT", 502, 507], ["antiprogestins", "SIMPLE_CHEMICAL", 549, 563], ["mifepristone", "SIMPLE_CHEMICAL", 575, 587], ["ulipristal", "SIMPLE_CHEMICAL", 592, 602], ["HSV-1 vectors", "DNA", 108, 121], ["replication-essential genes", "DNA", 142, 169], ["HSV-1 vectors", "DNA", 353, 366], ["HSP promoter", "DNA", 397, 409], ["transactivator GLP65", "PROTEIN", 487, 507], ["HSV-1", "SPECIES", 108, 113], ["HSV-1", "SPECIES", 353, 358], ["HSV-1", "SPECIES", 108, 113], ["HSV-1", "SPECIES", 353, 358], ["immune responses", "PROBLEM", 47, 63], ["a heat", "TREATMENT", 206, 212], ["SMR-dependent gene switch", "TREATMENT", 218, 243], ["Replication", "TREATMENT", 320, 331], ["two-component HSP promoter", "TREATMENT", 383, 409], ["mifepristone and ulipristal", "TREATMENT", 575, 602]]], ["GLP65 is a chimeric protein consisting of a DNA-binding domain from the Saccharomyces cerevisiae transcription factor GAL4, a truncated ligand-binding domain from a human progesterone receptor, and a transcriptional activation domain from human NF-\u03baB protein P65.", [["progesterone", "CHEMICAL", 171, 183], ["progesterone", "CHEMICAL", 171, 183], ["GLP65", "GENE_OR_GENE_PRODUCT", 0, 5], ["DNA", "CELLULAR_COMPONENT", 44, 47], ["Saccharomyces cerevisiae", "ORGANISM", 72, 96], ["GAL4", "GENE_OR_GENE_PRODUCT", 118, 122], ["human", "ORGANISM", 165, 170], ["progesterone receptor", "GENE_OR_GENE_PRODUCT", 171, 192], ["human", "ORGANISM", 239, 244], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 245, 250], ["P65", "GENE_OR_GENE_PRODUCT", 259, 262], ["GLP65", "PROTEIN", 0, 5], ["chimeric protein", "PROTEIN", 11, 27], ["DNA-binding domain", "PROTEIN", 44, 62], ["Saccharomyces cerevisiae transcription factor", "PROTEIN", 72, 117], ["GAL4", "PROTEIN", 118, 122], ["truncated ligand-binding domain", "PROTEIN", 126, 157], ["human progesterone receptor", "PROTEIN", 165, 192], ["transcriptional activation domain", "PROTEIN", 200, 233], ["human NF-\u03baB protein P65", "PROTEIN", 239, 262], ["Saccharomyces cerevisiae", "SPECIES", 72, 96], ["human", "SPECIES", 165, 170], ["human", "SPECIES", 239, 244], ["Saccharomyces cerevisiae", "SPECIES", 72, 96], ["human", "SPECIES", 165, 170], ["human", "SPECIES", 239, 244], ["a chimeric protein", "PROBLEM", 9, 27], ["a DNA-binding domain", "PROBLEM", 42, 62], ["a truncated ligand-binding domain", "PROBLEM", 124, 157], ["a human progesterone receptor", "TREATMENT", 163, 192], ["human NF", "TEST", 239, 247]]], ["A DNA segment containing a promoter cassette consisting of a human HSP70B promoter and a GAL4-binding site-containing (GAL4-responsive) promoter and a functionally linked GLP65 gene was inserted between the UL43 and UL44 genes of the HSV-1 wild-type strain 17syn+.", [["DNA", "CELLULAR_COMPONENT", 2, 5], ["human", "ORGANISM", 61, 66], ["HSP70B", "GENE_OR_GENE_PRODUCT", 67, 73], ["GAL4", "GENE_OR_GENE_PRODUCT", 89, 93], ["GAL4", "GENE_OR_GENE_PRODUCT", 119, 123], ["GLP65", "GENE_OR_GENE_PRODUCT", 171, 176], ["UL43", "GENE_OR_GENE_PRODUCT", 207, 211], ["UL44", "GENE_OR_GENE_PRODUCT", 216, 220], ["HSV-1 wild-type", "ORGANISM", 234, 249], ["DNA segment", "DNA", 2, 13], ["promoter cassette", "DNA", 27, 44], ["human HSP70B promoter", "DNA", 61, 82], ["GAL4-binding site", "DNA", 89, 106], ["GAL4-responsive) promoter", "DNA", 119, 144], ["GLP65 gene", "DNA", 171, 181], ["UL43 and UL44 genes", "DNA", 207, 226], ["human", "SPECIES", 61, 66], ["human", "SPECIES", 61, 66], ["HSV-1", "SPECIES", 234, 239], ["a promoter cassette", "TREATMENT", 25, 44], ["a human HSP70B promoter", "TREATMENT", 59, 82], ["a GAL4-binding site", "TREATMENT", 87, 106], ["GAL4-responsive) promoter", "TREATMENT", 119, 144], ["a functionally linked GLP65 gene", "TREATMENT", 149, 181], ["the HSV", "TEST", 230, 237], ["HSV", "ANATOMY", 234, 237]]], ["This intermediate vector was utilized for the construction of vectors HSV-GS3 and HSV-GS7.", [["HSV", "ORGANISM", 70, 73], ["-GS3", "ORGANISM", 73, 77], ["HSV-GS7", "ORGANISM", 82, 89], ["GS7", "DNA", 86, 89], ["HSV-GS7", "SPECIES", 82, 89], ["This intermediate vector", "TREATMENT", 0, 24], ["the construction of vectors HSV", "TEST", 42, 73], ["GS3", "TEST", 74, 77], ["HSV", "TEST", 82, 85]]], ["In vector HSV-GS3, the replication-essential immediate-early (IE) gene RS1/ICP4 and the early gene UL29/ICP8 had been placed under gene switch control by replacing the resident ICP4 and ICP8 promoters in the latter intermediate vector with GAL4-responsive promoters (Fig. 1B).", [["HSV-GS3", "ORGANISM", 10, 17], ["RS1", "GENE_OR_GENE_PRODUCT", 71, 74], ["ICP4", "GENE_OR_GENE_PRODUCT", 75, 79], ["UL29", "GENE_OR_GENE_PRODUCT", 99, 103], ["ICP8", "GENE_OR_GENE_PRODUCT", 104, 108], ["ICP4", "GENE_OR_GENE_PRODUCT", 177, 181], ["ICP8", "GENE_OR_GENE_PRODUCT", 186, 190], ["GAL4", "GENE_OR_GENE_PRODUCT", 240, 244], ["GS3", "DNA", 14, 17], ["replication-essential immediate-early (IE) gene", "DNA", 23, 70], ["RS1", "DNA", 71, 74], ["ICP4", "DNA", 75, 79], ["early gene", "DNA", 88, 98], ["UL29", "DNA", 99, 103], ["ICP8", "DNA", 104, 108], ["resident ICP4 and ICP8 promoters", "DNA", 168, 200], ["GAL4-responsive promoters", "DNA", 240, 265], ["HSV-GS3", "SPECIES", 10, 17], ["vector HSV", "TEST", 3, 13], ["the replication", "TREATMENT", 19, 34], ["gene RS1/ICP4", "TREATMENT", 66, 79], ["the early gene UL29/ICP8", "TREATMENT", 84, 108], ["gene switch control", "TREATMENT", 131, 150], ["the resident ICP4", "TREATMENT", 164, 181], ["ICP8 promoters", "TREATMENT", 186, 200], ["GAL4-responsive promoters", "TREATMENT", 240, 265]]], ["In vector HSV-GS7, the replication-essential late gene UL38/VP19c had been subjected to gene switch control by replacement of its promoter with a GAL4-responsive promoter.Replication-competent controlled HSV-1 vectors. ::: RESULTSReplication of HSV-GS3 had previously been shown to be strictly dependent on activation by heat and antiprogestin in single-step growth experiments (35).", [["antiprogestin", "CHEMICAL", 330, 343], ["antiprogestin", "CHEMICAL", 330, 343], ["HSV-GS7", "ORGANISM", 10, 17], ["UL38", "GENE_OR_GENE_PRODUCT", 55, 59], ["VP19c", "GENE_OR_GENE_PRODUCT", 60, 65], ["GAL4", "GENE_OR_GENE_PRODUCT", 146, 150], ["HSV-1", "ORGANISM", 204, 209], ["HSV-GS3", "ORGANISM", 245, 252], ["antiprogestin", "SIMPLE_CHEMICAL", 330, 343], ["GS7", "DNA", 14, 17], ["replication-essential late gene", "DNA", 23, 54], ["UL38", "DNA", 55, 59], ["VP19c", "DNA", 60, 65], ["promoter", "DNA", 130, 138], ["GAL4-responsive promoter", "DNA", 146, 170], ["GS3", "PROTEIN", 249, 252], ["HSV-1", "SPECIES", 204, 209], ["HSV-GS7", "SPECIES", 10, 17], ["HSV-1", "SPECIES", 204, 209], ["vector HSV", "TEST", 3, 13], ["the replication", "TREATMENT", 19, 34], ["gene switch control", "TREATMENT", 88, 107], ["replacement of its promoter", "TREATMENT", 111, 138], ["a GAL4-responsive promoter", "TREATMENT", 144, 170], ["HSV", "TEST", 245, 248], ["antiprogestin", "TREATMENT", 330, 343], ["HSV", "OBSERVATION", 245, 248]]], ["When activated, the recombinant replicated nearly as efficiently as the wild-type virus, 17syn+.", [["wild-type virus", "ORGANISM", 72, 87], ["the wild-type virus", "PROBLEM", 68, 87]]], ["When administered to the footpads of mice, HSV-GS3 replicated only subsequent to an activating treatment with locally administered heat in the presence of systemic antiprogestin.", [["footpads", "ANATOMY", 25, 33], ["antiprogestin", "CHEMICAL", 164, 177], ["antiprogestin", "CHEMICAL", 164, 177], ["footpads", "ORGANISM_SUBDIVISION", 25, 33], ["mice", "ORGANISM", 37, 41], ["HSV-GS3", "ORGANISM", 43, 50], ["antiprogestin", "SIMPLE_CHEMICAL", 164, 177], ["mice", "SPECIES", 37, 41], ["mice", "SPECIES", 37, 41], ["HSV-GS3", "SPECIES", 43, 50], ["HSV", "TEST", 43, 46], ["an activating treatment", "TREATMENT", 81, 104], ["locally administered heat", "TREATMENT", 110, 135], ["systemic antiprogestin", "TREATMENT", 155, 177], ["systemic antiprogestin", "OBSERVATION", 155, 177]]], ["The results of a single-step growth experiment with HSV-GS7 are shown in Fig. 1C.", [["1C.", "CHEMICAL", 78, 81], ["HSV", "ORGANISM", 52, 55], ["-GS7", "ORGANISM", 55, 59], ["HSV-GS7", "SPECIES", 52, 59], ["HSV", "TEST", 52, 55]]], ["The recombinant replicated approximately as well as HSV-GS3 following heat treatment in the presence of the antiprogestin ulipristal (35).", [["ulipristal", "CHEMICAL", 122, 132], ["antiprogestin ulipristal", "CHEMICAL", 108, 132], ["HSV-GS3", "ORGANISM", 52, 59], ["antiprogestin", "SIMPLE_CHEMICAL", 108, 121], ["GS3", "PROTEIN", 56, 59], ["HSV-GS3", "SPECIES", 52, 59], ["HSV", "TEST", 52, 55], ["heat treatment", "TREATMENT", 70, 84], ["the antiprogestin ulipristal", "TREATMENT", 104, 132]]], ["No replication was observed after either heat or antiprogestin treatment or in the absence of any treatment.", [["antiprogestin", "CHEMICAL", 49, 62], ["antiprogestin", "CHEMICAL", 49, 62], ["antiprogestin", "SIMPLE_CHEMICAL", 49, 62], ["replication", "PROBLEM", 3, 14], ["heat or antiprogestin treatment", "TREATMENT", 41, 72], ["any treatment", "TREATMENT", 94, 107], ["replication", "OBSERVATION", 3, 14]]], ["To verify that HSV-GS7 replication was also tightly controlled in vivo, two of three groups of mice were administered HSV-GS7 virus (50,000 PFU per mouse) in the footpads, and the mice of one of the groups were given ulipristal intraperitoneally (i,p.) and, 3 h later, were subjected to a heat treatment to the footpads at 45\u00b0C for 10 min.", [["footpads", "ANATOMY", 162, 170], ["footpads", "ANATOMY", 311, 319], ["ulipristal", "CHEMICAL", 217, 227], ["ulipristal", "CHEMICAL", 217, 227], ["HSV-GS7", "ORGANISM", 15, 22], ["mice", "ORGANISM", 95, 99], ["HSV-GS7 virus", "ORGANISM", 118, 131], ["mouse", "ORGANISM", 148, 153], ["footpads", "ORGANISM_SUBDIVISION", 162, 170], ["mice", "ORGANISM", 180, 184], ["ulipristal", "SIMPLE_CHEMICAL", 217, 227], ["footpads", "ORGANISM_SUBDIVISION", 311, 319], ["mice", "SPECIES", 95, 99], ["mouse", "SPECIES", 148, 153], ["mice", "SPECIES", 180, 184], ["HSV", "SPECIES", 15, 18], ["mice", "SPECIES", 95, 99], ["HSV-GS7 virus", "SPECIES", 118, 131], ["mouse", "SPECIES", 148, 153], ["mice", "SPECIES", 180, 184], ["HSV", "TEST", 15, 18], ["GS7 replication", "PROBLEM", 19, 34], ["HSV", "TEST", 118, 121], ["GS7 virus", "PROBLEM", 122, 131], ["ulipristal intraperitoneally", "TREATMENT", 217, 245], ["a heat treatment", "TREATMENT", 287, 303], ["footpads", "ANATOMY", 162, 170], ["footpads", "ANATOMY", 311, 319]]], ["One day later, all the mice were euthanized, and DNA and RNA were extracted from their feet and analyzed by quantitative PCR (qPCR) and RT-qPCR, respectively.", [["feet", "ANATOMY", 87, 91], ["mice", "ORGANISM", 23, 27], ["DNA", "CELLULAR_COMPONENT", 49, 52], ["feet", "ORGANISM_SUBDIVISION", 87, 91], ["mice", "SPECIES", 23, 27], ["mice", "SPECIES", 23, 27], ["DNA and RNA", "PROBLEM", 49, 60], ["quantitative PCR", "TEST", 108, 124], ["qPCR", "TEST", 126, 130], ["RT-qPCR", "TEST", 136, 143], ["feet", "ANATOMY", 87, 91]]], ["Substantially larger amounts of HSV-1 DNA were detected in the feet of heat/ulipristal-treated mice than in untreated mice (Fig. 1D).", [["feet", "ANATOMY", 63, 67], ["ulipristal", "CHEMICAL", 76, 86], ["HSV-1", "GENE_OR_GENE_PRODUCT", 32, 37], ["DNA", "CELLULAR_COMPONENT", 38, 41], ["feet", "ORGANISM_SUBDIVISION", 63, 67], ["ulipristal", "SIMPLE_CHEMICAL", 76, 86], ["mice", "ORGANISM", 95, 99], ["mice", "ORGANISM", 118, 122], ["HSV-1 DNA", "DNA", 32, 41], ["HSV-1", "SPECIES", 32, 37], ["mice", "SPECIES", 95, 99], ["mice", "SPECIES", 118, 122], ["HSV-1", "SPECIES", 32, 37], ["mice", "SPECIES", 95, 99], ["mice", "SPECIES", 118, 122], ["HSV", "PROBLEM", 32, 35], ["1 DNA", "PROBLEM", 36, 41], ["heat/ulipristal", "TREATMENT", 71, 86], ["larger", "OBSERVATION_MODIFIER", 14, 20], ["amounts", "OBSERVATION_MODIFIER", 21, 28], ["HSV", "OBSERVATION", 32, 35], ["1 DNA", "OBSERVATION_MODIFIER", 36, 41], ["feet", "ANATOMY", 63, 67], ["ulipristal", "ANATOMY", 76, 86]]], ["Expression of several viral genes was observed for activated virus, but not for unactivated virus, strongly suggesting that viral replication and gene expression occurred only subsequent to heat/ulipristal activation.Protective immunity induced by activated HSV-GS3. ::: RESULTSInduction of protective immunity was evaluated in a mouse footpad lethal challenge model (36).", [["HSV-GS3", "ORGANISM", 258, 265], ["mouse", "ORGANISM", 330, 335], ["viral genes", "DNA", 22, 33], ["mouse", "SPECIES", 330, 335], ["HSV-GS3", "SPECIES", 258, 265], ["mouse", "SPECIES", 330, 335], ["several viral genes", "PROBLEM", 14, 33], ["activated virus", "PROBLEM", 51, 66], ["unactivated virus", "PROBLEM", 80, 97], ["viral replication", "PROBLEM", 124, 141], ["heat/ulipristal activation", "TREATMENT", 190, 216], ["protective immunity", "TREATMENT", 291, 310], ["a mouse footpad lethal challenge model", "TREATMENT", 328, 366], ["several", "OBSERVATION_MODIFIER", 14, 21], ["viral genes", "OBSERVATION", 22, 33], ["viral replication", "OBSERVATION", 124, 141], ["ulipristal activation", "OBSERVATION", 195, 216]]], ["In the first experiment, the virus vector HSV-GS3 or KD6 (an ICP4\u2212 replication-incompetent HSV-1 recombinant [37]) was administered under anesthesia to the plantar surfaces of both rear feet of adult Swiss Webster outbred female mice (50,000 PFU per animal; 20 animals per group).", [["plantar surfaces", "ANATOMY", 156, 172], ["HSV-GS3", "ORGANISM", 42, 49], ["KD6", "GENE_OR_GENE_PRODUCT", 53, 56], ["ICP4", "GENE_OR_GENE_PRODUCT", 61, 65], ["HSV-1", "ORGANISM", 91, 96], ["plantar surfaces", "MULTI-TISSUE_STRUCTURE", 156, 172], ["feet", "ORGANISM_SUBDIVISION", 186, 190], ["Swiss Webster outbred female mice", "ORGANISM", 200, 233], ["GS3", "DNA", 46, 49], ["KD6", "DNA", 53, 56], ["ICP4", "PROTEIN", 61, 65], ["HSV-1", "SPECIES", 91, 96], ["mice", "SPECIES", 229, 233], ["HSV-GS3", "SPECIES", 42, 49], ["HSV-1", "SPECIES", 91, 96], ["mice", "SPECIES", 229, 233], ["the virus vector HSV", "TEST", 25, 45], ["GS3", "TEST", 46, 49], ["KD6", "TEST", 53, 56], ["an ICP4\u2212 replication", "TREATMENT", 58, 78], ["incompetent HSV", "TREATMENT", 79, 94], ["anesthesia", "TREATMENT", 138, 148], ["plantar", "ANATOMY", 156, 163]]], ["Concurrently, and again 24 h later, the animals of one of the HSV-GS3 groups received an intraperitoneal injection of 0.5 mg/kg of body weight mifepristone.", [["intraperitoneal", "ANATOMY", 89, 104], ["body", "ANATOMY", 131, 135], ["mifepristone", "CHEMICAL", 143, 155], ["mifepristone", "CHEMICAL", 143, 155], ["animals", "ORGANISM", 40, 47], ["HSV", "ORGANISM", 62, 65], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 89, 104], ["body", "ORGANISM_SUBDIVISION", 131, 135], ["mifepristone", "SIMPLE_CHEMICAL", 143, 155], ["an intraperitoneal injection", "TREATMENT", 86, 114], ["body weight mifepristone", "TREATMENT", 131, 155]]], ["Three hours after inoculation, the mice in this group were subjected to heat treatment (43.5\u00b0C for 30 min) by immersion of their hind feet in a temperature-controlled water bath.", [["hind feet", "ANATOMY", 129, 138], ["mice", "ORGANISM", 35, 39], ["hind feet", "ORGANISM_SUBDIVISION", 129, 138], ["mice", "SPECIES", 35, 39], ["mice", "SPECIES", 35, 39], ["inoculation", "TREATMENT", 18, 29], ["heat treatment", "TREATMENT", 72, 86], ["a temperature-controlled water bath", "TREATMENT", 142, 177], ["hind feet", "ANATOMY", 129, 138]]], ["Twenty-two days later, all the animals were challenged with a 20-fold lethal dose of the HSV-1 wild-type strain 17syn+ administered by the same route as the original virus inoculum.", [["17syn", "CHEMICAL", 112, 117], ["animals", "ORGANISM", 31, 38], ["HSV-1", "ORGANISM", 89, 94], ["17syn", "ORGANISM", 112, 117], ["HSV-1 wild-type strain 17syn", "SPECIES", 89, 117], ["the HSV", "TEST", 85, 92], ["type strain 17syn", "TREATMENT", 100, 117], ["the original virus inoculum", "PROBLEM", 153, 180], ["virus inoculum", "OBSERVATION", 166, 180]]], ["KD6 induced a modest level of immunity.", [["KD6", "CHEMICAL", 0, 3], ["KD6", "GENE_OR_GENE_PRODUCT", 0, 3], ["KD6", "PROTEIN", 0, 3], ["modest", "OBSERVATION_MODIFIER", 14, 20]]], ["As had been expected, because it did not replicate and also did not express the major transcriptional regulator ICP4, unactivated HSV-GS3 provided a comparable degree of protection.", [["ICP4", "GENE_OR_GENE_PRODUCT", 112, 116], ["HSV-GS3", "ORGANISM", 130, 137], ["major transcriptional regulator", "PROTEIN", 80, 111], ["ICP4", "PROTEIN", 112, 116], ["GS3", "PROTEIN", 134, 137], ["unactivated HSV", "TEST", 118, 133]]], ["Activated HSV-GS3 produced a far greater protective effect.", [["HSV-GS3", "ORGANISM", 10, 17], ["Activated HSV", "TEST", 0, 13]]], ["Therefore, one round of efficient replication and/or expression of the master regulator ICP4, resulting in expression of all the viral proteins, produced a dramatic enhancement of protective immunity.", [["ICP4", "GENE_OR_GENE_PRODUCT", 88, 92], ["master regulator", "PROTEIN", 71, 87], ["ICP4", "PROTEIN", 88, 92], ["viral proteins", "PROTEIN", 129, 143], ["efficient replication", "TREATMENT", 24, 45], ["the master regulator ICP4", "PROBLEM", 67, 92], ["all the viral proteins", "PROBLEM", 121, 143], ["a dramatic enhancement of protective immunity", "PROBLEM", 154, 199], ["efficient", "OBSERVATION_MODIFIER", 24, 33], ["replication", "OBSERVATION", 34, 45], ["dramatic", "OBSERVATION_MODIFIER", 156, 164], ["enhancement", "OBSERVATION_MODIFIER", 165, 176]]], ["It was noted that the heat and antiprogestin treatment had no systematic effect on the level of protection induced by the replication-defective virus KD6 (see \u201cStatistical evaluation of data from all comparable experiments\u201d below).Protective immunity induced by activated HSV-GS3. ::: RESULTSTo determine whether immunization with activated HSV-GS3 reduced replication of the challenge virus more effectively than unactivated HSV-GS3 or the replication-defective KD6 virus, additional groups of animals (5 animals per group) were immunized and challenged with wild-type virus as described above.", [["antiprogestin", "CHEMICAL", 31, 44], ["antiprogestin", "CHEMICAL", 31, 44], ["antiprogestin", "SIMPLE_CHEMICAL", 31, 44], ["HSV-GS3", "ORGANISM", 272, 279], ["HSV-GS3", "ORGANISM", 341, 348], ["HSV-GS3", "ORGANISM", 426, 433], ["KD6 virus", "ORGANISM", 463, 472], ["animals", "ORGANISM", 495, 502], ["wild-type virus", "ORGANISM", 560, 575], ["GS3", "PROTEIN", 345, 348], ["HSV-GS3", "SPECIES", 272, 279], ["HSV-GS3", "SPECIES", 341, 348], ["HSV-GS3", "SPECIES", 426, 433], ["KD6 virus", "SPECIES", 463, 472], ["the heat", "TREATMENT", 18, 26], ["antiprogestin treatment", "TREATMENT", 31, 54], ["systematic effect", "PROBLEM", 62, 79], ["defective virus KD6", "PROBLEM", 134, 153], ["Statistical evaluation", "TEST", 160, 182], ["immunization", "TREATMENT", 313, 325], ["activated HSV", "TEST", 331, 344], ["the challenge virus", "TREATMENT", 372, 391], ["unactivated HSV", "TEST", 414, 429], ["GS3", "PROBLEM", 430, 433], ["the replication", "PROBLEM", 437, 452], ["defective KD6 virus", "PROBLEM", 453, 472], ["wild-type virus", "PROBLEM", 560, 575]]], ["Four days after challenge, the animals were euthanized, their feet were dissected and homogenized, and virus present in the homogenates was titrated on rabbit skin (RS) cells.", [["feet", "ANATOMY", 62, 66], ["homogenates", "ANATOMY", 124, 135], ["skin (RS) cells", "ANATOMY", 159, 174], ["animals", "ORGANISM", 31, 38], ["feet", "ORGANISM_SUBDIVISION", 62, 66], ["rabbit", "ORGANISM", 152, 158], ["skin (RS) cells", "CELL", 159, 174], ["rabbit skin (RS) cells", "CELL_LINE", 152, 174], ["rabbit", "SPECIES", 152, 158], ["rabbit", "SPECIES", 152, 158], ["virus", "PROBLEM", 103, 108], ["feet", "ANATOMY", 62, 66]]], ["The results revealed that activated HSV-GS3 reduced challenge virus replication by nearly 2 orders of magnitude (6.2 \u00d7 103 \u00b1 1.5 \u00d7 102 PFU) and unactivated recombinant virus (9.4 \u00d7 104 \u00b1 3.1 \u00d7 104 PFU) or KD6 (4.0 \u00d7 104 \u00b1 8.3 \u00d7 102 PFU) by only about 1 order of magnitude versus mock infection (5.5 \u00d7 105 \u00b1 1.2 \u00d7 104 PFU).Protective immunity induced by activated HSV-GS3. ::: RESULTSWe next examined in a similar experiment whether induction of enhanced protective immunity was caused by activation of the heat- and antiprogestin-dependent gene switch that controls the expression of ICP4 and ICP8 in the HSV-GS3 recombinant.", [["infection", "DISEASE", 284, 293], ["HSV-GS3", "ORGANISM", 36, 43], ["HSV-GS3", "ORGANISM", 363, 370], ["antiprogestin", "GENE_OR_GENE_PRODUCT", 516, 529], ["ICP4", "GENE_OR_GENE_PRODUCT", 584, 588], ["ICP8", "GENE_OR_GENE_PRODUCT", 593, 597], ["HSV-GS3 recombinant", "ORGANISM", 605, 624], ["antiprogestin", "PROTEIN", 516, 529], ["ICP4", "PROTEIN", 584, 588], ["ICP8", "PROTEIN", 593, 597], ["HSV-GS3 recombinant", "PROTEIN", 605, 624], ["HSV-GS3", "SPECIES", 36, 43], ["HSV-GS3", "SPECIES", 363, 370], ["HSV-GS3", "SPECIES", 605, 612], ["activated HSV", "TEST", 26, 39], ["GS3 reduced challenge virus replication", "TREATMENT", 40, 79], ["magnitude", "TEST", 102, 111], ["PFU", "TEST", 135, 138], ["unactivated recombinant virus", "PROBLEM", 144, 173], ["PFU", "TEST", 197, 200], ["KD6", "TEST", 205, 208], ["PFU", "TEST", 232, 235], ["mock infection", "PROBLEM", 279, 293], ["the heat", "PROBLEM", 502, 510], ["antiprogestin-dependent gene switch", "TREATMENT", 516, 551], ["ICP4 and ICP8", "TREATMENT", 584, 597], ["the HSV", "TEST", 601, 608], ["infection", "OBSERVATION", 284, 293]]], ["In this and all subsequent experiments, ulipristal was utilized instead of mifepristone because the former compound is a more active gene switch coactivator than the latter compound (35).", [["ulipristal", "CHEMICAL", 40, 50], ["mifepristone", "CHEMICAL", 75, 87], ["ulipristal", "CHEMICAL", 40, 50], ["mifepristone", "CHEMICAL", 75, 87], ["ulipristal", "SIMPLE_CHEMICAL", 40, 50], ["mifepristone", "SIMPLE_CHEMICAL", 75, 87], ["coactivator", "PROTEIN", 145, 156], ["ulipristal", "TREATMENT", 40, 50], ["mifepristone", "TREATMENT", 75, 87]]], ["Furthermore, the heat treatment regimen was changed to heat exposure at 45\u00b0C for 10 min to achieve greater reproducibility between experiments.", [["the heat treatment regimen", "TREATMENT", 13, 39], ["heat exposure", "TREATMENT", 55, 68]]], ["The results revealed that enhanced protection was achieved only following activation of HSV-GS3 by heat treatment in the presence of ulipristal (Fig. 3).", [["ulipristal", "CHEMICAL", 133, 143], ["ulipristal", "CHEMICAL", 133, 143], ["HSV", "ORGANISM", 88, 91], ["-GS3", "ORGANISM", 91, 95], ["ulipristal", "SIMPLE_CHEMICAL", 133, 143], ["GS3", "PROTEIN", 92, 95], ["HSV", "SPECIES", 88, 91], ["enhanced protection", "TREATMENT", 26, 45], ["HSV-GS3", "TREATMENT", 88, 95], ["heat treatment", "TREATMENT", 99, 113], ["ulipristal", "OBSERVATION", 133, 143]]], ["Heat treatment alone or ulipristal alone did not significantly increase the protective effect over that produced by the unactivated virus.", [["ulipristal", "CHEMICAL", 24, 34], ["ulipristal", "CHEMICAL", 24, 34], ["ulipristal", "SIMPLE_CHEMICAL", 24, 34], ["Heat treatment", "TREATMENT", 0, 14], ["ulipristal", "TREATMENT", 24, 34], ["the unactivated virus", "PROBLEM", 116, 137]]], ["These findings strongly suggested that it was the activation of the dual-responsive gene switch in HSV-GS3 that prompted the expression of the regulated replication-essential genes, as well as efficient virus replication that in turn resulted in the observed enhanced protective response.", [["HSV-GS3", "ORGANISM", 99, 106], ["GS3", "DNA", 103, 106], ["regulated replication-essential genes", "DNA", 143, 180], ["HSV-GS3", "SPECIES", 99, 106], ["HSV", "PROBLEM", 99, 102], ["the regulated replication", "TREATMENT", 139, 164], ["efficient virus replication", "TREATMENT", 193, 220]]], ["Note that in this experiment the virus inoculum was 500,000 PFU rather than 50,000 PFU, as in most other experiments (Table 1 and Fig. 2, 4, and 5A; see Fig. 7 and 8).", [["the virus inoculum", "PROBLEM", 29, 47]]], ["This may account for the somewhat elevated level of protection induced by unactivated HSV-GS3 and KD6.HSV-GS3 and HSV-GS7 induce comparable protective responses. ::: RESULTSThe greatly enhanced protective response that resulted from transient activation of the gene switch in HSV-GS3-immunized animals could have been due to the efficient virus replication triggered by the activation and/or to the activation of the genes for the major transcription regulator ICP4, which in turn stimulated expression of all the other viral genes in primarily infected cells.", [["cells", "ANATOMY", 554, 559], ["HSV-GS3", "ORGANISM", 86, 93], ["KD6", "GENE_OR_GENE_PRODUCT", 98, 101], ["HSV-GS3", "ORGANISM", 102, 109], ["HSV-GS7", "ORGANISM", 114, 121], ["HSV-GS3-immunized animals", "ORGANISM", 276, 301], ["ICP4", "GENE_OR_GENE_PRODUCT", 461, 465], ["cells", "CELL", 554, 559], ["GS3", "PROTEIN", 90, 93], ["KD6", "PROTEIN", 98, 101], ["major transcription regulator", "PROTEIN", 431, 460], ["ICP4", "PROTEIN", 461, 465], ["viral genes", "DNA", 520, 531], ["primarily infected cells", "CELL_TYPE", 535, 559], ["HSV", "SPECIES", 102, 105], ["HSV-GS7", "SPECIES", 114, 121], ["HSV", "SPECIES", 276, 279], ["the somewhat elevated level of protection", "PROBLEM", 21, 62], ["unactivated HSV", "TEST", 74, 89], ["KD6", "TREATMENT", 98, 101], ["HSV", "TEST", 102, 105], ["GS3", "TEST", 106, 109], ["HSV", "TEST", 114, 117], ["HSV", "TEST", 276, 279], ["GS3", "PROBLEM", 280, 283], ["immunized animals", "PROBLEM", 284, 301], ["the efficient virus replication", "PROBLEM", 325, 356], ["the major transcription regulator ICP4", "TREATMENT", 427, 465], ["all the other viral genes in primarily infected cells", "PROBLEM", 506, 559], ["may account for", "UNCERTAINTY", 5, 20], ["enhanced", "OBSERVATION_MODIFIER", 185, 193], ["protective response", "OBSERVATION", 194, 213], ["virus", "OBSERVATION", 339, 344], ["viral genes", "OBSERVATION", 520, 531], ["infected cells", "OBSERVATION", 545, 559]]], ["Another question was related to whether abundant viral gene expression in secondarily infected cells (which may include antigen-presenting cells) could further enhance the immune response.", [["cells", "ANATOMY", 95, 100], ["antigen-presenting cells", "ANATOMY", 120, 144], ["cells", "CELL", 95, 100], ["cells", "CELL", 139, 144], ["secondarily infected cells", "CELL_TYPE", 74, 100], ["antigen-presenting cells", "CELL_TYPE", 120, 144], ["abundant viral gene expression", "PROBLEM", 40, 70], ["secondarily infected cells", "PROBLEM", 74, 100], ["antigen-presenting cells", "PROBLEM", 120, 144], ["abundant", "OBSERVATION_MODIFIER", 40, 48], ["viral gene expression", "OBSERVATION", 49, 70], ["infected cells", "OBSERVATION", 86, 100]]], ["Since the ICP4 genes are regulated in HSV-GS3, little expression of viral genes was expected to occur in the absence of another activating treatment.", [["ICP4", "GENE_OR_GENE_PRODUCT", 10, 14], ["HSV-GS3", "ORGANISM", 38, 45], ["ICP4 genes", "DNA", 10, 20], ["GS3", "DNA", 42, 45], ["viral genes", "DNA", 68, 79], ["HSV-GS3", "SPECIES", 38, 45], ["the ICP4 genes", "TEST", 6, 20], ["HSV", "TEST", 38, 41], ["viral genes", "PROBLEM", 68, 79], ["another activating treatment", "TREATMENT", 120, 148], ["ICP4 genes", "OBSERVATION", 10, 20], ["viral genes", "OBSERVATION", 68, 79]]], ["Recombinant HSV-GS7 in which the late VP19c gene had been subjected to regulation was constructed to examine these issues.", [["HSV-GS7", "ORGANISM", 12, 19], ["VP19c", "GENE_OR_GENE_PRODUCT", 38, 43], ["Recombinant HSV-GS7", "DNA", 0, 19], ["VP19c gene", "DNA", 38, 48], ["HSV-GS7", "SPECIES", 12, 19], ["Recombinant HSV", "TEST", 0, 15], ["HSV", "OBSERVATION", 12, 15]]], ["HSV-GS3 and HSV-GS7 were compared in the mouse footpad challenge model.", [["HSV-GS3", "ORGANISM", 0, 7], ["HSV-GS7", "ORGANISM", 12, 19], ["mouse", "ORGANISM", 41, 46], ["footpad", "ORGANISM_SUBDIVISION", 47, 54], ["HSV-GS3 and HSV-GS7", "DNA", 0, 19], ["mouse", "SPECIES", 41, 46], ["HSV", "SPECIES", 0, 3], ["HSV-GS7", "SPECIES", 12, 19], ["mouse", "SPECIES", 41, 46], ["HSV", "TEST", 0, 3], ["GS3", "TEST", 4, 7], ["HSV", "TEST", 12, 15]]], ["The results revealed that activated HSV-GS3 and HSV-GS7 provided similar levels of protection (Fig. 4).", [["HSV-GS3", "ORGANISM", 36, 43], ["HSV-GS7", "ORGANISM", 48, 55], ["HSV-GS7", "SPECIES", 48, 55], ["activated HSV", "TEST", 26, 39], ["GS3", "TEST", 40, 43], ["HSV", "TEST", 48, 51]]], ["Taking data from other experiments into account, the average protective effect for unactivated HSV-GS3 was 22% and that for unactivated HSV-GS7 was 13% (see \u201cStatistical evaluation of data from all comparable experiments\u201d below).", [["HSV", "ORGANISM", 95, 98], ["-GS3", "ORGANISM", 98, 102], ["HSV-GS7", "ORGANISM", 136, 143], ["HSV-GS3", "SPECIES", 95, 102], ["HSV-GS7", "SPECIES", 136, 143], ["unactivated HSV-GS3", "TEST", 83, 102], ["unactivated HSV", "TEST", 124, 139], ["Statistical evaluation", "TEST", 158, 180]]], ["The fact that the two recombinants that lacked expression of different proteins in the absence of activation induced comparable (modest) protective responses strongly suggested that it was not the absence of one or the other viral protein that limited the immune response to the recombinants.", [["viral protein", "PROTEIN", 225, 238], ["different proteins", "PROBLEM", 61, 79], ["the other viral protein", "PROBLEM", 215, 238]]], ["It was instead the vigorous replication of the activated recombinants that enhanced the protective responses against them.", [["the activated recombinants", "TREATMENT", 43, 69], ["vigorous", "OBSERVATION_MODIFIER", 19, 27]]], ["In secondarily infected cells (in which HSF1 was not activated), HSV-GS7 was expected to express all viral proteins except the regulated capsid protein at approximately normal levels.", [["cells", "ANATOMY", 24, 29], ["cells", "CELL", 24, 29], ["HSF1", "GENE_OR_GENE_PRODUCT", 40, 44], ["HSV-GS7", "ORGANISM", 65, 72], ["secondarily infected cells", "CELL_TYPE", 3, 29], ["HSF1", "PROTEIN", 40, 44], ["GS7", "PROTEIN", 69, 72], ["viral proteins", "PROTEIN", 101, 115], ["regulated capsid protein", "PROTEIN", 127, 151], ["HSV-GS7", "SPECIES", 65, 72], ["secondarily infected cells", "PROBLEM", 3, 29], ["HSF1", "TEST", 40, 44], ["HSV", "TEST", 65, 68], ["all viral proteins", "PROBLEM", 97, 115], ["infected cells", "OBSERVATION", 15, 29], ["capsid protein", "OBSERVATION", 137, 151]]], ["In contrast, HSV-GS3 all but lacked ICP4 expression in the absence of activation and exhibited dramatically curtailed expression of other viral proteins (35).", [["HSV-GS3", "ORGANISM", 13, 20], ["ICP4", "GENE_OR_GENE_PRODUCT", 36, 40], ["ICP4", "PROTEIN", 36, 40], ["viral proteins", "PROTEIN", 138, 152], ["HSV-GS3", "SPECIES", 13, 20], ["HSV", "TEST", 13, 16], ["other viral proteins", "TEST", 132, 152], ["ICP4 expression", "OBSERVATION", 36, 51]]], ["The finding that HSV-GS3 and HSV-GS7 induced comparable protective responses suggested that viral proteins expressed in secondarily infected cells did not contribute in a relevant fashion to the immune response.", [["cells", "ANATOMY", 141, 146], ["HSV-GS3", "ORGANISM", 17, 24], ["HSV-GS7", "ORGANISM", 29, 36], ["cells", "CELL", 141, 146], ["GS7", "PROTEIN", 33, 36], ["viral proteins", "PROTEIN", 92, 106], ["secondarily infected cells", "CELL_TYPE", 120, 146], ["HSV", "SPECIES", 29, 32], ["HSV", "TEST", 17, 20], ["GS3", "TEST", 21, 24], ["HSV", "TEST", 29, 32], ["viral proteins", "PROBLEM", 92, 106], ["secondarily infected cells", "PROBLEM", 120, 146], ["infected cells", "OBSERVATION", 132, 146]]], ["However, we cannot exclude the possibility that the immune system was sufficiently sensitive to detect the very low levels of viral antigen expression occurring in cells secondarily infected with HSV-GS3.A second immunization further enhances protective immunity. ::: RESULTSWe next investigated whether a second activation treatment applied 2 days after the first treatment (i.e., at a time at which the initial round of replication of HSV-GS7 should have been completed) or a second immunization would further enhance protection against wild-type virus challenge.", [["cells", "ANATOMY", 164, 169], ["cells", "CELL", 164, 169], ["HSV-GS3", "ORGANISM", 196, 203], ["HSV", "ORGANISM", 437, 440], ["-GS7", "ORGANISM", 440, 444], ["wild-type virus", "ORGANISM", 539, 554], ["viral antigen", "PROTEIN", 126, 139], ["GS7", "PROTEIN", 441, 444], ["HSV-GS3", "SPECIES", 196, 203], ["the immune system", "TEST", 48, 65], ["the very low levels", "PROBLEM", 103, 122], ["viral antigen expression", "PROBLEM", 126, 150], ["HSV", "TEST", 196, 199], ["A second immunization", "TREATMENT", 204, 225], ["a second activation treatment", "TREATMENT", 304, 333], ["the first treatment", "TREATMENT", 355, 374], ["HSV-GS7", "TREATMENT", 437, 444], ["a second immunization", "TREATMENT", 476, 497], ["wild-type virus challenge", "TREATMENT", 539, 564], ["viral antigen expression", "OBSERVATION", 126, 150]]], ["The second immunization was administered 3 weeks after the initial virus application.", [["The second immunization", "TREATMENT", 0, 23], ["the initial virus application", "TREATMENT", 55, 84]]], ["Booster virus was either activated or left unactivated.", [["Booster virus", "ORGANISM", 0, 13], ["Booster virus", "SPECIES", 0, 13], ["Booster virus", "TREATMENT", 0, 13]]], ["As shown in Fig. 5A, groups of mice were immunized with 50,000 PFU/animal of recombinant HSV-GS7.", [["mice", "ORGANISM", 31, 35], ["HSV", "ORGANISM", 89, 92], ["-GS7", "ORGANISM", 92, 96], ["GS7", "PROTEIN", 93, 96], ["mice", "SPECIES", 31, 35], ["mice", "SPECIES", 31, 35], ["HSV-GS7", "SPECIES", 89, 96], ["recombinant HSV", "TEST", 77, 92]]], ["Activation of the virus induced an immune response that protected 75% of the animals after challenge with wild-type virus.", [["wild-type virus", "ORGANISM", 106, 121], ["the virus", "PROBLEM", 14, 23], ["wild-type virus", "PROBLEM", 106, 121]]], ["After the second immunization with a similar dose of HSV-GS7, all the animals were protected.", [["HSV-GS7", "ORGANISM", 53, 60], ["animals", "ORGANISM", 70, 77], ["HSV-GS7", "SPECIES", 53, 60], ["the second immunization", "TREATMENT", 6, 29], ["HSV", "TEST", 53, 56]]], ["However, this occurred only if the booster virus was also subjected to an activating treatment.", [["the booster virus", "PROBLEM", 31, 48], ["an activating treatment", "TREATMENT", 71, 94]]], ["A second activation after a single dose of HSV-GS7 had no apparent effect.", [["HSV-GS7", "CHEMICAL", 43, 50], ["HSV", "ORGANISM", 43, 46], ["-GS7", "ORGANISM", 46, 50], ["HSV", "SPECIES", 43, 46], ["HSV", "TEST", 43, 46], ["apparent effect", "PROBLEM", 58, 73], ["no apparent", "UNCERTAINTY", 55, 66]]], ["As effects of reimmunization may be more apparent in mice immunized with smaller quantities of virus, the experiment also featured parallel groups of animals that were immunized and boosted with 5,000 PFU/animal of recombinant HSV-GS7.", [["mice", "ORGANISM", 53, 57], ["HSV-GS7", "ORGANISM", 227, 234], ["GS7", "PROTEIN", 231, 234], ["mice", "SPECIES", 53, 57], ["mice", "SPECIES", 53, 57], ["HSV-GS7", "SPECIES", 227, 234], ["reimmunization", "TREATMENT", 14, 28], ["smaller quantities of virus", "PROBLEM", 73, 100], ["recombinant HSV", "TEST", 215, 230]]], ["As Fig. 5B documents, a second immunization followed by virus activation had an even more pronounced effect at the 10-fold-reduced virus doses.", [["a second immunization", "TREATMENT", 22, 43], ["virus activation", "PROBLEM", 56, 72], ["reduced virus doses", "TREATMENT", 123, 142]]], ["It was noted that in this part of the experiment a second activation appeared to modestly enhance the protective immune response (not statistically significant).Statistical evaluation of data from all comparable experiments. ::: RESULTSRelevant data from all immunization/challenge experiments that were conducted using essentially identical protocols are assembled in Table 1.", [["Statistical evaluation", "TEST", 161, 183], ["RESULTSRelevant data", "TEST", 229, 249], ["all immunization", "TREATMENT", 255, 271], ["challenge experiments", "TEST", 272, 293]]], ["The results of a meta-analysis of the HSV-GS7 data are presented graphically in Fig. 6.", [["HSV", "ORGANISM", 38, 41], ["GS7", "DNA", 42, 45], ["a meta-analysis", "TEST", 15, 30], ["the HSV", "TEST", 34, 41]]], ["The difference in immunization efficacy between activated and unactivated HSV-GS7 was found to be highly significant.", [["HSV-GS7", "ORGANISM", 74, 81], ["HSV-GS7", "SPECIES", 74, 81], ["immunization efficacy", "TREATMENT", 18, 39], ["activated and unactivated HSV-GS7", "TEST", 48, 81], ["difference", "OBSERVATION_MODIFIER", 4, 14]]], ["Also significant was the increase in protection afforded by a second immunization with an activated HSV-GS7 vector.", [["HSV", "ORGANISM", 100, 103], ["GS7", "GENE_OR_GENE_PRODUCT", 104, 107], ["activated HSV-GS7 vector", "DNA", 90, 114], ["HSV-GS7", "SPECIES", 100, 107], ["a second immunization", "TREATMENT", 60, 81], ["significant", "OBSERVATION_MODIFIER", 5, 16], ["increase", "OBSERVATION_MODIFIER", 25, 33]]], ["The effect of the second activation 2 days after virus administration and the first activation was not statistically relevant.Immune correlates of protection against challenge. ::: RESULTSThe presence and levels of antibodies capable of neutralizing HSV-1 strain 17syn+ were assessed in sera of mice that had been treated with activated or unactivated HSV-GS vectors or with the replication-incompetent virus KD6 (all at 50,000 PFU per animal) 3 weeks earlier.", [["sera", "ANATOMY", 287, 291], ["HSV-1", "ORGANISM", 250, 255], ["17syn", "ORGANISM", 263, 268], ["sera", "ORGANISM_SUBSTANCE", 287, 291], ["mice", "ORGANISM", 295, 299], ["HSV", "ORGANISM", 352, 355], ["antibodies", "PROTEIN", 215, 225], ["HSV-1", "SPECIES", 250, 255], ["mice", "SPECIES", 295, 299], ["HSV-1", "SPECIES", 250, 255], ["mice", "SPECIES", 295, 299], ["virus administration", "TREATMENT", 49, 69], ["antibodies", "TEST", 215, 225], ["neutralizing HSV", "TEST", 237, 253], ["unactivated HSV-GS vectors", "TREATMENT", 340, 366], ["the replication", "TREATMENT", 375, 390], ["incompetent virus KD6", "PROBLEM", 391, 412]]], ["As expected, neutralizing antibodies could be detected subsequent to immunization with KD6 or unactivated HSV-GS (Fig. 7A).", [["KD6", "GENE_OR_GENE_PRODUCT", 87, 90], ["HSV-GS", "ORGANISM", 106, 112], ["Fig. 7A", "ORGANISM", 114, 121], ["neutralizing antibodies", "PROTEIN", 13, 36], ["KD6", "PROTEIN", 87, 90], ["neutralizing antibodies", "TEST", 13, 36], ["immunization", "TREATMENT", 69, 81], ["KD6", "TREATMENT", 87, 90], ["unactivated HSV", "TEST", 94, 109]]], ["Antibody levels in sera from KD6-immunized and unactivated HSV-GS vector-immunized animals were comparable.", [["sera", "ANATOMY", 19, 23], ["sera", "ORGANISM_SUBSTANCE", 19, 23], ["KD6", "GENE_OR_GENE_PRODUCT", 29, 32], ["HSV-GS", "ORGANISM", 59, 65], ["animals", "ORGANISM", 83, 90], ["HSV", "SPECIES", 59, 62], ["Antibody levels", "TEST", 0, 15], ["sera", "TEST", 19, 23], ["KD6", "TEST", 29, 32], ["immunized", "PROBLEM", 33, 42], ["unactivated HSV", "TEST", 47, 62]]], ["Both activated HSV-GS3 and HSV-GS7 induced neutralizing antibody responses clearly superior to those induced by unactivated HSV-GS3 or HSV-GS7 or by KD6.", [["HSV-GS3", "ORGANISM", 15, 22], ["HSV-GS7", "ORGANISM", 27, 34], ["HSV-GS3", "ORGANISM", 124, 131], ["HSV-GS7", "ORGANISM", 135, 142], ["KD6", "GENE_OR_GENE_PRODUCT", 149, 152], ["GS7", "PROTEIN", 31, 34], ["GS3", "PROTEIN", 128, 131], ["GS7", "PROTEIN", 139, 142], ["KD6", "PROTEIN", 149, 152], ["HSV-GS7", "SPECIES", 27, 34], ["HSV", "SPECIES", 124, 127], ["HSV-GS7", "SPECIES", 135, 142], ["Both activated HSV", "TEST", 0, 18], ["GS3", "TEST", 19, 22], ["HSV", "TEST", 27, 30], ["neutralizing antibody responses", "TEST", 43, 74], ["unactivated HSV", "TEST", 112, 127], ["GS3", "PROBLEM", 128, 131], ["HSV", "PROBLEM", 135, 138]]], ["To assess cellular immune responses, HSV-1-specific responder cells present in peripheral blood mononuclear cells (PBMCs) of mice that had been immunized 3 weeks earlier were quantified by a modified limiting dilution lymphoproliferation assay.", [["cellular", "ANATOMY", 10, 18], ["cells", "ANATOMY", 62, 67], ["peripheral blood mononuclear cells", "ANATOMY", 79, 113], ["PBMCs", "ANATOMY", 115, 120], ["lymphoproliferation", "DISEASE", 218, 237], ["cellular", "CELL", 10, 18], ["HSV-1", "ORGANISM", 37, 42], ["responder cells", "CELL", 52, 67], ["peripheral blood mononuclear cells", "CELL", 79, 113], ["PBMCs", "CELL", 115, 120], ["mice", "ORGANISM", 125, 129], ["responder cells", "CELL_TYPE", 52, 67], ["peripheral blood mononuclear cells", "CELL_TYPE", 79, 113], ["PBMCs", "CELL_TYPE", 115, 120], ["HSV-1", "SPECIES", 37, 42], ["mice", "SPECIES", 125, 129], ["HSV-1", "SPECIES", 37, 42], ["mice", "SPECIES", 125, 129], ["cellular immune responses", "TEST", 10, 35], ["HSV", "TEST", 37, 40], ["specific responder cells", "PROBLEM", 43, 67], ["peripheral blood mononuclear cells", "TEST", 79, 113], ["a modified limiting dilution lymphoproliferation assay", "PROBLEM", 189, 243], ["peripheral", "ANATOMY_MODIFIER", 79, 89], ["blood", "ANATOMY", 90, 95], ["mononuclear cells", "OBSERVATION", 96, 113], ["lymphoproliferation assay", "OBSERVATION", 218, 243]]], ["Both unactivated HSV-GS vectors and KD6 virus were found to be capable of inducing detectable levels of HSV-1-specific responder cells (Fig. 7B).", [["cells", "ANATOMY", 129, 134], ["HSV-GS vectors", "ORGANISM", 17, 31], ["KD6 virus", "ORGANISM", 36, 45], ["HSV-1", "ORGANISM", 104, 109], ["responder cells", "CELL", 119, 134], ["Fig. 7B", "CELL", 136, 143], ["responder cells", "CELL_TYPE", 119, 134], ["HSV-1", "SPECIES", 104, 109], ["KD6 virus", "SPECIES", 36, 45], ["HSV-1", "SPECIES", 104, 109], ["Both unactivated HSV", "TEST", 0, 20], ["GS vectors", "TREATMENT", 21, 31], ["KD6 virus", "PROBLEM", 36, 45], ["HSV", "TEST", 104, 107]]], ["Substantially better responses were produced by activated HSV-GS3 and HSV-GS7.Immune responses to a heterologous antigen presented in the context of vigorous viral replication. ::: RESULTSTo evaluate immune responses to a heterologous antigen expressed from an HSV-GS vector, recombinant HSV-GS11 was constructed.", [["HSV-GS3", "ORGANISM", 58, 65], ["HSV-GS7", "ORGANISM", 70, 77], ["HSV", "ORGANISM", 261, 264], ["HSV-GS11", "ORGANISM", 288, 296], ["GS3", "PROTEIN", 62, 65], ["GS7", "PROTEIN", 74, 77], ["heterologous antigen", "PROTEIN", 100, 120], ["heterologous antigen", "PROTEIN", 222, 242], ["HSV-GS vector", "DNA", 261, 274], ["GS11", "PROTEIN", 292, 296], ["HSV-GS7", "SPECIES", 70, 77], ["HSV", "SPECIES", 261, 264], ["HSV-GS11", "SPECIES", 288, 296], ["activated HSV", "TEST", 48, 61], ["HSV", "TEST", 70, 73], ["a heterologous antigen", "PROBLEM", 98, 120], ["vigorous viral replication", "TREATMENT", 149, 175], ["a heterologous antigen", "TEST", 220, 242], ["an HSV", "TEST", 258, 264], ["recombinant HSV", "TEST", 276, 291], ["viral replication", "OBSERVATION", 158, 175]]], ["The recombinant was derived from HSV-GS3 by the insertion in the UL37-UL38 intergenic region of an expression cassette comprising a gene for an equine influenza virus (EIV) hemagglutinin (HA) (EIV Prague/56 HA) functionally linked to a cytomegalovirus (CMV) (immediate-early) promoter (Fig. 8A).", [["HSV-GS3", "ORGANISM", 33, 40], ["UL37", "GENE_OR_GENE_PRODUCT", 65, 69], ["equine influenza virus", "ORGANISM", 144, 166], ["(EIV) hemagglutinin", "GENE_OR_GENE_PRODUCT", 167, 186], ["EIV Prague/56 HA", "ORGANISM", 193, 209], ["cytomegalovirus", "ORGANISM", 236, 251], ["CMV", "ORGANISM", 253, 256], ["GS3", "DNA", 37, 40], ["UL37-UL38 intergenic region", "DNA", 65, 92], ["expression cassette", "DNA", 99, 118], ["cytomegalovirus (CMV) (immediate-early) promoter", "DNA", 236, 284], ["equine influenza virus", "SPECIES", 144, 166], ["HSV-GS3", "SPECIES", 33, 40], ["equine influenza virus", "SPECIES", 144, 166], ["EIV", "SPECIES", 168, 171], ["CMV", "SPECIES", 253, 256], ["HSV", "TEST", 33, 36], ["an expression cassette", "TREATMENT", 96, 118], ["an equine influenza virus (EIV) hemagglutinin (HA)", "TREATMENT", 141, 191], ["EIV Prague/56 HA)", "TREATMENT", 193, 210], ["a cytomegalovirus (CMV", "TREATMENT", 234, 256], ["cytomegalovirus", "OBSERVATION", 236, 251]]], ["Expression of the influenza virus gene was verified in groups of adult female BALB/c mice inoculated on the rear footpads with either saline, HSV-GS3, or HSV-GS11 (50,000 PFU per animal).", [["footpads", "ANATOMY", 113, 121], ["HSV-GS11", "CHEMICAL", 154, 162], ["influenza virus", "ORGANISM", 18, 33], ["BALB/c mice", "ORGANISM", 78, 89], ["footpads", "ORGANISM_SUBDIVISION", 113, 121], ["saline", "SIMPLE_CHEMICAL", 134, 140], ["HSV-GS3", "ORGANISM", 142, 149], ["HSV-GS11", "ORGANISM", 154, 162], ["influenza virus gene", "DNA", 18, 38], ["influenza virus", "SPECIES", 18, 33], ["mice", "SPECIES", 85, 89], ["influenza virus", "SPECIES", 18, 33], ["mice", "SPECIES", 85, 89], ["HSV-GS11", "SPECIES", 154, 162], ["the influenza virus gene", "PROBLEM", 14, 38], ["saline", "TREATMENT", 134, 140], ["HSV", "TEST", 142, 145], ["GS3", "TEST", 146, 149], ["HSV", "TEST", 154, 157], ["GS11", "TEST", 158, 162], ["influenza virus", "OBSERVATION", 18, 33]]], ["The HSV-GS3 group, as well as one of the HSV-GS11 groups, was subjected to activation treatment.", [["HSV-GS3", "ORGANISM", 4, 11], ["HSV", "ORGANISM", 41, 44], ["The HSV", "TEST", 0, 7], ["activation treatment", "TREATMENT", 75, 95], ["HSV", "OBSERVATION", 4, 7], ["HSV", "OBSERVATION", 41, 44]]], ["Another HSV-GS11 group underwent an activation treatment twice; the second treatment was administered 2 days after the first treatment.", [["HSV-GS11", "ORGANISM", 8, 16], ["Another HSV", "TEST", 0, 11], ["an activation treatment", "TREATMENT", 33, 56], ["the second treatment", "TREATMENT", 64, 84], ["the first treatment", "TREATMENT", 115, 134]]], ["One day after the last treatment, the animals were euthanized, and RNA was extracted from one hind foot and protein from the other.", [["hind foot", "ANATOMY", 94, 103], ["animals", "ORGANISM", 38, 45], ["hind foot", "ORGANISM_SUBDIVISION", 94, 103], ["the last treatment", "TREATMENT", 14, 32]]], ["The results from an RT-qPCR analysis of HA gene expression are shown in Fig. 8B and the results from an EIV Prague/56 HA-specific enzyme-linked immunosorbent assay (ELISA) in Fig. 8C.", [["HA", "GENE_OR_GENE_PRODUCT", 40, 42], ["8B", "GENE_OR_GENE_PRODUCT", 77, 79], ["HA gene", "DNA", 40, 47], ["an RT-qPCR analysis", "TEST", 17, 36], ["HA gene expression", "PROBLEM", 40, 58], ["HA", "TEST", 118, 120], ["specific enzyme", "TEST", 121, 136], ["immunosorbent assay", "TEST", 144, 163], ["ELISA", "TEST", 165, 170]]], ["HA RNA and HA could be detected in samples from HSV-GS11-inoculated animals, most abundantly when the animals had been subjected to activation treatment.", [["samples", "ANATOMY", 35, 42], ["HA", "GENE_OR_GENE_PRODUCT", 0, 2], ["HA", "GENE_OR_GENE_PRODUCT", 11, 13], ["HSV-GS11", "ORGANISM", 48, 56], ["animals", "ORGANISM", 68, 75], ["animals", "ORGANISM", 102, 109], ["HA RNA", "RNA", 0, 6], ["HSV", "SPECIES", 48, 51], ["HA RNA", "PROBLEM", 0, 6], ["HA", "PROBLEM", 11, 13], ["HSV", "TEST", 48, 51], ["activation treatment", "TREATMENT", 132, 152]]], ["Both HA RNA and protein levels appeared to be somewhat higher in twice-activated animals than in once-activated animals.Immune responses to a heterologous antigen presented in the context of vigorous viral replication. ::: RESULTSTo assess immune responses, additional groups of mice were inoculated with saline (mock immunization) or with 50,000 PFU of HSV-GS3 or HSV-GS11 (three groups).", [["HA", "GENE_OR_GENE_PRODUCT", 5, 7], ["mice", "ORGANISM", 279, 283], ["saline", "SIMPLE_CHEMICAL", 305, 311], ["HSV", "ORGANISM", 354, 357], ["-GS3", "ORGANISM", 357, 361], ["HSV-GS11", "ORGANISM", 365, 373], ["HA RNA", "RNA", 5, 11], ["heterologous antigen", "PROTEIN", 142, 162], ["mice", "SPECIES", 279, 283], ["mice", "SPECIES", 279, 283], ["HSV", "SPECIES", 354, 357], ["HSV-GS11", "SPECIES", 365, 373], ["Both HA RNA", "TEST", 0, 11], ["protein levels", "TEST", 16, 30], ["a heterologous antigen", "TEST", 140, 162], ["vigorous viral replication", "TREATMENT", 191, 217], ["additional groups of mice", "TREATMENT", 258, 283], ["saline (mock immunization", "TREATMENT", 305, 330], ["HSV", "TEST", 354, 357], ["HSV", "PROBLEM", 365, 368], ["somewhat", "OBSERVATION_MODIFIER", 46, 54], ["higher", "OBSERVATION_MODIFIER", 55, 61], ["vigorous", "OBSERVATION_MODIFIER", 191, 199], ["viral replication", "OBSERVATION", 200, 217]]], ["All the animals in the HSV-GS3 group and in two of the HSV-GS11 groups were subjected to an activation treatment.", [["animals", "ORGANISM", 8, 15], ["HSV-GS3", "ORGANISM", 23, 30], ["HSV", "ORGANISM", 55, 58], ["GS11", "ORGANISM", 59, 63], ["HSV-GS11", "SPECIES", 55, 63], ["the HSV", "TEST", 19, 26], ["an activation treatment", "TREATMENT", 89, 112], ["HSV", "OBSERVATION", 23, 26]]], ["The animals of one of the HSV-GS11 groups received a second activation treatment 2 days later.", [["animals", "ORGANISM", 4, 11], ["HSV", "ORGANISM", 26, 29], ["a second activation treatment", "TREATMENT", 51, 80]]], ["All the animals were sacrificed 21 days postimmunization.", [["animals", "ORGANISM", 8, 15]]], ["Serum samples were tested for their ability to neutralize EIV Prague/56.", [["Serum samples", "ANATOMY", 0, 13], ["Serum samples", "ORGANISM_SUBSTANCE", 0, 13], ["EIV Prague/56", "SPECIES", 58, 71], ["Serum samples", "TEST", 0, 13]]], ["As expected, neutralizing antibodies were not detected in unimmunized (not shown), mock-immunized, or vector-immunized animals (Fig. 8D).", [["neutralizing antibodies", "PROTEIN", 13, 36], ["neutralizing antibodies", "TEST", 13, 36]]], ["Unactivated HSV-GS11 was capable of inducing a modest neutralizing antibody response.", [["HSV-GS11", "ORGANISM", 12, 20], ["GS11", "PROTEIN", 16, 20], ["HSV-GS11", "SPECIES", 12, 20], ["Unactivated HSV", "TEST", 0, 15], ["a modest neutralizing antibody response", "PROBLEM", 45, 84]]], ["Activation of HSV-GS11 shortly after inoculation resulted in a severalfold-magnified response.", [["HSV-GS11", "ORGANISM", 14, 22], ["GS11", "PROTEIN", 18, 22], ["HSV", "PROBLEM", 14, 17]]], ["It was noted that twice-activated HSV-GS11 elicited a response only marginally better than that elicited by once-activated virus (not statistically significant).", [["HSV", "ORGANISM", 34, 37], ["-GS11", "ORGANISM", 37, 42], ["GS11", "PROTEIN", 38, 42], ["activated HSV", "TEST", 24, 37], ["activated virus", "PROBLEM", 113, 128]]], ["HA-specific responder cells present in PBMCs were quantified by the same type of responder cell frequency (RCF) assay that had been used to assess the numbers of HSV-1-specific responder cells.", [["cells", "ANATOMY", 22, 27], ["PBMCs", "ANATOMY", 39, 44], ["cell", "ANATOMY", 91, 95], ["cells", "ANATOMY", 187, 192], ["HA", "GENE_OR_GENE_PRODUCT", 0, 2], ["responder cells", "CELL", 12, 27], ["PBMCs", "CELL", 39, 44], ["responder cell", "CELL", 81, 95], ["HSV-1", "ORGANISM", 162, 167], ["responder cells", "CELL", 177, 192], ["responder cells", "CELL_TYPE", 12, 27], ["PBMCs", "CELL_TYPE", 39, 44], ["responder cells", "CELL_TYPE", 177, 192], ["HSV-1", "SPECIES", 162, 167], ["HSV-1", "SPECIES", 162, 167], ["HA", "PROBLEM", 0, 2], ["specific responder cells", "PROBLEM", 3, 27], ["HSV", "TEST", 162, 165], ["responder cells", "OBSERVATION", 12, 27]]], ["HA-specific responder cells were not detected in unimmunized (not shown) or mock-immunized (Fig. 8E) animals.", [["cells", "ANATOMY", 22, 27], ["HA", "GENE_OR_GENE_PRODUCT", 0, 2], ["responder cells", "CELL", 12, 27], ["HA-specific responder cells", "CELL_LINE", 0, 27], ["HA", "PROBLEM", 0, 2], ["specific responder cells", "PROBLEM", 3, 27], ["responder cells", "OBSERVATION", 12, 27]]], ["Induction of a cellular immune response was observed in animals immunized with HSV-GS11 but not subjected to an activation treatment.", [["cellular", "ANATOMY", 15, 23], ["cellular", "CELL", 15, 23], ["HSV-GS11", "ORGANISM", 79, 87], ["HSV", "SPECIES", 79, 82], ["a cellular immune response", "PROBLEM", 13, 39], ["HSV", "TEST", 79, 82], ["an activation treatment", "TREATMENT", 109, 132]]], ["An activated vector (HSV-GS3) produced a similar response.", [["HSV", "ORGANISM", 21, 24], ["-GS3", "ORGANISM", 24, 28], ["GS3", "DNA", 25, 28], ["An activated vector (HSV", "TEST", 0, 24]]], ["Far greater numbers of HA-specific responder cells were found in animals immunized with once- or twice-activated HSV-GS11.DISCUSSIONThe once-activated replication-competent controlled HSV-1 recombinants HSV-GS3 and HSV-GS7 induced considerably more potent protective immune responses than the replication-defective HSV-1 strain KD6.", [["cells", "ANATOMY", 45, 50], ["HA", "GENE_OR_GENE_PRODUCT", 23, 25], ["responder cells", "CELL", 35, 50], ["HSV", "ORGANISM", 113, 116], ["-GS11", "ORGANISM", 116, 121], ["HSV-1", "ORGANISM", 184, 189], ["HSV-GS3", "ORGANISM", 203, 210], ["HSV-GS7", "ORGANISM", 215, 222], ["HSV-1 strain", "ORGANISM", 315, 327], ["KD6", "ORGANISM", 328, 331], ["responder cells", "CELL_TYPE", 35, 50], ["GS11", "PROTEIN", 117, 121], ["HSV-1", "SPECIES", 184, 189], ["HSV-1", "SPECIES", 315, 320], ["HSV-1", "SPECIES", 184, 189], ["HSV-GS7", "SPECIES", 215, 222], ["HSV-1", "SPECIES", 315, 320], ["HA", "PROBLEM", 23, 25], ["specific responder cells", "PROBLEM", 26, 50], ["-activated replication", "TREATMENT", 140, 162], ["HSV", "TEST", 184, 187], ["HSV", "TEST", 203, 206], ["GS3", "TEST", 207, 210], ["HSV", "TEST", 215, 218], ["the replication", "TREATMENT", 289, 304], ["defective HSV", "PROBLEM", 305, 318], ["greater", "OBSERVATION_MODIFIER", 4, 11], ["numbers", "OBSERVATION_MODIFIER", 12, 19]]], ["Twice-immunized animals were completely protected against lethal challenge.", [["animals", "ORGANISM", 16, 23]]], ["The levels of partial protection engendered by unactivated HSV-GS3, unactivated HSV-GS7, and KD6 (lacking expression of different viral proteins) were comparable, which strongly suggests that the much-enhanced protection provided by the activated HSV-GS recombinants was a consequence of their ability to efficiently replicate.", [["HSV-GS3", "ORGANISM", 59, 66], ["HSV-GS7", "ORGANISM", 80, 87], ["KD6", "GENE_OR_GENE_PRODUCT", 93, 96], ["HSV-GS recombinants", "ORGANISM", 247, 266], ["GS3", "PROTEIN", 63, 66], ["GS7", "PROTEIN", 84, 87], ["KD6", "PROTEIN", 93, 96], ["viral proteins", "PROTEIN", 130, 144], ["partial protection", "TREATMENT", 14, 32], ["unactivated HSV", "TEST", 47, 62], ["GS3", "TEST", 63, 66], ["unactivated HSV", "TEST", 68, 83], ["GS7", "TEST", 84, 87], ["KD6", "TREATMENT", 93, 96], ["different viral proteins", "PROBLEM", 120, 144], ["enhanced protection", "TREATMENT", 201, 220], ["the activated HSV-GS recombinants", "PROBLEM", 233, 266], ["partial protection", "OBSERVATION", 14, 32]]], ["Both better neutralizing antibody and better cellular immune responses were induced by the activated HSV-GS vectors, indicating that the replicating vectors not only boosted cellular immunity, but broadly enhanced immune responses.", [["cellular", "ANATOMY", 45, 53], ["cellular", "ANATOMY", 174, 182], ["cellular", "CELL", 45, 53], ["HSV-GS vectors", "ORGANISM", 101, 115], ["cellular", "CELL", 174, 182], ["neutralizing antibody", "PROTEIN", 12, 33], ["neutralizing antibody", "TEST", 12, 33], ["neutralizing antibody", "OBSERVATION", 12, 33]]], ["Generalizing these findings, it appears that replication-competent controlled vectors are promising new agents that may better protect against diseases caused by the viruses from which they were derived than replication-incompetent/inactivated vaccines and possibly also live attenuated vaccines.", [["competent controlled vectors", "TREATMENT", 57, 85], ["new agents", "TREATMENT", 100, 110], ["diseases", "PROBLEM", 143, 151], ["the viruses", "PROBLEM", 162, 173], ["incompetent/inactivated vaccines", "TREATMENT", 220, 252], ["live attenuated vaccines", "TREATMENT", 271, 295], ["viruses", "OBSERVATION", 166, 173]]], ["Perhaps even more important, our observations suggest that replication-competent controlled vectors can be excellent immunization platforms that may be exploited for the elaboration of new \u201cvaccines.\u201d", [["competent controlled vectors", "TREATMENT", 71, 99], ["new \u201cvaccines", "TREATMENT", 185, 198]]], ["Expression of an influenza virus antigen induced far more potent neutralizing antibody and antigen-specific responder cell responses when the antigen was expressed in the context of vector replication than in the absence of vector replication.", [["cell", "ANATOMY", 118, 122], ["influenza virus", "ORGANISM", 17, 32], ["cell", "CELL", 118, 122], ["influenza virus antigen", "PROTEIN", 17, 40], ["neutralizing antibody", "PROTEIN", 65, 86], ["influenza virus", "SPECIES", 17, 32], ["influenza virus", "SPECIES", 17, 32], ["an influenza virus antigen", "PROBLEM", 14, 40], ["neutralizing antibody", "TEST", 65, 86], ["antigen", "TEST", 91, 98], ["the antigen", "TEST", 138, 149], ["vector replication", "TREATMENT", 182, 200], ["vector replication", "TREATMENT", 224, 242], ["influenza virus", "OBSERVATION", 17, 32], ["vector replication", "OBSERVATION", 224, 242]]], ["To the extent that such a comparison is valid, neutralizing antibody responses, as well as antigen-specific responder cell responses, against the influenza virus antigen elicited by activated HSV-GS11 were both stronger than the corresponding responses against vector antigens.DISCUSSIONA second activation treatment administered 2 days after the initial activation of a replication-competent controlled HSV-1 vector did not consistently enhance the protective immune response against challenge by the wild-type virus from which the vector was derived.", [["cell", "ANATOMY", 118, 122], ["cell", "CELL", 118, 122], ["influenza virus", "ORGANISM", 146, 161], ["HSV-GS11", "ORGANISM", 192, 200], ["HSV-1", "ORGANISM", 404, 409], ["wild-type virus", "ORGANISM", 502, 517], ["influenza virus antigen", "PROTEIN", 146, 169], ["GS11", "PROTEIN", 196, 200], ["vector antigens", "PROTEIN", 261, 276], ["HSV-1 vector", "DNA", 404, 416], ["influenza virus", "SPECIES", 146, 161], ["influenza virus", "SPECIES", 146, 161], ["HSV", "SPECIES", 192, 195], ["HSV-1", "SPECIES", 404, 409], ["neutralizing antibody responses", "TEST", 47, 78], ["antigen", "TEST", 91, 98], ["the influenza virus antigen", "PROBLEM", 142, 169], ["activated HSV", "TEST", 182, 195], ["second activation treatment", "TREATMENT", 289, 316], ["a replication", "TREATMENT", 369, 382], ["type virus", "PROBLEM", 507, 517]]], ["Also, humoral and cellular immune responses against an influenza virus antigen expressed from a replication-competent controlled HSV-1 vector were only marginally enhanced by a second activation treatment.", [["cellular", "ANATOMY", 18, 26], ["cellular", "CELL", 18, 26], ["influenza virus", "ORGANISM", 55, 70], ["HSV-1", "ORGANISM", 129, 134], ["influenza virus antigen", "PROTEIN", 55, 78], ["HSV-1 vector", "DNA", 129, 141], ["influenza virus", "SPECIES", 55, 70], ["HSV-1", "SPECIES", 129, 134], ["influenza virus", "SPECIES", 55, 70], ["HSV-1", "SPECIES", 129, 134], ["an influenza virus antigen", "PROBLEM", 52, 78], ["a second activation treatment", "TREATMENT", 175, 204], ["cellular immune", "OBSERVATION", 18, 33], ["influenza virus", "OBSERVATION", 55, 70]]], ["At this time, we cannot determine whether the second activation was only marginally effective because the immune system was already maximally engaged by the initial immunization or because optimal conditions for the second activation treatment had not been identified.DISCUSSIONImmunization by replication-competent controlled vectors represents a novel paradigm that may be elaborated in various ways.", [["immune system", "ANATOMY", 106, 119], ["the initial immunization", "TREATMENT", 153, 177], ["the second activation treatment", "TREATMENT", 212, 243], ["a novel paradigm", "PROBLEM", 346, 362]]], ["In general, any of a number of DNA viruses, including members of all the herpesvirus subfamilies, may be employed for the construction of replication-competent controlled vectors.", [["DNA", "CELLULAR_COMPONENT", 31, 34], ["herpesvirus", "ORGANISM", 73, 84], ["DNA viruses", "PROBLEM", 31, 42], ["viruses", "OBSERVATION", 35, 42]]], ["We selected a fully virulent HSV-1 strain as the backbone of the GS vectors for several reasons, including the fact that HSV has a double-stranded DNA genome that does not integrate into the host genome and that it is tolerant of sizeable insertions, supports stable expression of heterologous genes, replicates and lyses cells efficiently, and responds to antiviral drugs (38\u201341).", [["cells", "ANATOMY", 322, 327], ["HSV-1", "ORGANISM", 29, 34], ["HSV", "ORGANISM", 121, 124], ["DNA", "CELLULAR_COMPONENT", 147, 150], ["cells", "CELL", 322, 327], ["double-stranded DNA genome", "DNA", 131, 157], ["host genome", "DNA", 191, 202], ["heterologous genes", "DNA", 281, 299], ["HSV-1", "SPECIES", 29, 34], ["HSV-1", "SPECIES", 29, 34], ["HSV", "SPECIES", 121, 124], ["a fully virulent HSV", "PROBLEM", 12, 32], ["HSV", "PROBLEM", 121, 124], ["a double-stranded DNA genome", "TREATMENT", 129, 157], ["heterologous genes", "PROBLEM", 281, 299], ["antiviral drugs", "TREATMENT", 357, 372], ["host genome", "OBSERVATION", 191, 202], ["stable", "OBSERVATION_MODIFIER", 260, 266]]], ["Although HSV is endemic in the human population, available data indicate that preexisting immunity is not an obstacle to vaccination/immunization uses of HSV vectors (discussed in reference 35).", [["HSV", "ORGANISM", 9, 12], ["human", "ORGANISM", 31, 36], ["HSV", "ORGANISM", 154, 157], ["human", "SPECIES", 31, 36], ["HSV", "SPECIES", 9, 12], ["human", "SPECIES", 31, 36], ["HSV", "SPECIES", 154, 157], ["HSV", "PROBLEM", 9, 12], ["endemic", "PROBLEM", 16, 23], ["vaccination/immunization", "TREATMENT", 121, 145], ["HSV vectors", "TREATMENT", 154, 165], ["endemic", "OBSERVATION_MODIFIER", 16, 23]]], ["Furthermore, latent infection was considered a manageable issue because replication of replication-competent controlled vectors can be stringently controlled, and reactivation should not be capable of occurring in the absence of activation.DISCUSSIONRegarding the two-component HSP promoter-based gene switch that is used for controlling viral replication, several ligand-dependent transactivators are known that may be considered for incorporation in such a gene switch.", [["infection", "DISEASE", 20, 29], ["HSP", "GENE_OR_GENE_PRODUCT", 278, 281], ["HSP promoter", "DNA", 278, 290], ["ligand-dependent transactivators", "PROTEIN", 365, 397], ["latent infection", "PROBLEM", 13, 29], ["replication", "TREATMENT", 87, 98], ["competent controlled vectors", "TREATMENT", 99, 127], ["the two-component HSP promoter", "TREATMENT", 260, 290], ["based gene switch", "TREATMENT", 291, 308], ["viral replication", "TREATMENT", 338, 355], ["several ligand-dependent transactivators", "TREATMENT", 357, 397], ["a gene switch", "TREATMENT", 457, 470], ["latent", "OBSERVATION_MODIFIER", 13, 19], ["infection", "OBSERVATION", 20, 29]]], ["They include transactivators that are derived from the bacterial tetracycline repressor or other bacterial repressors, as well as chimeric transactivators that exploit ligand-binding domains of various steroid receptors, e.g., human progesterone, human estrogen, or insect ecdysone receptors, or are activated by dimerization (28).", [["tetracycline", "CHEMICAL", 65, 77], ["steroid", "CHEMICAL", 202, 209], ["progesterone", "CHEMICAL", 233, 245], ["estrogen", "CHEMICAL", 253, 261], ["tetracycline", "CHEMICAL", 65, 77], ["steroid", "CHEMICAL", 202, 209], ["progesterone", "CHEMICAL", 233, 245], ["estrogen", "CHEMICAL", 253, 261], ["tetracycline", "SIMPLE_CHEMICAL", 65, 77], ["human", "ORGANISM", 227, 232], ["progesterone", "SIMPLE_CHEMICAL", 233, 245], ["human", "ORGANISM", 247, 252], ["estrogen", "SIMPLE_CHEMICAL", 253, 261], ["ecdysone receptors", "GENE_OR_GENE_PRODUCT", 273, 291], ["transactivators", "PROTEIN", 13, 28], ["bacterial tetracycline repressor", "PROTEIN", 55, 87], ["bacterial repressors", "PROTEIN", 97, 117], ["chimeric transactivators", "PROTEIN", 130, 154], ["ligand-binding domains", "PROTEIN", 168, 190], ["steroid receptors", "PROTEIN", 202, 219], ["insect ecdysone receptors", "PROTEIN", 266, 291], ["human", "SPECIES", 227, 232], ["human", "SPECIES", 247, 252], ["human", "SPECIES", 227, 232], ["human", "SPECIES", 247, 252], ["transactivators", "TREATMENT", 13, 28], ["the bacterial tetracycline repressor", "TREATMENT", 51, 87], ["other bacterial repressors", "TREATMENT", 91, 117], ["chimeric transactivators", "TREATMENT", 130, 154], ["various steroid receptors", "TREATMENT", 194, 219], ["human progesterone", "TREATMENT", 227, 245], ["human estrogen", "TREATMENT", 247, 261]]], ["We previously constructed and analyzed two-component HSP promoter-based gene switches that are coactivated by antiprogestins, ecdysteroid ponasterone A, and rapamycin/rapalog (31, 42).", [["ecdysteroid ponasterone A", "CHEMICAL", 126, 151], ["rapamycin", "CHEMICAL", 157, 166], ["antiprogestins", "CHEMICAL", 110, 124], ["ponasterone A", "CHEMICAL", 138, 151], ["rapamycin", "CHEMICAL", 157, 166], ["rapalog", "CHEMICAL", 167, 174], ["HSP", "GENE_OR_GENE_PRODUCT", 53, 56], ["antiprogestins", "SIMPLE_CHEMICAL", 110, 124], ["ecdysteroid ponasterone A", "SIMPLE_CHEMICAL", 126, 151], ["rapamycin", "SIMPLE_CHEMICAL", 157, 166], ["rapalog", "SIMPLE_CHEMICAL", 167, 174], ["HSP promoter", "DNA", 53, 65], ["component HSP promoter", "TREATMENT", 43, 65], ["based gene switches", "TREATMENT", 66, 85], ["ecdysteroid ponasterone A", "TREATMENT", 126, 151], ["rapamycin/rapalog", "TREATMENT", 157, 174]]], ["For regulating the HSV-GS vectors, we made use of a heat- and antiprogestin-activated gene switch that is strictly dependent on both heat and antiprogestin.", [["antiprogestin", "CHEMICAL", 142, 155], ["antiprogestin", "CHEMICAL", 142, 155], ["HSV", "ORGANISM", 19, 22], ["antiprogestin", "SIMPLE_CHEMICAL", 62, 75], ["antiprogestin", "SIMPLE_CHEMICAL", 142, 155], ["HSV-GS vectors", "DNA", 19, 33], ["HSV", "SPECIES", 19, 22], ["a heat", "TREATMENT", 50, 56], ["antiprogestin", "TREATMENT", 62, 75], ["activated gene switch", "TREATMENT", 76, 97], ["antiprogestin", "TREATMENT", 142, 155]]], ["It comprises the transactivator GLP65, which is activated by a narrow spectrum of antiprogestins but not progestins (35).", [["progestins", "CHEMICAL", 105, 115], ["antiprogestins", "CHEMICAL", 82, 96], ["progestins", "CHEMICAL", 105, 115], ["GLP65", "GENE_OR_GENE_PRODUCT", 32, 37], ["antiprogestins", "SIMPLE_CHEMICAL", 82, 96], ["progestins", "SIMPLE_CHEMICAL", 105, 115], ["transactivator GLP65", "PROTEIN", 17, 37], ["the transactivator GLP65", "TEST", 13, 37], ["a narrow spectrum of antiprogestins", "TREATMENT", 61, 96]]], ["Since it includes only a truncated ligand-binding domain of a progesterone receptor, GLP65 should not be susceptible to ligand-independent activation; in fact, after many years of experimental use, no antiprogestin-independent activation has been reported.", [["progesterone", "CHEMICAL", 62, 74], ["progesterone", "CHEMICAL", 62, 74], ["progesterone receptor", "GENE_OR_GENE_PRODUCT", 62, 83], ["GLP65", "GENE_OR_GENE_PRODUCT", 85, 90], ["antiprogestin", "SIMPLE_CHEMICAL", 201, 214], ["truncated ligand-binding domain", "PROTEIN", 25, 56], ["progesterone receptor", "PROTEIN", 62, 83], ["GLP65", "PROTEIN", 85, 90], ["antiprogestin", "PROTEIN", 201, 214], ["a progesterone receptor", "TREATMENT", 60, 83], ["antiprogestin", "TREATMENT", 201, 214]]], ["At the low doses at which they activate GLP65, antiprogestins, such as mifepristone and ulipristal, are not expected to have any negative effects on the immune system (26).", [["immune system", "ANATOMY", 153, 166], ["mifepristone", "CHEMICAL", 71, 83], ["ulipristal", "CHEMICAL", 88, 98], ["mifepristone", "CHEMICAL", 71, 83], ["ulipristal", "CHEMICAL", 88, 98], ["GLP65", "GENE_OR_GENE_PRODUCT", 40, 45], ["antiprogestins", "SIMPLE_CHEMICAL", 47, 61], ["mifepristone", "SIMPLE_CHEMICAL", 71, 83], ["ulipristal", "SIMPLE_CHEMICAL", 88, 98], ["GLP65", "PROTEIN", 40, 45], ["antiprogestins", "TREATMENT", 47, 61], ["mifepristone and ulipristal", "TREATMENT", 71, 98], ["the immune system", "TEST", 149, 166], ["low doses", "OBSERVATION_MODIFIER", 7, 16]]], ["These antiprogestins have also been safety tested in human subjects and are readily available.", [["antiprogestins", "CHEMICAL", 6, 20], ["antiprogestins", "SIMPLE_CHEMICAL", 6, 20], ["human", "ORGANISM", 53, 58], ["human", "SPECIES", 53, 58], ["human", "SPECIES", 53, 58]]], ["They are not considered essential active ingredients by the WHO, and their primary use has been in emergency contraception.", [["not considered", "UNCERTAINTY", 9, 23], ["active", "OBSERVATION_MODIFIER", 34, 40]]], ["To maintain maximal safety in a human immunization scenario, i.e., to preclude any possibility of reactivation from latency, antiprogestins should not be administered subsequent to immunization with an HSV-GS-type vector.", [["human", "ORGANISM", 32, 37], ["antiprogestins", "SIMPLE_CHEMICAL", 125, 139], ["HSV", "ORGANISM", 202, 205], ["HSV-GS-type vector", "DNA", 202, 220], ["human", "SPECIES", 32, 37], ["human", "SPECIES", 32, 37], ["HSV", "SPECIES", 202, 205], ["a human immunization scenario", "TREATMENT", 30, 59], ["reactivation from latency", "PROBLEM", 98, 123], ["antiprogestins", "TREATMENT", 125, 139], ["immunization", "TREATMENT", 181, 193], ["an HSV", "TEST", 199, 205]]], ["Therefore, the vectors may not be employed for immunization of healthy female subjects of reproductive age or younger, or the subjects may forego later use of antiprogestins for emergency contraception.", [["antiprogestins", "CHEMICAL", 159, 173], ["antiprogestins", "CHEMICAL", 159, 173], ["antiprogestins", "SIMPLE_CHEMICAL", 159, 173], ["the vectors", "TREATMENT", 11, 22], ["immunization", "TREATMENT", 47, 59], ["antiprogestins", "TREATMENT", 159, 173], ["emergency contraception", "TREATMENT", 178, 201]]], ["In contrast, the HSV-GS vectors may be well suited to be immunization agents or platforms in middle-aged or elderly subjects.", [["HSV", "ORGANISM", 17, 20], ["HSV", "SPECIES", 17, 20], ["the HSV-GS vectors", "TREATMENT", 13, 31], ["immunization agents", "TREATMENT", 57, 76]]], ["Note that it may be feasible to disable replication of fully activated HSV-GS vectors in latently infected cells through further engineering.DISCUSSIONReplication-competent controlled virus vectors may be capable of making a unique contribution to immunization of immunocompromised patients.", [["cells", "ANATOMY", 107, 112], ["latently infected", "DISEASE", 89, 106], ["HSV", "ORGANISM", 71, 74], ["cells", "CELL", 107, 112], ["patients", "ORGANISM", 282, 290], ["latently infected cells", "CELL_TYPE", 89, 112], ["patients", "SPECIES", 282, 290], ["fully activated HSV-GS vectors", "TREATMENT", 55, 85], ["latently infected cells", "PROBLEM", 89, 112], ["DISCUSSIONReplication", "TREATMENT", 141, 162], ["competent controlled virus vectors", "TREATMENT", 163, 197], ["immunization of immunocompromised patients", "TREATMENT", 248, 290], ["infected cells", "OBSERVATION", 98, 112]]], ["It has been estimated that in 2012 over 3% of the adult populations of the United States and the United Kingdom were immunocompromised (43).", [["immunocompromised", "PROBLEM", 117, 134]]], ["These patients are particularly vulnerable to vaccine-preventable disease and would greatly benefit from effective vaccination.", [["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["preventable disease", "PROBLEM", 54, 73], ["effective vaccination", "TREATMENT", 105, 126]]], ["Owing to their condition, their immune response to inactivated or subunit vaccines may be inadequate.", [["subunit vaccines", "TREATMENT", 66, 82]]], ["Unfortunately, the use of live attenuated vaccines that might produce a more balanced and more persistent immune response is problematic because of the perceived danger that such vaccines may be insufficiently controlled by the weakened immune system and may cause the disease they are intended to prevent.", [["immune system", "ANATOMY", 237, 250], ["immune system", "ANATOMICAL_SYSTEM", 237, 250], ["live attenuated vaccines", "TREATMENT", 26, 50], ["such vaccines", "TREATMENT", 174, 187], ["the weakened immune system", "PROBLEM", 224, 250], ["the disease", "PROBLEM", 265, 276]]], ["According to most relevant guidelines, live attenuated vaccines are contraindicated in patients under immunosuppressive therapy or in HIV patients with low CD4 counts (44).", [["patients", "ORGANISM", 87, 95], ["HIV", "ORGANISM", 134, 137], ["patients", "ORGANISM", 138, 146], ["CD4", "GENE_OR_GENE_PRODUCT", 156, 159], ["CD4", "PROTEIN", 156, 159], ["patients", "SPECIES", 87, 95], ["HIV", "SPECIES", 134, 137], ["patients", "SPECIES", 138, 146], ["HIV", "SPECIES", 134, 137], ["live attenuated vaccines", "TREATMENT", 39, 63], ["immunosuppressive therapy", "TREATMENT", 102, 127], ["low CD4 counts", "PROBLEM", 152, 166]]], ["Hence, use of currently marketed vaccines against tuberculosis (BCG); measles, mumps, and rubella; varicella-zoster virus; rotavirus; influenza virus (nasal); and yellow fever virus is universally discouraged.", [["nasal", "ANATOMY", 151, 156], ["tuberculosis", "DISEASE", 50, 62], ["BCG", "DISEASE", 64, 67], ["measles, mumps, and rubella", "DISEASE", 70, 97], ["varicella-zoster virus", "DISEASE", 99, 121], ["rotavirus", "DISEASE", 123, 132], ["influenza virus (nasal); and yellow fever", "DISEASE", 134, 175], ["mumps", "ORGANISM", 79, 84], ["rubella;", "ORGANISM", 90, 98], ["varicella-zoster virus", "ORGANISM", 99, 121], ["rotavirus; influenza virus", "ORGANISM", 123, 149], ["nasal", "ORGAN", 151, 156], ["yellow fever virus", "ORGANISM", 163, 181], ["varicella-zoster virus", "SPECIES", 99, 121], ["rotavirus; influenza virus", "SPECIES", 123, 149], ["yellow fever virus", "SPECIES", 163, 181], ["varicella-zoster virus", "SPECIES", 99, 121], ["rotavirus; influenza virus", "SPECIES", 123, 149], ["yellow fever virus", "SPECIES", 163, 181], ["currently marketed vaccines", "TREATMENT", 14, 41], ["tuberculosis", "PROBLEM", 50, 62], ["BCG", "TEST", 64, 67], ["measles", "PROBLEM", 70, 77], ["mumps", "PROBLEM", 79, 84], ["rubella", "PROBLEM", 90, 97], ["varicella", "PROBLEM", 99, 108], ["zoster virus", "PROBLEM", 109, 121], ["rotavirus", "PROBLEM", 123, 132], ["influenza virus (nasal)", "PROBLEM", 134, 157], ["yellow fever virus", "PROBLEM", 163, 181], ["varicella", "ANATOMY", 99, 108], ["zoster virus", "OBSERVATION", 109, 121], ["nasal", "ANATOMY", 151, 156]]], ["Newer, more effective vaccines under development, e.g., the new pertussis vaccine BPZE1 (45), also may not become available to the immunocompromised.", [["BPZE1", "CHEMICAL", 82, 87], ["pertussis vaccine BPZE1", "ORGANISM", 64, 87], ["the new pertussis vaccine BPZE1", "TEST", 56, 87], ["immunocompromised", "OBSERVATION", 131, 148]]], ["Replication-competent controlled virus vectors expressing antigens of these microbes in the context of efficient viral replication can be expected to elicit immune reactions similar to or more potent than those of the contraindicated live attenuated vaccines.", [["Replication", "TREATMENT", 0, 11], ["competent controlled virus vectors", "TREATMENT", 12, 46], ["efficient viral replication", "PROBLEM", 103, 130], ["immune reactions", "PROBLEM", 157, 173], ["the contraindicated live attenuated vaccines", "TREATMENT", 214, 258], ["viral replication", "OBSERVATION", 113, 130]]], ["Escape from immune control will not be an issue because replication of the vectors can be activated and safely deactivated independent of the immune status of a patient.DISCUSSIONIn this report, we have focused on the immunization effects of once-activated replication-competent controlled vectors that undergo one round of replication.", [["patient", "ORGANISM", 161, 168], ["patient", "SPECIES", 161, 168], ["immune control", "TREATMENT", 12, 26], ["the vectors", "TREATMENT", 71, 82], ["the immunization effects", "TREATMENT", 214, 238], ["activated replication", "TREATMENT", 247, 268], ["competent controlled vectors", "TREATMENT", 269, 297], ["replication", "TREATMENT", 324, 335]]], ["We note that viral vectors that were intended to be limited to one cycle of replication were advanced before as potential vaccines (46).", [["viral vectors", "TREATMENT", 13, 26], ["replication", "TREATMENT", 76, 87]]], ["These so-called disabled infectious single-cycle (DISC) viruses typically had the gene for glycoprotein H, which is critical for infection, deleted.", [["infection", "DISEASE", 129, 138], ["glycoprotein H", "GENE_OR_GENE_PRODUCT", 91, 105], ["glycoprotein H", "PROTEIN", 91, 105], ["These so-called disabled infectious single-cycle (DISC) viruses", "PROBLEM", 0, 63], ["glycoprotein H", "TREATMENT", 91, 105], ["infection", "PROBLEM", 129, 138], ["infectious", "OBSERVATION", 25, 35], ["DISC", "ANATOMY", 50, 54], ["infection", "OBSERVATION", 129, 138]]], ["Comparing DISC viruses and replication-competent controlled viruses, the latter replicate nearly as efficiently as the wild-type virus that was used for their construction while no comparable information is available for the DISC viruses that were advanced as vaccine candidates.", [["DISC", "GENE_OR_GENE_PRODUCT", 10, 14], ["wild-type virus", "ORGANISM", 119, 134], ["DISC", "GENE_OR_GENE_PRODUCT", 225, 229], ["DISC viruses", "PROBLEM", 10, 22], ["competent controlled viruses", "PROBLEM", 39, 67], ["the wild-type virus", "PROBLEM", 115, 134], ["the DISC viruses", "PROBLEM", 221, 237], ["DISC", "ANATOMY", 10, 14], ["viruses", "OBSERVATION", 15, 22], ["replication", "OBSERVATION_MODIFIER", 27, 38], ["controlled", "OBSERVATION_MODIFIER", 49, 59], ["viruses", "OBSERVATION", 60, 67], ["DISC", "ANATOMY", 225, 229], ["viruses", "OBSERVATION", 230, 237]]], ["Replication of DISC viruses is not localized but occurs throughout the host.", [["DISC", "GENE_OR_GENE_PRODUCT", 15, 19], ["DISC viruses", "PROBLEM", 15, 27], ["DISC", "ANATOMY", 15, 19], ["viruses", "OBSERVATION", 20, 27]]], ["Depending on the dose of virus administered, a single round of replication of disseminated virus can be expected to result in significant toxicity.", [["toxicity", "DISEASE", 138, 146], ["virus", "TREATMENT", 25, 30], ["disseminated virus", "PROBLEM", 78, 96], ["significant toxicity", "PROBLEM", 126, 146], ["disseminated virus", "OBSERVATION", 78, 96], ["significant", "OBSERVATION_MODIFIER", 126, 137], ["toxicity", "OBSERVATION", 138, 146]]], ["Not surprisingly, intracranial administration of the DISC virus TA-HSV resulted in neurotoxicity that was only about 2 orders of magnitude lower than that of the wild-type virus from which the strain was derived (47).", [["intracranial", "ANATOMY", 18, 30], ["neurotoxicity", "DISEASE", 83, 96], ["intracranial", "IMMATERIAL_ANATOMICAL_ENTITY", 18, 30], ["DISC", "GENE_OR_GENE_PRODUCT", 53, 57], ["TA-HSV", "ORGANISM", 64, 70], ["wild-type virus", "ORGANISM", 162, 177], ["the DISC virus TA", "PROBLEM", 49, 66], ["HSV", "PROBLEM", 67, 70], ["neurotoxicity", "PROBLEM", 83, 96], ["type virus", "PROBLEM", 167, 177], ["DISC", "ANATOMY", 53, 57]]], ["Replication-competent controlled viruses should be devoid of such toxicity because they are virtually incapable of replicating unless deliberately activated.", [["toxicity", "DISEASE", 66, 74], ["Replication", "TREATMENT", 0, 11], ["competent controlled viruses", "PROBLEM", 12, 40], ["such toxicity", "PROBLEM", 61, 74], ["viruses", "OBSERVATION", 33, 40]]], ["We note that the stringency of the replication block could be increased further by subjecting additional replication-essential genes to gene switch control.", [["the replication block", "TREATMENT", 31, 52], ["additional replication", "TREATMENT", 94, 116], ["gene switch control", "TREATMENT", 136, 155], ["replication block", "OBSERVATION", 35, 52], ["increased", "OBSERVATION_MODIFIER", 62, 71]]], ["Furthermore, even though progeny virus produced by a DISC virus upon immunization is not supposed to be capable of reinfecting cells, latent infection has been observed (47).", [["cells", "ANATOMY", 127, 132], ["infection", "DISEASE", 141, 150], ["progeny virus", "ORGANISM", 25, 38], ["DISC", "GENE_OR_GENE_PRODUCT", 53, 57], ["cells", "CELL", 127, 132], ["reinfecting cells", "CELL_TYPE", 115, 132], ["progeny virus", "PROBLEM", 25, 38], ["a DISC virus", "PROBLEM", 51, 63], ["immunization", "TREATMENT", 69, 81], ["reinfecting cells", "PROBLEM", 115, 132], ["latent infection", "PROBLEM", 134, 150], ["DISC", "ANATOMY", 53, 57], ["latent", "OBSERVATION_MODIFIER", 134, 140], ["infection", "OBSERVATION", 141, 150]]], ["Latent infection is known to involve spread from cell to cell (48).", [["cell", "ANATOMY", 49, 53], ["cell", "ANATOMY", 57, 61], ["Latent infection", "DISEASE", 0, 16], ["cell", "CELL", 49, 53], ["cell", "CELL", 57, 61], ["Latent infection", "PROBLEM", 0, 16], ["infection", "OBSERVATION", 7, 16], ["cell", "OBSERVATION", 49, 53]]], ["Hence, as has been pointed out before (49), DISC viruses, such as TA-HSV, appear to be leaky for replication in vivo.", [["DISC", "GENE_OR_GENE_PRODUCT", 44, 48], ["TA-HSV", "ORGANISM", 66, 72], ["DISC viruses", "PROBLEM", 44, 56], ["HSV", "PROBLEM", 69, 72], ["replication in vivo", "TREATMENT", 97, 116], ["DISC", "ANATOMY", 44, 48], ["viruses", "OBSERVATION", 49, 56], ["leaky", "OBSERVATION", 87, 92]]], ["The above-mentioned properties of DISC viruses are not desirable in an immunization agent or vector administered to healthy people and would disqualify such viruses from use in persons with impaired immune systems.", [["impaired immune systems", "DISEASE", 190, 213], ["DISC", "GENE_OR_GENE_PRODUCT", 34, 38], ["people", "ORGANISM", 124, 130], ["persons", "ORGANISM", 177, 184], ["people", "SPECIES", 124, 130], ["persons", "SPECIES", 177, 184], ["DISC viruses", "PROBLEM", 34, 46], ["an immunization agent", "TREATMENT", 68, 89], ["impaired immune systems", "PROBLEM", 190, 213], ["DISC", "ANATOMY", 34, 38], ["viruses", "OBSERVATION", 39, 46]]], ["A clinical trial was conducted that investigated a DISC virus as a therapeutic vaccine against recurrent genital herpes (50).", [["genital", "ANATOMY", 105, 112], ["genital herpes", "DISEASE", 105, 119], ["DISC", "GENE_OR_GENE_PRODUCT", 51, 55], ["genital herpes", "ORGANISM", 105, 119], ["a DISC virus", "PROBLEM", 49, 61], ["a therapeutic vaccine", "TREATMENT", 65, 86], ["recurrent genital herpes", "PROBLEM", 95, 119], ["DISC", "ANATOMY", 51, 55]]], ["The results were negative.", [["negative", "OBSERVATION", 17, 25]]], ["The DISC virus (TA-HSV) studied had been derived from a minimally virulent HSV-2 wild-type strain (47, 51).", [["DISC", "GENE_OR_GENE_PRODUCT", 4, 8], ["TA-HSV", "ORGANISM", 16, 22], ["HSV-2", "ORGANISM", 75, 80], ["HSV-2", "SPECIES", 75, 80], ["HSV", "SPECIES", 19, 22], ["HSV-2 wild-type strain", "SPECIES", 75, 97], ["The DISC virus", "PROBLEM", 0, 14], ["a minimally virulent HSV", "PROBLEM", 54, 78], ["DISC", "ANATOMY", 4, 8], ["virus", "OBSERVATION", 9, 14], ["minimally", "OBSERVATION_MODIFIER", 56, 65], ["virulent", "OBSERVATION_MODIFIER", 66, 74]]], ["Moreover, the virus was administered at a relatively low dose, apparently to avoid toxicity.", [["toxicity", "DISEASE", 83, 91], ["the virus", "PROBLEM", 10, 19], ["toxicity", "PROBLEM", 83, 91]]], ["The failure of the trial should not be surprising.DISCUSSIONUnlike a conventional vaccine, a replication-competent controlled vector requires activation after administration to a subject to be immunized.", [["The failure", "PROBLEM", 0, 11], ["a conventional vaccine", "TREATMENT", 67, 89], ["a replication", "TREATMENT", 91, 104], ["failure", "OBSERVATION", 4, 11]]], ["A single ulipristal dose can be administered orally at the time of immunization.", [["ulipristal", "CHEMICAL", 9, 19], ["ulipristal", "SIMPLE_CHEMICAL", 9, 19], ["A single ulipristal dose", "TREATMENT", 0, 24], ["immunization", "TREATMENT", 67, 79]]], ["Regarding heat treatment, we have developed small pads that conduction heat the inoculation region by crystallization of a supercooled salt solution (52).", [["heat treatment", "TREATMENT", 10, 24], ["small pads that conduction heat the inoculation region", "PROBLEM", 44, 98], ["a supercooled salt solution", "TREATMENT", 121, 148], ["small", "OBSERVATION_MODIFIER", 44, 49], ["pads", "OBSERVATION", 50, 54]]], ["The pads are capable of maintaining a temperature of 45\u00b0C for 15 min.", [["pads", "ORGANISM_SUBDIVISION", 4, 8], ["The pads", "TREATMENT", 0, 8]]], ["This heat dose was shown to be sufficient for strong activation of the HSP70B promoter, which is the promoter used in the two-component gene switch that controls the HSV-GS vectors, in all layers of the skin of human subjects.Cells, plasmids, and viruses. ::: MATERIALS AND METHODSRS cells were a gift from E. Wagner and were propagated in minimal essential medium with Eagle's salts (MEM) (Life Technologies/Thermo Fisher Scientific) supplemented with 5% heat-inactivated calf serum (Atlanta Biologicals, Lawrenceville, GA), 292 mg/ml l-glutamine, 250 U/ml of penicillin, and 250 \u03bcg/ml of streptomycin (Life Technologies).", [["skin", "ANATOMY", 203, 207], ["Cells", "ANATOMY", 226, 231], ["plasmids", "ANATOMY", 233, 241], ["METHODSRS cells", "ANATOMY", 274, 289], ["serum", "ANATOMY", 478, 483], ["Eagle's salts", "CHEMICAL", 370, 383], ["l-glutamine", "CHEMICAL", 536, 547], ["penicillin", "CHEMICAL", 561, 571], ["streptomycin", "CHEMICAL", 590, 602], ["l-glutamine", "CHEMICAL", 536, 547], ["penicillin", "CHEMICAL", 561, 571], ["streptomycin", "CHEMICAL", 590, 602], ["HSP70B", "GENE_OR_GENE_PRODUCT", 71, 77], ["HSV-GS", "GENE_OR_GENE_PRODUCT", 166, 172], ["skin", "ORGAN", 203, 207], ["human", "ORGANISM", 211, 216], ["Cells", "CELL", 226, 231], ["METHODSRS cells", "CELL", 274, 289], ["calf", "ORGANISM", 473, 477], ["serum", "ORGANISM_SUBSTANCE", 478, 483], ["Lawrenceville", "SIMPLE_CHEMICAL", 506, 519], ["l-glutamine", "SIMPLE_CHEMICAL", 536, 547], ["penicillin", "SIMPLE_CHEMICAL", 561, 571], ["streptomycin", "SIMPLE_CHEMICAL", 590, 602], ["HSP70B promoter", "DNA", 71, 86], ["promoter", "DNA", 101, 109], ["-component gene switch", "DNA", 125, 147], ["HSV-GS vectors", "DNA", 166, 180], ["plasmids", "DNA", 233, 241], ["METHODSRS cells", "CELL_LINE", 274, 289], ["human", "SPECIES", 211, 216], ["calf", "SPECIES", 473, 477], ["human", "SPECIES", 211, 216], ["This heat dose", "TREATMENT", 0, 14], ["the HSP70B promoter", "TREATMENT", 67, 86], ["the two-component gene switch", "TREATMENT", 118, 147], ["the HSV-GS vectors", "TREATMENT", 162, 180], ["Cells", "TEST", 226, 231], ["plasmids", "TREATMENT", 233, 241], ["5% heat-inactivated calf serum (Atlanta Biologicals", "TREATMENT", 453, 504], ["Lawrenceville, GA", "TREATMENT", 506, 523], ["glutamine", "TREATMENT", 538, 547], ["penicillin", "TREATMENT", 561, 571], ["streptomycin", "TREATMENT", 590, 602], ["skin", "ANATOMY", 203, 207], ["viruses", "OBSERVATION", 247, 254]]], ["Vero cells (procured from the American Type Culture Collection [ATCC]) and Vero cell-derived E5 cells (53) (obtained from N. DeLuca) were propagated in Dulbecco's modified Eagle's medium (DMEM) with 10% heat-inactivated fetal calf serum, 250 U/ml of penicillin, and 250 \u03bcg/ml of streptomycin.", [["Vero cells", "ANATOMY", 0, 10], ["Vero cell-derived E5 cells", "ANATOMY", 75, 101], ["fetal calf serum", "ANATOMY", 220, 236], ["penicillin", "CHEMICAL", 250, 260], ["streptomycin", "CHEMICAL", 279, 291], ["penicillin", "CHEMICAL", 250, 260], ["streptomycin", "CHEMICAL", 279, 291], ["Vero cells", "CELL", 0, 10], ["ATCC]", "CELL", 64, 69], ["Vero cell-derived E5 cells", "CELL", 75, 101], ["calf", "ORGANISM", 226, 230], ["serum", "ORGANISM_SUBSTANCE", 231, 236], ["penicillin", "SIMPLE_CHEMICAL", 250, 260], ["streptomycin", "SIMPLE_CHEMICAL", 279, 291], ["Vero cells", "CELL_LINE", 0, 10], ["Vero cell", "CELL_LINE", 75, 84], ["E5 cells", "CELL_LINE", 93, 101], ["calf", "SPECIES", 226, 230], ["Vero cells", "PROBLEM", 0, 10], ["Culture Collection", "TEST", 44, 62], ["ATCC", "TEST", 64, 68], ["Vero cell-derived E5 cells", "TEST", 75, 101], ["10% heat-inactivated fetal calf serum", "TREATMENT", 199, 236], ["penicillin", "TREATMENT", 250, 260], ["streptomycin", "TREATMENT", 279, 291], ["calf", "ANATOMY", 226, 230]]], ["HSV-1 strain 17syn+ and ICP4 deletion strain KD6 (37) were obtained from J. Stevens.", [["HSV-1", "ORGANISM", 0, 5], ["strain 17syn", "ORGANISM", 6, 18], ["ICP4", "GENE_OR_GENE_PRODUCT", 24, 28], ["HSV-1", "SPECIES", 0, 5], ["HSV-1", "SPECIES", 0, 5], ["HSV", "TEST", 0, 3], ["ICP4 deletion strain KD6", "TREATMENT", 24, 48]]], ["Stocks of KD6, HSV-GS3, and HSV-GS7 were propagated on E5 cells.", [["E5 cells", "ANATOMY", 55, 63], ["KD6", "GENE_OR_GENE_PRODUCT", 10, 13], ["HSV-GS3", "ORGANISM", 15, 22], ["HSV-GS7", "ORGANISM", 28, 35], ["E5 cells", "CELL", 55, 63], ["KD6, HSV-GS3, and HSV-GS7", "DNA", 10, 35], ["E5 cells", "CELL_LINE", 55, 63], ["HSV-GS7", "SPECIES", 28, 35], ["KD6", "TEST", 10, 13], ["HSV", "TEST", 15, 18], ["GS3", "TEST", 19, 22], ["HSV", "TEST", 28, 31]]], ["For HSV-GS3 and HSV-GS7, the medium was supplemented with 10 nM mifepristone, and infected cultures were subjected to daily heat treatment at 43.5\u00b0C for 30 min for three successive days.", [["cultures", "ANATOMY", 91, 99], ["mifepristone", "CHEMICAL", 64, 76], ["mifepristone", "CHEMICAL", 64, 76], ["HSV-GS3", "ORGANISM", 4, 11], ["HSV-GS7", "ORGANISM", 16, 23], ["mifepristone", "SIMPLE_CHEMICAL", 64, 76], ["infected cultures", "CELL_LINE", 82, 99], ["HSV", "SPECIES", 4, 7], ["HSV-GS7", "SPECIES", 16, 23], ["HSV", "TEST", 4, 7], ["GS3", "TEST", 8, 11], ["HSV", "TEST", 16, 19], ["10 nM mifepristone", "TREATMENT", 58, 76], ["infected cultures", "PROBLEM", 82, 99], ["daily heat treatment", "TREATMENT", 118, 138]]], ["EIV Prague/56 was a gift from T. Lengsfeld and was propagated on Madin-Darby canine kidney (MDCK) cells (ATCC) in DMEM supplemented with 10% heat-inactivated horse serum as previously described (54).", [["canine kidney (MDCK) cells", "ANATOMY", 77, 103], ["ATCC", "ANATOMY", 105, 109], ["serum", "ANATOMY", 164, 169], ["Madin-Darby canine kidney (MDCK) cells", "CELL", 65, 103], ["ATCC", "CELL", 105, 109], ["horse", "ORGANISM", 158, 163], ["serum", "ORGANISM_SUBSTANCE", 164, 169], ["Madin-Darby canine kidney (MDCK) cells", "CELL_LINE", 65, 103], ["horse", "SPECIES", 158, 163], ["EIV Prague/56", "SPECIES", 0, 13], ["T. Lengsfeld", "SPECIES", 30, 42], ["canine", "SPECIES", 77, 83], ["Madin", "TREATMENT", 65, 70], ["Darby canine kidney (MDCK) cells (ATCC) in DMEM", "TREATMENT", 71, 118], ["horse serum", "TEST", 158, 169], ["kidney", "ANATOMY", 84, 90]]], ["Stocks of EIV were titrated using 50% tissue culture infective dose (TCID50) assays in MDCK cells.", [["tissue", "ANATOMY", 38, 44], ["MDCK cells", "ANATOMY", 87, 97], ["EIV", "GENE_OR_GENE_PRODUCT", 10, 13], ["tissue", "TISSUE", 38, 44], ["MDCK cells", "CELL", 87, 97], ["MDCK cells", "CELL_LINE", 87, 97], ["EIV", "TREATMENT", 10, 13], ["50% tissue culture infective dose", "TREATMENT", 34, 67]]], ["All the cells were cultured at 37\u00b0C under 5% CO2.Chemical reagents. ::: MATERIALS AND METHODSMifepristone was obtained from Sigma-Aldrich, and ulipristal acetate was from D-Innovation Pharmaceutical Inc., Chengdu, Sichuan, People's Republic of China.", [["cells", "ANATOMY", 8, 13], ["CO2", "CHEMICAL", 45, 48], ["METHODSMifepristone", "CHEMICAL", 86, 105], ["ulipristal acetate", "CHEMICAL", 143, 161], ["CO2", "CHEMICAL", 45, 48], ["METHODSMifepristone", "CHEMICAL", 86, 105], ["ulipristal acetate", "CHEMICAL", 143, 161], ["cells", "CELL", 8, 13], ["CO2", "SIMPLE_CHEMICAL", 45, 48], ["METHODSMifepristone", "SIMPLE_CHEMICAL", 86, 105], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 124, 137], ["ulipristal acetate", "SIMPLE_CHEMICAL", 143, 161], ["METHODSMifepristone", "TREATMENT", 86, 105], ["ulipristal acetate", "TREATMENT", 143, 161]]], ["Both compounds were USP grade.Construction of viruses. ::: MATERIALS AND METHODSAll the viruses were constructed using wild-type HSV-1 strain 17syn+ as the backbone.", [["HSV-1", "ORGANISM", 129, 134], ["17syn", "ORGANISM", 142, 147], ["HSV-1", "SPECIES", 129, 134], ["HSV-1", "SPECIES", 129, 134], ["wild-type HSV", "TEST", 119, 132], ["viruses", "OBSERVATION", 46, 53], ["viruses", "OBSERVATION", 88, 95]]], ["Viral recombinants were generated by homologous recombination of engineered plasmids, along with purified virion DNA, in RS cells transfected by the calcium phosphate precipitation method, as previously described (41).", [["plasmids", "ANATOMY", 76, 84], ["RS cells", "ANATOMY", 121, 129], ["calcium phosphate", "CHEMICAL", 149, 166], ["calcium phosphate", "CHEMICAL", 149, 166], ["Viral", "ORGANISM", 0, 5], ["DNA", "CELLULAR_COMPONENT", 113, 116], ["RS cells", "CELL", 121, 129], ["calcium", "SIMPLE_CHEMICAL", 149, 156], ["engineered plasmids", "DNA", 65, 84], ["purified virion DNA", "DNA", 97, 116], ["RS cells", "CELL_LINE", 121, 129], ["Viral recombinants", "TREATMENT", 0, 18], ["engineered plasmids", "TREATMENT", 65, 84], ["purified virion DNA", "TREATMENT", 97, 116], ["the calcium phosphate precipitation method", "TEST", 145, 187], ["engineered plasmids", "OBSERVATION", 65, 84], ["virion DNA", "OBSERVATION", 106, 116]]], ["Plasmids used to engineer the insertions of the transactivator cassette or the GAL4-responsive promoters comprised HSV-1 sequences cloned from strain 17syn+.", [["GAL4", "GENE_OR_GENE_PRODUCT", 79, 83], ["HSV-1", "ORGANISM", 115, 120], ["transactivator cassette", "DNA", 48, 71], ["GAL4-responsive promoters", "DNA", 79, 104], ["HSV-1 sequences", "DNA", 115, 130], ["HSV-1", "SPECIES", 115, 120], ["Plasmids", "TREATMENT", 0, 8], ["the transactivator cassette", "TREATMENT", 44, 71], ["the GAL4", "TREATMENT", 75, 83], ["HSV", "TEST", 115, 118], ["GAL4", "ANATOMY", 79, 83]]], ["HSV-GS3 (Fig. 1B) was constructed as previously described (3, 35).", [["HSV-GS3", "ORGANISM", 0, 7], ["Fig. 1B", "ORGANISM", 9, 16], ["GS3", "DNA", 4, 7], ["HSV-GS3 (Fig. 1B", "SPECIES", 0, 16], ["HSV", "TEST", 0, 3]]], ["HSV-GS7 was derived from the intermediate vector HSV-17GS43 (35), which contains an insertion between the UL43 and UL44 genes of a transactivator cassette containing a GLP65 gene under the control of a promoter cassette that combined a human HSP70B promoter and a GAL4-responsive promoter (31).", [["HSV-GS7", "ORGANISM", 0, 7], ["HSV-17GS43 (35", "ORGANISM", 49, 63], ["UL43", "GENE_OR_GENE_PRODUCT", 106, 110], ["UL44", "GENE_OR_GENE_PRODUCT", 115, 119], ["GLP65", "GENE_OR_GENE_PRODUCT", 168, 173], ["human", "ORGANISM", 236, 241], ["HSP70B", "GENE_OR_GENE_PRODUCT", 242, 248], ["GAL4", "GENE_OR_GENE_PRODUCT", 264, 268], ["GS7", "DNA", 4, 7], ["UL43 and UL44 genes", "DNA", 106, 125], ["transactivator cassette", "DNA", 131, 154], ["GLP65 gene", "DNA", 168, 178], ["promoter cassette", "DNA", 202, 219], ["human HSP70B promoter", "DNA", 236, 257], ["GAL4-responsive promoter", "DNA", 264, 288], ["human", "SPECIES", 236, 241], ["HSV-GS7", "SPECIES", 0, 7], ["HSV-17GS43", "SPECIES", 49, 59], ["human", "SPECIES", 236, 241], ["HSV", "TEST", 0, 3], ["a transactivator cassette", "TREATMENT", 129, 154], ["a promoter cassette", "TREATMENT", 200, 219], ["a human HSP70B promoter", "TREATMENT", 234, 257], ["a GAL4-responsive promoter", "TREATMENT", 262, 288]]], ["To place the UL38/VP19c gene under the regulation of a GAL4-responsive promoter, plasmid pBS-KS:GAL4-UL38 was constructed.", [["UL38", "GENE_OR_GENE_PRODUCT", 13, 17], ["VP19c", "GENE_OR_GENE_PRODUCT", 18, 23], ["GAL4", "GENE_OR_GENE_PRODUCT", 55, 59], ["pBS", "GENE_OR_GENE_PRODUCT", 89, 92], ["GAL4-UL38", "GENE_OR_GENE_PRODUCT", 96, 105], ["UL38/VP19c gene", "DNA", 13, 28], ["GAL4-responsive promoter", "DNA", 55, 79], ["plasmid pBS-KS:GAL4", "DNA", 81, 100], ["UL38", "DNA", 101, 105], ["a GAL4-responsive promoter", "TREATMENT", 53, 79], ["plasmid pBS", "TEST", 81, 92], ["GAL4-UL38", "TEST", 96, 105]]], ["The plasmid contains a GAL4 promoter inserted between the HSV-1 UL38 recombination arms of the plasmid pBS-KS:UL38\u0394promoter.", [["plasmid", "ANATOMY", 4, 11], ["plasmid", "ANATOMY", 95, 102], ["GAL4", "GENE_OR_GENE_PRODUCT", 23, 27], ["HSV-1", "ORGANISM", 58, 63], ["UL38", "GENE_OR_GENE_PRODUCT", 64, 68], ["pBS", "GENE_OR_GENE_PRODUCT", 103, 106], ["plasmid", "DNA", 4, 11], ["GAL4 promoter", "DNA", 23, 36], ["HSV-1 UL38 recombination arms", "DNA", 58, 87], ["pBS", "DNA", 103, 106], ["UL38\u0394promoter", "DNA", 110, 123], ["HSV-1", "SPECIES", 58, 63], ["The plasmid", "TREATMENT", 0, 11], ["a GAL4 promoter", "TREATMENT", 21, 36], ["the HSV", "TEST", 54, 61], ["GAL4 promoter", "OBSERVATION", 23, 36]]], ["A GAL4-responsive promoter comprising six copies of the yeast GAL4 upstream activating sequence (UAS), the adenovirus E1b TATA sequence, and the synthetic intron Ivs8 was excised from the plasmid pGene/V5-His A (Invitrogen, Life Technologies) with AatII and HindIII, and the resulting 473-bp fragment was gel purified.", [["plasmid", "ANATOMY", 188, 195], ["GAL4", "GENE_OR_GENE_PRODUCT", 2, 6], ["GAL4", "GENE_OR_GENE_PRODUCT", 62, 66], ["UAS", "GENE_OR_GENE_PRODUCT", 97, 100], ["adenovirus", "ORGANISM", 107, 117], ["E1b", "GENE_OR_GENE_PRODUCT", 118, 121], ["Ivs8", "GENE_OR_GENE_PRODUCT", 162, 166], ["AatII", "GENE_OR_GENE_PRODUCT", 248, 253], ["HindIII", "GENE_OR_GENE_PRODUCT", 258, 265], ["GAL4-responsive promoter", "DNA", 2, 26], ["yeast GAL4 upstream activating sequence", "DNA", 56, 95], ["UAS", "DNA", 97, 100], ["adenovirus E1b TATA sequence", "DNA", 107, 135], ["synthetic intron Ivs8", "DNA", 145, 166], ["plasmid pGene", "DNA", 188, 201], ["V5", "DNA", 202, 204], ["His A", "DNA", 205, 210], ["Invitrogen, Life Technologies", "DNA", 212, 241], ["AatII", "DNA", 248, 253], ["HindIII", "DNA", 258, 265], ["473-bp fragment", "DNA", 285, 300], ["yeast", "SPECIES", 56, 61], ["yeast", "SPECIES", 56, 61], ["A GAL4-responsive promoter", "TREATMENT", 0, 26], ["the adenovirus E1b TATA sequence", "TEST", 103, 135], ["the synthetic intron Ivs8", "TREATMENT", 141, 166], ["His A (Invitrogen, Life Technologies", "TREATMENT", 205, 241], ["AatII and HindIII", "TREATMENT", 248, 265], ["bp fragment", "PROBLEM", 289, 300]]], ["For the vector, pBS-KS:UL38\u0394promoter was digested with AatII and HindIII, and the resulting 4,285-bp fragment was gel purified and treated with shrimp alkaline phosphatase.", [["pBS-KS", "GENE_OR_GENE_PRODUCT", 16, 22], ["UL38\u0394promoter", "GENE_OR_GENE_PRODUCT", 23, 36], ["AatII", "GENE_OR_GENE_PRODUCT", 55, 60], ["HindIII", "GENE_OR_GENE_PRODUCT", 65, 72], ["shrimp alkaline phosphatase", "GENE_OR_GENE_PRODUCT", 144, 171], ["pBS-KS:UL38\u0394promoter", "DNA", 16, 36], ["AatII", "DNA", 55, 60], ["HindIII", "DNA", 65, 72], ["4,285-bp fragment", "DNA", 92, 109], ["shrimp alkaline phosphatase", "PROTEIN", 144, 171], ["AatII and HindIII", "TREATMENT", 55, 72], ["bp fragment", "PROBLEM", 98, 109], ["shrimp alkaline phosphatase", "TEST", 144, 171]]], ["Ligation of the last two fragments placed the GAL4 promoter in front of the UL38 transcriptional start site.", [["fragments", "ANATOMY", 25, 34], ["GAL4", "GENE_OR_GENE_PRODUCT", 46, 50], ["UL38", "GENE_OR_GENE_PRODUCT", 76, 80], ["GAL4 promoter", "DNA", 46, 59], ["UL38 transcriptional start site", "DNA", 76, 107], ["Ligation", "TREATMENT", 0, 8], ["the last two fragments", "PROBLEM", 12, 34], ["the GAL4 promoter", "TREATMENT", 42, 59], ["fragments", "OBSERVATION", 25, 34], ["GAL4 promoter", "OBSERVATION", 46, 59]]], ["To produce recombinant HSV-GS7, RS cells were cotransfected with the plasmid pBS-KS:GAL4-UL38 and purified HSV-17GS43 virion DNA.", [["RS cells", "ANATOMY", 32, 40], ["HSV", "ORGANISM", 23, 26], ["-GS7", "ORGANISM", 26, 30], ["RS cells", "CELL", 32, 40], ["pBS-KS", "GENE_OR_GENE_PRODUCT", 77, 83], ["GAL4-UL38", "GENE_OR_GENE_PRODUCT", 84, 93], ["HSV", "ORGANISM", 107, 110], ["DNA", "CELLULAR_COMPONENT", 125, 128], ["GS7", "PROTEIN", 27, 30], ["RS cells", "CELL_LINE", 32, 40], ["plasmid pBS-KS:GAL4-UL38 and purified HSV-17GS43 virion DNA", "DNA", 69, 128], ["HSV", "SPECIES", 23, 26], ["HSV-17GS43", "SPECIES", 107, 117], ["recombinant HSV", "TEST", 11, 26], ["RS cells", "PROBLEM", 32, 40], ["the plasmid pBS", "TEST", 65, 80], ["GAL4", "TEST", 84, 88], ["purified HSV", "TEST", 98, 110], ["virion DNA", "PROBLEM", 118, 128]]], ["Subsequent to the addition of mifepristone to the medium, the cotransfected cells were exposed to 43.5\u00b0C for 30 min and then incubated at 37\u00b0C. Subsequently, on days 2 and 3, the cells were again incubated at 43.5\u00b0C for 30 min and then returned to 37\u00b0C. Picking and amplification of plaques, screening, and plaque purification were performed essentially as described for HSV-GS3 (3, 35).", [["cells", "ANATOMY", 76, 81], ["cells", "ANATOMY", 179, 184], ["plaques", "ANATOMY", 283, 290], ["plaque", "ANATOMY", 307, 313], ["mifepristone", "CHEMICAL", 30, 42], ["mifepristone", "CHEMICAL", 30, 42], ["mifepristone", "SIMPLE_CHEMICAL", 30, 42], ["cells", "CELL", 76, 81], ["cells", "CELL", 179, 184], ["HSV-GS3", "ORGANISM", 371, 378], ["cotransfected cells", "CELL_LINE", 62, 81], ["HSV-GS3", "SPECIES", 371, 378], ["mifepristone", "TREATMENT", 30, 42], ["the cotransfected cells", "TREATMENT", 58, 81], ["plaques", "PROBLEM", 283, 290], ["screening", "TEST", 292, 301], ["plaque purification", "TEST", 307, 326], ["HSV", "TEST", 371, 374], ["plaques", "OBSERVATION", 283, 290]]], ["The resulting plaque-purified HSV-GS7 was verified by Southern blotting, as well as by PCR and DNA sequence analysis of the recombination junctions.", [["plaque", "ANATOMY", 14, 20], ["plaque", "PATHOLOGICAL_FORMATION", 14, 20], ["HSV", "ORGANISM", 30, 33], ["GS7", "GENE_OR_GENE_PRODUCT", 34, 37], ["DNA", "CELLULAR_COMPONENT", 95, 98], ["GS7", "PROTEIN", 34, 37], ["The resulting plaque", "PROBLEM", 0, 20], ["purified HSV", "TEST", 21, 33], ["Southern blotting", "TEST", 54, 71], ["PCR", "TEST", 87, 90], ["DNA sequence analysis", "TEST", 95, 116], ["plaque", "OBSERVATION", 14, 20], ["HSV", "OBSERVATION", 30, 33], ["recombination junctions", "OBSERVATION", 124, 147]]], ["Plasmid pBS-KS:UL38\u0394promoter was constructed by deletion of the region from \u22121 to \u221247 of the UL38 promoter, i.e., by synthesizing two PCR fragments (one 437 bp and the other 550 bp) on either side of the deletion and cloning them into pBS KS+.", [["pBS-KS", "GENE_OR_GENE_PRODUCT", 8, 14], ["UL38\u0394promoter", "GENE_OR_GENE_PRODUCT", 15, 28], ["UL38", "GENE_OR_GENE_PRODUCT", 93, 97], ["Plasmid pBS-KS:UL38\u0394promoter", "DNA", 0, 28], ["\u22121 to \u221247", "DNA", 76, 85], ["UL38 promoter", "DNA", 93, 106], ["PCR fragments", "DNA", 134, 147], ["pBS KS", "DNA", 235, 241], ["Plasmid pBS", "TEST", 0, 11], ["synthesizing two PCR fragments", "PROBLEM", 117, 147], ["bp", "TEST", 157, 159], ["bp", "TEST", 178, 180], ["the deletion", "PROBLEM", 200, 212], ["region", "ANATOMY_MODIFIER", 64, 70]]], ["HSV-GS11 was derived from the vector HSV-GS3 (35) and contains an insertion between the UL37 and UL38 genes of a gene cassette expressing the EIV Prague/56 HA gene driven by the CMV IE promoter.", [["HSV-GS11", "ORGANISM", 0, 8], ["HSV-GS3 (35", "ORGANISM", 37, 48], ["UL37", "GENE_OR_GENE_PRODUCT", 88, 92], ["UL38", "GENE_OR_GENE_PRODUCT", 97, 101], ["EIV", "GENE_OR_GENE_PRODUCT", 142, 145], ["HA", "GENE_OR_GENE_PRODUCT", 156, 158], ["CMV", "ORGANISM", 178, 181], ["GS11", "DNA", 4, 8], ["UL37 and UL38 genes", "DNA", 88, 107], ["EIV Prague/56 HA gene", "DNA", 142, 163], ["CMV IE promoter", "DNA", 178, 193], ["HSV-GS11", "SPECIES", 0, 8], ["HSV-GS3", "SPECIES", 37, 44], ["HSV", "TEST", 0, 3], ["the vector HSV", "TEST", 26, 40], ["an insertion", "TREATMENT", 63, 75], ["a gene cassette", "TREATMENT", 111, 126]]], ["A recombination plasmid was constructed by the following sequential steps.", [["plasmid", "ANATOMY", 16, 23], ["recombination plasmid", "DNA", 2, 23], ["A recombination plasmid", "TREATMENT", 0, 23]]], ["First, an 814-bp fragment containing the region spanning the HSV-1 UL37/UL38 intergenic region from nucleotides (nt) 83603 to 84417 from plasmid NK470 was subcloned into pBS that had had the multiple-cloning site (MCS) removed (by digestion with KpnI/SacI) to yield pBS:UL37/38.", [["plasmid", "ANATOMY", 137, 144], ["nucleotides", "CHEMICAL", 100, 111], ["HSV-1", "ORGANISM", 61, 66], ["UL37", "GENE_OR_GENE_PRODUCT", 67, 71], ["UL38", "GENE_OR_GENE_PRODUCT", 72, 76], ["pBS", "GENE_OR_GENE_PRODUCT", 170, 173], ["KpnI", "GENE_OR_GENE_PRODUCT", 246, 250], ["SacI", "GENE_OR_GENE_PRODUCT", 251, 255], ["814-bp fragment", "DNA", 10, 25], ["HSV-1 UL37/UL38 intergenic region", "DNA", 61, 94], ["nucleotides (nt) 83603 to 84417", "DNA", 100, 131], ["plasmid NK470", "DNA", 137, 150], ["pBS", "DNA", 170, 173], ["multiple-cloning site", "DNA", 191, 212], ["MCS", "DNA", 214, 217], ["KpnI", "DNA", 246, 250], ["SacI", "DNA", 251, 255], ["HSV-1", "SPECIES", 61, 66], ["bp fragment", "TREATMENT", 14, 25], ["the HSV", "TEST", 57, 64], ["nucleotides (nt)", "TEST", 100, 116], ["KpnI/SacI", "TREATMENT", 246, 255], ["UL37", "TEST", 270, 274], ["region", "ANATOMY_MODIFIER", 41, 47], ["HSV", "ANATOMY", 61, 64], ["multiple", "OBSERVATION_MODIFIER", 191, 199]]], ["A cassette containing a synthetic CMV IE promoter flanked by the pBS-SK+ MCS was ligated into pBS:UL37/38 digested with BspE1/AflII, which cut between the UL37 and UL38 genes, to yield the plasmid pIN:UL37/38.", [["CMV", "ORGANISM", 34, 37], ["pBS", "GENE_OR_GENE_PRODUCT", 65, 68], ["SK", "GENE_OR_GENE_PRODUCT", 69, 71], ["pBS", "GENE_OR_GENE_PRODUCT", 94, 97], ["BspE1", "GENE_OR_GENE_PRODUCT", 120, 125], ["AflII", "GENE_OR_GENE_PRODUCT", 126, 131], ["UL37", "GENE_OR_GENE_PRODUCT", 155, 159], ["UL38", "GENE_OR_GENE_PRODUCT", 164, 168], ["pIN", "GENE_OR_GENE_PRODUCT", 197, 200], ["UL37/38", "GENE_OR_GENE_PRODUCT", 201, 208], ["synthetic CMV IE promoter", "DNA", 24, 49], ["pBS", "DNA", 65, 68], ["SK", "PROTEIN", 69, 71], ["MCS", "DNA", 73, 76], ["pBS:UL37/38", "DNA", 94, 105], ["BspE1", "DNA", 120, 125], ["AflII", "DNA", 126, 131], ["UL37 and UL38 genes", "DNA", 155, 174], ["plasmid pIN", "DNA", 189, 200], ["UL37/38", "DNA", 201, 208], ["A cassette", "TREATMENT", 0, 10], ["a synthetic CMV IE promoter", "TREATMENT", 22, 49], ["the pBS", "TEST", 61, 68], ["UL37", "TEST", 98, 102], ["BspE1/AflII", "PROBLEM", 120, 131]]], ["The EIV Prague/56 HA gene was PCR cloned from cDNA prepared from EIV Prague/56.", [["EIV", "GENE_OR_GENE_PRODUCT", 4, 7], ["HA", "GENE_OR_GENE_PRODUCT", 18, 20], ["EIV Prague/56 HA gene", "DNA", 4, 25], ["cDNA", "DNA", 46, 50], ["EIV Prague/56", "SPECIES", 65, 78]]], ["Briefly, RNA was prepared by TRIzol extraction of a stock of EIV Prague 56 and was reverse transcribed using Omni-Script reverse transcriptase (Qiagen) according to the manufacturer's instructions.", [["Omni-Script reverse transcriptase", "PROTEIN", 109, 142], ["EIV Prague 56", "SPECIES", 61, 74], ["TRIzol extraction", "TREATMENT", 29, 46], ["Omni-Script reverse transcriptase (Qiagen)", "TREATMENT", 109, 151]]], ["The cDNAs were cloned into pBS, and the clone containing the HA gene (pBS-EIVPrague56/HA) was confirmed by sequence analysis.", [["pBS", "GENE_OR_GENE_PRODUCT", 27, 30], ["clone", "CELL", 40, 45], ["HA", "GENE_OR_GENE_PRODUCT", 61, 63], ["pBS-EIVPrague56", "GENE_OR_GENE_PRODUCT", 70, 85], ["cDNAs", "DNA", 4, 9], ["pBS", "DNA", 27, 30], ["HA gene", "DNA", 61, 68], ["pBS", "DNA", 70, 73], ["EIVPrague56", "DNA", 74, 85], ["HA", "DNA", 86, 88], ["The cDNAs", "TREATMENT", 0, 9], ["the clone", "TREATMENT", 36, 45], ["the HA gene (pBS-EIVPrague56/HA", "TREATMENT", 57, 88], ["sequence analysis", "TEST", 107, 124]]], ["The Prague/56 HA gene was subcloned from this plasmid and inserted behind the CMV promoter in the plasmid pIN:UL37/38 to yield plasmid pIN:37/38-Prague56/HA.", [["plasmid", "ANATOMY", 46, 53], ["plasmid", "ANATOMY", 98, 105], ["Prague/56 HA", "ORGANISM", 4, 16], ["CMV", "ORGANISM", 78, 81], ["HA", "GENE_OR_GENE_PRODUCT", 154, 156], ["Prague/56 HA gene", "DNA", 4, 21], ["plasmid", "DNA", 46, 53], ["CMV promoter", "DNA", 78, 90], ["plasmid pIN", "DNA", 98, 109], ["UL37/38", "DNA", 110, 117], ["Prague56", "DNA", 145, 153], ["this plasmid", "TREATMENT", 41, 53], ["the CMV promoter", "TREATMENT", 74, 90], ["plasmid pIN", "TEST", 127, 138], ["HA", "PROBLEM", 154, 156], ["CMV promoter", "OBSERVATION", 78, 90]]], ["To produce recombinant HSV-GS11, RS cells were cotransfected with plasmid pIN:37/38-Prague56/HA and purified HSV-GS3 virion DNA.", [["RS cells", "ANATOMY", 33, 41], ["plasmid", "ANATOMY", 66, 73], ["HSV", "ORGANISM", 23, 26], ["-GS11", "ORGANISM", 26, 31], ["RS cells", "CELL", 33, 41], ["pIN", "GENE_OR_GENE_PRODUCT", 74, 77], ["Prague56", "GENE_OR_GENE_PRODUCT", 84, 92], ["HA", "GENE_OR_GENE_PRODUCT", 93, 95], ["HSV", "ORGANISM", 109, 112], ["DNA", "CELLULAR_COMPONENT", 124, 127], ["GS11", "PROTEIN", 27, 31], ["RS cells", "CELL_LINE", 33, 41], ["plasmid pIN:37/38-Prague56/HA and purified HSV-GS3 virion DNA", "DNA", 66, 127], ["HSV", "SPECIES", 23, 26], ["HSV-GS3", "SPECIES", 109, 116], ["recombinant HSV", "TEST", 11, 26], ["RS cells", "TEST", 33, 41], ["plasmid pIN", "TEST", 66, 77], ["HA", "PROBLEM", 93, 95], ["purified HSV", "TEST", 100, 112], ["GS3 virion DNA", "PROBLEM", 113, 127], ["virion DNA", "OBSERVATION", 117, 127]]], ["Subsequent to the addition of mifepristone to the medium, the cotransfected cells were exposed to 43.5\u00b0C for 30 min and then incubated at 37\u00b0C. Subsequently, on days 2 and 3, the cells were again incubated at 43.5\u00b0C for 30 min and then returned to 37\u00b0C. Picking and amplification of plaques, screening, and plaque purification were performed essentially as described for HSV-GS3 (3, 35).", [["cells", "ANATOMY", 76, 81], ["cells", "ANATOMY", 179, 184], ["plaques", "ANATOMY", 283, 290], ["plaque", "ANATOMY", 307, 313], ["mifepristone", "CHEMICAL", 30, 42], ["mifepristone", "CHEMICAL", 30, 42], ["mifepristone", "SIMPLE_CHEMICAL", 30, 42], ["cells", "CELL", 76, 81], ["cells", "CELL", 179, 184], ["HSV-GS3", "ORGANISM", 371, 378], ["cotransfected cells", "CELL_LINE", 62, 81], ["HSV-GS3", "SPECIES", 371, 378], ["mifepristone", "TREATMENT", 30, 42], ["the cotransfected cells", "TREATMENT", 58, 81], ["plaques", "PROBLEM", 283, 290], ["screening", "TEST", 292, 301], ["plaque purification", "TEST", 307, 326], ["HSV", "TEST", 371, 374], ["plaques", "OBSERVATION", 283, 290]]], ["The resulting plaque-purified HSV-GS11 was verified by Southern blotting, as well as by PCR and DNA sequence analysis of the recombination junctions.Construction of expression plasmid pVP19c. ::: MATERIALS AND METHODSPlasmid pVP19c was constructed by PCR cloning of the promoter and coding sequence of the HSV-1 VP19c gene into pBS KS+ using HSV-1 strain 17syn+ virion DNA as the PCR target.Single-step growth analysis. ::: MATERIALS AND METHODSConfluent monolayers of Vero cells were infected with HSV-GS7 at a multiplicity of infection (MOI) of 3.", [["plaque", "ANATOMY", 14, 20], ["METHODSConfluent monolayers", "ANATOMY", 438, 465], ["Vero cells", "ANATOMY", 469, 479], ["multiplicity of infection", "DISEASE", 512, 537], ["plaque", "PATHOLOGICAL_FORMATION", 14, 20], ["HSV", "ORGANISM", 30, 33], ["GS11", "GENE_OR_GENE_PRODUCT", 34, 38], ["DNA", "CELLULAR_COMPONENT", 96, 99], ["pVP19c", "GENE_OR_GENE_PRODUCT", 225, 231], ["HSV-1", "ORGANISM", 306, 311], ["VP19c", "GENE_OR_GENE_PRODUCT", 312, 317], ["HSV-1", "ORGANISM", 342, 347], ["17syn", "ORGANISM", 355, 360], ["DNA", "CELLULAR_COMPONENT", 369, 372], ["METHODSConfluent monolayers", "CELL", 438, 465], ["Vero cells", "CELL", 469, 479], ["HSV", "ORGANISM", 499, 502], ["-GS7", "ORGANISM", 502, 506], ["GS11", "PROTEIN", 34, 38], ["expression plasmid pVP19c", "DNA", 165, 190], ["METHODSPlasmid pVP19c", "DNA", 210, 231], ["promoter", "DNA", 270, 278], ["HSV-1 VP19c gene", "DNA", 306, 322], ["pBS KS", "DNA", 328, 334], ["HSV-1 strain 17syn+ virion DNA", "DNA", 342, 372], ["PCR target", "DNA", 380, 390], ["METHODSConfluent monolayers", "CELL_LINE", 438, 465], ["Vero cells", "CELL_LINE", 469, 479], ["HSV-1", "SPECIES", 306, 311], ["HSV-1", "SPECIES", 342, 347], ["HSV-1", "SPECIES", 306, 311], ["HSV-1", "SPECIES", 342, 347], ["HSV-GS7", "SPECIES", 499, 506], ["The resulting plaque", "PROBLEM", 0, 20], ["purified HSV", "TEST", 21, 33], ["Southern blotting", "TEST", 55, 72], ["PCR", "TEST", 88, 91], ["DNA sequence analysis", "TEST", 96, 117], ["expression plasmid pVP19c", "TREATMENT", 165, 190], ["METHODSPlasmid pVP19c", "TREATMENT", 210, 231], ["the HSV", "TEST", 302, 309], ["pBS KS", "TEST", 328, 334], ["HSV", "TEST", 342, 345], ["virion DNA", "TREATMENT", 362, 372], ["the PCR target", "TEST", 376, 390], ["Single-step growth analysis", "TEST", 391, 418], ["Vero cells", "PROBLEM", 469, 479], ["HSV", "TEST", 499, 502], ["infection", "PROBLEM", 528, 537], ["plaque", "OBSERVATION", 14, 20], ["recombination junctions", "OBSERVATION", 125, 148], ["Vero cells", "OBSERVATION", 469, 479], ["infection", "OBSERVATION", 528, 537]]], ["Virus was allowed to adsorb for 1 h at 37\u00b0C; then, the inoculum was removed, and the cells were overlaid with complete medium.", [["cells", "ANATOMY", 85, 90], ["Virus", "ORGANISM", 0, 5], ["cells", "CELL", 85, 90], ["Virus", "PROBLEM", 0, 5], ["the inoculum", "TREATMENT", 51, 63]]], ["Ulipristal treatment (10 nM) was initiated at the time of the initial infection.", [["Ulipristal", "CHEMICAL", 0, 10], ["infection", "DISEASE", 70, 79], ["Ulipristal", "CHEMICAL", 0, 10], ["Ulipristal", "SIMPLE_CHEMICAL", 0, 10], ["Ulipristal treatment", "TREATMENT", 0, 20], ["the initial infection", "PROBLEM", 58, 79], ["infection", "OBSERVATION", 70, 79]]], ["Heat treatment was performed either immediately after infection or 4 h later by floating the sealed dishes in a 43.5\u00b0C water bath for 30 min.", [["infection", "DISEASE", 54, 63], ["Heat treatment", "TREATMENT", 0, 14], ["infection", "PROBLEM", 54, 63]]], ["The dishes were then incubated for 72 h at 37\u00b0C. At 0, 4 or 8, 12 or 16, and 24 or 28 h postinfection, two dishes were removed, and the cells were scraped into medium for harvesting and subjected to two freeze-thaw cycles.", [["cells", "ANATOMY", 136, 141], ["cells", "CELL", 136, 141], ["harvesting", "TREATMENT", 171, 181]]], ["Infectious virus was then determined by titrating the lysate of each dish in triplicate on 24-well plates of confluent E5 cells transfected 24 h prior to infection with the expression vector pVP19c using Lipofectamine 2000 (Life Technologies).", [["lysate", "ANATOMY", 54, 60], ["E5 cells", "ANATOMY", 119, 127], ["infection", "DISEASE", 154, 163], ["E5 cells", "CELL", 119, 127], ["confluent E5 cells", "CELL_LINE", 109, 127], ["pVP19c", "DNA", 191, 197], ["Infectious virus", "SPECIES", 0, 16], ["Infectious virus", "PROBLEM", 0, 16], ["the lysate of each dish", "TREATMENT", 50, 73], ["confluent E5 cells", "PROBLEM", 109, 127], ["infection", "PROBLEM", 154, 163], ["the expression vector pVP19c", "TREATMENT", 169, 197], ["Lipofectamine", "TREATMENT", 204, 217]]], ["Plaques were visualized 2 days after infection using an antibody plaque assay, essentially as previously described (35).Immunization. ::: MATERIALS AND METHODSBriefly, 4- to 6-week-old female outbred Swiss Webster mice (Envigo, Tampa, FL) (or BALB/c mice [Envigo, Tampa, FL] for experiments involving HSV-GS11) were inoculated with the appropriate viral vector or phosphate-buffered saline (PBS) (pH 7.3; 50 \u03bcl/mouse) on the lightly abraded plantar surfaces of both rear feet as previously described (41).", [["Plaques", "ANATOMY", 0, 7], ["plantar surfaces", "ANATOMY", 441, 457], ["infection", "DISEASE", 37, 46], ["phosphate", "CHEMICAL", 364, 373], ["phosphate", "CHEMICAL", 364, 373], ["outbred", "ORGANISM", 192, 199], ["Swiss Webster mice", "ORGANISM", 200, 218], ["BALB/c mice", "ORGANISM", 243, 254], ["HSV", "ORGANISM", 301, 304], ["-GS11", "ORGANISM", 304, 309], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 364, 389], ["mouse", "ORGANISM", 411, 416], ["feet", "ORGANISM_SUBDIVISION", 471, 475], ["mice", "SPECIES", 214, 218], ["mice", "SPECIES", 250, 254], ["mouse", "SPECIES", 411, 416], ["Swiss Webster mice", "SPECIES", 200, 218], ["mice", "SPECIES", 250, 254], ["mouse", "SPECIES", 411, 416], ["Plaques", "PROBLEM", 0, 7], ["infection", "PROBLEM", 37, 46], ["an antibody plaque assay", "TEST", 53, 77], ["HSV", "TEST", 301, 304], ["phosphate", "TEST", 364, 373], ["buffered saline (PBS", "TREATMENT", 374, 394], ["pH", "TEST", 397, 399], ["antibody plaque", "OBSERVATION", 56, 71], ["plantar", "ANATOMY", 441, 448], ["surfaces", "ANATOMY_MODIFIER", 449, 457], ["both", "ANATOMY_MODIFIER", 461, 465], ["rear feet", "ANATOMY", 466, 475]]], ["To facilitate efficient uptake of the vector, and to minimize the amount of abrasion required, the feet were saline treated prior to infection.", [["infection", "DISEASE", 133, 142], ["feet", "ORGANISM_SUBDIVISION", 99, 103], ["the vector", "TREATMENT", 34, 44], ["abrasion", "PROBLEM", 76, 84], ["saline", "TREATMENT", 109, 115], ["infection", "PROBLEM", 133, 142], ["abrasion", "OBSERVATION", 76, 84], ["feet", "ANATOMY", 99, 103], ["infection", "OBSERVATION", 133, 142]]], ["The following procedure was employed.", [["The following procedure", "TREATMENT", 0, 23]]], ["Mice were first anesthetized with isoflurane by inhalation.", [["isoflurane", "CHEMICAL", 34, 44], ["isoflurane", "CHEMICAL", 34, 44], ["Mice", "ORGANISM", 0, 4], ["isoflurane", "SIMPLE_CHEMICAL", 34, 44], ["Mice", "SPECIES", 0, 4], ["isoflurane", "TREATMENT", 34, 44]]], ["Flunixin meglumine (1.1 mg/kg) was then administered intramuscularly (i.m.) to alleviate any pain associated with the procedure.", [["Flunixin meglumine", "CHEMICAL", 0, 18], ["pain", "DISEASE", 93, 97], ["Flunixin meglumine", "CHEMICAL", 0, 18], ["Flunixin meglumine", "SIMPLE_CHEMICAL", 0, 18], ["Flunixin meglumine", "TREATMENT", 0, 18], ["any pain", "PROBLEM", 89, 97], ["the procedure", "TREATMENT", 114, 127]]], ["Thereafter, 25 to 50 \u03bcl (no more than 50 \u03bcl) of sterile 10% saline was injected subepidermally under both rear footpads.", [["footpads", "ANATOMY", 111, 119], ["saline", "SIMPLE_CHEMICAL", 60, 66], ["footpads", "ORGANISM_SUBDIVISION", 111, 119], ["sterile 10% saline", "TREATMENT", 48, 66], ["rear footpads", "ANATOMY", 106, 119]]], ["The mice were then returned to their cages.", [["mice", "ORGANISM", 4, 8], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 4, 8]]], ["Four hours later, the mice were anesthetized by i.m. injection of 10 to 20 \u03bcl of a cocktail of acepromazine (2.5 to 3.75 mg/kg), xylazine (7.5 to 11.5 mg/kg), and ketamine (30 to 45 mg/kg).", [["acepromazine", "CHEMICAL", 95, 107], ["xylazine", "CHEMICAL", 129, 137], ["ketamine", "CHEMICAL", 163, 171], ["acepromazine", "CHEMICAL", 95, 107], ["xylazine", "CHEMICAL", 129, 137], ["ketamine", "CHEMICAL", 163, 171], ["mice", "ORGANISM", 22, 26], ["acepromazine", "SIMPLE_CHEMICAL", 95, 107], ["xylazine", "SIMPLE_CHEMICAL", 129, 137], ["ketamine", "SIMPLE_CHEMICAL", 163, 171], ["mice", "SPECIES", 22, 26], ["mice", "SPECIES", 22, 26], ["a cocktail of acepromazine", "TREATMENT", 81, 107], ["xylazine", "TREATMENT", 129, 137], ["ketamine", "TREATMENT", 163, 171]]], ["Both rear footpads of the anesthetized mice were then lightly abraded with an emery board to scratch the keratinized layer of the skin to allow the virus to adsorb efficiently.", [["footpads", "ANATOMY", 10, 18], ["keratinized layer", "ANATOMY", 105, 122], ["skin", "ANATOMY", 130, 134], ["footpads", "ORGANISM_SUBDIVISION", 10, 18], ["mice", "ORGANISM", 39, 43], ["keratinized layer", "TISSUE", 105, 122], ["skin", "ORGAN", 130, 134], ["mice", "SPECIES", 39, 43], ["mice", "SPECIES", 39, 43], ["the anesthetized mice", "TREATMENT", 22, 43], ["an emery board", "TREATMENT", 75, 89], ["the virus", "PROBLEM", 144, 153], ["rear", "ANATOMY_MODIFIER", 5, 9], ["footpads", "ANATOMY", 10, 18], ["skin", "ANATOMY", 130, 134]]], ["The anesthetized mice were rested on their backs, and 50 \u03bcl of the appropriate dilution of viral vector was placed on the footpads using a pipette.", [["footpads", "ANATOMY", 122, 130], ["mice", "ORGANISM", 17, 21], ["footpads", "ORGANISM_SUBDIVISION", 122, 130], ["mice", "SPECIES", 17, 21], ["mice", "SPECIES", 17, 21], ["The anesthetized mice", "TREATMENT", 0, 21], ["viral vector", "TREATMENT", 91, 103], ["a pipette", "TREATMENT", 137, 146], ["viral vector", "OBSERVATION", 91, 103], ["footpads", "ANATOMY", 122, 130]]], ["The viral vector was allowed to adsorb until the mice awoke.", [["mice", "ORGANISM", 49, 53], ["mice", "SPECIES", 49, 53], ["mice", "SPECIES", 49, 53], ["The viral vector", "TREATMENT", 0, 16], ["viral vector", "OBSERVATION", 4, 16]]], ["To activate vector replication, a combination of heat and mifepristone/ulipristal treatment was used.", [["mifepristone", "CHEMICAL", 58, 70], ["ulipristal", "CHEMICAL", 71, 81], ["mifepristone", "CHEMICAL", 58, 70], ["ulipristal", "CHEMICAL", 71, 81], ["mifepristone", "SIMPLE_CHEMICAL", 58, 70], ["ulipristal", "SIMPLE_CHEMICAL", 71, 81], ["vector replication", "TREATMENT", 12, 30], ["heat and mifepristone/ulipristal treatment", "TREATMENT", 49, 91], ["vector replication", "OBSERVATION", 12, 30]]], ["Heat treatment was performed by immersion of the hind limbs in a temperature-controlled water bath 3 h after virus administration.", [["hind limbs", "ANATOMY", 49, 59], ["hind limbs", "ORGANISM_SUBDIVISION", 49, 59], ["Heat treatment", "TREATMENT", 0, 14], ["a temperature-controlled water bath", "TREATMENT", 63, 98], ["virus administration", "TREATMENT", 109, 129], ["hind limbs", "ANATOMY", 49, 59]]], ["The mice were allowed to recover at 37\u00b0C for 15 min.", [["mice", "ORGANISM", 4, 8], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 4, 8]]], ["Mifepristone (0.5 mg/kg) or ulipristal (50 \u03bcg/kg) in dimethyl sulfoxide (DMSO) was administered intraperitoneally (i.p.) at the time of immunization and again 24 h later.HSV-1 challenge in mice. ::: MATERIALS AND METHODSImmunized and control mice were challenged by infection on both rear footpads with 10,000 PFU, typically, of HSV-1 strain 17syn+.", [["footpads", "ANATOMY", 289, 297], ["Mifepristone", "CHEMICAL", 0, 12], ["ulipristal", "CHEMICAL", 28, 38], ["dimethyl sulfoxide", "CHEMICAL", 53, 71], ["DMSO", "CHEMICAL", 73, 77], ["infection", "DISEASE", 266, 275], ["Mifepristone", "CHEMICAL", 0, 12], ["ulipristal", "CHEMICAL", 28, 38], ["dimethyl sulfoxide", "CHEMICAL", 53, 71], ["DMSO", "CHEMICAL", 73, 77], ["Mifepristone", "SIMPLE_CHEMICAL", 0, 12], ["ulipristal", "SIMPLE_CHEMICAL", 28, 38], ["dimethyl sulfoxide", "SIMPLE_CHEMICAL", 53, 71], ["DMSO", "SIMPLE_CHEMICAL", 73, 77], ["HSV-1", "ORGANISM", 170, 175], ["mice", "ORGANISM", 189, 193], ["mice", "ORGANISM", 242, 246], ["footpads", "ORGANISM_SUBDIVISION", 289, 297], ["HSV-1", "ORGANISM", 329, 334], ["HSV-1", "SPECIES", 170, 175], ["mice", "SPECIES", 189, 193], ["mice", "SPECIES", 242, 246], ["HSV-1", "SPECIES", 329, 334], ["HSV-1", "SPECIES", 170, 175], ["mice", "SPECIES", 189, 193], ["mice", "SPECIES", 242, 246], ["HSV-1", "SPECIES", 329, 334], ["Mifepristone", "TREATMENT", 0, 12], ["ulipristal", "TREATMENT", 28, 38], ["dimethyl sulfoxide (DMSO)", "TREATMENT", 53, 78], ["immunization", "TREATMENT", 136, 148], ["HSV", "TEST", 170, 173], ["METHODSImmunized and control mice", "TREATMENT", 213, 246], ["infection", "PROBLEM", 266, 275], ["HSV", "TEST", 329, 332], ["infection", "OBSERVATION", 266, 275]]], ["The procedure for the saline pretreatment, anesthesia, and application of virus was the same as that described above for application of the viral vector, except that no mifepristone/ulipristal or heat treatment was administered.", [["mifepristone", "CHEMICAL", 169, 181], ["ulipristal", "CHEMICAL", 182, 192], ["mifepristone", "CHEMICAL", 169, 181], ["saline", "SIMPLE_CHEMICAL", 22, 28], ["mifepristone", "SIMPLE_CHEMICAL", 169, 181], ["ulipristal", "SIMPLE_CHEMICAL", 182, 192], ["The procedure", "TREATMENT", 0, 13], ["the saline pretreatment", "TREATMENT", 18, 41], ["anesthesia", "TREATMENT", 43, 53], ["virus", "TREATMENT", 74, 79], ["the viral vector", "TREATMENT", 136, 152], ["mifepristone/ulipristal", "TREATMENT", 169, 192], ["heat treatment", "TREATMENT", 196, 210]]], ["For the efficacy determination, a modified endpoint analysis was used.", [["a modified endpoint analysis", "TEST", 32, 60]]], ["The mice were monitored daily (with cages coded in a masked fashion).", [["mice", "ORGANISM", 4, 8], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 4, 8], ["cages", "TREATMENT", 36, 41]]], ["When the mice reached clinical endpoints indicating severe central nervous system (CNS) infection (bilateral hind limb paralysis, inability to move when touched, or trembling), they were euthanized.Blood collection, and serum and lymphocyte isolation. ::: MATERIALS AND METHODSFor serum neutralization studies, blood was collected by retro-orbital bleeding prior to immunization.", [["central nervous system", "ANATOMY", 59, 81], ["CNS", "ANATOMY", 83, 86], ["hind limb", "ANATOMY", 109, 118], ["Blood", "ANATOMY", 198, 203], ["serum", "ANATOMY", 220, 225], ["lymphocyte", "ANATOMY", 230, 240], ["serum", "ANATOMY", 281, 286], ["blood", "ANATOMY", 311, 316], ["retro-orbital", "ANATOMY", 334, 347], ["central nervous system (CNS) infection", "DISEASE", 59, 97], ["paralysis", "DISEASE", 119, 128], ["retro-orbital bleeding", "DISEASE", 334, 356], ["mice", "ORGANISM", 9, 13], ["central nervous system", "ANATOMICAL_SYSTEM", 59, 81], ["CNS", "ANATOMICAL_SYSTEM", 83, 86], ["hind limb", "ORGANISM_SUBDIVISION", 109, 118], ["Blood", "ORGANISM_SUBSTANCE", 198, 203], ["serum", "ORGANISM_SUBSTANCE", 220, 225], ["lymphocyte", "CELL", 230, 240], ["serum", "ORGANISM_SUBSTANCE", 281, 286], ["blood", "ORGANISM_SUBSTANCE", 311, 316], ["retro-orbital", "ORGANISM_SUBDIVISION", 334, 347], ["mice", "SPECIES", 9, 13], ["mice", "SPECIES", 9, 13], ["severe central nervous system (CNS) infection", "PROBLEM", 52, 97], ["bilateral hind limb paralysis", "PROBLEM", 99, 128], ["trembling", "PROBLEM", 165, 174], ["Blood collection", "TEST", 198, 214], ["serum and lymphocyte isolation", "TEST", 220, 250], ["METHODSFor serum neutralization studies", "TEST", 270, 309], ["blood", "TEST", 311, 316], ["retro-orbital bleeding", "PROBLEM", 334, 356], ["immunization", "TREATMENT", 366, 378], ["severe", "OBSERVATION_MODIFIER", 52, 58], ["central", "ANATOMY_MODIFIER", 59, 66], ["nervous system", "ANATOMY", 67, 81], ["CNS", "ANATOMY", 83, 86], ["infection", "OBSERVATION", 88, 97], ["bilateral", "ANATOMY_MODIFIER", 99, 108], ["hind limb", "ANATOMY", 109, 118], ["paralysis", "OBSERVATION", 119, 128], ["collection", "OBSERVATION", 204, 214], ["lymphocyte isolation", "OBSERVATION", 230, 250], ["retro-orbital", "ANATOMY", 334, 347], ["bleeding", "OBSERVATION", 348, 356]]], ["For retro-orbital bleeding, mice were anesthetized with ketamine (90 mg/kg) and xylazine (10 mg/kg) i.p.", [["retro-orbital", "ANATOMY", 4, 17], ["retro-orbital bleeding", "DISEASE", 4, 26], ["ketamine", "CHEMICAL", 56, 64], ["xylazine", "CHEMICAL", 80, 88], ["ketamine", "CHEMICAL", 56, 64], ["xylazine", "CHEMICAL", 80, 88], ["retro-orbital", "ORGANISM_SUBDIVISION", 4, 17], ["mice", "ORGANISM", 28, 32], ["ketamine", "SIMPLE_CHEMICAL", 56, 64], ["xylazine", "SIMPLE_CHEMICAL", 80, 88], ["mice", "SPECIES", 28, 32], ["mice", "SPECIES", 28, 32], ["retro-orbital bleeding", "PROBLEM", 4, 26], ["ketamine", "TREATMENT", 56, 64], ["xylazine", "TREATMENT", 80, 88], ["retro-orbital", "ANATOMY", 4, 17], ["bleeding", "OBSERVATION", 18, 26]]], ["For the collection of serum and lymphocytes at 3 weeks after immunization, mice from each group were anesthetized by inhalation of 2 to 3% isoflurane.", [["serum", "ANATOMY", 22, 27], ["lymphocytes", "ANATOMY", 32, 43], ["isoflurane", "CHEMICAL", 139, 149], ["isoflurane", "CHEMICAL", 139, 149], ["serum", "ORGANISM_SUBSTANCE", 22, 27], ["lymphocytes", "CELL", 32, 43], ["mice", "ORGANISM", 75, 79], ["isoflurane", "SIMPLE_CHEMICAL", 139, 149], ["lymphocytes", "CELL_TYPE", 32, 43], ["mice", "SPECIES", 75, 79], ["mice", "SPECIES", 75, 79], ["the collection of serum and lymphocytes", "TEST", 4, 43], ["immunization", "TREATMENT", 61, 73], ["serum", "ANATOMY", 22, 27], ["lymphocytes", "ANATOMY", 32, 43]]], ["The total blood volume of each mouse was collected, and the mice were euthanized by cervical dislocation.", [["blood", "ANATOMY", 10, 15], ["cervical", "ANATOMY", 84, 92], ["cervical dislocation", "DISEASE", 84, 104], ["blood", "ORGANISM_SUBSTANCE", 10, 15], ["mouse", "ORGANISM", 31, 36], ["mice", "ORGANISM", 60, 64], ["cervical", "ORGAN", 84, 92], ["mouse", "SPECIES", 31, 36], ["mice", "SPECIES", 60, 64], ["mouse", "SPECIES", 31, 36], ["mice", "SPECIES", 60, 64], ["cervical dislocation", "PROBLEM", 84, 104], ["total", "OBSERVATION_MODIFIER", 4, 9], ["volume", "OBSERVATION_MODIFIER", 16, 22], ["cervical", "ANATOMY", 84, 92], ["dislocation", "OBSERVATION", 93, 104]]], ["PBMCs were isolated by Ficoll gradient separation using Lymphoprep (Miltenyi Biotec, Bergisch Gladbach.", [["PBMCs", "ANATOMY", 0, 5], ["PBMCs", "CELL", 0, 5], ["Gladbach", "GENE_OR_GENE_PRODUCT", 94, 102], ["PBMCs", "CELL_TYPE", 0, 5], ["Lymphoprep", "PROTEIN", 56, 66], ["Miltenyi Biotec", "PROTEIN", 68, 83], ["Bergisch Gladbach", "PROTEIN", 85, 102], ["PBMCs", "TREATMENT", 0, 5], ["Ficoll gradient separation", "TREATMENT", 23, 49], ["Lymphoprep (Miltenyi Biotec", "TREATMENT", 56, 83], ["Ficoll gradient", "OBSERVATION", 23, 38]]], ["Germany) according to the manufacturer's protocol.Neutralizing antibody assay. ::: MATERIALS AND METHODSAfter collection, the blood was allowed to clot for 30 min.", [["blood", "ANATOMY", 126, 131], ["clot", "ANATOMY", 147, 151], ["blood", "ORGANISM_SUBSTANCE", 126, 131], ["clot", "ORGANISM_SUBSTANCE", 147, 151], ["the manufacturer's protocol", "TREATMENT", 22, 49], ["Neutralizing antibody assay", "TEST", 50, 77], ["the blood", "TEST", 122, 131], ["clot", "PROBLEM", 147, 151], ["clot", "OBSERVATION", 147, 151]]], ["After centrifugation at 800 \u00d7 g, the serum was collected.", [["serum", "ANATOMY", 37, 42], ["serum", "ORGANISM_SUBSTANCE", 37, 42], ["centrifugation", "TREATMENT", 6, 20], ["the serum", "TEST", 33, 42]]], ["Serum samples were heated to 56\u00b0C for 1 h to inactivate complement and were then diluted 1:10 in complete DMEM containing 10% heat-inactivated fetal bovine serum (FBS).", [["Serum samples", "ANATOMY", 0, 13], ["fetal bovine serum", "ANATOMY", 143, 161], ["FBS", "ANATOMY", 163, 166], ["Serum samples", "ORGANISM_SUBSTANCE", 0, 13], ["bovine", "ORGANISM", 149, 155], ["serum", "ORGANISM_SUBSTANCE", 156, 161], ["FBS", "ORGANISM_SUBSTANCE", 163, 166], ["bovine", "SPECIES", 149, 155], ["bovine", "SPECIES", 149, 155], ["Serum samples", "TEST", 0, 13], ["fetal bovine serum", "TEST", 143, 161]]], ["For HSV-1 neutralization, 50 \u03bcl of a suspension containing approximately 100 PFU of HSV-1 strain 17syn+ was added to each dilution of serum to a final volume of 100 \u03bcl.", [["serum", "ANATOMY", 134, 139], ["17syn", "CHEMICAL", 97, 102], ["HSV-1", "ORGANISM", 4, 9], ["HSV-1", "ORGANISM", 84, 89], ["17syn+", "SIMPLE_CHEMICAL", 97, 103], ["serum", "ORGANISM_SUBSTANCE", 134, 139], ["HSV-1", "SPECIES", 4, 9], ["HSV-1", "SPECIES", 84, 89], ["HSV-1", "SPECIES", 4, 9], ["HSV-1", "SPECIES", 84, 89], ["HSV", "PROBLEM", 4, 7], ["a suspension", "TREATMENT", 35, 47], ["HSV", "PROBLEM", 84, 87], ["a final volume", "TEST", 143, 157]]], ["For EIV neutralization, 50 \u03bcl of a suspension containing approximately 100 TCID50 units of EIV Prague/56 were added to each dilution of serum to a final volume of 100 \u03bcl.", [["serum", "ANATOMY", 136, 141], ["EIV", "SIMPLE_CHEMICAL", 4, 7], ["serum", "ORGANISM_SUBSTANCE", 136, 141], ["EIV neutralization", "TREATMENT", 4, 22], ["a suspension", "TREATMENT", 33, 45], ["EIV Prague", "TREATMENT", 91, 101]]], ["The initial serum dilution, therefore, was 1:20.", [["serum", "ANATOMY", 12, 17], ["serum", "ORGANISM_SUBSTANCE", 12, 17], ["The initial serum dilution", "TEST", 0, 26]]], ["The serum-virus mixtures were placed on a rocker at room temperature for 1 h, and the amount of virus that was not neutralized at a given concentration of serum was titrated on RS (HSV-1) or MDCK (EIV) cell monolayers in order to calculate the neutralizing antibody titers.RCF assay. ::: MATERIALS AND METHODSHSV-1- or EIV-specific responder cells were quantified by a modified limiting dilution lymphoproliferation assay (55), using either cell-free HSV-1 or EIV Prague/56 HA protein lysate and control antigen lysate.", [["serum", "ANATOMY", 4, 9], ["serum", "ANATOMY", 155, 160], ["MDCK", "ANATOMY", 191, 195], ["EIV) cell monolayers", "ANATOMY", 197, 217], ["EIV", "ANATOMY", 319, 322], ["cells", "ANATOMY", 342, 347], ["cell", "ANATOMY", 441, 445], ["lysate", "ANATOMY", 485, 491], ["lysate", "ANATOMY", 512, 518], ["serum", "ORGANISM_SUBSTANCE", 4, 9], ["serum", "ORGANISM_SUBSTANCE", 155, 160], ["HSV-1", "ORGANISM", 181, 186], ["MDCK", "CELL", 191, 195], ["EIV) cell monolayers", "CELL", 197, 217], ["METHODSHSV-1", "GENE_OR_GENE_PRODUCT", 302, 314], ["EIV", "CELL", 319, 322], ["responder cells", "CELL", 332, 347], ["cell", "CELL", 441, 445], ["HSV-1", "ORGANISM", 451, 456], ["EIV", "ORGANISM", 460, 463], ["MDCK (EIV) cell monolayers", "CELL_LINE", 191, 217], ["EIV-specific responder cells", "CELL_LINE", 319, 347], ["HSV-1", "SPECIES", 181, 186], ["HSV-1", "SPECIES", 451, 456], ["EIV", "SPECIES", 460, 463], ["The serum-virus mixtures", "TEST", 0, 24], ["virus", "PROBLEM", 96, 101], ["serum", "TEST", 155, 160], ["RS", "TEST", 177, 179], ["HSV", "TEST", 181, 184], ["MDCK (EIV) cell monolayers", "PROBLEM", 191, 217], ["the neutralizing antibody titers", "TEST", 240, 272], ["RCF assay", "TEST", 273, 282], ["MATERIALS", "TEST", 288, 297], ["METHODSHSV", "TEST", 302, 312], ["EIV-specific responder cells", "TREATMENT", 319, 347], ["dilution lymphoproliferation assay", "TEST", 387, 421], ["HA protein lysate", "TREATMENT", 474, 491], ["control antigen lysate", "TREATMENT", 496, 518], ["virus", "OBSERVATION", 96, 101]]], ["Briefly, wells of 96-well plates were coated with 20 \u03bcl/well of antigen extract (HSV-1 or RS cell control lysate, or EIV Prague/56 HA or Vero cell control lysate) and were allowed to air dry in a laminar flow hood.", [["extract", "ANATOMY", 72, 79], ["cell", "ANATOMY", 93, 97], ["lysate", "ANATOMY", 106, 112], ["cell", "ANATOMY", 142, 146], ["lysate", "ANATOMY", 155, 161], ["HSV-1", "CELL", 81, 86], ["RS cell", "CELL", 90, 97], ["Vero cell", "CELL", 137, 146], ["HSV-1", "SPECIES", 81, 86], ["antigen extract", "TEST", 64, 79], ["HSV", "TEST", 81, 84], ["RS cell control lysate", "TREATMENT", 90, 112], ["EIV Prague", "TREATMENT", 117, 127], ["HA", "PROBLEM", 131, 133], ["Vero cell control lysate", "TREATMENT", 137, 161], ["laminar flow", "OBSERVATION", 196, 208]]], ["Dilutions of mouse PBMCs in DMEM were added to each well so that each well contained a minimum of 1 and a maximum of 10 lymphocytes per well in a volume of 100 \u03bcl complete medium (with serum).", [["PBMCs", "ANATOMY", 19, 24], ["lymphocytes", "ANATOMY", 120, 131], ["serum", "ANATOMY", 185, 190], ["mouse", "ORGANISM", 13, 18], ["PBMCs", "CELL", 19, 24], ["DMEM", "CELL", 28, 32], ["lymphocytes", "CELL", 120, 131], ["serum", "ORGANISM_SUBSTANCE", 185, 190], ["mouse PBMCs", "CELL_TYPE", 13, 24], ["lymphocytes", "CELL_TYPE", 120, 131], ["mouse", "SPECIES", 13, 18], ["mouse", "SPECIES", 13, 18], ["mouse PBMCs in DMEM", "TREATMENT", 13, 32], ["a volume", "TEST", 144, 152]]], ["The plates were then incubated at 37\u00b0C. After 24 h, medium containing 10 \u03bcCi of [3H]thymidine was added to each plate for 12 h, the medium was replaced, and the plates were incubated for an additional 72 h.", [["[3H]thymidine", "CHEMICAL", 80, 93], ["[3H]thymidine", "CHEMICAL", 80, 93], ["[3H]thymidine", "SIMPLE_CHEMICAL", 80, 93], ["The plates", "TREATMENT", 0, 10], ["3H]thymidine", "TREATMENT", 81, 93], ["the plates", "TREATMENT", 157, 167], ["plates", "OBSERVATION_MODIFIER", 4, 10]]], ["The wells were harvested, and the DNA was precipitated in 20 volumes of cold 10% trichloroacetic acid, transferred onto glass fiber discs (Whatman; GF/C) by filtration, rinsed with 95% ethanol, and dried using a heat lamp.", [["trichloroacetic acid", "CHEMICAL", 81, 101], ["ethanol", "CHEMICAL", 185, 192], ["trichloroacetic acid", "CHEMICAL", 81, 101], ["ethanol", "CHEMICAL", 185, 192], ["DNA", "CELLULAR_COMPONENT", 34, 37], ["trichloroacetic acid", "SIMPLE_CHEMICAL", 81, 101], ["ethanol", "SIMPLE_CHEMICAL", 185, 192], ["cold 10% trichloroacetic acid", "TREATMENT", 72, 101], ["glass fiber discs", "TREATMENT", 120, 137], ["GF/C)", "TREATMENT", 148, 153], ["a heat lamp", "TREATMENT", 210, 221], ["harvested", "OBSERVATION", 15, 24]]], ["The filters were then transferred to scintillation vials with Scintiverse (Fisher Scientific) and counted.", [["The filters", "TREATMENT", 0, 11]]], ["The counts per minute (cpm) of [3H]thymidine were converted to RCF using the maximum-likelihood estimate method of Levin et al. (56).Viral DNA replication and transcription. ::: MATERIALS AND METHODSGroups (n = 5) of 4- to 6-week-old female outbred Swiss Webster mice were anesthetized and inoculated with an HSV-GS vector on both rear footpads as described above.", [["footpads", "ANATOMY", 336, 344], ["[3H]thymidine", "CHEMICAL", 31, 44], ["[3H]thymidine", "CHEMICAL", 31, 44], ["[3H]thymidine", "SIMPLE_CHEMICAL", 31, 44], ["DNA", "CELLULAR_COMPONENT", 139, 142], ["outbred", "ORGANISM", 241, 248], ["Swiss Webster mice", "ORGANISM", 249, 267], ["HSV", "ORGANISM", 309, 312], ["footpads", "ORGANISM_SUBDIVISION", 336, 344], ["mice", "SPECIES", 263, 267], ["Swiss Webster mice", "SPECIES", 249, 267], ["HSV", "SPECIES", 309, 312], ["thymidine", "TREATMENT", 35, 44], ["Viral DNA replication", "TREATMENT", 133, 154], ["an HSV", "TEST", 306, 312], ["DNA replication", "OBSERVATION", 139, 154], ["rear footpads", "ANATOMY", 331, 344]]], ["Ulipristal (50 \u03bcg/kg) was administered i.p. at the time of infection.", [["Ulipristal", "CHEMICAL", 0, 10], ["infection", "DISEASE", 59, 68], ["Ulipristal", "CHEMICAL", 0, 10], ["Ulipristal", "SIMPLE_CHEMICAL", 0, 10], ["Ulipristal", "TREATMENT", 0, 10], ["infection", "PROBLEM", 59, 68], ["infection", "OBSERVATION", 59, 68]]], ["Three hours after virus administration, heat treatment was performed by immersion of the rear feet in a 45\u00b0C water bath for 10 min.", [["feet", "ORGANISM_SUBDIVISION", 94, 98], ["virus administration", "TREATMENT", 18, 38], ["heat treatment", "TREATMENT", 40, 54], ["a 45\u00b0C water bath", "TREATMENT", 102, 119]]], ["The mice were allowed to recover at 37\u00b0C for 15 min.", [["mice", "ORGANISM", 4, 8], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 4, 8]]], ["The mice were sacrificed 24 h after heat induction, and the feet were dissected and snap-frozen in RNAlater (Sigma-Aldrich).", [["feet", "ANATOMY", 60, 64], ["mice", "ORGANISM", 4, 8], ["feet", "ORGANISM_SUBDIVISION", 60, 64], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 4, 8], ["heat induction", "TEST", 36, 50], ["snap", "TEST", 84, 88], ["feet", "ANATOMY", 60, 64]]], ["DNA and RNA were extracted by grinding the tissues in TRIzol (Thermo Fisher Scientific) and back extracting the DNA from the interface.", [["tissues", "ANATOMY", 43, 50], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["tissues", "TISSUE", 43, 50], ["DNA", "CELLULAR_COMPONENT", 112, 115], ["DNA and RNA", "PROBLEM", 0, 11], ["TRIzol", "TREATMENT", 54, 60], ["RNA", "OBSERVATION", 8, 11], ["tissues", "ANATOMY", 43, 50]]], ["The extracted DNA was subjected to TaqMan real-time PCR (qPCR) for quantitative analysis of HSV-1 DNA (using HSV-1 DNA polymerase primers/probe) (57).", [["DNA", "CELLULAR_COMPONENT", 14, 17], ["HSV-1", "ORGANISM", 92, 97], ["DNA", "CELLULAR_COMPONENT", 98, 101], ["HSV-1", "ORGANISM", 109, 114], ["DNA", "CELLULAR_COMPONENT", 115, 118], ["HSV-1 DNA", "DNA", 92, 101], ["HSV-1 DNA polymerase primers", "DNA", 109, 137], ["HSV-1", "SPECIES", 92, 97], ["HSV-1", "SPECIES", 92, 97], ["HSV-1", "SPECIES", 109, 114], ["The extracted DNA", "PROBLEM", 0, 17], ["TaqMan", "TEST", 35, 41], ["PCR", "TEST", 52, 55], ["qPCR", "TEST", 57, 61], ["quantitative analysis", "TEST", 67, 88], ["HSV", "TEST", 92, 95], ["DNA", "PROBLEM", 98, 101], ["HSV", "TEST", 109, 112], ["DNA polymerase primers", "TEST", 115, 137]]], ["RNA was analyzed by reverse transcription and TaqMan real-time PCR (RT-qPCR) for the presence of ICP4, thymidine kinase (TK), capsid protein VP19c, and glycoprotein C (gC) transcripts.", [["thymidine", "CHEMICAL", 103, 112], ["thymidine", "CHEMICAL", 103, 112], ["ICP4", "GENE_OR_GENE_PRODUCT", 97, 101], ["thymidine kinase", "GENE_OR_GENE_PRODUCT", 103, 119], ["VP19c", "GENE_OR_GENE_PRODUCT", 141, 146], ["glycoprotein C", "GENE_OR_GENE_PRODUCT", 152, 166], ["gC", "GENE_OR_GENE_PRODUCT", 168, 170], ["RNA", "RNA", 0, 3], ["ICP4", "PROTEIN", 97, 101], ["thymidine kinase", "PROTEIN", 103, 119], ["TK", "PROTEIN", 121, 123], ["capsid protein", "PROTEIN", 126, 140], ["VP19c", "PROTEIN", 141, 146], ["glycoprotein C (gC) transcripts", "RNA", 152, 183], ["TaqMan", "TEST", 46, 52], ["PCR", "TEST", 63, 66], ["RT", "TEST", 68, 70], ["ICP4", "TEST", 97, 101], ["thymidine kinase", "TEST", 103, 119], ["TK", "TEST", 121, 123], ["capsid protein VP19c", "TEST", 126, 146], ["glycoprotein C (gC) transcripts", "TREATMENT", 152, 183]]], ["Normalization of DNA and RNA quantities was relative to the adenine phosphoribosyltransferase (APRT) cellular gene.", [["cellular", "ANATOMY", 101, 109], ["adenine", "CHEMICAL", 60, 67], ["adenine", "CHEMICAL", 60, 67], ["DNA", "CELLULAR_COMPONENT", 17, 20], ["adenine phosphoribosyltransferase", "GENE_OR_GENE_PRODUCT", 60, 93], ["APRT) cellular", "GENE_OR_GENE_PRODUCT", 95, 109], ["adenine phosphoribosyltransferase (APRT) cellular gene", "DNA", 60, 114], ["DNA and RNA quantities", "PROBLEM", 17, 39], ["the adenine phosphoribosyltransferase (APRT) cellular gene", "PROBLEM", 56, 114], ["RNA quantities", "OBSERVATION_MODIFIER", 25, 39], ["cellular gene", "OBSERVATION", 101, 114]]], ["The sequences of the primers and probes used are provided in Table 2.EIV Prague/56 HA ELISA. ::: MATERIALS AND METHODSIn order to produce the antigen for the ELISA, the insert from plasmid pBS-EIVPrague56/HA (described above) was subcloned into the expression vector pET-31b (Millipore), and the EIVPrague56/HA protein was expressed in Escherichia coli in accordance with the manufacturer's instructions.", [["pBS", "GENE_OR_GENE_PRODUCT", 189, 192], ["EIVPrague56", "GENE_OR_GENE_PRODUCT", 193, 204], ["HA", "GENE_OR_GENE_PRODUCT", 205, 207], ["EIVPrague56", "GENE_OR_GENE_PRODUCT", 296, 307], ["HA", "GENE_OR_GENE_PRODUCT", 308, 310], ["Escherichia coli", "ORGANISM", 336, 352], ["pBS", "DNA", 189, 192], ["EIVPrague56", "DNA", 193, 204], ["HA", "DNA", 205, 207], ["expression vector pET-31b", "DNA", 249, 274], ["EIVPrague56", "DNA", 296, 307], ["HA protein", "PROTEIN", 308, 318], ["Escherichia coli", "SPECIES", 336, 352], ["Escherichia coli", "SPECIES", 336, 352], ["the primers", "TREATMENT", 17, 28], ["the ELISA", "TEST", 154, 163], ["the insert from plasmid pBS", "TREATMENT", 165, 192], ["HA", "PROBLEM", 205, 207], ["the expression vector pET", "TEST", 245, 270], ["the EIVPrague56/HA protein", "TREATMENT", 292, 318], ["Escherichia coli", "PROBLEM", 336, 352], ["Escherichia coli", "OBSERVATION", 336, 352]]], ["After induction and growth, the bacteria were lysed, proteins were isolated in the presence of protease inhibitors, and the proteins were used to coat a 96-well ELISA plate, which was allowed to air dry.", [["the bacteria", "PROBLEM", 28, 40], ["proteins", "TEST", 53, 61], ["protease inhibitors", "TREATMENT", 95, 114], ["the proteins", "TEST", 120, 132], ["air dry", "OBSERVATION", 195, 202]]], ["Dilutions (1:10 to 1:200) of murine serum were applied to the wells, and the plate was incubated at room temperature for 30 min.", [["serum", "ANATOMY", 36, 41], ["murine", "ORGANISM", 29, 35], ["serum", "ORGANISM_SUBSTANCE", 36, 41], ["murine", "SPECIES", 29, 35], ["Dilutions", "TREATMENT", 0, 9], ["murine serum", "TEST", 29, 41]]], ["The serum was removed, and the wells were washed 2 times with PBS.", [["serum", "ANATOMY", 4, 9], ["serum", "ORGANISM_SUBSTANCE", 4, 9], ["The serum", "TEST", 0, 9], ["PBS", "TREATMENT", 62, 65]]], ["Horseradish peroxidase-conjugated anti-IgG antibody was added to the wells, the plate was incubated for 30 min at room temperature, and the wells were washed 2 times with PBS.", [["Horseradish peroxidase", "SIMPLE_CHEMICAL", 0, 22], ["Horseradish peroxidase", "PROTEIN", 0, 22], ["anti-IgG antibody", "PROTEIN", 34, 51], ["Horseradish", "SPECIES", 0, 11], ["Horseradish", "SPECIES", 0, 11], ["Horseradish peroxidase", "TREATMENT", 0, 22], ["conjugated anti-IgG antibody", "TREATMENT", 23, 51], ["PBS", "TREATMENT", 171, 174]]], ["3,3\u2032,5,5\u2032-Tetramethylbenzidine was added to the wells, and the plate was incubated for 10 min and then read with a spectrophotometer plate reader.", [["3,3\u2032,5,5\u2032-Tetramethylbenzidine", "CHEMICAL", 0, 30], ["3,3\u2032,5,5\u2032-Tetramethylbenzidine", "CHEMICAL", 0, 30], ["3,3\u2032,5,5\u2032-Tetramethylbenzidine", "SIMPLE_CHEMICAL", 0, 30], ["Tetramethylbenzidine", "TREATMENT", 10, 30], ["a spectrophotometer plate reader", "TREATMENT", 113, 145]]], ["The results were evaluated based on the sample mean/negative-control mean (S/N) ratio.Statistical analyses. ::: MATERIALS AND METHODSData sets were analyzed using a two-way analysis of variance (ANOVA) (no repeated measures [RM]).", [["the sample mean", "TEST", 36, 51], ["Statistical analyses", "TEST", 86, 106], ["METHODSData sets", "TEST", 126, 142]]], ["Kaplan-Meier survival curves were analyzed for significance using the log rank test.", [["Meier survival curves", "TEST", 7, 28], ["the log rank test", "TEST", 66, 83]]], ["No data sets that were analyzed for statistical significance varied in sample size by more than 3-fold.Ethics statement. ::: MATERIALS AND METHODSThe animal studies were approved by the University of Florida Institutional Animal Care and Use Committee (IACUC) and were performed in accordance with the approved protocol (protocol 0541).", [["data sets", "TEST", 3, 12], ["METHODSThe animal studies", "TEST", 139, 164], ["size", "OBSERVATION_MODIFIER", 78, 82]]]], "PMC7436689": [["Background ::: INTRODUCTIONOn March 11, 2020, the World Health Organization declared the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS\u2010CoV\u20102) a pandemic.1As of July 17, SARS\u2010CoV\u20102 has infected >14 million worldwide and caused at least 600,000 deaths,2with significant burden placed on healthcare systems in communities with substantial viral seeding.3,4,5", [["acute respiratory syndrome coronavirus", "DISEASE", 108, 146], ["CoV\u20102", "CHEMICAL", 194, 199], ["deaths", "DISEASE", 263, 269], ["3,4,5", "CHEMICAL", 370, 375], ["3,4,5", "SIMPLE_CHEMICAL", 370, 375], ["severe acute respiratory syndrome coronavirus", "SPECIES", 101, 146], ["SARS\u2010CoV", "SPECIES", 150, 158], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 101, 146], ["a pandemic", "PROBLEM", 162, 172], ["significant burden", "PROBLEM", 276, 294], ["substantial viral seeding", "PROBLEM", 344, 369], ["severe", "OBSERVATION_MODIFIER", 101, 107], ["acute", "OBSERVATION_MODIFIER", 108, 113], ["respiratory syndrome", "OBSERVATION", 114, 134], ["infected", "OBSERVATION_MODIFIER", 204, 212], ["significant", "OBSERVATION_MODIFIER", 276, 287], ["burden", "OBSERVATION", 288, 294], ["substantial", "OBSERVATION_MODIFIER", 344, 355], ["viral seeding", "OBSERVATION", 356, 369]]]], "2f6739ba72d4131e172953e349c42b51b9a3a37d": [["A cluster of pneumonia cases with an unknown etiology were identified in China in December 2019, 1 and later confirmed to be caused by the severe acute respiratory syndrome coronavirus-2 and subsequently named coronavirus disease 2019 .", [["pneumonia", "DISEASE", 13, 22], ["acute respiratory syndrome coronavirus", "DISEASE", 146, 184], ["coronavirus disease", "DISEASE", 210, 229], ["severe acute respiratory syndrome coronavirus", "SPECIES", 139, 184], ["pneumonia cases", "PROBLEM", 13, 28], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 135, 184], ["coronavirus disease", "PROBLEM", 210, 229], ["cluster", "OBSERVATION_MODIFIER", 2, 9], ["pneumonia", "OBSERVATION", 13, 22], ["severe", "OBSERVATION_MODIFIER", 139, 145], ["acute", "OBSERVATION_MODIFIER", 146, 151], ["respiratory syndrome coronavirus", "OBSERVATION", 152, 184], ["coronavirus disease", "OBSERVATION", 210, 229]]], ["So far, the vast majority of patients are presented as mild cases, with approximately 20% of patients categorized with severe or critical illness.", [["patients", "ORGANISM", 29, 37], ["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 29, 37], ["patients", "SPECIES", 93, 101], ["mild cases", "PROBLEM", 55, 65], ["severe or critical illness", "PROBLEM", 119, 145], ["mild", "OBSERVATION_MODIFIER", 55, 59], ["critical", "OBSERVATION_MODIFIER", 129, 137], ["illness", "OBSERVATION", 138, 145]]], ["2 Patients with severe or critical COVID-19 may develop hypoxemic respiratory failure and require respiratory support to improve hypoxia or relieve dyspnea.", [["respiratory", "ANATOMY", 66, 77], ["respiratory", "ANATOMY", 98, 109], ["hypoxemic respiratory failure", "DISEASE", 56, 85], ["hypoxia", "DISEASE", 129, 136], ["dyspnea", "DISEASE", 148, 155], ["Patients", "ORGANISM", 2, 10], ["Patients", "SPECIES", 2, 10], ["severe or critical COVID", "PROBLEM", 16, 40], ["hypoxemic respiratory failure", "PROBLEM", 56, 85], ["respiratory support", "TREATMENT", 98, 117], ["hypoxia", "PROBLEM", 129, 136], ["dyspnea", "PROBLEM", 148, 155], ["severe", "OBSERVATION_MODIFIER", 16, 22], ["hypoxemic", "OBSERVATION_MODIFIER", 56, 65], ["respiratory failure", "OBSERVATION", 66, 85], ["respiratory support", "OBSERVATION", 98, 117]]]], "PMC7102702": [["LMW Proteins in Human Serum/Plasma Represent a Treasure Trove of Diagnostic Molecules ::: IntroductionHuman blood collected and accumulated a vast trove of biochemical molecules while going through different organs or tissues, which can ultimately reflect the physiological or pathological status of the body [1], [2], and thereby provide valuable information for early diagnosis and prognosis, as well as for the monitoring of therapeutic efficiency.", [["blood", "ANATOMY", 108, 113], ["organs", "ANATOMY", 208, 214], ["tissues", "ANATOMY", 218, 225], ["body", "ANATOMY", 304, 308], ["Human", "ORGANISM", 16, 21], ["Serum", "ORGANISM_SUBSTANCE", 22, 27], ["Plasma", "ORGANISM_SUBSTANCE", 28, 34], ["blood", "ORGANISM_SUBSTANCE", 108, 113], ["organs", "ORGAN", 208, 214], ["tissues", "TISSUE", 218, 225], ["biochemical molecules", "PROTEIN", 156, 177], ["Human", "SPECIES", 16, 21], ["LMW Proteins", "TEST", 0, 12], ["Human Serum", "TEST", 16, 27], ["IntroductionHuman blood", "TEST", 90, 113], ["biochemical molecules", "PROBLEM", 156, 177], ["therapeutic efficiency", "PROBLEM", 428, 450], ["Proteins", "OBSERVATION", 4, 12], ["Plasma", "ANATOMY", 28, 34], ["biochemical molecules", "OBSERVATION", 156, 177], ["tissues", "ANATOMY", 218, 225]]], ["Cumulative evidence suggests that low-molecular-weight (LMW) region of human serum proteome, including small intact proteins, truncated fragments of larger proteins, along with some other small components, has been implicated in various human diseases such as cancer [3], diabetes [4], cardiovascular [5], and infectious diseases [6] and represents a treasure trove of diagnostic molecules.", [["serum", "ANATOMY", 77, 82], ["cancer", "ANATOMY", 260, 266], ["cardiovascular", "ANATOMY", 286, 300], ["cancer", "DISEASE", 260, 266], ["diabetes", "DISEASE", 272, 280], ["infectious diseases", "DISEASE", 310, 329], ["human", "ORGANISM", 71, 76], ["serum", "ORGANISM_SUBSTANCE", 77, 82], ["human", "ORGANISM", 237, 242], ["cancer", "CANCER", 260, 266], ["low-molecular-weight (LMW) region", "PROTEIN", 34, 67], ["small intact proteins", "PROTEIN", 103, 124], ["truncated fragments", "PROTEIN", 126, 145], ["human", "SPECIES", 71, 76], ["human", "SPECIES", 237, 242], ["human", "SPECIES", 71, 76], ["human", "SPECIES", 237, 242], ["Cumulative evidence", "TEST", 0, 19], ["human serum proteome", "TEST", 71, 91], ["small intact proteins", "PROBLEM", 103, 124], ["truncated fragments of larger proteins", "PROBLEM", 126, 164], ["some other small components", "PROBLEM", 177, 204], ["various human diseases", "PROBLEM", 229, 251], ["cancer", "PROBLEM", 260, 266], ["diabetes", "PROBLEM", 272, 280], ["infectious diseases", "PROBLEM", 310, 329], ["low", "OBSERVATION_MODIFIER", 34, 37], ["small", "OBSERVATION_MODIFIER", 103, 108], ["intact proteins", "OBSERVATION_MODIFIER", 109, 124], ["fragments", "OBSERVATION_MODIFIER", 136, 145], ["larger proteins", "OBSERVATION_MODIFIER", 149, 164], ["small", "OBSERVATION_MODIFIER", 188, 193], ["components", "OBSERVATION", 194, 204], ["various human", "OBSERVATION_MODIFIER", 229, 242], ["infectious", "OBSERVATION", 310, 320]]], ["There are several facts that might support this view.", [["this view", "TEST", 43, 52]]], ["To begin with, the LMW proteins are usually made up of physiologically important proteins such as cytokines, growth factors, peptide hormones, as well as proteins/peptides originating from normal cell or tissue leakage as a result of cell death or damage, which are believed to be more important to reflect valuable disease-related information than high-abundant proteins from a diagnostic point of view [7], [8].", [["cell", "ANATOMY", 196, 200], ["tissue", "ANATOMY", 204, 210], ["cell", "ANATOMY", 234, 238], ["death", "DISEASE", 239, 244], ["LMW proteins", "GENE_OR_GENE_PRODUCT", 19, 31], ["cell", "CELL", 196, 200], ["tissue", "TISSUE", 204, 210], ["cell", "CELL", 234, 238], ["LMW proteins", "PROTEIN", 19, 31], ["cytokines", "PROTEIN", 98, 107], ["growth factors", "PROTEIN", 109, 123], ["high-abundant proteins", "PROTEIN", 349, 371], ["the LMW proteins", "PROBLEM", 15, 31], ["peptide hormones", "PROBLEM", 125, 141], ["proteins/peptides", "PROBLEM", 154, 171], ["tissue leakage", "PROBLEM", 204, 218], ["cell death", "PROBLEM", 234, 244], ["damage", "PROBLEM", 248, 254], ["valuable disease", "PROBLEM", 307, 323], ["normal cell", "OBSERVATION", 189, 200], ["tissue leakage", "OBSERVATION", 204, 218], ["cell death", "OBSERVATION", 234, 244]]], ["For instance, the LMW protein family human serum amyloid A (SAA), a hot spot in the field of biomarker research, has been associated in various types of cancers such as ovarian cancer [9], lung cancer [10], pancreatic cancer [11], as well as the other diseases like coronary artery disease, obesity, and severe acute respiratory syndrome [12], [13], [14].", [["serum", "ANATOMY", 43, 48], ["cancers", "ANATOMY", 153, 160], ["ovarian cancer", "ANATOMY", 169, 183], ["lung cancer", "ANATOMY", 189, 200], ["pancreatic cancer", "ANATOMY", 207, 224], ["coronary artery", "ANATOMY", 266, 281], ["cancers", "DISEASE", 153, 160], ["ovarian cancer", "DISEASE", 169, 183], ["lung cancer", "DISEASE", 189, 200], ["pancreatic cancer", "DISEASE", 207, 224], ["coronary artery disease", "DISEASE", 266, 289], ["obesity", "DISEASE", 291, 298], ["acute respiratory syndrome", "DISEASE", 311, 337], ["LMW", "GENE_OR_GENE_PRODUCT", 18, 21], ["human", "ORGANISM", 37, 42], ["serum amyloid A", "GENE_OR_GENE_PRODUCT", 43, 58], ["SAA", "GENE_OR_GENE_PRODUCT", 60, 63], ["cancers", "CANCER", 153, 160], ["ovarian cancer", "CANCER", 169, 183], ["lung cancer", "CANCER", 189, 200], ["pancreatic cancer", "CANCER", 207, 224], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 266, 281], ["LMW protein family", "PROTEIN", 18, 36], ["human serum amyloid A", "PROTEIN", 37, 58], ["SAA", "PROTEIN", 60, 63], ["human", "SPECIES", 37, 42], ["human", "SPECIES", 37, 42], ["the LMW protein", "TEST", 14, 29], ["a hot spot", "PROBLEM", 66, 76], ["cancers", "PROBLEM", 153, 160], ["ovarian cancer", "PROBLEM", 169, 183], ["lung cancer", "PROBLEM", 189, 200], ["pancreatic cancer", "PROBLEM", 207, 224], ["the other diseases", "PROBLEM", 242, 260], ["coronary artery disease", "PROBLEM", 266, 289], ["obesity", "PROBLEM", 291, 298], ["severe acute respiratory syndrome", "PROBLEM", 304, 337], ["cancers", "OBSERVATION", 153, 160], ["ovarian", "ANATOMY", 169, 176], ["cancer", "OBSERVATION", 177, 183], ["lung", "ANATOMY", 189, 193], ["cancer", "OBSERVATION", 194, 200], ["pancreatic", "ANATOMY", 207, 217], ["cancer", "OBSERVATION", 218, 224], ["diseases", "OBSERVATION", 252, 260], ["coronary artery", "ANATOMY", 266, 281], ["disease", "OBSERVATION", 282, 289], ["obesity", "OBSERVATION", 291, 298], ["severe", "OBSERVATION_MODIFIER", 304, 310], ["acute", "OBSERVATION_MODIFIER", 311, 316], ["respiratory syndrome", "OBSERVATION", 317, 337]]], ["Moreover, increasing evidence shows that tumor cells excrete biomolecules (< 10 kDa) to the bloodstream that are specific to the tumor type at a rate proportional to the tumor age/size [15], [16].", [["tumor cells", "ANATOMY", 41, 52], ["bloodstream", "ANATOMY", 92, 103], ["tumor", "ANATOMY", 129, 134], ["tumor", "ANATOMY", 170, 175], ["tumor", "DISEASE", 41, 46], ["tumor", "DISEASE", 129, 134], ["tumor", "DISEASE", 170, 175], ["tumor cells", "CELL", 41, 52], ["tumor", "CANCER", 129, 134], ["tumor", "CANCER", 170, 175], ["tumor cells", "CELL_TYPE", 41, 52], ["tumor cells excrete biomolecules", "PROBLEM", 41, 73], ["tumor", "OBSERVATION", 41, 46], ["biomolecules", "OBSERVATION_MODIFIER", 61, 73], ["bloodstream", "ANATOMY", 92, 103], ["tumor", "OBSERVATION", 129, 134], ["tumor", "OBSERVATION", 170, 175]]], ["Second, the LMW proteins are readily to enter the blood.", [["blood", "ANATOMY", 50, 55], ["LMW proteins", "GENE_OR_GENE_PRODUCT", 12, 24], ["blood", "ORGANISM_SUBSTANCE", 50, 55], ["LMW proteins", "PROTEIN", 12, 24], ["the LMW proteins", "PROBLEM", 8, 24], ["LMW", "OBSERVATION_MODIFIER", 12, 15], ["proteins", "OBSERVATION", 16, 24]]], ["In contrast to larger proteins, which enter the bloodstream intact only if they are actively secreted, or if the vascular wall becomes permeable owing to disease, the LMW proteins are small enough to enter the blood passively and produce diagnostic traces [2].", [["bloodstream", "ANATOMY", 48, 59], ["vascular wall", "ANATOMY", 113, 126], ["blood", "ANATOMY", 210, 215], ["vascular wall", "MULTI-TISSUE_STRUCTURE", 113, 126], ["LMW proteins", "GENE_OR_GENE_PRODUCT", 167, 179], ["blood", "ORGANISM_SUBSTANCE", 210, 215], ["LMW proteins", "PROTEIN", 167, 179], ["disease", "PROBLEM", 154, 161], ["the LMW proteins", "PROBLEM", 163, 179], ["larger proteins", "OBSERVATION_MODIFIER", 15, 30], ["bloodstream", "OBSERVATION_MODIFIER", 48, 59], ["intact", "OBSERVATION", 60, 66], ["vascular wall", "ANATOMY", 113, 126], ["small", "OBSERVATION_MODIFIER", 184, 189]]], ["In fact, many LMW proteins and peptides that potentially contain disease-specific information were found to be fragments derived from larger parent molecules that are normally too large to passively diffuse through the endothelium into the circulation.", [["fragments", "ANATOMY", 111, 120], ["endothelium", "ANATOMY", 219, 230], ["LMW", "GENE_OR_GENE_PRODUCT", 14, 17], ["endothelium", "TISSUE", 219, 230], ["LMW proteins", "PROTEIN", 14, 26], ["many LMW proteins and peptides", "PROBLEM", 9, 39], ["disease", "PROBLEM", 65, 72], ["many", "OBSERVATION_MODIFIER", 9, 13], ["LMW", "OBSERVATION_MODIFIER", 14, 17], ["proteins", "OBSERVATION", 18, 26], ["larger", "OBSERVATION_MODIFIER", 134, 140], ["too large", "OBSERVATION_MODIFIER", 176, 185], ["endothelium", "ANATOMY", 219, 230], ["circulation", "ANATOMY", 240, 251]]], ["Third, proteinase-mediated ex vivo enzymatic cleavage as part of the coagulation and complement activation pathways also leads to the produce of the LMW protein biomarkers.", [["proteinase", "GENE_OR_GENE_PRODUCT", 7, 17], ["proteinase", "PROTEIN", 7, 17], ["LMW protein biomarkers", "PROTEIN", 149, 171], ["proteinase-mediated ex vivo enzymatic cleavage", "TREATMENT", 7, 53], ["the coagulation", "TEST", 65, 80], ["the LMW protein biomarkers", "TEST", 145, 171], ["enzymatic cleavage", "OBSERVATION", 35, 53]]], ["This is really true as circulating blood already contains an abundance of protein fragments apparently derived from cells and tissues that are produced in vivo.", [["blood", "ANATOMY", 35, 40], ["cells", "ANATOMY", 116, 121], ["tissues", "ANATOMY", 126, 133], ["blood", "ORGANISM_SUBSTANCE", 35, 40], ["cells", "CELL", 116, 121], ["tissues", "TISSUE", 126, 133], ["protein fragments", "PROTEIN", 74, 91], ["circulating blood", "PROBLEM", 23, 40], ["protein fragments", "PROBLEM", 74, 91], ["abundance", "OBSERVATION_MODIFIER", 61, 70], ["protein fragments", "OBSERVATION", 74, 91]]], ["For instance, Villanueva and coworkers showed that diagnostic protein fragments can be generated ex vivo by circulating enzymes derived from the diseased tissue microenvironment acting on exogenously derived peptides produced by serum collection methodology [17].Characterization of LMW Proteins From the Human Serum/Plasma Is Analytically Challenging ::: IntroductionHowever, identification of LMW proteins from human serum/plasma is analytically challenging due to several aspects.", [["tissue", "ANATOMY", 154, 160], ["serum", "ANATOMY", 229, 234], ["serum", "ANATOMY", 419, 424], ["plasma", "ANATOMY", 425, 431], ["tissue", "TISSUE", 154, 160], ["serum", "ORGANISM_SUBSTANCE", 229, 234], ["LMW Proteins", "GENE_OR_GENE_PRODUCT", 283, 295], ["Human", "ORGANISM", 305, 310], ["Serum", "ORGANISM_SUBSTANCE", 311, 316], ["Plasma", "ORGANISM_SUBSTANCE", 317, 323], ["LMW", "GENE_OR_GENE_PRODUCT", 395, 398], ["human", "ORGANISM", 413, 418], ["serum", "ORGANISM_SUBSTANCE", 419, 424], ["plasma", "ORGANISM_SUBSTANCE", 425, 431], ["circulating enzymes", "PROTEIN", 108, 127], ["LMW Proteins", "PROTEIN", 283, 295], ["LMW proteins", "PROTEIN", 395, 407], ["Human", "SPECIES", 305, 310], ["human", "SPECIES", 413, 418], ["human", "SPECIES", 413, 418], ["diagnostic protein fragments", "PROBLEM", 51, 79], ["circulating enzymes", "TEST", 108, 127], ["the diseased tissue microenvironment", "PROBLEM", 141, 177], ["exogenously derived peptides", "TREATMENT", 188, 216], ["serum collection methodology", "TEST", 229, 257], ["the Human Serum", "TEST", 301, 316], ["LMW proteins", "PROBLEM", 395, 407], ["human serum/plasma", "TEST", 413, 431], ["diseased tissue", "OBSERVATION", 145, 160]]], ["First, the dynamic complexity of serum/plasma, spanning more than 10 orders of magnitude in terms of concentration, greatly hinders the characterization of LMW proteins.", [["serum", "ANATOMY", 33, 38], ["plasma", "ANATOMY", 39, 45], ["serum", "ORGANISM_SUBSTANCE", 33, 38], ["plasma", "ORGANISM_SUBSTANCE", 39, 45], ["LMW proteins", "GENE_OR_GENE_PRODUCT", 156, 168], ["LMW proteins", "PROTEIN", 156, 168], ["serum/plasma", "TEST", 33, 45], ["LMW proteins", "PROBLEM", 156, 168]]], ["As we known, many high-abundant proteins exist at concentrations billion-fold higher than those of the low-abundant LMW proteins thereby masking the potential LMW protein biomarkers and hindering their detection.", [["LMW", "GENE_OR_GENE_PRODUCT", 116, 119], ["high-abundant proteins", "PROTEIN", 18, 40], ["LMW proteins", "PROTEIN", 116, 128], ["LMW protein", "PROTEIN", 159, 170], ["many high-abundant proteins", "PROBLEM", 13, 40], ["the potential LMW protein biomarkers", "TEST", 145, 181], ["their detection", "TEST", 196, 211], ["high", "OBSERVATION_MODIFIER", 18, 22], ["abundant", "OBSERVATION_MODIFIER", 23, 31], ["proteins", "OBSERVATION", 32, 40]]], ["For instance, in the human plasma proteome, 22 abundant proteins, including albumin, immunoglobulin, fibrinogen, alpha 1-antitrypsin, alpha 2-macroglobulin, are responsible for 99% of the bulk mass of the total protein content in human plasma [7], [18].", [["plasma proteome", "ANATOMY", 27, 42], ["plasma", "ANATOMY", 236, 242], ["human", "ORGANISM", 21, 26], ["plasma", "ORGANISM_SUBSTANCE", 27, 33], ["albumin", "GENE_OR_GENE_PRODUCT", 76, 83], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 85, 99], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 101, 111], ["alpha 1-antitrypsin", "GENE_OR_GENE_PRODUCT", 113, 132], ["alpha 2-macroglobulin", "GENE_OR_GENE_PRODUCT", 134, 155], ["human", "ORGANISM", 230, 235], ["plasma", "ORGANISM_SUBSTANCE", 236, 242], ["albumin", "PROTEIN", 76, 83], ["immunoglobulin", "PROTEIN", 85, 99], ["fibrinogen", "PROTEIN", 101, 111], ["alpha 1-antitrypsin", "PROTEIN", 113, 132], ["alpha 2-macroglobulin", "PROTEIN", 134, 155], ["human", "SPECIES", 21, 26], ["human", "SPECIES", 230, 235], ["human", "SPECIES", 21, 26], ["human", "SPECIES", 230, 235], ["the human plasma proteome", "TEST", 17, 42], ["abundant proteins", "TEST", 47, 64], ["albumin", "TEST", 76, 83], ["immunoglobulin", "TEST", 85, 99], ["fibrinogen", "TEST", 101, 111], ["alpha", "TEST", 113, 118], ["antitrypsin", "TEST", 121, 132], ["alpha", "TEST", 134, 139], ["macroglobulin", "TEST", 142, 155], ["the bulk mass", "TEST", 184, 197], ["the total protein content", "TEST", 201, 226], ["human plasma", "TEST", 230, 242], ["mass", "OBSERVATION", 193, 197]]], ["Some proteins like albumin can even reach concentrations of 35\u201350 mg/mL in serum [8].", [["serum", "ANATOMY", 75, 80], ["albumin", "GENE_OR_GENE_PRODUCT", 19, 26], ["serum", "ORGANISM_SUBSTANCE", 75, 80], ["albumin", "PROTEIN", 19, 26], ["Some proteins like albumin", "PROBLEM", 0, 26]]], ["Second, compounded by the relatively low concentration of LMW biomarkers present in the circulation (levels of some LMW proteins in serum were estimated to be as low as picomole or even femtomole), accurate and consistent comprehensive measurement is difficult.", [["serum", "ANATOMY", 132, 137], ["serum", "ORGANISM_SUBSTANCE", 132, 137], ["LMW proteins", "PROTEIN", 116, 128], ["the relatively low concentration of LMW biomarkers", "PROBLEM", 22, 72], ["some LMW proteins", "PROBLEM", 111, 128], ["serum", "TEST", 132, 137], ["relatively", "OBSERVATION_MODIFIER", 26, 36], ["low concentration", "OBSERVATION_MODIFIER", 37, 54], ["LMW", "OBSERVATION_MODIFIER", 58, 61], ["biomarkers", "OBSERVATION", 62, 72], ["circulation", "ANATOMY_MODIFIER", 88, 99]]], ["Moreover, cumulative evidence shows that many LMW proteins in serum consisted of truncated soluble forms resulting from an in vivo or ex vivo cleavage, which further lowers the concentration of these proteins and decreases their detectability.", [["serum", "ANATOMY", 62, 67], ["LMW", "GENE_OR_GENE_PRODUCT", 46, 49], ["serum", "ORGANISM_SUBSTANCE", 62, 67], ["LMW proteins", "PROTEIN", 46, 58], ["truncated soluble forms", "PROTEIN", 81, 104], ["many LMW proteins in serum", "PROBLEM", 41, 67], ["truncated soluble forms", "PROBLEM", 81, 104], ["ex vivo cleavage", "TREATMENT", 134, 150], ["these proteins", "TEST", 194, 208], ["many", "OBSERVATION_MODIFIER", 41, 45], ["LMW", "OBSERVATION_MODIFIER", 46, 49], ["proteins", "OBSERVATION", 50, 58]]], ["Indeed, degradation of target biomarkers occurs during transportation and storage of blood, leading to serious false-positive and false-negative results.", [["blood", "ANATOMY", 85, 90], ["blood", "ORGANISM_SUBSTANCE", 85, 90], ["target biomarkers", "TEST", 23, 40]]], ["Third, filtration of molecules through the glomerular capillary wall (glomerular filtration) is highly dependent on molecule size and is referred to as the filtration-size threshold [19], which means the size of a protein generally determines how fast it would be cleared from the blood by kidney filtration and uptake by the liver.", [["glomerular capillary wall", "ANATOMY", 43, 68], ["glomerular", "ANATOMY", 70, 80], ["blood", "ANATOMY", 281, 286], ["kidney", "ANATOMY", 290, 296], ["liver", "ANATOMY", 326, 331], ["glomerular capillary wall", "TISSUE", 43, 68], ["glomerular", "TISSUE", 70, 80], ["blood", "ORGANISM_SUBSTANCE", 281, 286], ["kidney", "ORGAN", 290, 296], ["liver", "ORGAN", 326, 331], ["the filtration", "TEST", 152, 166], ["filtration", "OBSERVATION", 7, 17], ["molecules", "OBSERVATION", 21, 30], ["glomerular", "ANATOMY_MODIFIER", 43, 53], ["capillary", "ANATOMY_MODIFIER", 54, 63], ["wall", "ANATOMY_MODIFIER", 64, 68], ["glomerular filtration", "OBSERVATION", 70, 91], ["highly", "OBSERVATION_MODIFIER", 96, 102], ["dependent", "OBSERVATION_MODIFIER", 103, 112], ["molecule", "OBSERVATION_MODIFIER", 116, 124], ["size", "OBSERVATION_MODIFIER", 125, 129], ["size", "OBSERVATION_MODIFIER", 167, 171], ["size", "OBSERVATION_MODIFIER", 204, 208], ["kidney", "ANATOMY", 290, 296], ["filtration", "OBSERVATION", 297, 307], ["uptake", "OBSERVATION", 312, 318], ["liver", "ANATOMY", 326, 331]]], ["For instance, insulin achieves 100% renal filtration with a blood half-life of only 9 min [20].", [["renal", "ANATOMY", 36, 41], ["blood", "ANATOMY", 60, 65], ["insulin", "GENE_OR_GENE_PRODUCT", 14, 21], ["renal", "ORGAN", 36, 41], ["blood", "ORGANISM_SUBSTANCE", 60, 65], ["insulin", "TREATMENT", 14, 21], ["renal", "ANATOMY", 36, 41], ["filtration", "OBSERVATION", 42, 52]]], ["Therefore, LMW molecules generated in vivo would be cleared rather quickly, thereby reducing the concentration of the molecule to potentially undetectable levels.", [["LMW molecules", "GENE_OR_GENE_PRODUCT", 11, 24], ["LMW molecules", "PROTEIN", 11, 24], ["LMW molecules", "PROBLEM", 11, 24]]], ["Last but not least, the effective way for a small proteins to avoid to be rapidly cleared as mentioned earlier and stay in circulation is to hitch a ride with a carrier protein.", [["carrier protein", "PROTEIN", 161, 176], ["a small proteins", "PROBLEM", 42, 58], ["a carrier protein", "TREATMENT", 159, 176]]], ["This is really true as many studies have showed that LMW biomarkers are associated noncovalently with high-molecular-weight (HMW) protein [21].", [["LMW", "GENE_OR_GENE_PRODUCT", 53, 56], ["high-molecular-weight (HMW) protein", "PROTEIN", 102, 137], ["many studies", "TEST", 23, 35], ["LMW biomarkers", "TEST", 53, 67], ["protein", "TEST", 130, 137]]], ["Therefore, removing HMW proteins from the sample may further dilute the samples from LMW biomarkers.Organic Solvent Precipitation ::: Prefractionation Methods to Reduce Dynamic Complexity ::: Strategies for the Prefractionation or Enrichment of Small Intact or Truncated Proteins From the Human PlasmaThe simplest approach to deplete high-abundant proteins from serum would be to precipitate the proteins with organic solvent (methanol or acetonitrile) or ammonium sulfate (or other inorganic salt).", [["sample", "ANATOMY", 42, 48], ["samples", "ANATOMY", 72, 79], ["serum", "ANATOMY", 362, 367], ["methanol or acetonitrile", "CHEMICAL", 427, 451], ["ammonium sulfate", "CHEMICAL", 456, 472], ["inorganic salt", "CHEMICAL", 483, 497], ["methanol", "CHEMICAL", 427, 435], ["acetonitrile", "CHEMICAL", 439, 451], ["ammonium sulfate", "CHEMICAL", 456, 472], ["HMW", "GENE_OR_GENE_PRODUCT", 20, 23], ["LMW", "GENE_OR_GENE_PRODUCT", 85, 88], ["Human", "ORGANISM", 289, 294], ["Plasma", "ORGANISM_SUBSTANCE", 295, 301], ["serum", "ORGANISM_SUBSTANCE", 362, 367], ["methanol", "SIMPLE_CHEMICAL", 427, 435], ["acetonitrile", "SIMPLE_CHEMICAL", 439, 451], ["ammonium sulfate", "SIMPLE_CHEMICAL", 456, 472], ["inorganic salt", "SIMPLE_CHEMICAL", 483, 497], ["HMW proteins", "PROTEIN", 20, 32], ["Small Intact or Truncated Proteins", "PROTEIN", 245, 279], ["high-abundant proteins", "PROTEIN", 334, 356], ["Human", "SPECIES", 289, 294], ["HMW proteins", "TREATMENT", 20, 32], ["LMW biomarkers", "TEST", 85, 99], ["the Prefractionation", "PROBLEM", 207, 227], ["deplete high-abundant proteins from serum", "PROBLEM", 326, 367], ["organic solvent (methanol", "TREATMENT", 410, 435], ["acetonitrile", "TREATMENT", 439, 451], ["ammonium sulfate", "TREATMENT", 456, 472], ["other inorganic salt)", "TREATMENT", 477, 498], ["Small", "OBSERVATION_MODIFIER", 245, 250], ["Intact", "OBSERVATION", 251, 257]]], ["Most of the HMW proteins (MW > 20 kDa) would be precipitated, and only lower-molecular-weight ones would remain in the supernatant.", [["supernatant", "ANATOMY", 119, 130], ["HMW", "GENE_OR_GENE_PRODUCT", 12, 15], ["HMW proteins", "PROTEIN", 12, 24], ["MW", "PROTEIN", 26, 28], ["the HMW proteins", "TEST", 8, 24]]], ["So far, acetonitrile precipitation, which has been shown to effectively precipitate large, abundant proteins out of serum, is believe to be a superior method to remove serum albumin and immunoglobulins from serum [25].", [["serum", "ANATOMY", 116, 121], ["serum", "ANATOMY", 168, 173], ["serum", "ANATOMY", 207, 212], ["acetonitrile", "CHEMICAL", 8, 20], ["acetonitrile", "CHEMICAL", 8, 20], ["acetonitrile", "SIMPLE_CHEMICAL", 8, 20], ["serum", "ORGANISM_SUBSTANCE", 116, 121], ["serum", "ORGANISM_SUBSTANCE", 168, 173], ["albumin", "GENE_OR_GENE_PRODUCT", 174, 181], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 186, 201], ["serum", "ORGANISM_SUBSTANCE", 207, 212], ["serum albumin", "PROTEIN", 168, 181], ["immunoglobulins", "PROTEIN", 186, 201], ["acetonitrile precipitation", "TREATMENT", 8, 34], ["large, abundant proteins out of serum", "PROBLEM", 84, 121], ["a superior method", "TREATMENT", 140, 157], ["serum albumin", "TEST", 168, 181], ["immunoglobulins from serum", "TEST", 186, 212]]], ["This may due to the facts that ACN not only denatures these large proteins allowing for their removal but causes the small, low-abundance proteins and peptides normally bound to these carrier proteins to dissociate, thus making them available for detection [8].", [["ACN", "CHEMICAL", 31, 34], ["ACN", "CHEMICAL", 31, 34], ["ACN", "SIMPLE_CHEMICAL", 31, 34], ["low-abundance proteins", "PROTEIN", 124, 146], ["carrier proteins", "PROTEIN", 184, 200], ["their removal", "TREATMENT", 88, 101], ["the small, low-abundance proteins and peptides", "PROBLEM", 113, 159], ["large", "OBSERVATION_MODIFIER", 60, 65], ["proteins", "OBSERVATION", 66, 74], ["small", "OBSERVATION_MODIFIER", 117, 122]]], ["Indeed, our experience suggests that mass spectrometry (MS) analysis of serum LMW proteins was greatly improved with enhanced signal intensity and higher resolution (Fig. 2), which facilitated tracing of the targeted proteins [26].", [["serum", "ANATOMY", 72, 77], ["serum", "ORGANISM_SUBSTANCE", 72, 77], ["LMW", "GENE_OR_GENE_PRODUCT", 78, 81], ["serum LMW proteins", "PROTEIN", 72, 90], ["mass spectrometry", "PROBLEM", 37, 54], ["MS) analysis", "TEST", 56, 68], ["serum LMW proteins", "TEST", 72, 90], ["enhanced signal intensity", "PROBLEM", 117, 142], ["mass", "OBSERVATION", 37, 41], ["improved", "OBSERVATION_MODIFIER", 103, 111], ["intensity", "OBSERVATION_MODIFIER", 133, 142], ["higher", "OBSERVATION_MODIFIER", 147, 153], ["resolution", "OBSERVATION_MODIFIER", 154, 164]]], ["However, caution is required, as the risk of coprecipitating the low-abundant proteins would be great.Centrifugal Ultrafiltration ::: Prefractionation Methods to Reduce Dynamic Complexity ::: Strategies for the Prefractionation or Enrichment of Small Intact or Truncated Proteins From the Human PlasmaCentrifugal ultrafiltration, which utilizes both centrifugation force and a semipermeable membrane to retain HMW proteins, while LMW proteins pass through the membrane (filtrate) of nominal molecular weight cutoff, is another common strategy for the depletion of high-abundant proteins from human serum/plasma.", [["membrane", "ANATOMY", 391, 399], ["membrane", "ANATOMY", 460, 468], ["serum", "ANATOMY", 598, 603], ["plasma", "ANATOMY", 604, 610], ["Human", "ORGANISM", 289, 294], ["membrane", "CELLULAR_COMPONENT", 391, 399], ["HMW", "GENE_OR_GENE_PRODUCT", 410, 413], ["membrane", "CELLULAR_COMPONENT", 460, 468], ["human", "ORGANISM", 592, 597], ["serum", "ORGANISM_SUBSTANCE", 598, 603], ["plasma", "ORGANISM_SUBSTANCE", 604, 610], ["low-abundant proteins", "PROTEIN", 65, 86], ["Small Intact or Truncated Proteins", "PROTEIN", 245, 279], ["HMW proteins", "PROTEIN", 410, 422], ["LMW proteins", "PROTEIN", 430, 442], ["high-abundant proteins", "PROTEIN", 564, 586], ["Human", "SPECIES", 289, 294], ["human", "SPECIES", 592, 597], ["human", "SPECIES", 592, 597], ["coprecipitating the low-abundant proteins", "PROBLEM", 45, 86], ["Centrifugal Ultrafiltration", "TREATMENT", 102, 129], ["the Prefractionation", "PROBLEM", 207, 227], ["the Human PlasmaCentrifugal ultrafiltration", "TREATMENT", 285, 328], ["both centrifugation force", "TREATMENT", 345, 370], ["a semipermeable membrane", "TREATMENT", 375, 399], ["the depletion", "PROBLEM", 547, 560], ["human serum/plasma", "TEST", 592, 610], ["Ultrafiltration", "OBSERVATION", 114, 129], ["Small", "OBSERVATION_MODIFIER", 245, 250], ["Intact", "OBSERVATION", 251, 257]]], ["However, it is critical to disrupt the peptide/protein\u2013protein interactions prior to centrifugal ultrafiltration to released LMW components bound to larger species, as many physiologically important low-abundant proteins are often found to be bound to carrier proteins in plasma [18].", [["plasma", "ANATOMY", 272, 278], ["plasma", "ORGANISM_SUBSTANCE", 272, 278], ["LMW components", "PROTEIN", 125, 139], ["carrier proteins", "PROTEIN", 252, 268], ["the peptide/protein\u2013protein interactions", "TREATMENT", 35, 75], ["centrifugal ultrafiltration", "TREATMENT", 85, 112], ["LMW components bound", "PROBLEM", 125, 145], ["larger species", "PROBLEM", 149, 163], ["LMW components", "OBSERVATION_MODIFIER", 125, 139], ["larger", "OBSERVATION_MODIFIER", 149, 155], ["species", "OBSERVATION", 156, 163]]], ["Moreover, it is important to recognize that retention of a protein by centrifugal ultrafiltration membrane is determined by a variety of factors, including molecular weight, molecular shape, electrical charge, sample concentration, buffer composition, and operating conditions.", [["centrifugal ultrafiltration membrane", "ANATOMY", 70, 106], ["sample", "ANATOMY", 210, 216], ["membrane", "CELLULAR_COMPONENT", 98, 106], ["centrifugal ultrafiltration membrane", "TREATMENT", 70, 106], ["sample concentration", "TREATMENT", 210, 230], ["buffer composition", "TREATMENT", 232, 250]]], ["Therefore, multiple studies showed that HMW proteins will still appear in the filtrate when use different commercially available filter membranes.", [["membranes", "ANATOMY", 136, 145], ["HMW proteins", "GENE_OR_GENE_PRODUCT", 40, 52], ["HMW proteins", "PROTEIN", 40, 52], ["multiple studies", "TEST", 11, 27], ["HMW proteins", "PROBLEM", 40, 52], ["filter membranes", "TREATMENT", 129, 145]]], ["One of the reasons was supposed to be that the shape of some HMW proteins changes after denature, thereby leading their size change and making them pass through the membrane.", [["membrane", "ANATOMY", 165, 173], ["HMW", "GENE_OR_GENE_PRODUCT", 61, 64], ["membrane", "CELLULAR_COMPONENT", 165, 173], ["HMW proteins", "PROTEIN", 61, 73], ["some HMW proteins changes", "PROBLEM", 56, 81], ["HMW", "OBSERVATION_MODIFIER", 61, 64], ["proteins", "OBSERVATION", 65, 73], ["size", "OBSERVATION_MODIFIER", 120, 124]]], ["Therefore, multidimensional separation, such as the combination of centrifugal ultrafiltration and reversed-phase solid-phase extraction, was recommend to improve the enrichment of LMW proteins and peptides [27].Affinity-Based Techniques ::: Prefractionation Methods to Reduce Dynamic Complexity ::: Strategies for the Prefractionation or Enrichment of Small Intact or Truncated Proteins From the Human PlasmaThe organic solvent precipitation and centrifugal ultrafiltration approaches mentioned earlier are quite nonselective because it generally removes the HMW proteins.", [["LMW proteins", "GENE_OR_GENE_PRODUCT", 181, 193], ["Human", "ORGANISM", 397, 402], ["Plasma", "ORGANISM_SUBSTANCE", 403, 409], ["HMW", "GENE_OR_GENE_PRODUCT", 560, 563], ["LMW proteins", "PROTEIN", 181, 193], ["Small Intact or Truncated Proteins", "PROTEIN", 353, 387], ["HMW proteins", "PROTEIN", 560, 572], ["Human", "SPECIES", 397, 402], ["centrifugal ultrafiltration", "TREATMENT", 67, 94], ["reversed-phase solid-phase extraction", "TREATMENT", 99, 136], ["the Prefractionation", "PROBLEM", 315, 335], ["The organic solvent precipitation", "TREATMENT", 409, 442], ["centrifugal ultrafiltration approaches", "TREATMENT", 447, 485], ["the HMW proteins", "PROBLEM", 556, 572], ["Small", "OBSERVATION_MODIFIER", 353, 358], ["Intact", "OBSERVATION", 359, 365]]], ["To remove high-abundant proteins from serum more specifically, many techniques based on affinity matrices such as antibodies, antibody-mimicking peptides, or other kinds of natural compounds are often employed.", [["serum", "ANATOMY", 38, 43], ["serum", "ORGANISM_SUBSTANCE", 38, 43], ["high-abundant proteins", "PROTEIN", 10, 32], ["antibodies", "PROTEIN", 114, 124], ["antibody", "PROTEIN", 126, 134], ["affinity matrices", "TEST", 88, 105], ["antibodies", "TEST", 114, 124], ["antibody", "TEST", 126, 134], ["mimicking peptides", "PROBLEM", 135, 153], ["natural compounds", "PROBLEM", 173, 190], ["natural compounds", "OBSERVATION", 173, 190]]], ["For instance, the most popular method to remove HSA is using Cibacron Blue-based affinity chromatography [28], [29].", [["Cibacron Blue", "CHEMICAL", 61, 74], ["Cibacron Blue", "CHEMICAL", 61, 74], ["HSA", "SIMPLE_CHEMICAL", 48, 51], ["Cibacron Blue", "SIMPLE_CHEMICAL", 61, 74], ["Cibacron Blue", "TREATMENT", 61, 74], ["affinity chromatography", "TEST", 81, 104]]], ["For depletion of immunoglobulin, the second most abundant serum/plasma protein, the use of immobilized protein A or G media, which specifically binds to the Fc region of IgG, is the technique of choice [30].", [["serum", "ANATOMY", 58, 63], ["plasma", "ANATOMY", 64, 70], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 17, 31], ["serum", "ORGANISM_SUBSTANCE", 58, 63], ["plasma", "ORGANISM_SUBSTANCE", 64, 70], ["IgG", "GENE_OR_GENE_PRODUCT", 170, 173], ["immunoglobulin", "PROTEIN", 17, 31], ["plasma protein", "PROTEIN", 64, 78], ["immobilized protein A", "PROTEIN", 91, 112], ["Fc region", "PROTEIN", 157, 166], ["IgG", "PROTEIN", 170, 173], ["immunoglobulin", "TREATMENT", 17, 31], ["plasma protein", "TEST", 64, 78], ["immobilized protein A or G media", "TREATMENT", 91, 123]]], ["However, the depletion of HSA by dye-based resins is not entirely straightforward due to the enormous load of HSA species in serum and plasma and nonspecific binding of some other serum proteins as well [31].", [["serum", "ANATOMY", 125, 130], ["plasma", "ANATOMY", 135, 141], ["serum", "ANATOMY", 180, 185], ["HSA", "GENE_OR_GENE_PRODUCT", 26, 29], ["HSA species", "SIMPLE_CHEMICAL", 110, 121], ["serum", "ORGANISM_SUBSTANCE", 125, 130], ["plasma", "ORGANISM_SUBSTANCE", 135, 141], ["serum", "ORGANISM_SUBSTANCE", 180, 185], ["HSA", "PROTEIN", 26, 29], ["HSA species", "PROTEIN", 110, 121], ["serum proteins", "PROTEIN", 180, 194], ["the depletion of HSA", "PROBLEM", 9, 29], ["HSA species", "PROBLEM", 110, 121], ["serum and plasma", "TEST", 125, 141], ["nonspecific binding of some other serum proteins", "PROBLEM", 146, 194], ["HSA species", "OBSERVATION", 110, 121]]], ["Moreover, Cibacron Blue dye does not only show affinity for albumin but also for NAD, FAD, and ATP-binding sites of proteins, which often results in the unwanted removal of proteins of interest [32], [33], [34].", [["NAD", "CHEMICAL", 81, 84], ["ATP", "CHEMICAL", 95, 98], ["Cibacron Blue", "CHEMICAL", 10, 23], ["NAD", "CHEMICAL", 81, 84], ["FAD", "CHEMICAL", 86, 89], ["ATP", "CHEMICAL", 95, 98], ["Cibacron Blue dye", "SIMPLE_CHEMICAL", 10, 27], ["albumin", "GENE_OR_GENE_PRODUCT", 60, 67], ["NAD", "SIMPLE_CHEMICAL", 81, 84], ["FAD", "SIMPLE_CHEMICAL", 86, 89], ["ATP", "SIMPLE_CHEMICAL", 95, 98], ["[33]", "SIMPLE_CHEMICAL", 200, 204], ["albumin", "PROTEIN", 60, 67], ["Cibacron Blue dye", "TREATMENT", 10, 27], ["albumin", "TEST", 60, 67], ["NAD", "PROBLEM", 81, 84], ["FAD", "TEST", 86, 89], ["ATP-binding sites of proteins", "PROBLEM", 95, 124], ["the unwanted removal of proteins", "TREATMENT", 149, 181]]], ["In addition, the protein A for antibody capture also shows widely varying degrees of affinity for the antibody isotypes and subtypes, which results in incomplete removal of some subtypes of IgG.", [["protein A", "GENE_OR_GENE_PRODUCT", 17, 26], ["IgG", "GENE_OR_GENE_PRODUCT", 190, 193], ["protein A", "PROTEIN", 17, 26], ["antibody isotypes", "PROTEIN", 102, 119], ["IgG", "PROTEIN", 190, 193], ["the protein A", "TEST", 13, 26], ["antibody capture", "TEST", 31, 47], ["widely varying degrees of affinity", "PROBLEM", 59, 93], ["the antibody isotypes", "PROBLEM", 98, 119], ["incomplete removal", "TREATMENT", 151, 169], ["some subtypes of IgG", "PROBLEM", 173, 193], ["antibody isotypes", "OBSERVATION", 102, 119], ["some subtypes", "OBSERVATION_MODIFIER", 173, 186]]], ["Therefore, the use of specific ligands for the capture of HSA and IgG, such as antibodies, was employed.", [["HSA", "GENE_OR_GENE_PRODUCT", 58, 61], ["IgG", "GENE_OR_GENE_PRODUCT", 66, 69], ["HSA", "PROTEIN", 58, 61], ["IgG", "PROTEIN", 66, 69], ["antibodies", "PROTEIN", 79, 89], ["HSA", "TEST", 58, 61], ["IgG", "TEST", 66, 69]]], ["Steel and coworkers demonstrated to develop an immune-affinity resin using monoclonal antibodies against HSA to effectively removal of both full-length HSA and many of the HSA fragments present in serum, which shows markedly better performance than dye-based resins in terms of both the efficiency and specificity of albumin removal [31].", [["serum", "ANATOMY", 197, 202], ["HSA", "SIMPLE_CHEMICAL", 105, 108], ["HSA", "GENE_OR_GENE_PRODUCT", 152, 155], ["HSA", "GENE_OR_GENE_PRODUCT", 172, 175], ["serum", "ORGANISM_SUBSTANCE", 197, 202], ["albumin", "GENE_OR_GENE_PRODUCT", 317, 324], ["monoclonal antibodies", "PROTEIN", 75, 96], ["HSA", "PROTEIN", 105, 108], ["HSA", "PROTEIN", 152, 155], ["HSA fragments", "DNA", 172, 185], ["albumin", "PROTEIN", 317, 324], ["an immune-affinity resin", "TREATMENT", 44, 68], ["monoclonal antibodies", "TREATMENT", 75, 96], ["HSA", "TREATMENT", 105, 108], ["removal", "TREATMENT", 124, 131], ["both full-length HSA", "TREATMENT", 135, 155], ["the HSA fragments", "PROBLEM", 168, 185], ["serum", "TEST", 197, 202], ["dye-based resins", "TREATMENT", 249, 265], ["albumin removal", "TREATMENT", 317, 332], ["HSA fragments", "OBSERVATION", 172, 185]]], ["Furthermore, when a protein G affinity resin is used together with the immunoaffinity resin, IgG and HSA can be simultaneously removed from the samples.Affinity-Based Techniques ::: Prefractionation Methods to Reduce Dynamic Complexity ::: Strategies for the Prefractionation or Enrichment of Small Intact or Truncated Proteins From the Human PlasmaHowever, it still leaves behind many high-abundance proteins, though the single-antibody columns that are specific to IgG and HSA can capture a good percentage of their target protein.", [["samples", "ANATOMY", 144, 151], ["IgG", "GENE_OR_GENE_PRODUCT", 93, 96], ["HSA", "GENE_OR_GENE_PRODUCT", 101, 104], ["Human", "ORGANISM", 337, 342], ["IgG", "GENE_OR_GENE_PRODUCT", 467, 470], ["HSA", "GENE_OR_GENE_PRODUCT", 475, 478], ["IgG", "PROTEIN", 93, 96], ["HSA", "PROTEIN", 101, 104], ["Small Intact or Truncated Proteins", "PROTEIN", 293, 327], ["high-abundance proteins", "PROTEIN", 386, 409], ["IgG", "PROTEIN", 467, 470], ["HSA", "PROTEIN", 475, 478], ["target protein", "PROTEIN", 518, 532], ["Human", "SPECIES", 337, 342], ["a protein G affinity resin", "TREATMENT", 18, 44], ["the immunoaffinity resin", "TREATMENT", 67, 91], ["IgG and HSA", "TREATMENT", 93, 104], ["the Prefractionation", "PROBLEM", 255, 275], ["many high-abundance proteins", "PROBLEM", 381, 409], ["the single-antibody columns", "TEST", 418, 445], ["IgG", "TEST", 467, 470], ["Small", "OBSERVATION_MODIFIER", 293, 298], ["Intact", "OBSERVATION", 299, 305], ["high", "OBSERVATION_MODIFIER", 386, 390]]], ["Thus, the selective simultaneous removal of more than a single high-abundance protein became more desirable.", [["high-abundance protein", "PROTEIN", 63, 85], ["the selective simultaneous removal", "TREATMENT", 6, 40], ["a single high-abundance protein", "PROBLEM", 54, 85], ["selective", "OBSERVATION_MODIFIER", 10, 19], ["simultaneous", "OBSERVATION_MODIFIER", 20, 32], ["removal", "OBSERVATION", 33, 40], ["more desirable", "OBSERVATION_MODIFIER", 93, 107]]], ["During the last decades, there has been a gradual development of several multiple affinity removal columns for the simultaneous depletion of even more high-abundant proteins.", [["high-abundant proteins", "PROTEIN", 151, 173], ["several multiple affinity removal columns", "TREATMENT", 65, 106], ["the simultaneous depletion", "TREATMENT", 111, 137], ["gradual", "OBSERVATION_MODIFIER", 42, 49], ["several", "OBSERVATION_MODIFIER", 65, 72], ["multiple", "OBSERVATION_MODIFIER", 73, 81], ["affinity removal", "OBSERVATION", 82, 98], ["columns", "OBSERVATION_MODIFIER", 99, 106], ["simultaneous depletion", "OBSERVATION", 115, 137]]], ["The multiple affinity removal system (MARS) (Agilent Technologies, Santa Clara, California), which combines the specificity of antibody\u2013antigen recognition and the efficiency of standard liquid chromatography, was one of the first MARS on the market.", [["The multiple affinity removal system", "TREATMENT", 0, 36], ["antibody\u2013antigen recognition", "PROBLEM", 127, 155], ["standard liquid chromatography", "TEST", 178, 208], ["multiple", "OBSERVATION_MODIFIER", 4, 12], ["affinity removal", "OBSERVATION", 13, 29]]], ["The affinity column removes HSA, IgG, transferrin, alpha 1-antitrypsin, haptoglobin, and immunoglobulin by using six affinity-purified polyclonal antibodies that bonded to polymeric microbeads via their Fc region.Affinity-Based Techniques ::: Prefractionation Methods to Reduce Dynamic Complexity ::: Strategies for the Prefractionation or Enrichment of Small Intact or Truncated Proteins From the Human PlasmaA number of other commercial products, based upon specific antibodies to the high-abundance proteins or using ion-exchange mechanism, have also been designed to remove high-abundant proteins from serum and plasma [35].", [["serum", "ANATOMY", 606, 611], ["plasma", "ANATOMY", 616, 622], ["HSA", "SIMPLE_CHEMICAL", 28, 31], ["IgG", "GENE_OR_GENE_PRODUCT", 33, 36], ["transferrin", "GENE_OR_GENE_PRODUCT", 38, 49], ["alpha 1-antitrypsin", "GENE_OR_GENE_PRODUCT", 51, 70], ["haptoglobin", "GENE_OR_GENE_PRODUCT", 72, 83], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 89, 103], ["Human", "ORGANISM", 398, 403], ["serum", "ORGANISM_SUBSTANCE", 606, 611], ["plasma", "ORGANISM_SUBSTANCE", 616, 622], ["HSA", "PROTEIN", 28, 31], ["IgG", "PROTEIN", 33, 36], ["transferrin", "PROTEIN", 38, 49], ["alpha 1-antitrypsin", "PROTEIN", 51, 70], ["haptoglobin", "PROTEIN", 72, 83], ["immunoglobulin", "PROTEIN", 89, 103], ["affinity-purified polyclonal antibodies", "PROTEIN", 117, 156], ["Fc region", "PROTEIN", 203, 212], ["Small Intact or Truncated Proteins", "PROTEIN", 354, 388], ["antibodies", "PROTEIN", 469, 479], ["high-abundance proteins", "PROTEIN", 487, 510], ["high-abundant proteins", "PROTEIN", 578, 600], ["Human", "SPECIES", 398, 403], ["The affinity column", "TEST", 0, 19], ["HSA", "TEST", 28, 31], ["IgG", "TEST", 33, 36], ["transferrin", "TEST", 38, 49], ["alpha", "TEST", 51, 56], ["antitrypsin", "TEST", 59, 70], ["haptoglobin", "TEST", 72, 83], ["immunoglobulin", "TREATMENT", 89, 103], ["six affinity", "TEST", 113, 125], ["purified polyclonal antibodies", "PROBLEM", 126, 156], ["the Prefractionation", "PROBLEM", 316, 336], ["other commercial products", "TREATMENT", 422, 447], ["specific antibodies", "TEST", 460, 479], ["ion-exchange mechanism", "TREATMENT", 520, 542], ["serum and plasma", "TEST", 606, 622], ["polymeric microbeads", "OBSERVATION", 172, 192], ["Small", "OBSERVATION_MODIFIER", 354, 359], ["Intact", "OBSERVATION", 360, 366]]], ["These products are claimed to be ranging from the depletion of 4 proteins all the way up to more than 20 proteins, such as Seppro IgY14 and ProteoPrep 20 (Sigma Aldrich), as well as ProteoSpin (Norgen Biotek Corp.)", [["Seppro IgY14", "GENE_OR_GENE_PRODUCT", 123, 135], ["ProteoPrep 20", "GENE_OR_GENE_PRODUCT", 140, 153], ["Sigma Aldrich", "ORGANISM", 155, 168], ["Seppro IgY14", "PROTEIN", 123, 135], ["ProteoPrep 20", "PROTEIN", 140, 153], ["Seppro IgY14", "TREATMENT", 123, 135], ["ProteoPrep", "TREATMENT", 140, 150], ["ProteoSpin (Norgen Biotek Corp.", "TREATMENT", 182, 213], ["ranging", "OBSERVATION_MODIFIER", 33, 40]]], ["However, cautions are required, as recent evidence has shown that increasing the number of depleted proteins from 12 to 20 had only little beneficial effect and could in fact even increase the removal of peptides and proteins of interest which are associated with the abundant proteins [24], [36].", [["depleted proteins", "PROTEIN", 91, 108], ["depleted proteins", "PROBLEM", 91, 108], ["the removal of peptides", "TREATMENT", 189, 212], ["increasing", "OBSERVATION_MODIFIER", 66, 76], ["depleted", "OBSERVATION", 91, 99], ["increase", "OBSERVATION_MODIFIER", 180, 188], ["removal", "OBSERVATION_MODIFIER", 193, 200]]], ["In addition, the next layer of abundant protein, moderately abundant proteins, after separating the highly abundant proteins, becomes an obstacle to access the low-abundant proteins.", [["abundant protein", "PROTEIN", 31, 47], ["moderately abundant proteins", "PROTEIN", 49, 77], ["low-abundant proteins", "PROTEIN", 160, 181], ["abundant protein", "PROBLEM", 31, 47], ["moderately abundant proteins", "PROBLEM", 49, 77], ["moderately", "OBSERVATION_MODIFIER", 49, 59], ["abundant", "OBSERVATION_MODIFIER", 60, 68], ["proteins", "OBSERVATION", 69, 77]]], ["To tackle this challenge, Fang and coworkers further developed the IgY-microbead system by immunizing chickens with a flow-through fraction of IgY12 column and constructing the column with affinity-purified IgY antibodies against the flow-through proteins of IgY12 column, which enabled specific capturing of 207 moderately abundant proteins and thereby enables deeper and more effective access into the population of LAPs [37].Affinity Enrichment of Low-Abundance LMW Proteins ::: Enrichment of Low-Abundance LMW Proteins ::: Strategies for the Prefractionation or Enrichment of Small Intact or Truncated Proteins From the Human PlasmaIn contrast to depletion techniques, specific enrichment processes allow for fast and high specific detection at picomolar or even femtomolar quantities of target protein.Affinity Enrichment of Low-Abundance LMW Proteins ::: Enrichment of Low-Abundance LMW Proteins ::: Strategies for the Prefractionation or Enrichment of Small Intact or Truncated Proteins From the Human PlasmaOne of such enrichment processes is magnetic beads coated with ligands of interest, which enable identifying low-abundant LMW protein faster, more efficiently, and at lower cost than other methods.", [["IgY", "ORGANISM", 67, 70], ["chickens", "ORGANISM", 102, 110], ["IgY12", "SIMPLE_CHEMICAL", 143, 148], ["IgY", "ORGANISM", 207, 210], ["IgY12", "SIMPLE_CHEMICAL", 259, 264], ["Human", "ORGANISM", 624, 629], ["Human", "ORGANISM", 1003, 1008], ["IgY", "PROTEIN", 67, 70], ["IgY antibodies", "PROTEIN", 207, 221], ["207 moderately abundant proteins", "PROTEIN", 309, 341], ["Small Intact or Truncated Proteins", "PROTEIN", 580, 614], ["target protein", "PROTEIN", 792, 806], ["Small Intact or Truncated Proteins", "PROTEIN", 959, 993], ["LMW protein", "PROTEIN", 1137, 1148], ["chickens", "SPECIES", 102, 110], ["Human", "SPECIES", 624, 629], ["Human", "SPECIES", 1003, 1008], ["chickens", "SPECIES", 102, 110], ["immunizing chickens", "PROBLEM", 91, 110], ["a flow", "TEST", 116, 122], ["affinity", "TEST", 189, 197], ["IgY antibodies", "TEST", 207, 221], ["the flow", "TEST", 230, 238], ["moderately abundant proteins", "PROBLEM", 313, 341], ["the Prefractionation", "PROBLEM", 542, 562], ["the Human PlasmaIn contrast", "TREATMENT", 620, 647], ["depletion techniques", "TREATMENT", 651, 671], ["the Prefractionation", "PROBLEM", 921, 941], ["Truncated Proteins", "PROBLEM", 975, 993], ["such enrichment processes", "TREATMENT", 1022, 1047], ["IgY12 column", "ANATOMY", 143, 155], ["column", "ANATOMY", 177, 183], ["Low", "OBSERVATION_MODIFIER", 451, 454], ["Low", "OBSERVATION_MODIFIER", 496, 499], ["Small", "OBSERVATION_MODIFIER", 580, 585], ["Intact", "OBSERVATION", 586, 592], ["Low", "OBSERVATION_MODIFIER", 830, 833], ["Low", "OBSERVATION_MODIFIER", 875, 878], ["Small", "OBSERVATION_MODIFIER", 959, 964], ["Intact", "OBSERVATION", 965, 971], ["abundant LMW", "OBSERVATION_MODIFIER", 1128, 1140], ["protein faster", "OBSERVATION", 1141, 1155]]], ["This may primarily due to the fact that magnetic particles comprise a convenient solid support for a variety of assays and procedures based on affinity purification.", [["magnetic particles", "TREATMENT", 40, 58], ["a convenient solid support", "TREATMENT", 68, 94], ["assays", "TEST", 112, 118], ["procedures", "TREATMENT", 123, 133], ["affinity purification", "TREATMENT", 143, 164]]], ["For instance, the high density of the beads allows rapid capture by magnetic devices, while the visibility of the beads ensures reliable collection of all target protein bound in the immunoprecipitation/pull-down application, which allows concentration of low-abundant target protein samples from milliliter down to microliter scale.", [["samples", "ANATOMY", 284, 291], ["the high density of the beads", "PROBLEM", 14, 43], ["magnetic devices", "TREATMENT", 68, 84], ["all target protein bound", "PROBLEM", 151, 175], ["the immunoprecipitation", "TREATMENT", 179, 202], ["pull-down application", "TREATMENT", 203, 224], ["microliter scale", "TEST", 316, 332], ["high", "OBSERVATION_MODIFIER", 18, 22], ["density", "OBSERVATION", 23, 30]]], ["Anderson and coworkers reported a SISCAPA (stable isotope standards and capture by antipeptide antibodies) method for specific antibody-based capture of individual tryptic peptides from a digest of whole human plasma based on a simplified magnetic bead protocol [38].", [["plasma", "ANATOMY", 210, 216], ["human", "ORGANISM", 204, 209], ["plasma", "ORGANISM_SUBSTANCE", 210, 216], ["antipeptide antibodies", "PROTEIN", 83, 105], ["human", "SPECIES", 204, 209], ["human", "SPECIES", 204, 209], ["a SISCAPA (stable isotope standards", "TREATMENT", 32, 67], ["antipeptide antibodies", "TREATMENT", 83, 105], ["specific antibody", "TEST", 118, 135], ["individual tryptic peptides", "PROBLEM", 153, 180], ["whole human plasma", "TREATMENT", 198, 216], ["a simplified magnetic bead protocol", "TREATMENT", 226, 261]]], ["With this protocol, selected tryptic peptides of \u03b11-antichymotrypsin and lipopolysaccharide-binding protein were enriched relative to a high-abundance serum albumin peptide by 1800- and 18,000-fold, respectively, as measured by multiple reaction monitoring (MRM).", [["serum", "ANATOMY", 151, 156], ["\u03b11-antichymotrypsin", "CHEMICAL", 49, 68], ["lipopolysaccharide", "CHEMICAL", 73, 91], ["\u03b11-antichymotrypsin", "SIMPLE_CHEMICAL", 49, 68], ["lipopolysaccharide-binding protein", "GENE_OR_GENE_PRODUCT", 73, 107], ["serum", "ORGANISM_SUBSTANCE", 151, 156], ["albumin", "GENE_OR_GENE_PRODUCT", 157, 164], ["\u03b11", "PROTEIN", 49, 51], ["antichymotrypsin", "PROTEIN", 52, 68], ["lipopolysaccharide-binding protein", "PROTEIN", 73, 107], ["this protocol", "TREATMENT", 5, 18], ["selected tryptic peptides", "TEST", 20, 45], ["lipopolysaccharide-binding protein", "TEST", 73, 107], ["serum albumin peptide", "TEST", 151, 172], ["multiple reaction monitoring", "TEST", 228, 256], ["MRM", "TEST", 258, 261]]], ["In contrast to the magnetic bead, which is of excellent properties for small-scale experiments, the experimental features of antibody microarrays have the advantages of performing the simultaneous enrichment of several hundreds of proteins in parallel [39].", [["small-scale experiments", "PROBLEM", 71, 94], ["antibody microarrays", "TREATMENT", 125, 145], ["the simultaneous enrichment", "TREATMENT", 180, 207], ["small", "OBSERVATION_MODIFIER", 71, 76]]], ["Desrosiers and coworkers demonstrated a proteomic analysis of human plasma proteins using antibody arrays coated with 350 antibodies directed against signaling proteins after removal depletion of high-abundance proteins [40].", [["plasma", "ANATOMY", 68, 74], ["human", "ORGANISM", 62, 67], ["plasma", "ORGANISM_SUBSTANCE", 68, 74], ["human plasma proteins", "PROTEIN", 62, 83], ["350 antibodies", "PROTEIN", 118, 132], ["signaling proteins", "PROTEIN", 150, 168], ["high-abundance proteins", "PROTEIN", 196, 219], ["human", "SPECIES", 62, 67], ["human", "SPECIES", 62, 67], ["a proteomic analysis", "TEST", 38, 58], ["human plasma proteins", "TREATMENT", 62, 83], ["antibody arrays coated", "TREATMENT", 90, 112], ["350 antibodies", "TREATMENT", 118, 132], ["signaling proteins", "PROBLEM", 150, 168], ["removal depletion", "TREATMENT", 175, 192], ["high-abundance proteins", "PROBLEM", 196, 219]]], ["The results showed that antibody microarrays allowing the identification of 61 lower-abundance plasma proteins using 350 antibodies directed against signaling proteins, and authors suggest that this strategy is a valuable approach for detecting potential plasma biomarkers.", [["plasma", "ANATOMY", 95, 101], ["plasma", "ANATOMY", 255, 261], ["plasma", "ORGANISM_SUBSTANCE", 95, 101], ["plasma", "ORGANISM_SUBSTANCE", 255, 261], ["61 lower-abundance plasma proteins", "PROTEIN", 76, 110], ["350 antibodies", "PROTEIN", 117, 131], ["signaling proteins", "PROTEIN", 149, 167], ["antibody microarrays", "TEST", 24, 44], ["the identification", "TEST", 54, 72], ["plasma proteins", "TEST", 95, 110], ["350 antibodies", "TEST", 117, 131], ["signaling proteins", "PROBLEM", 149, 167], ["plasma biomarkers", "TEST", 255, 272]]], ["This combinatorial solid-phase library contains a large and highly diverse library of hexapeptides bound to a chromatographic support, allowing each unique hexapeptide to bind to a unique protein sequence.", [["hexapeptides", "SIMPLE_CHEMICAL", 86, 98], ["hexapeptides", "PROTEIN", 86, 98], ["unique protein sequence", "PROTEIN", 181, 204], ["a large and highly diverse library of hexapeptides bound", "PROBLEM", 48, 104], ["a chromatographic support", "TREATMENT", 108, 133], ["each unique hexapeptide", "TREATMENT", 144, 167], ["a unique protein sequence", "TEST", 179, 204], ["large", "OBSERVATION_MODIFIER", 50, 55], ["highly", "OBSERVATION_MODIFIER", 60, 66], ["diverse", "OBSERVATION_MODIFIER", 67, 74], ["library of", "OBSERVATION", 75, 85], ["hexapeptides bound", "OBSERVATION", 86, 104]]], ["When the sample is added, the limiting binding capacity of the beads enables high-abundance proteins to rapidly saturate their ligands, and excess protein is washed out.Affinity Enrichment of Low-Abundance LMW Proteins ::: Enrichment of Low-Abundance LMW Proteins ::: Strategies for the Prefractionation or Enrichment of Small Intact or Truncated Proteins From the Human PlasmaHowever, cautions are required, as one potential pitfall remains with regarding to the elution of target molecules for specific enrichment.", [["sample", "ANATOMY", 9, 15], ["Human", "ORGANISM", 365, 370], ["high-abundance proteins", "PROTEIN", 77, 100], ["Small Intact or Truncated Proteins", "PROTEIN", 321, 355], ["Human", "SPECIES", 365, 370], ["excess protein", "PROBLEM", 140, 154], ["the Prefractionation", "PROBLEM", 283, 303], ["Low", "OBSERVATION_MODIFIER", 192, 195], ["Low", "OBSERVATION_MODIFIER", 237, 240], ["Small", "OBSERVATION_MODIFIER", 321, 326], ["Intact", "OBSERVATION", 327, 333]]], ["If the antibodies have very high selectivity, then in the case of low-abundance proteins, only a very small amount of proteins will be eluted from the antibody, which are easily lost through the following procedures.Enrichment of Low-Abundance LMW Proteins Based on Nanotechnology ::: Enrichment of Low-Abundance LMW Proteins ::: Strategies for the Prefractionation or Enrichment of Small Intact or Truncated Proteins From the Human PlasmaAdvances in microfabrication offer great opportunities to provide \u201cnanoharvesting\u201d agents designed specifically to capture and amplify classes of LMW proteins.", [["Human", "ORGANISM", 427, 432], ["LMW", "GENE_OR_GENE_PRODUCT", 585, 588], ["antibodies", "PROTEIN", 7, 17], ["low-abundance proteins", "PROTEIN", 66, 88], ["LMW proteins", "PROTEIN", 585, 597], ["Human", "SPECIES", 427, 432], ["the antibodies", "TEST", 3, 17], ["low-abundance proteins", "PROBLEM", 66, 88], ["a very small amount of proteins", "PROBLEM", 95, 126], ["the antibody", "TEST", 147, 159], ["the Prefractionation", "PROBLEM", 345, 365], ["the Human PlasmaAdvances in microfabrication", "TREATMENT", 423, 467], ["nanoharvesting\u201d agents", "TREATMENT", 506, 528], ["LMW proteins", "PROBLEM", 585, 597], ["small", "OBSERVATION_MODIFIER", 102, 107], ["amount", "OBSERVATION_MODIFIER", 108, 114], ["Low", "OBSERVATION_MODIFIER", 230, 233], ["Low", "OBSERVATION_MODIFIER", 299, 302], ["Small", "OBSERVATION_MODIFIER", 383, 388], ["Intact", "OBSERVATION", 389, 395]]], ["In fact, in the past few years, a variety of types of nanoparticles have been applied to capture and separate proteins from complex mixtures [42], [43], [44], [45], [46].Enrichment of Low-Abundance LMW Proteins Based on Nanotechnology ::: Enrichment of Low-Abundance LMW Proteins ::: Strategies for the Prefractionation or Enrichment of Small Intact or Truncated Proteins From the Human PlasmaAmong these nanomaterials, golden nanoparticles (GNPs) are found to be readily available, relatively stable, have low toxicity, and excellent compatibility with biomolecules [47].", [["GNPs", "CHEMICAL", 442, 446], ["toxicity", "DISEASE", 511, 519], ["[43]", "SIMPLE_CHEMICAL", 147, 151], ["[44]", "SIMPLE_CHEMICAL", 153, 157], ["[45]", "SIMPLE_CHEMICAL", 159, 163], ["[46]", "SIMPLE_CHEMICAL", 165, 169], ["Human", "ORGANISM", 381, 386], ["golden nanoparticles", "SIMPLE_CHEMICAL", 420, 440], ["GNPs", "SIMPLE_CHEMICAL", 442, 446], ["Human", "SPECIES", 381, 386], ["a variety of types of nanoparticles", "TREATMENT", 32, 67], ["complex mixtures", "TEST", 124, 140], ["the Prefractionation", "PROBLEM", 299, 319], ["low toxicity", "PROBLEM", 507, 519], ["Low", "OBSERVATION_MODIFIER", 184, 187], ["Low", "OBSERVATION_MODIFIER", 253, 256], ["Small", "OBSERVATION_MODIFIER", 337, 342], ["Intact", "OBSERVATION", 343, 349], ["stable", "OBSERVATION_MODIFIER", 494, 500], ["low toxicity", "OBSERVATION_MODIFIER", 507, 519]]], ["Self-assembly monolayer technology further increases GNP solubility and improves interfacial interactions.", [["GNP", "CHEMICAL", 53, 56], ["monolayer", "CELL", 14, 23], ["GNP", "SIMPLE_CHEMICAL", 53, 56], ["GNP solubility", "TREATMENT", 53, 67], ["increases", "OBSERVATION_MODIFIER", 43, 52], ["GNP solubility", "OBSERVATION", 53, 67], ["interfacial interactions", "OBSERVATION", 81, 105]]], ["By coating with selection of functional motifs, GNPs can be functionalized to harvest LMW proteins [48].", [["GNPs", "CHEMICAL", 48, 52], ["GNPs", "SIMPLE_CHEMICAL", 48, 52], ["LMW proteins", "PROTEIN", 86, 98], ["functional motifs", "TREATMENT", 29, 46], ["GNPs", "TREATMENT", 48, 52], ["harvest LMW proteins", "TEST", 78, 98]]], ["Recently, Khoury and coworkers [49] demonstrated a poly(acrylic acid)-coated gold NPs created by the layer-by-layer method to be used to selectively harvest positively charged LMW biomarkers (< 10 kDa) such as SDFR and FITC-labeled peptide in one step.", [["poly(acrylic acid", "CHEMICAL", 51, 68], ["poly(acrylic acid)", "CHEMICAL", 51, 69], ["FITC", "CHEMICAL", 219, 223], ["poly(acrylic acid", "SIMPLE_CHEMICAL", 51, 68], ["gold NPs", "SIMPLE_CHEMICAL", 77, 85], ["SDFR", "SIMPLE_CHEMICAL", 210, 214], ["FITC", "SIMPLE_CHEMICAL", 219, 223], ["SDFR", "PROTEIN", 210, 214], ["a poly(acrylic acid)", "TREATMENT", 49, 69], ["coated gold NPs", "TREATMENT", 70, 85], ["LMW biomarkers", "TEST", 176, 190], ["SDFR", "TEST", 210, 214], ["FITC-labeled peptide", "TREATMENT", 219, 239]]], ["In addition, specialized affinity bait-containing hydrogel particles, which simultaneously conduct molecular sieve chromatography and affinity chromatography in one step, have shown great promise for LMW proteins harvesting.", [["LMW proteins", "GENE_OR_GENE_PRODUCT", 200, 212], ["LMW proteins", "PROTEIN", 200, 212], ["specialized affinity bait", "TREATMENT", 13, 38], ["hydrogel particles", "TREATMENT", 50, 68], ["molecular sieve chromatography", "TEST", 99, 129], ["affinity chromatography", "TEST", 134, 157], ["LMW proteins harvesting", "TREATMENT", 200, 223], ["proteins harvesting", "OBSERVATION", 204, 223]]], ["Cumulative evidence shows that hydrogel particles can conduct enrichment and encapsulation of selected classes of proteins and peptides from complex mixtures of biomolecules such as native human serum and urine, purify them from endogenous high-abundance proteins such as albumin, and protect them from degradation during subsequent sample handling [45], [50], [51].Enrichment of Low-Abundance LMW Proteins Based on Nanotechnology ::: Enrichment of Low-Abundance LMW Proteins ::: Strategies for the Prefractionation or Enrichment of Small Intact or Truncated Proteins From the Human PlasmaCarbon nanotubes are another type of important nanomaterial useful for enrichment of low-abundant LMW proteins, due to their extraordinary electronic and mechanical properties.", [["serum", "ANATOMY", 195, 200], ["urine", "ANATOMY", 205, 210], ["sample", "ANATOMY", 333, 339], ["PlasmaCarbon", "CHEMICAL", 583, 595], ["human", "ORGANISM", 189, 194], ["serum", "ORGANISM_SUBSTANCE", 195, 200], ["urine", "ORGANISM_SUBSTANCE", 205, 210], ["albumin", "GENE_OR_GENE_PRODUCT", 272, 279], ["Human", "ORGANISM", 577, 582], ["endogenous high-abundance proteins", "PROTEIN", 229, 263], ["albumin", "PROTEIN", 272, 279], ["LMW proteins", "PROTEIN", 687, 699], ["human", "SPECIES", 189, 194], ["Human", "SPECIES", 577, 582], ["human", "SPECIES", 189, 194], ["hydrogel particles", "PROBLEM", 31, 49], ["proteins and peptides", "PROBLEM", 114, 135], ["complex mixtures of biomolecules", "PROBLEM", 141, 173], ["native human serum and urine", "TEST", 182, 210], ["endogenous high-abundance proteins", "PROBLEM", 229, 263], ["albumin", "TEST", 272, 279], ["the Prefractionation", "PROBLEM", 495, 515], ["Small Intact or Truncated Proteins", "PROBLEM", 533, 567], ["the Human PlasmaCarbon nanotubes", "TREATMENT", 573, 605], ["low-abundant LMW proteins", "PROBLEM", 674, 699], ["hydrogel particles", "OBSERVATION", 31, 49], ["Low", "OBSERVATION_MODIFIER", 380, 383], ["Low", "OBSERVATION_MODIFIER", 449, 452], ["Small", "OBSERVATION_MODIFIER", 533, 538], ["Intact", "OBSERVATION", 539, 545], ["abundant LMW", "OBSERVATION_MODIFIER", 678, 690], ["mechanical properties", "OBSERVATION", 743, 764]]], ["CNTs offer a number of advantages for enrichment of proteins that may result in more efficient enrichment than nanoparticles.", [["CNTs", "SIMPLE_CHEMICAL", 0, 4], ["enrichment of proteins", "TREATMENT", 38, 60]]], ["CNTs have a large inner volume which allows molecules to be encapsulated, and this volume is more easily accessible because the end caps can be easily removed.", [["CNTs", "SIMPLE_CHEMICAL", 0, 4], ["a large inner volume", "TREATMENT", 10, 30], ["this volume", "TEST", 78, 89], ["the end caps", "TREATMENT", 124, 136], ["large", "OBSERVATION_MODIFIER", 12, 17], ["inner", "OBSERVATION_MODIFIER", 18, 23], ["volume", "OBSERVATION", 24, 30], ["encapsulated", "OBSERVATION_MODIFIER", 60, 72]]], ["In addition, they have distinct inner and outer surfaces for functionalization to be biocompatible and to be capable of recognizing proteins [52].", [["inner", "ANATOMY", 32, 37], ["inner", "TISSUE", 32, 37], ["functionalization", "TREATMENT", 61, 78], ["distinct", "OBSERVATION_MODIFIER", 23, 31], ["inner", "OBSERVATION_MODIFIER", 32, 37]]], ["Broadly, CNTs may be classed either as single-walled nanotubes (SWNTs) or multiwalled nanotubes (MWNTs).", [["SWNTs", "CHEMICAL", 64, 69], ["multiwalled nanotubes", "CHEMICAL", 74, 95], ["MWNTs", "CHEMICAL", 97, 102], ["CNTs", "SIMPLE_CHEMICAL", 9, 13], ["single-walled nanotubes", "SIMPLE_CHEMICAL", 39, 62], ["SWNTs", "SIMPLE_CHEMICAL", 64, 69], ["multiwalled nanotubes", "SIMPLE_CHEMICAL", 74, 95], ["MWNTs", "SIMPLE_CHEMICAL", 97, 102], ["CNTs", "TREATMENT", 9, 13], ["single-walled nanotubes (SWNTs", "TREATMENT", 39, 69], ["multiwalled nanotubes (MWNTs", "TREATMENT", 74, 102]]], ["MWNTs are composed of several coaxial layers of SWNTs, which allow them interact strongly with organic molecules, and thereby might offer interesting opportunities for the development of new, unique adsorbent material for the capture of LMW proteins.", [["MWNTs", "CHEMICAL", 0, 5], ["MWNTs", "SIMPLE_CHEMICAL", 0, 5], ["SWNTs", "SIMPLE_CHEMICAL", 48, 53], ["LMW proteins", "GENE_OR_GENE_PRODUCT", 237, 249], ["LMW proteins", "PROTEIN", 237, 249], ["several coaxial layers of SWNTs", "TREATMENT", 22, 53], ["unique adsorbent material", "TREATMENT", 192, 217], ["LMW proteins", "PROBLEM", 237, 249]]], ["Li and coworkers described a novel peptidome analysis approach using multiwalled carbon nanotubes as an alternative adsorbent to capture endogenous peptides from human plasma [53].", [["plasma", "ANATOMY", 168, 174], ["Li", "CHEMICAL", 0, 2], ["multiwalled carbon nanotubes", "CHEMICAL", 69, 97], ["carbon", "CHEMICAL", 81, 87], ["multiwalled carbon nanotubes", "SIMPLE_CHEMICAL", 69, 97], ["human", "ORGANISM", 162, 167], ["plasma", "ORGANISM_SUBSTANCE", 168, 174], ["human", "SPECIES", 162, 167], ["human", "SPECIES", 162, 167], ["a novel peptidome analysis approach", "TREATMENT", 27, 62], ["multiwalled carbon nanotubes", "TREATMENT", 69, 97], ["an alternative adsorbent", "TREATMENT", 101, 125], ["human plasma", "TEST", 162, 174]]], ["By coupling with liquid chromatography-mass spectrometry, this method allowed detection of 2521 peptide features (m/z 300\u20131800 range) in about 50 \u03bcL of plasma.Enrichment of Low-Abundance LMW Proteins Based on Nanotechnology ::: Enrichment of Low-Abundance LMW Proteins ::: Strategies for the Prefractionation or Enrichment of Small Intact or Truncated Proteins From the Human PlasmaDue to its well-defined pore network and surface reactivity, the use of mesoporous silica surfaces as a size-exclusion method for harvesting the peptides and small proteins has also been widely reported [[42], [54]].", [["plasma", "ANATOMY", 152, 158], ["pore network", "ANATOMY", 406, 418], ["surface", "ANATOMY", 423, 430], ["mesoporous silica", "CHEMICAL", 454, 471], ["silica", "CHEMICAL", 465, 471], ["plasma", "ORGANISM_SUBSTANCE", 152, 158], ["Human", "ORGANISM", 370, 375], ["pore network", "MULTI-TISSUE_STRUCTURE", 406, 418], ["[[42], [54]]", "SIMPLE_CHEMICAL", 585, 597], ["Small Intact or Truncated Proteins", "PROTEIN", 326, 360], ["Human", "SPECIES", 370, 375], ["liquid chromatography", "TEST", 17, 38], ["mass spectrometry", "PROBLEM", 39, 56], ["this method", "TEST", 58, 69], ["the Prefractionation", "TEST", 288, 308], ["mesoporous silica surfaces", "TREATMENT", 454, 480], ["harvesting the peptides", "TREATMENT", 512, 535], ["small proteins", "PROBLEM", 540, 554], ["Low", "OBSERVATION_MODIFIER", 173, 176], ["Low", "OBSERVATION_MODIFIER", 242, 245], ["Small", "OBSERVATION_MODIFIER", 326, 331], ["Intact", "OBSERVATION", 332, 338], ["surface", "OBSERVATION_MODIFIER", 423, 430], ["reactivity", "OBSERVATION_MODIFIER", 431, 441], ["size", "OBSERVATION_MODIFIER", 486, 490], ["small", "OBSERVATION_MODIFIER", 540, 545]]], ["In addition, the chemical and structural modification of porous silicon enables optimization of the ionization of the porous silicon surface, which allows it to be sensitive and compatible with silicon-based microfluidics and microchip technologies.", [["silicon", "CHEMICAL", 64, 71], ["silicon", "CHEMICAL", 194, 201], ["silicon", "CHEMICAL", 64, 71], ["silicon", "CHEMICAL", 125, 132], ["silicon", "CHEMICAL", 194, 201], ["the chemical and structural modification of porous silicon", "TREATMENT", 13, 71], ["the ionization of the porous silicon surface", "TREATMENT", 96, 140], ["silicon-based microfluidics", "TREATMENT", 194, 221], ["microchip technologies", "TREATMENT", 226, 248], ["porous silicon", "OBSERVATION", 57, 71]]], ["Based on this, nanoporous surfaces have been used to capture LMW peptides from human plasma.", [["plasma", "ANATOMY", 85, 91], ["human", "ORGANISM", 79, 84], ["plasma", "ORGANISM_SUBSTANCE", 85, 91], ["human", "SPECIES", 79, 84], ["human", "SPECIES", 79, 84], ["this, nanoporous surfaces", "TREATMENT", 9, 34], ["human plasma", "TEST", 79, 91]]], ["For instance, Fan and coworkers have described a peptide extraction approach based on nanoporous silica thin films to successfully detect low concentrations of hepcidin from human body fluids collected from 119 healthy volunteers and 19 inflammation patients [55].", [["body fluids", "ANATOMY", 180, 191], ["inflammation", "DISEASE", 237, 249], ["silica", "CHEMICAL", 97, 103], ["hepcidin", "GENE_OR_GENE_PRODUCT", 160, 168], ["human", "ORGANISM", 174, 179], ["body fluids", "ORGANISM_SUBSTANCE", 180, 191], ["volunteers", "ORGANISM", 219, 229], ["patients", "ORGANISM", 250, 258], ["hepcidin", "PROTEIN", 160, 168], ["human", "SPECIES", 174, 179], ["patients", "SPECIES", 250, 258], ["human", "SPECIES", 174, 179], ["a peptide extraction approach", "TREATMENT", 47, 76], ["nanoporous silica thin films", "TREATMENT", 86, 114], ["low concentrations of hepcidin", "PROBLEM", 138, 168], ["human body fluids", "TREATMENT", 174, 191], ["low concentrations", "OBSERVATION_MODIFIER", 138, 156]]], ["Recently, Tang and coworkers reported an approach for the adsorption and enrichment of low-abundance protein in mammalian cell extract by using nanostructured surface-imprinted polymers with sufficiently thin shells and high surface-to-volume ratios [56].Discover-Based Identification of LMW Proteins ::: Characterization of LMW Proteins Based on MSWith a discovery-based strategy, the goal is usually to discover proteins that are associated with the ongoing physiological and pathological events, and thereby a further elucidation of LMW protein identities or clinical validation.", [["cell extract", "ANATOMY", 122, 134], ["surface", "ANATOMY", 225, 232], ["mammalian cell", "CELL", 112, 126], ["LMW Proteins", "GENE_OR_GENE_PRODUCT", 325, 337], ["LMW", "GENE_OR_GENE_PRODUCT", 536, 539], ["low-abundance protein", "PROTEIN", 87, 108], ["LMW Proteins", "PROTEIN", 288, 300], ["LMW Proteins", "PROTEIN", 325, 337], ["LMW protein", "PROTEIN", 536, 547], ["the adsorption", "TREATMENT", 54, 68], ["enrichment of low-abundance protein", "TREATMENT", 73, 108], ["mammalian cell extract", "TREATMENT", 112, 134], ["nanostructured surface-imprinted polymers", "TREATMENT", 144, 185], ["sufficiently thin shells", "PROBLEM", 191, 215], ["LMW Proteins", "PROBLEM", 325, 337], ["the ongoing physiological and pathological events", "PROBLEM", 448, 497], ["LMW protein identities", "PROBLEM", 536, 558], ["mammalian cell", "OBSERVATION", 112, 126]]], ["MS-based strategies that most frequently used in the identification of proteins always involve a combination of gel- or LC-based separation techniques and MS, such as SDS-PAGE or 2-DE coupled with MALDI/ESI-MS(/MS), and LC-MALDI/ESI-MS(/MS).", [["MS", "PROBLEM", 155, 157], ["MS", "PROBLEM", 207, 209]]], ["However, prior efforts in the search for serum and plasma protein biomarkers utilized gel-based separation technologies showed that gel cannot readily separate and distinguish molecules of less than 10 kDa in size [57].", [["serum", "ANATOMY", 41, 46], ["plasma", "ANATOMY", 51, 57], ["serum", "ORGANISM_SUBSTANCE", 41, 46], ["plasma", "ORGANISM_SUBSTANCE", 51, 57], ["serum and plasma protein biomarkers", "TEST", 41, 76], ["gel", "TEST", 86, 89], ["based separation technologies", "TEST", 90, 119], ["size", "OBSERVATION_MODIFIER", 209, 213]]], ["In contrast, high-performance liquid chromatography (HPLC) separation, coupling with MS, is highly automated and has the capacity to separate low-abundance proteins for subsequent detachment and thus widely used to separate the proteins in serum/plasma before or after high-abundant protein depletion.", [["serum", "ANATOMY", 240, 245], ["plasma", "ANATOMY", 246, 252], ["serum", "ORGANISM_SUBSTANCE", 240, 245], ["plasma", "ORGANISM_SUBSTANCE", 246, 252], ["low-abundance proteins", "PROTEIN", 142, 164], ["high-performance liquid chromatography (HPLC) separation", "TREATMENT", 13, 69], ["MS", "PROBLEM", 85, 87], ["the capacity", "PROBLEM", 117, 129], ["subsequent detachment", "PROBLEM", 169, 190], ["serum/plasma", "TEST", 240, 252], ["high-abundant protein depletion", "PROBLEM", 269, 300], ["detachment", "OBSERVATION", 180, 190], ["protein depletion", "OBSERVATION", 283, 300]]], ["In a typical ESI-MS/MS-based experiment, especially LC-MS/MS approach, protein is digested into peptides, and then peptide ions are selected in the mass spectrometer for fragmentation to generate tandem mass spectra for sequencing, which involving automatic and sophisticated bioinformatics tools.", [["MS", "PROBLEM", 20, 22], ["LC", "TEST", 52, 54], ["MS/MS approach", "PROBLEM", 55, 69], ["protein", "TEST", 71, 78], ["peptide ions", "PROBLEM", 115, 127], ["fragmentation", "PROBLEM", 170, 183], ["tandem mass spectra", "PROBLEM", 196, 215], ["sequencing", "TEST", 220, 230]]], ["In laser desorption/ionization techniques (SELDI or MALDI) based experiment, many reports of biomarker were limited to a general description of protein peaks, due to the inherent low resolution and mass accuracy of SELDI-TOF-MS or limited capability of tandem MS/MS for protein analysis by MALDI-TOF-MS.", [["laser desorption/ionization techniques", "TREATMENT", 3, 41], ["protein peaks", "PROBLEM", 144, 157], ["the inherent low resolution", "PROBLEM", 166, 193], ["SELDI", "TEST", 215, 220], ["MS", "PROBLEM", 225, 227], ["tandem MS", "TEST", 253, 262], ["protein analysis", "TEST", 270, 286], ["MALDI", "TEST", 290, 295]]], ["Therefore, an additional efficient isolation procedure is needed for a further elucidation of LMW protein identities.", [["LMW", "GENE_OR_GENE_PRODUCT", 94, 97], ["LMW protein", "PROTEIN", 94, 105], ["an additional efficient isolation procedure", "TREATMENT", 11, 54], ["LMW protein identities", "PROBLEM", 94, 116]]], ["Our group has developed an approach combining ZipTip-C18 pipette tip desalting, acetonitrile (ACN) precipitation, reverse-phase C18 HPLC purification, and MALDI-TOF-MS analysis (Fig. 3), which we believed is suitable to profiling, purification, and identification of low-abundance, LMW targeted proteins in human serum.", [["serum", "ANATOMY", 313, 318], ["ZipTip-C18", "CHEMICAL", 46, 56], ["acetonitrile", "CHEMICAL", 80, 92], ["ACN", "CHEMICAL", 94, 97], ["acetonitrile", "CHEMICAL", 80, 92], ["ACN", "CHEMICAL", 94, 97], ["ZipTip", "SIMPLE_CHEMICAL", 46, 52], ["acetonitrile", "SIMPLE_CHEMICAL", 80, 92], ["ACN", "SIMPLE_CHEMICAL", 94, 97], ["human", "ORGANISM", 307, 312], ["serum", "ORGANISM_SUBSTANCE", 313, 318], ["LMW targeted proteins", "PROTEIN", 282, 303], ["human", "SPECIES", 307, 312], ["human", "SPECIES", 307, 312], ["an approach", "TREATMENT", 24, 35], ["ZipTip-C18 pipette tip desalting", "TREATMENT", 46, 78], ["acetonitrile (ACN) precipitation", "TREATMENT", 80, 112], ["HPLC purification", "TEST", 132, 149], ["MALDI", "TEST", 155, 160], ["MS analysis", "TEST", 165, 176], ["purification", "TEST", 231, 243], ["low-abundance", "PROBLEM", 267, 280], ["LMW targeted proteins in human serum", "PROBLEM", 282, 318]]], ["Using this workflow, we purified and identified 10 SAA isoforms with or without truncations from sera of advanced-stage cancer patients [26].Targeted Quantification of LMW Proteins ::: Characterization of LMW Proteins Based on MSIn targeted quantification of LMW proteins, several strategies have been applied, which are mainly fall into two categories: selected reaction monitoring (SRM, also termed MRM) and parallel reaction monitoring (PRM).Targeted Quantification of LMW Proteins ::: Characterization of LMW Proteins Based on MSDue to its high specificity and sensitivity, MRM is presently the most widely used MS-based targeted proteomic approach [58], [59].", [["sera", "ANATOMY", 97, 101], ["cancer", "ANATOMY", 120, 126], ["cancer", "DISEASE", 120, 126], ["SAA", "GENE_OR_GENE_PRODUCT", 51, 54], ["sera", "ORGANISM_SUBSTANCE", 97, 101], ["advanced-stage cancer", "CANCER", 105, 126], ["patients", "ORGANISM", 127, 135], ["LMW Proteins", "GENE_OR_GENE_PRODUCT", 205, 217], ["MSIn", "SIMPLE_CHEMICAL", 227, 231], ["LMW proteins", "GENE_OR_GENE_PRODUCT", 259, 271], ["LMW Proteins", "GENE_OR_GENE_PRODUCT", 509, 521], ["SAA isoforms", "PROTEIN", 51, 63], ["LMW Proteins", "PROTEIN", 168, 180], ["LMW Proteins", "PROTEIN", 205, 217], ["LMW proteins", "PROTEIN", 259, 271], ["LMW Proteins", "PROTEIN", 472, 484], ["LMW Proteins", "PROTEIN", 509, 521], ["patients", "SPECIES", 127, 135], ["truncations", "PROBLEM", 80, 91], ["advanced-stage cancer", "PROBLEM", 105, 126], ["LMW Proteins", "PROBLEM", 205, 217], ["LMW proteins", "PROBLEM", 259, 271], ["several strategies", "TREATMENT", 273, 291], ["selected reaction monitoring", "TEST", 354, 382], ["MRM", "TEST", 401, 404], ["parallel reaction monitoring", "TEST", 410, 438], ["LMW Proteins", "PROBLEM", 509, 521], ["MRM", "TEST", 578, 581], ["cancer", "OBSERVATION", 120, 126], ["LMW Proteins", "OBSERVATION", 168, 180], ["LMW proteins", "OBSERVATION_MODIFIER", 259, 271], ["LMW Proteins", "OBSERVATION", 472, 484]]], ["MRM is typically carried out in triple quadrupole (QQQ) mass spectrometers, in which the first mass analyzer (Q1) is set to only transmit the target ion of the selected peptide, the collision energy is optimized to produce diagnostic charged fragments from this ion in the second mass analyzer (Q2), and the third mass analyzer (Q3) is set to transmit one to three selected diagnostic fragments for monitoring (Fig. 4A).", [["MRM", "TEST", 0, 3], ["mass spectrometers", "PROBLEM", 56, 74], ["the first mass analyzer", "TEST", 85, 108], ["diagnostic charged fragments", "PROBLEM", 223, 251], ["the third mass analyzer", "TEST", 304, 327], ["charged fragments", "OBSERVATION", 234, 251], ["mass", "OBSERVATION", 280, 284]]], ["The advantages of MRM compared to other quantitative analytical methods such as Western blotting, ELISA, and immunohistochemistry include multiplexed detection and the ability to use spiked-in, stable isotope-labeled standards to foster the absolute or precise relative quantification of endogenous analytes.", [["MRM", "TEST", 18, 21], ["Western blotting", "TEST", 80, 96], ["ELISA", "TEST", 98, 103], ["immunohistochemistry", "TEST", 109, 129], ["multiplexed detection", "TEST", 138, 159], ["endogenous analytes", "PROBLEM", 288, 307], ["endogenous analytes", "OBSERVATION", 288, 307]]], ["The MRM assay approach has been applied to the measurement of various low-abundant specific peptides in tryptic digests of plasma, such as C-reactive protein [60] and prostate-specific antigen [61].Targeted Quantification of LMW Proteins ::: Characterization of LMW Proteins Based on MSPRM, first published in 2012, is a targeted proteomics strategy where all product ions of the target peptides are simultaneously monitored at high-resolution and high mass accuracy [62].", [["plasma", "ANATOMY", 123, 129], ["prostate", "ANATOMY", 167, 175], ["plasma", "ORGANISM_SUBSTANCE", 123, 129], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 139, 157], ["prostate-specific antigen", "GENE_OR_GENE_PRODUCT", 167, 192], ["LMW Proteins", "GENE_OR_GENE_PRODUCT", 262, 274], ["C-reactive protein", "PROTEIN", 139, 157], ["LMW Proteins", "PROTEIN", 225, 237], ["LMW Proteins", "PROTEIN", 262, 274], ["The MRM assay approach", "TEST", 0, 22], ["the measurement", "TEST", 43, 58], ["plasma", "TEST", 123, 129], ["C-reactive protein", "TEST", 139, 157], ["prostate-specific antigen", "TEST", 167, 192], ["LMW Proteins", "PROBLEM", 262, 274], ["MSPRM", "TEST", 284, 289], ["a targeted proteomics strategy", "TREATMENT", 319, 349], ["the target peptides", "TREATMENT", 376, 395], ["high mass accuracy", "PROBLEM", 448, 466], ["prostate", "ANATOMY", 167, 175], ["LMW Proteins", "OBSERVATION", 225, 237], ["high", "OBSERVATION_MODIFIER", 448, 452], ["mass", "OBSERVATION", 453, 457]]], ["The principle of PRM is comparable to SRM/MRM, but it permits the parallel detection of all target product ions in one high-resolution mass analysis, as the third quadrupole of a QQQ mass spectrometer is substituted with a high-resolution and accurate-mass analyzer in PRM case (Fig. 4B).", [["SRM/MRM", "TEST", 38, 45], ["a QQQ mass spectrometer", "PROBLEM", 177, 200], ["MRM", "OBSERVATION", 42, 45], ["mass", "OBSERVATION", 135, 139]]], ["There are several advantages of PRM when compared to MRM.", [["MRM", "TEST", 53, 56], ["several", "OBSERVATION_MODIFIER", 10, 17], ["advantages", "OBSERVATION_MODIFIER", 18, 28]]], ["To begin with, the PRM performs a full scan for fragment ions, instead of recording just 3\u20135 transitions as in MRM, enables high-quality quantitative measurements.", [["a full scan", "TEST", 32, 43], ["fragment ions", "PROBLEM", 48, 61], ["MRM", "TEST", 111, 114]]], ["Moreover, the background interference could be greatly eliminated with high resolution and accuracy, thus improve the detection limit and sensitivity in complex background effectively.", [["the detection limit", "TEST", 114, 133], ["high", "OBSERVATION_MODIFIER", 71, 75], ["resolution", "OBSERVATION_MODIFIER", 76, 86]]], ["In addition, requiring minimal upfront efforts for selection of target transitions and optimization of fragmentation energy facilitates assay development.", [["minimal upfront efforts", "TREATMENT", 23, 46], ["target transitions", "PROBLEM", 64, 82], ["fragmentation energy", "PROBLEM", 103, 123], ["fragmentation", "OBSERVATION", 103, 116]]], ["Thus, PRM was believed to be suitable for quantification of multiple proteins in low abundant in complex sample.", [["sample", "ANATOMY", 105, 111], ["multiple proteins", "PROTEIN", 60, 77], ["multiple proteins in low abundant in complex sample", "PROBLEM", 60, 111], ["multiple", "OBSERVATION_MODIFIER", 60, 68], ["proteins", "OBSERVATION", 69, 77], ["low abundant", "OBSERVATION_MODIFIER", 81, 93]]], ["For instance, Kim and coworkers have developed a PRM assay to selectively measure isotypes of SAA and successfully measured five allelic variants (1\u03b1, 1\u03b2, 1\u03b3, 2\u03b1, 2\u03b2) of SAA1 and SAA2 in plasma samples from lung cancer patients [63].", [["plasma samples", "ANATOMY", 187, 201], ["lung cancer", "ANATOMY", 207, 218], ["lung cancer", "DISEASE", 207, 218], ["SAA", "GENE_OR_GENE_PRODUCT", 94, 97], ["\u03b1", "GENE_OR_GENE_PRODUCT", 148, 149], ["1\u03b2", "GENE_OR_GENE_PRODUCT", 151, 153], ["1\u03b3", "GENE_OR_GENE_PRODUCT", 155, 157], ["2\u03b1", "GENE_OR_GENE_PRODUCT", 159, 161], ["2", "GENE_OR_GENE_PRODUCT", 163, 164], ["\u03b2", "GENE_OR_GENE_PRODUCT", 164, 165], ["SAA1", "GENE_OR_GENE_PRODUCT", 170, 174], ["SAA2", "GENE_OR_GENE_PRODUCT", 179, 183], ["plasma samples", "ORGANISM_SUBSTANCE", 187, 201], ["lung cancer", "CANCER", 207, 218], ["patients", "ORGANISM", 219, 227], ["SAA", "PROTEIN", 94, 97], ["SAA1", "PROTEIN", 170, 174], ["SAA2", "PROTEIN", 179, 183], ["patients", "SPECIES", 219, 227], ["a PRM assay", "TEST", 47, 58], ["isotypes of SAA", "PROBLEM", 82, 97], ["SAA1", "TEST", 170, 174], ["SAA2", "TEST", 179, 183], ["plasma samples", "TEST", 187, 201], ["lung cancer", "PROBLEM", 207, 218], ["lung", "ANATOMY", 207, 211], ["cancer", "OBSERVATION", 212, 218]]], ["Ronsein et al. have developed a PRM method for quantification of the high-density lipoprotein proteome in plasma samples using 15N-labeled apolipoprotein A-1 as an internal standard [64].Future Perspectives and Concluding RemarksDespite various advancements in characterization of low-abundant LMW proteins from human serum/plasma, there are still many challenges remain.", [["plasma samples", "ANATOMY", 106, 120], ["serum", "ANATOMY", 318, 323], ["plasma", "ANATOMY", 324, 330], ["15N", "CHEMICAL", 127, 130], ["lipoprotein", "SIMPLE_CHEMICAL", 82, 93], ["plasma samples", "ORGANISM_SUBSTANCE", 106, 120], ["15N", "SIMPLE_CHEMICAL", 127, 130], ["apolipoprotein A-1", "GENE_OR_GENE_PRODUCT", 139, 157], ["LMW", "GENE_OR_GENE_PRODUCT", 294, 297], ["human", "ORGANISM", 312, 317], ["serum", "ORGANISM_SUBSTANCE", 318, 323], ["plasma", "ORGANISM_SUBSTANCE", 324, 330], ["LMW proteins", "PROTEIN", 294, 306], ["human", "SPECIES", 312, 317], ["human", "SPECIES", 312, 317], ["a PRM method", "TEST", 30, 42], ["plasma samples", "TEST", 106, 120], ["human serum/plasma", "TEST", 312, 330], ["many", "OBSERVATION_MODIFIER", 348, 352], ["challenges", "OBSERVATION", 353, 363]]], ["For instance, even though with significant recent advances, current proteomics technologies still fall short of being able to reliably detect in blood plasma low ng/mL to sub-ng/mL protein concentrations, a level of detection often required for discovering disease-specific biomarkers.", [["blood plasma", "ANATOMY", 145, 157], ["blood plasma", "ORGANISM_SUBSTANCE", 145, 157], ["blood plasma", "TEST", 145, 157], ["discovering disease", "PROBLEM", 245, 264], ["specific biomarkers", "TEST", 265, 284]]], ["Moreover, the depletion of high-abundance proteins could potentially alleviate their \u201cmasking\u201d effect; however, the removal or reduction of the high-abundance proteins without affecting the minor proteins represents a challenge.", [["high-abundance proteins", "PROTEIN", 27, 50], ["high-abundance proteins", "PROTEIN", 144, 167], ["minor proteins", "PROTEIN", 190, 204], ["the depletion of high-abundance proteins", "PROBLEM", 10, 50], ["the removal", "TREATMENT", 112, 123], ["the high-abundance proteins", "PROBLEM", 140, 167], ["high", "OBSERVATION_MODIFIER", 27, 31], ["reduction", "OBSERVATION_MODIFIER", 127, 136], ["high", "OBSERVATION_MODIFIER", 144, 148]]], ["Furthermore, sample preparation introduces preanalytical variations and poses major challenges to analyze the serum proteome.", [["sample", "ANATOMY", 13, 19], ["serum", "ANATOMY", 110, 115], ["serum", "ORGANISM_SUBSTANCE", 110, 115], ["sample preparation", "TREATMENT", 13, 31], ["preanalytical variations", "TREATMENT", 43, 67], ["the serum proteome", "TEST", 106, 124]]], ["Therefore, the possibility to develop new technologies or strategies allowing selective identification and quantification of LMW proteins from serum/plasma may accelerate the discovery rate of potential biomarkers and drug targets.", [["serum", "ANATOMY", 143, 148], ["plasma", "ANATOMY", 149, 155], ["LMW proteins", "GENE_OR_GENE_PRODUCT", 125, 137], ["serum", "ORGANISM_SUBSTANCE", 143, 148], ["plasma", "ORGANISM_SUBSTANCE", 149, 155], ["LMW proteins", "PROTEIN", 125, 137], ["selective identification", "TEST", 78, 102], ["LMW proteins", "PROBLEM", 125, 137], ["serum/plasma", "TEST", 143, 155]]]]}